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Abstract		
	
Tissue	 engineered	 skin	 has	 advanced	 significantly	 in	 creating	 a	 substitute	 to	
mimic	human	skin.	Advances	in	biomaterial	sciences	and	a	better	understanding	
of	wound	healing	have	been	the	catalyst	for	development	of	tissue-engineered	
skin	 substitutes.	We	 aimed	 to	 develop	 and	 evaluate	 a	 biodegradable	 dermal	
alternative	 composed	 of	 FDA	 approved	 polymers	 consisting	 of	 polyhydroxy-
butyrate-co-hydroxyvalerate	 (PHBV)	 (nanofibres)	 and	 polylactide-co-	 glycolide	
(75:25)	(microfibers)to	be	combined	with	skin	explants	as	a	one-step	approach	
for	full	thickness	skin	defects	reconstruction.		
	
The	 scaffolds	 consisted	 of	 an	 upper	 and	 under	 layer	 of	 PGLA	 75:25	which	 is	
known	to	facilitate	the	migration	of	epithelial	cells	and	a	middle	layer	of	PHBV	
to	act	as	a	basement	membrane	separating	the	epidermis	from	the	underlying	
dermis.	 The	 undulating	 topography	 of	 the	 dermo	 epidermal	 junction	 was	
replicated	by	templating	these	undulations	on	the	middle	layer	of	scaffolds	using	
metal	collectors.	The	rete	ridges	are	thought	to	create	a	microenvironment	for	
stem	cells	to	reside.	To	assess	this,	we	undertook	Ki67	immunohistochemistry	
which	 demonstrated	 that	 there	 was	 some	 activity	 in	 the	 trough	 of	 the	
undulations	but	this	was	not	convincing.		
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As	part	of	the	one	step	approach	we	used	skin	explants	to	populate	the	scaffolds	
as	opposed	to	isolated	epithelial	cells	which	requires	planning	and	appropriate	
staff	 and	 facilities.	We	 investigated	 the	 ability	 for	 cells	 from	 skin	 explants	 to	
migrate	from	the	cut	edges	of	onto	the	electrospun	scaffolds	compared	to	using	
isolated	keratinocytes	and	fibroblasts.	It	was	found	that	cells	from	the	explants	
will	migrate	along	the	fibres	of	the	scaffold	but	not	as	much	as	using	 isolated	
cells	in	the	same	time	period	in	terms	of	metabolic	activity,	collagen	production	
and	qualitative	assessments	using	DAPI	and	H&E.		
	
The	 ability	 for	 optimization	 of	 migration	 of	 cells	 from	 the	 skin	 explants	 was	
assessed	using	fibrin,	a	biological	tissue	glue	in	current	clinical	use	in	its	ability	
to	 retain	 the	 explants	 on	 the	 scaffold.	 We	 found	 that	 a	 fibrin	 constituent	
combination	of	thrombin	2.5	I.U	and	fibrinogen	18.75mg	allowed	manipulation	
of	skin	explants	on	the	scaffold	and	migration	of	cells	along	the	fibres.	We	also	
found	that	explants	with	less	dermis	had	more	outward	cellular	migration	from	
their	cut	edges	compared	to	those	with	more	dermis.	Finally,	we	assessed	the	
ability	for	the	constructs	to	have	another	layer	of	scaffold	on	top	to	aid	cellular	
migration	but	found	that	this	did	not	significantly	influence	outgrowth.		
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Furthermore,	we	tested	the	effect	of	keratinocyte	migration	from	skin	explants	
in	 the	presence	of	 isolated	 fibroblasts	pre-cultured	on	scaffolds	as	an	 in	vitro	
wound	 bed	 model.	 This	 revealed	 significantly	 increased	 metabolic	 and	
proliferative	 activity	 of	 constructs	 in	 production	 of	 collagen.	 Although	 in	 our	
model	for	clinical	translation	we	do	not	intend	to	use	isolated	fibroblasts	to	pre	
culture	scaffolds,	it	was	felt	that	this	was	the	closest	to	a	wound	bed	model	as	
the	 scaffolds	 would	 be	 placed	 onto	 a	 prepared	 wound	 bed.	
Immunohistochemistry	 was	 used	 to	 demonstrate	 that	 keratinocytes	 were	
migrating	 from	 the	 cut	 edges	 of	 the	 skin	 explants	 and	 confocal	 imaging	
demonstrated	that	the	cells	penetrated	the	layers	of	the	trilayer	scaffold.		
		
In	 summary	 were	 able	 to	 design	 a	 suitable	 synthetic	 dermal	 scaffold	 and	
populate	it	with	cells	from	skin	explants.	To	facilitate	this,	we	propose	the	use	of	
fibrin	and	skin	explants	with	less	dermis	to	facilitate	skin	cell	migration.	Animal	
studies	are	now	needed	to	further	define	parameters	of	the	use	of	this	in	the	
clinical	environment.			
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1.1	Structure	of	Human	Skin		
	
The	skin	 is	 the	 largest	organ	 in	 the	body,	covering	around	2m2	 in	an	average	
adult(1).	 It	 functions	 as	 a	 barrier	 protector	 against	 external	microorganisms,	
water	loss	and	has	a	role	in	thermoregulation.	Skin	loss,	when	significant	enough	
can	activate	the	systemic	 inflammatory	response	resulting	 in	shock	and	multi	
organ	dysfunction	as	a	result	prompt	wound	coverage	is	a	key	objective	in	many	
aspects	of	plastic,	burns	and	reconstructive	surgery.	In	order	to	augment	wound	
healing	 by	 creating	 a	 skin	 substitute	 we	 must	 firstly	 understand	 the	
microstructure	and	topographical	anatomy	of	skin,	which	allows	 it	to	 fulfil	 its	
most	pertinent	role	as	an	anatomical	barrier	against	evaporative	and	heat	losses	
and	the	entry	of	micro-organisms.		
	
Human	skin	can	be	thought	of	as	having	three	identifiable	layers.		The	epidermis	
or	 the	 waterproofing	 layer;	 the	 dermis	 or	 the	 supportive	 layer	 and	 the	
hypodermis	or	the	padding	layer	(Figure	1.1).	Although	these	layers	have	been	
listed	distinctly,	 they	do	not	 function	 independently	 and	are	 interlinked	by	 a	
series	of	complex	protein	systems	that	determines	the	skin’s	functionality	as	an	
organ.		
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Figure	1.1	Schematic	Representation	of	layers	of	human	skin.	Source:	Bhusan	et	
al	2010(2).		Reproduced	with	permission	from	John	Wiley	and	Sons.			
	
1.1.1	Epidermis	
The	epidermis	consists	mainly	of	stratified	keratinocytes.	The	layers	include	the	
strata	basale,	spinosum,	granulosum	and	corneum.	The	epidermis	continuously	
regenerates	itself	from	the	basal	layer	over	approximately	four	weeks	to	form	
anuclear	 keratin	 cells	 that	make	up	 the	 stratum	corneum.	 Stratification	 is	 an	
essential	 feature	of	 the	 topography	of	 the	epidermis,	as	 cells	exist	 in	various	
stages	 of	 proliferation	 and	 differentiation	 in	 the	 differing	 layers.	 It	 is	 this	
combination	 of	 differentiation	 and	 stratification	 that	 is	 responsible	 for	 the	
barrier	function	of	the	skin(3).	Therefore,	any	skin	replacement	should	facilitate	
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the	migration,	proliferation	and	stratification	of	keratinocytes	in	order	to	sustain	
a	functional	epidermis.	
	
1.1.2	Basement	Membrane	
	
The	basement	membrane,	located	between	the	epidermis	and	the	dermis	is	a	
thin	 layer	 of	 specialized	 extracellular	 matrix	 onto	 which	 the	 epidermis	 is	
attached.		It	serves	to	tightly	link	the	epidermis	to	the	dermis;	provides	a	barrier	
against	epidermal	migration;	determines	the	polarity	of	the	epidermis	and	acts	
as	 the	 middleman	 communicator	 between	 the	 epidermis	 and	 dermis	 to	
maintain	haemostasis,	which	is	one	of	the	main	functions	of	the	skin(4).	
Inoue	demonstrated	 that	 the	basement	membrane	 could	be	morphologically	
distinguished	into	four	layers:	the	plasma	membrane	of	the	basal	keratinocytes;	
lamina	lucida;	lamina	densa	and	sublamina	densa.	These	all	act	collectively	to	
augment	 the	 keratinocyte	 –dermis	 attachment(5).	 The	 lamina	 lucida	 is	 the	
interface	between	the	basement	membrane	and	the	basal	keratinocytes.	In	this	
layer,	Integrins	link	hemidesmosomes,	which	are	stud	like	structures	attached	
to	the	plasma	membrane	of	the	basal	keratinocytes	to	the	extracellular	matrix	
of	 the	 basement	membrane.	 These	 integrins	 are	 known	 as	 laminin	 332	 and	
511(6).	 The	 lamina	densa	provides	mechanical	 strength	and	 the	middle	 layer	
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that	forms	a	sheet	like	structure	comprising	of	type	IV	collagen,	nidogens	and	
perlecan(7).		The	sublamina	densa	(lamina	fibroreticularis)	is	the	deepest	layer	
of	the	basement	membrane	which	contains	collagen	VII	that	extends	through	
fibrils	and	insert	into	plaques	in	the	reticular	dermis(8).		
1.1.3	Rete	ridges	
	
The	anatomical	structure	of	skin	reflects	the	mechanical	stress	that	cells	in	that	
region	 are	 likely	 to	 experience.	 The	 basement	 membrane	 is	 topographically	
organized	 into	 peaks	 and	 troughs	 in	 the	 post-natal	 skin.	 These	 develop	mid-
gestation	where	 prior	 to	 this;	 the	 dermal	 epidermal	 junction	 is	 flat(9).These	
structures	referred	to	as	rete	ridges	range	from	50-400	micrometres	 in	width	
and	50-200	micrometres	in	depth(10),(11)	(Figure	1.2).		
	
Epidermal	stem	cells	lie	in	specific	locations	relative	to	the	rete	ridges	depending	
on	their	location	in	the	body.	In	the	palmoplantar	regions	the	peak	of	the	rete	
ridges	 are	 those	 areas	 where	 the	 epithelium	 projects	 most	 deeply	 into	 the	
dermis.	Lavker	and	Sun	observed	that	there	were	different	shapes	and	rates	of	
cell	division	in	the	basal	keratinocytes	based	on	whether	they	were	located	in	
the	tip	or	trough	of	the	rete	ridges.	They	concluded	that	the	stem	cells	might	
inhabit	the	tips	only	of	the	deep	rete	ridges(12).	However	in	non-	palmoplantar	
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skin	the	stem	cells	seem	to	inhabit	the	troughs	of	the	rete	ridges	i.e.	where	the	
dermis	comes	closest	to	the	skin(13).		
The	 rete	 ridges	 are	 an	 important	 feature	 in	 the	 topography	 of	 the	 dermal-
epidermal	junction.	They	provide	structural	integrity	for	the	epidermal-dermal	
interface	and	define	the	cellular	microenvironments,	which	then	determines	the	
functioning	of	the	basal	and	suprabasal	keratinocytes	in	these	regions.	Studies	
have	demonstrated,	using	biopsies	 followed	by	histological	 analysis,	 that	 this	
specialized	3D	topography	 is	not	present	 in	 the	dermal-epidermal	 junction	of	
tissue-engineered	bio-substitutes,	which	maybe	a	limiting	factor	in	the	ultimate	
long	term	aim	of	any	tissue	replacement-	to	create	a	structure	that	ultimately	
will	look	and	function	like	its	intended	replacement	(14).		
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Figure	1.2a	Sketch	of	Rete	Ridges	and	Stem	Cell	locations	in	the	Dermis	
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Figure	1.2b	Histology	image	(Haematoxylin	and	Eosin	staining)	of	a	section	of	
abdominal	skin.	This	illustrates	the	various	layers;	epidermis	(E),	dermis	(D)	and	
the	rete	ridges	(RR).	Scale	bar	represents	100	μm.	
	 	
1.1.4	Dermis	
The	dermis	is	divided	into	the	papillary	(uppermost)	and	reticular	(lower)	layers.	
The	 papillary	 layer	 is	 undulating	 and	 intertwines	with	 the	 rete	 ridges	 of	 the	
epithelium	at	the	dermal-epidermal	junction.	Molecularly	it	consists	of	loosely	
arranged	type	III	collagen	fibres.		
The	 reticular	 dermis	 is	 composed	 of	 a	 dense	 irregular	 meshwork	 of	 tightly	
packed	 type	 I	 collagen	 fibres	 elastin	 and	 glycosaminoglycans	 (extracellular	
matrix).	Fibroblasts	in	the	dermis	are	primarily	responsible	for	the	synthesis	of	
the	 extracellular	matrix.	 The	 reticular	 dermis	 provides	 skin	 with	 elasticity	 or	
resilience	 to	 deformity.	 Therefore,	 any	 skin	 substitute	 must	 have	 a	 robust	
Undulating	pattern	of	the	Epidermal	-	Dermal	Interface
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dermal	 component,	which	 can	 support	 and	 facilitate	 collagen	deposition	and	
possess	 the	 tensile	 strength	 to	allow	 the	 skin	 to	maintain	 its	mechanical	and	
elastic	properties.	
	
1.1.5	Hypodermis	
The	hypodermis	lies	just	under	the	dermis	separated	from	it	by	a	thin	layer	of	
superficial	fascia.	It	contains	variable	amounts	of	adipose	tissue	depending	on	
the	part	of	the	body	that	is	being	examined.	This	subcutaneous	fat	layer	gives	a	
smooth	contour	to	the	body.	When	it	is	lost	for	example	in	traumatic	injuries,	
lack	of	regeneration	results	in	contour	defects	to	that	particular	area.	
	
1.1.6	Blood	Supply	to	the	Skin	
	
There	are	 two	horizontal	plexuses	or	vascular	 trees	 that	 supply	 the	 skin.	The	
upper	 one	 lies	 at	 the	 level	 of	 the	 papillary	 dermis	 and	 the	 lower	 lies	 at	 the	
dermal-hypodermal	junction.	Communication	occurs	between	these	2	plexuses	
by	way	of	paired	arterial	and	venous	networks.	It	 is	therefore	essential	that	a	
skin	substitute	should	be	able	to	support	and	encourage	timely	vascularization	
which	is	generally	accepted	as	5	days	clinically	in	order	to	ensure	take	(	defined	
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as	 integration	of	 the	material	 to	 the	underlying	wound	bed)	and	ultimately	a	
successful	skin	replacement.		
	
1.2	Characteristics	of	cells	used	to	populate	the	electrospun	scaffolds		
	
1.2.1	Keratinocyte	biology		
In	order	 to	produce	a	scaffold	 that	supports	 the	growth	of	keratinocytes	and	
fibroblasts	 it	 is	 essential	 to	 understand	 their	 behaviour,	 organization	 and	
requirements.		Keratinocyte	migration	occurs	in	wound	healing	after	about	18-
24	hours.	 	Migrating	keratinocytes	are	morphologically	altered	in	order	to	aid	
this.	 Some	 of	 the	 changes	 include	 disassembly	 of	 the	 links	 	 between	 the	
basement	 membrane	 and	 the	 keratinocytes	 and	 retraction	 of	 intracellular	
filaments	 to	allow	propagation	and	 formation	of	peripheral	cytoplasmic	actin	
filaments	 (lamellopodia).	 Epithelization	 is	 controlled	 by	 communication	
between	 three	main	 sets	 of	molecules:	 growth	 factors,	 integrins	 and	matrix	
metalloproteinases	(MMPs)(15).	These	systems	all	integrate	to	form	a	migrating	
sheet	 of	 keratinocytes	 at	 the	 edge	 of	 the	 wound.	 The	 leading	 edge	 of	 this	
advancing	sheet	shows	no	mitotic	activity.	Instead	the	suprabasal	keratinocytes	
are	the	first	to	migrate	onto	the	wound;	this	reduces	the	number	of	cells	and	act	
as	 a	 stimulus	 for	 cell	 proliferation.	 Migrating	 keratinocytes	 produce	 MMPs,	
which	 loosens	the	adhesion	of	the	keratinocyte	to	the	dermal	matrix	thereby	
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allowing	migration	and	re-epithelization.	Once	re-epithelization	is	complete	the	
keratinocytes	 revert	 to	 their	 normal	 phenotypes,	 which	 is	 initiated	 by	 the	
process	of	contact	inhibition(16).	
	
1.2.2	Fibroblast	Biology		
Fibroblasts	 are	 the	 principal	 cellular	 components	 of	 connective	 tissues	 and	
populate	the	dermis	of	the	skin.	They	are	elongated,	spindle	shaped	cells	that	
have	 a	 high	 proliferative	 and	migration	 potential.	 They	 function	 not	 only	 to	
synthesize	and	secrete	extracellular	matrix	molecules	but	also	growth	factors,	
cytokines	 and	 chemokines	 that	 contribute	 to	 immune	 regulation	 and	wound	
healing	by	influencing	the	migration	and	proliferation	of	keratinocytes(17).		
Historical	data	has	demonstrated	that	fibroblasts	cultured	in	a	blood	clot	varied	
in	 shape	 from	stellate	 to	bipolar	depending	on	 the	orientation	of	 the	 fibrous	
network	 of	 the	 clot.	 This	 led	 to	 the	 conclusion	 that	 there	 was	 a	 dynamic	
interaction	between	cells	and	their	physical	environment(18).	When	fibroblasts	
are	cultured	within	an	extracellular	matrix	eg	fibrin	as	 is	planned	in	this	work	
they	 experience	 a	 richer,	 more	 complex	 physical	 environment	 and	 different	
geometry	 than	 cells	 on	 2D	 surfaces.	 Cells	 do	 not	 only	 migrate	 but	 work	 to	
remodel	 the	matrix.	The	mechanical	signals	 from	the	remodelled	matrix	 then	
feedback	to	influence	the	phenotype	of	the	cell(19).		
	 41	
The	role	of	keratinocytes	and	Fibroblasts	in	wound	healing	
Wound	healing	can	be	divided	into	different	phases	based	on	the	time	from	
injury.	Initially	there	is	haemostasis	where	a	clot	is	formed.	This	clot	is	
composed	of	both	platelets	and	fibrin.	The	fibrin	serves	also	as	a	meshwork	to	
direct	the	movement	of	fibroblasts	into	the	wound.	The	inflammatory	phase	is	
next	where	the	main	cell,	the	macrophage	releases	chemoattractant	like	basic	
fibroblast	growth	factor,	IL6,	TNF	alpha	to	attract	other	inflammatory	cells	to	
the	wound	but	also	to	encourage	the	migration	of	fibroblasts	into	the	
wound(20).	Following	this	the	proliferative	phase	sets	in,	where	fibroblasts	
produce	not	only	collagen	but	extracellular	matrix	proteins	and	secrete	factors	
to	attract	keratinocytes	into	the	wound.	This	then	becomes	a	feedback	loop	
where	migrating	keratinocytes	stimulate	the	increased	activity	of	fibroblasts	
and	vice	versa.	This	continues	until	the	remodelling	phase	which	starts	from	
week	6	and	can	last	until	18	months.	Here	type	III	collagen	is	remodelled	to	
type	1	with	no	net	increase	in	the	quantity	of	collagen	in	the	wound.	The	
keratinocytes	would	have	established	a	waterproof	epidermal	layer.	It	is	
important	to	note	that	these	phases	and	cells	accompanying	are	not	mutually	
exclusive	but	occur	in	a	continuum.		
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1.2.3	Epidermal	Stem	Cell	Biology		
The	skin	continuously	renews	itself	throughout	life	as	part	of	its	role	as	a	barrier	
and	in	response	to	pathological	states	like	injury	and	degeneration.	It	is	able	to	
undertake	 this	due	 to	 the	proliferating	 cells	 that	 reside	 there.	There	are	 two	
main	types	of	proliferating	cells:	the	stem	cells	(SC)	and	the	transit	amplifying	
cells	 (TA	cells).	TA	cells	are	undifferentiated	cells	 that	can	be	 thought	of	as	a	
transition	between	SCs	and	differentiated	cells.	They	function	as	a	feedback	loop	
to	SCs,	to	drive	continued	regeneration	and	they	are	also	believed	to	influence	
other	cell	types	to	create	an	optimal	environment	for	regenerating	tissue	(21).	
Stem	cells	on	the	other	hand	are	undifferentiated	cells	with	a	capacity	for	self-
renewal	 and	 differentiation	 into	 multiple	 lineages(22).	 They	 receive	 their	
regulatory	cues	from	neighbouring	cells	within	a	defined	and	tightly	controlled	
local	microenvironment	called	the	stem	cell	niche	(SC	niche).	Some	of	the	cells	
that	constitute	the	niche	are	differentiated	daughter	cells	of	the	stem	cells	and	
provide	feedback	regulation	to	their	parent	SCs.		
Stem	cells	within	adult	skin	are	known	to	be	concentrated	in	a	few	distinct	areas.		
The	first	area	is	the	bulge	area	around	the	pilosebaceous	unit	and	the	second	is	
the	interfollicullar	epidermis	(areas	of	the	epidermis	that	is	located	between	the	
exit	of	the	hair	follicle	from	the	dermis	through	the	epidermis	onto	the	surface	
of	 the	 skin)(23).	 The	 stem	 cells	 that	 reside	 in	 these	 two	 areas	 have	 distinct	
functions	and	reside	in	different	microenvironments	or	niches	that	determine	
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and	 regulate	 much	 of	 their	 activity.	 The	 interfollicular	 stem	 cells	 contain	
progenitor	cells	that	ensures	cell	renewal	in	the	absence	of	injury.	This	is	a	key	
feature	of	the	self-renewing	capacity	of	the	epidermis.	Studies	on	the	progenitor	
cells	in	the	interfollicular	epidermis	demonstrate	that	the	epidermis	undulates	
to	form	deep	epidermal	ridges	called	rete	ridges	that	extend	into	the	dermis.	
One	 function	 of	 the	 rete	 ridges	 is	 to	 anchor	 the	 epidermis	 to	 the	 dermis,	
however	it	also	serves	to	create	a	microenvironment	for	the	IFE	stem	cells	at	the	
base	of	the	ridges.	This	is	a	more	protected	site	than	other	areas	of	the	IFE(12).	
The	 stem	 cells	 that	 reside	 in	 the	 rete	 ridges	 have	 been	 investigated	 using	
cultured	human	interfollicular	keratinocytes	which	have	determined	that	cells	
expressing	 the	 highest	 level	 of	 ß	 integrins	 have	 the	 highest	 proliferative	
potential	in	vitro(24).	These	so	called	ß1	bright	cells	are	found	especially	in	the	
basal	 layers	 of	 the	 epidermis	 in	 clusters(25)	 and	 at	 the	 base	 of	 the	 deepest	
epidermal	ridges	of	palmoplantar	skin	
The	bulge	area	around	the	pilosebaceous	unit	contains	multipotent	stem	cells	
that	are	activated	primarily	upon	cutaneous	wounding.	They	provide	cells	 for	
hair	follicle	regeneration	and	repair	of	the	epidermis.	There	are	various	methods	
and	markers	published	to	isolate	and	potentially	label	epidermal	stem	cells.	In	
vivo	stem	cells	express	higher	levels	of	integrins	than	TA	cells(25).	Conjugated	
antibodies	 against	 integrin	 and	 anti-CD71	 have	 been	 used	 to	 indicate	 the	
	 44	
location	of	stem	cells	in	the	epidermis	by	some	groups(26).	Other	markers	found	
to	be	increased	in	the	stem	cell	population	of	the	epidermis	include	S100A4	and	
S100A6	proteins(27),	K19(28),	K15(29)	and	CD34(30).	Although	most	of	 these	
antibodies	are	not	useful	 in	proving	isolated	stem	cells	by	flow	cytometry	the	
CD34	antibody	seems	to	be	an	exception(23).		
	
	
1.2.4	The	concept	of		Skin	Explants	being	used	to	regenerate	an	epidermis	
	
The	 work	 in	 this	 thesis	 investigates	 the	 use	 of	 skin	 explants	 as	 a	 source	 of	
fibroblasts	and	keratinocytes	as	opposed	to	using	isolated	laboratory	cultured	
cells	 to	 populate	 the	 electrospun	 scaffolds.	 Skin	 explants	 are	 small	 squares	
(5x5mm2)	of	skin	containing	both	epidermis	and	dermis,	devoid	of	subcutaneous	
fat.	We	aim	to	encourage	 fibroblast	and	keratinocyte	proliferation	by	placing	
explants	onto	electrospun	scaffolds.		
This	method	of	expanding	fibroblasts	for	culture	in	the	laboratory	is	supported	
from	the	literature	as	it	is	a	commonly	used	technique	for	establishing	fibroblast	
culture(31).	 Traditional	methods	 of	 fibroblast	 culture	 consisted	 of	 using	 skin	
biopsy	pieces	placed	 in	a	tissue	culture	flask.	This	 is	then	covered	with	a	thin	
layer	of	medium.	The	media	is	changed	periodically	until	the	fibroblasts	migrate	
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out	of	the	biopsy	and	divide	to	cover	the	bottom	of	the	flask	with	a	confluent	
monolayer	of	cells.	This	method	of	fibroblast	explant	culture	has	the	advantage	
over	enzymatic	processes	in	that	there	is	reproducibility	of	the	technique	from	
small	amounts	of	tissue,	it	is	technically	a	simpler	approach	versus	culture	with	
enzymes	and	the	effect	on	cells(31).	Enzymatic	treatments	have	the	problems	
of	over	digestion,	reduction	of	cell	viability	and	subsequent	poor	attachment	of	
cells	 when	 not	 handled	 properly.	 	 There	 are	 no	 recommendations	 in	 the	
literature	on	the	size	that	the	pieces	need	to	be,	some	groups	have	used	a	4mm	
human	 skin	 biopsy	 which	 presumably	 reflects	 a	 common	 size	 of	 skin	 punch	
biopsies	that	are	used	in	the	clinic	for	diagnostic	purposes(31).		
	
1.3	The	clinical	need	for	skin	replacement		
 
Historically	 a	 large	 portion	 of	 reconstructive	 surgery	 consists	 of	 autologous	
tissue	rearrangement	to	fill	defects	most	commonly	involving	soft	tissues	and	
skin,	 singularly	or	 in	 combination.	The	advancement	 in	 the	knowledge	of	 the	
vascular	 anatomy	 of	 the	 skin	 and	 the	 evolution	 of	 perforator	 flaps	 have	
decreased	 the	 morbidity	 that	 was	 associated	 with	 the	 original	 concept	 of	
robbing	 Peter	 to	 pay	 Paul.	 Here,	 skin	 and	 subcutaneous	 tissue	 or	 muscle	 if	
required	can	be	isolated	on	its	vascular	supply,	thereby	ensuring	its	viability.	This	
refinement	has	 led	 to	only	 taking	what	only	 is	 required,	which	 results	 in	 less	
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donor	 morbidity.	 For	 example,	 the	 workhorse	 abdominal	 flap	 has	 seen	 an	
evolution	 from	 using	 all	 of	 the	muscle	 of	 the	 abdominal	 wall	 which	 lead	 to	
hernias	to	now	only	using	the	skin	and	fat	which	has	a	quicker	recovery	and	less	
abdominal	wall	 insult.	Additionally,	 industry	has	weighed	 in	on	 this	evolution	
and	 produced	 better	 equipment	 for	 the	 microsurgical	 techniques	 that	 are	
required.	 	 As	 a	 result,	 we	 are	 now	 in	 the	 era	 where	 reconstruction	 using	
autologous	tissue	is	at	an	all-time	high,	with	improving	results	and	lower	donor	
co-morbidities.	Despite	this	competition	tissue	engineered	skin	substitutes	will	
have	a	clinical	need.	The	most	obvious	areas	are	sudden	large	areas	of	skin	loss	
due	 to	 burns,	 trauma	 or	 infection	 (necrotising	 fasciitis).	 Apart	 from	 a	 size	
limitation,	autologous	tissue	transfer	requires	optimal	conditions	for	success	for	
example	 the	 success	 of	 a	 skin	 graft	 is	 dependent	 on	 a	 non-infected,	 well	
vascularised	wound	bed	and	is	not	ideal	for	coverage	of	bare	tendon	or	bone	
devoid	of	 vascularized	periosteium	or	paratenon.	Additionally,	 recipient	 sites	
with	significant	zones	of	injury	can	result	in	unsuitable	vessels	for	microvascular	
anastomosis.	 	 In	these	situations,	biological	tissue	engineered	skin	substitutes	
can	be	a	valuable	source	of	skin	cover	for	the	patient.		
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1.4	Approaches	to	Skin	Reconstruction	
	
1.4.1	Introduction	
	
The	reconstructive	ladder	is	one	of	the	first	principles	learnt	in	Plastic	Surgery	
with	respect	to	skin	wound	reconstruction	and	has	been	passed	down	through	
generations	 of	 surgeons	 (Figure	 1.3).	 Although	 it	 has	 evolved	 overtime	 its	
message	remains	the	same:	a	logical	progression	of	the	surgical	approaches	that	
can	be	utilized	in	wound	healing.	The	earliest	descriptions	start	with	healing	via	
secondary	 intention	 (leaving	 a	 wound	 to	 granulate	 and	 ultimately	 heal	 with	
simple	dressings),	followed	by	direct	closure	with	sutures,	skin	grafts	and	flaps.	
A	flap	is	the	transfer	of	tissue	on	the	basis	of	its	vascular	anatomy	from	one	part	
of	 the	 body	 to	 another.	 It	 can	 consist	 of	 almost	 any	 tissue	 type,	 the	 most	
common	ones	being	skin,	skin	and	fascia,	skin	and	muscle	or	skin,	muscle	and	
bone.	 They	 have	 evolved	 significantly	 over	 the	 years	 in	 parallel	 with	 the	
increasing	knowledge	of	the	intricate	vasculature	to	the	skin.	Vascularization	is	
a	key	principle	 in	plastic	 surgery	as	 tissue	 reconstruction,	be	 it	autologous	or	
from	other	sources,	survives	by	the	establishment	of	a	good	blood	supply	in	a	
timely	 fashion.	 As	 a	 result	 the	 reconstructive	 ladder	 has	 been	 modified	
throughout	the	years	to	reflect	the	advances	in	technology	that	the	speciality	
has	adopted	for	example	advancement	in	microscope	technology	that	aids		free	
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tissue	 transfer(9).	 We	 are	 now	 choosing	 the	 most	 appropriate	 form	 of	
reconstruction	for	the	patient,	given	the	anatomy	of	the	wound	and	physiology	
of	the	patient	and	can	use	techniques	from	any	level	eg	free	tissue	transfer	is	a	
common	first	choice	technique	for	lower	limb	trauma	defects	as	opposed	to	the	
simplest	 option	 before	 moving	 to	 the	 next	 stage.	 The	 reconstructive	 ladder	
however	 despite	 its	 many	 modifications	 has	 not	 reflected	 the	 advances	 in	
wound	 healing,	 specifically	 the	 development	 and	 widespread	 use	 of	 dermal	
matrices.	 Dermal	matrices	 are	 dermal	 substitutes	 that	 are	 FDA	 approved	 for	
wound	cover.	Furthermore,	the	potential	contribution	that	tissue	engineering	
of	 skin	and	other	 tissues	 can	make	 to	 reconstruction	cannot	be	 ignored.	The	
principle	 being	 to	 use	 biodegradable,	 synthetic	 polymers	 as	 scaffolds	 to	 aid	
tissue	regeneration.	Over	time	these	products	degrade	at	a	controlled	rate	and	
leave	behind	the	patient’s	own	tissue.	Therefore,	we	propose	another	addition	
to	this	reconstructive	ladder:	biomaterials.	This	can	be	thought	of	as	biological	
(consisting	 of	 components	 of	 human	 or	 animal	 origin)	 or	 synthetic.	 This	 will	
facilitate	incorporation	of	these	products	as	routine	in	the	clinical	environment	
thereby	 increasing	 the	 choice	 that	 is	 given	 to	patients	with	 regard	 to	wound	
reconstruction,	and	at	the	same	time	embracing	the	advances	in	the	evolving	
field	of	tissue	engineering.	
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Figure	1.3:	Reconstructive	Approaches	in	Plastic	Surgery.	A:	An	early	version	of	
the	reconstructive	ladder.	Reproduced	with	permission	from	Elsevier.	Janis	JE,	
Kwon	RK,	Attinger	CE.	The	new	reconstructive	ladder:	modifications	to	the	
traditional	model.	Plast	Reconstr	Surg.	2011	Jan;	127	Suppl	1:205S-212S		
	
1.4.2	Current	Clinical	Approach	to	Reconstruction	in	Burns		
	
A	burn	injury	depending	on	the	size	is	one	of	the	very	few	situations	where	a	
patient	can	lose	a	lot	of	skin	in	a	short	space	of	time	to	the	extent	that	wound	
coverage	 becomes	 a	 lifesaving	 procedure	 after	 the	 patient	 has	 been	
resuscitated.	Other	situations	where	this	can	occur	are	necrotizing	fasciitis	and	
Steven	Johnsons	Syndrome.	The	decision	of	how	to	reconstruct	a	burn	wound	
in	the	acute	setting	is	centred	on	the	size	of	the	affected	area,	the	depth	of	the	
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burn	and	patient	factors	 like	underlying	physiology	and	co-morbidities.	 In	the	
chronic	setting	reconstructions	are	functional	addressing	scar	contractures	that	
result	from	healing	of	full	thickness	burns	or	the	effect	of	using	of	split	thickness	
skin	 grafts.	 Historically	 burn	 wounds	 were	 medically	 managed	 with	 topical	
therapies	applied	to	the	burn	eschar(32).	In	partial	thickness	burns	this	worked	
as,	regeneration	occurs	from	the	dermal	appendages	that	are	left	behand.	In	full	
thickness	 burns,	 once	 the	 eschar	 separates	 from	 the	 underlying	 wound	 bed	
there	 is	was	a	bed	of	 vascularized	granulation	 tissue	 suitable	 for	 subsequent	
grafting.	This	posed	morbidities	such	as	prolonged	wound	healing	 time,	pain,	
hypertrophic	scarring	and	contractures.	The	only	advantage	here	was	that	there	
was	 a	 clearer	 ability	 to	distinguish	between	 viable	 skin	 that	 those	 areas	 that	
would	require	grafting.	This	decision	can	be	challenging	in	the	early	stages	of	a	
burn	as	the	appearance	evolves	based	on	the	first	aid	received,	depth	of	burn	
and	level	of	fluid	resuscitation	performed	if	applicable.	Early	excision	and	skin	
grafting	 of	 smaller	 burns	 was	 described	 first	 in	 1891	 by	 Lusgarten(33).	 This	
principle	 was	 increasingly	 adopted	 by	 other	 groups	 with	 variable	
outcomes(34),(35).	It	was	only	in	1981	when	Janzekovic	reported	good	surgical	
outcomes	 that	 it	 became	 part	 of	 the	 routine	 practice	 amongst	 surgeons	
worldwide(36).	With	any	burn	in	the	acute	setting	the	immediate	management	
is	centred	on	first	aid,	assessment	and	fluid	resuscitation	only	if	the	burn	is	more	
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than	10%	total	body	surface	area	(TBSA)	 in	a	child	and	15%	TBSA	in	an	adult.	
Once	the	patient	is	stable,	the	next	step	is	to	decide	the	overall	management	of	
the	burn.	This	usually	fits	into:	immediate	excision	(obvious	full	thickness	based	
on	 clinical	 assessment	 and	 mechanism	 of	 injury),	 initial	 conservative	
management	using	dressings	under	 close	 supervision	with	a	 view	 to	possible	
excision	within	two	weeks	(mixed	depth	burns)	and	conservative	management	
(partial	thickness	burns).	With	regards	to	surgical	management,	the	approach	
taken	is	dependent	on	the	size	of	the	burn	and	the	aim	of	the	excision.	In	burns	
that	are	<20%	TBSA,	excision	occurs	on	planned	burns	trauma	lists.	These	burns	
are	 often	 reconstructed	 with	 autologous	 split	 thickness	 grafts	 or	 dermal	
regenerative	templates	depending	on	the	site	of	the	wound.	Larger	burns	(>20%	
to	 50%	 TBSA)	 undergo	 as	much	 excision	 as	 possible	 and	 reconstruction	with	
widely	 meshed	 split	 skin	 graft	 or	 in	 some	 cases	 cadaveric	 skin	 (as	 will	 be	
discussed	subsequently)	if	there	is	insufficient	autologous	skin	graft	to	be	used.	
These	patients	often	require	multiple	visits	 to	 theatre	as	not	all	areas	maybe	
excised	at	the	same	time	depending	on	the	availability	of	autologous	skin.	With	
larger	burns	(TBSA	>50%),	the	aim	of	excision	shifts	to	survival.		
The	 principle	 here	 is	 that	 by	 removing	 large	 quantities	 of	 eschar,	 there	 is	 a	
reduction	 in	bacteraemia,	 endotoxin	production	and	 release	of	 inflammatory	
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mediators.	This	would	decrease	the	chances	of	sepsis	and	multi-organ	failure	
which	are	the	leading	cause	of	death	in	major	burn	injuries(37).		
The	amount	of	skin	excised	in	a	session	is	guided	by	the	evolving	physiology	of	
the	 patient	 during	 the	 procedure.	 Furthermore,	 with	 larger	 burns	 that	 are	
predominantly	 full	 thickness,	 the	 excision	 changes	 from	 tangential	 (layer	 by	
layer	excision	of	non	-viable	skin	until	healthy	subcutaneous	tissue	is	seen	that	
is	graftable)	to	fascial.	Fascial	excision,	where	all	the	tissue	(skin	subcutaneous	
fat)	is	removed	en	block,	has	the	advantage	of	being	quicker	with	less	blood	loss	
than	tangential	excision.	The	amount	of	skin	excised	and	the	type	of	excision	
undertaken	 influences	 the	 reconstructive	 procedure	 and	 ultimately	 the	
outcome.	The	gold	standard	 in	 large	burns	 is	 resurfacing	as	much	as	possible	
with	autologous	split	thickness	skin	grafting.	 It	 is	often	meshed,	which	means	
that	 it	 is	passed	through	a	machine	that	makes	even	perforations	throughout	
the	skin	sheet	to	increase	its	surface	area	and	ability	to	contour	around	curves	(	
looks	like	a	net).	The	mesh	ratio	can	be	increased	to	amplify	the	yield	however	
outcomes	 such	 as	 delayed	 wound	 healing,	 pain	 and	 contracture	 increase	
exponentially.	 Commonly	 used	 ratios	 are	 1:2,	 1:4	 and	 1:6	 for	 major	 burns.	
Another	 option	 in	 this	 setting	 is	 the	 use	 of	 cadaver	 skin.	 This	 provides	 an	
immediate	barrier	that	prevents	evaporative	and	thermal	losses	and	allows	the	
patient	 to	stabilize,	 regenerate	used	donor	sites.	A	 return	 to	 theatre	about	3	
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weeks	 later	 is	 undertaken	 to	 remove	 the	 cadaver	 skin	 and	 graft	 onto	 the	
underlying	wound	bed.		
In	 the	 long	 term	 setting	 surgical	 intervention	 is	 centred	on	 scar	 revision	 and	
contracture	release.	Early	excision	is	proposed	as	a	technique	to	circumvent	this	
and	the	Burns	multidisciplinary	team	is	established	to	optimize	patient	care.	This	
can	 have	 a	 profound	 effect	 on	 scar	 outcome;	 however,	 there	 will	 be	 some	
patients	 that	 present	 with	 hypertrophic,	 pigment	 -variable	 scars	 and	
contractures	in	reconstructed	areas.		
Contractures	usually	arise	because	of	a	deficit	of	skin	and	surgery	is	designed	to	
replace	that	deficit.	The	two	main	decision	making	points	at	this	stage	rely	on	
whether	local	skin	is	suitable.	Skin	and	subcutaneous	fat	can	be	imported	either	
from	a	distant	area	in	the	body	using	regional	pedicled	flaps	(tissue	containing	
normal	skin	and	fat,	free	of	contracture	but	comes	with	its	own	blood	supply)	or	
free	tissue	transfer	(skin	and	fat	free	of	contracture	but	has	to	establish	its	own	
blood	supply	via	microanastamosis	of	veins	and	arteries	at	the	site	of	the	skin	
deficit).	 Additionally,	 skin	 can	 be	 imported	 by	 using	 dermal	 regenerative	
templates.	The	general	consensus	is	that,	if	possible	full	thickness	grafts	or	flaps	
are	 the	 best	 options	 if	 available.	 This	 is	 because	 split	 skin	 grafts	 and	 dermal	
substitutes	have	a	significant	amount	of	secondary	contracture	compared	to	full	
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thickness	 grafts	 and	 flaps.	 Furthermore,	 they	 require	more	aftercare	 (splints,	
physiotherapy	and	pressure	garment	use)	and	revisional	surgery	later	on.		
Full	thickness	grafts	are	used	for	moderate	sized	defects	following	contracture	
release.	Large	donor	sites	can	be	obtained	provided	that	these	are	burn	free.	
For	 example,	 the	 abdomen	 can	 provide	 large	 quantities	 of	 skin	 (depends	 on	
patient	 size	 and	 abdominal	 excess)	 via	 various	 transverse	 lower	 abdominal	
incisions	and	also	performing	an	abdominoplasty	(removal	of	excess	skin	and	fat	
from	the	abdomen	en	bloc).	Other	sites	like	post	auricular	and	supraclavicular	
skin	can	provide	small	amounts	of	skin	(<0.5%	TBSA)	but	good	colour	matching	
to	the	head	and	neck	area.	As	a	rule,	any	site	of	skin	laxity	that	can	be	closed	
directly	can	be	the	donor	site	of	the	full	thickness	graft	and	can	utilize	aesthetic	
techniques	to	obtain	skin.	These	include	offering	the	patient	a	breast	reduction	
or	 a	 mastopexy	 (breast	 lift)	 (females	 only	 and	 males	 with	 gynecomastia	 or	
enlarged	breasts).	These	procedures	often	result	in	large	quantities	of	skin	and	
subcutaneous	fat	that	are	not	needed	by	the	patient.	Therefore,	full	thickness	
grafts	 in	 these	 settings	 are	 large,	 require	 careful	 handling	 and	 removal	 of	 as	
much	subcutaneous	fat	as	possible	to	ensure	successful	graft	take.		
Flaps	are	another	source	of	excellent	skin	and	subcutaneous	tissue	to	resurface	
scars	and	contractures.	Local	flaps	if	suitable	tissue	exists	are	the	ideal	method	
of	 reconstruction	 as	 it	 provides	 good	 colour	 and	 texture	 match	 and	 little	
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aftercare.	However,	these	are	limited	depending	on	the	site	and	size	of	the	skin	
defect	 resulting	 from	 the	 contracture	 release.	 Furthermore,	 even	 if	 suitable	
tissue	 exists	 they	 maybe	 bulky	 as	 flaps	 may	 have	 variable	 amounts	 of	
subcutaneous	tissue	compared	to	the	wound	bed	of	the	contracture	release.		
Free	tissue	transfer	has	become	quite	popular	as	a	method	of	reconstruction	for	
contracture	release	due	to	advances	in	microscope	and	equipment	technology	
and	greater	understanding	about	the	vascular	anatomy	of	the	skin.	Free	flaps	
however	are	reserved	for	complex	and	difficult	areas	like	the	head	and	neck	area	
and	the	upper	and	lower	limb.	The	recipient	vessels	must	be	free	of	burn	injury,	
as	the	flap	would	simply	fail	which	would	lead	to	significant	morbidity	for	the	
patient.	Colour	and	contour	matching	are	challenging	as	in	principle	the	free	flap	
transfer	dictates	that	it	can	be	taken	from	any	suitable	area	in	the	body	distant	
to	the	skin	deficit	site.		
	
1.4.3	Skin	Grafting			
	
1.4.3.1	History		
	
Skin	 grafting,	 one	 of	 the	 oldest	 and	 most	 common	 techniques	 used	 in	 skin	
reconstruction	dates	back	to	1500	BC	(38).	It	was	modified	and	gained	popularity	
in	Europe	during	the	late	1800s.	Pinch	grafting	developed	by	Reverdin	involved	
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placing	1mm	square	pieces	of	epidermis	on	the	granulating	tissues	 leading	to	
rapid	 re-epithelization	 of	 wounds(39).	 This	 technique	 was	 associated	 with	
significant	 contracture	and	 therefore	 led	 to	 the	use	of	 strips	of	 tissue	placed	
close	 together	 containing	 both	 epidermis	 and	 dermis	 resulting	 in	 better	
outcomes	in	terms	of	time	to	wound	healing	and	scar	contracture.	This	was	the	
main	method	of	skin	grafting	used	in	Europe	until	the	1940s(40).	At	this	time,	
the	evolution	of	how	skin	grafts	needed	to	be	optimized	for	successful	take	was	
investigated.	It	was	determined	at	this	time	that	grafts	with	thinner	dermis	are	
better	suited	for	coverage	of	granulating	wound	bases	as	opposed	to	recipient	
areas	that	subjected	to	trauma	and	where	it	was	necessary	to	avoid	contractures	
like	over	the	flexor	surface	of	a	joint.	Grafts	were	therefore	classified	according	
to	their	dermal	thickness	(Table1)(41).	This	classification	on	dermal	thickness	for	
split	thickness	grafts	was	discussed	in	one	of	the	investigative	chapters	in	this	
thesis,	as	we	wanted	to	determine	the	effect	of	cellular	migration	from	the	cut	
edges	of	 the	split	 thickness	skin	explants.	Following	 this,	 surgeons	wanted	 to	
standardize	the	method	of	harvesting	grafts	so	as	to	get	a	fixed	proportion	of	
dermis	 needed	 for	 a	 particular	 application.	 This	 lead	 to	 the	 evolution	 of	 the	
various	instruments	used	to	harvest	a	graft.	In	the	late	19th	and	20th	centuries	
the	Humby	knife	was	used	however	dermal	thickness	was	still	not	reproducible	
using	 this	 technique(42).	 The	 dermatome	 was	 then	 developed,	 which	 was	
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initially	manual,	relying	on	a	rotating	blade	fixed	to	a	drum.	This	harvested	skin	
of	uniform	thickness	however	the		graft	tended	to	separate	from	the	drum(43).	
It	was	then	refined	and	the	air	powered	dermatome	was	developed,	which	is	
currently	 the	most	widely	 adopted	 instrument	 in	 harvesting	 a	 split	 thickness	
graft	containing	a	consistent	amount	of	dermis(44).		
After	refinements	were	made	in	harvesting	grafts,	there	was	focus	on	the	best	
method	to	expand	them.	It	was	known	that	grafts	could	be	expanded	to	cover	
large	areas	without	compromising	re-epithelization	if	done	in	the	correct	ratio.	
Furthermore,	 expansion	 revolutionized	 the	 treatment	of	major	burns,	 as	 less	
donor	 sites	were	 needed	 to	 treat	 a	 given	 surface	 area	 of	 burn.	 Additionally,	
expanded	 grafts	 contour	 curves	 easier	 and	 the	 spaces	 in	 between	 the	 grafts	
allow	 for	 the	 extrusion	 of	 blood	 and	 tissue	 fluid	 that	 can	 collect	 under	 an	
unexpanded	 graft	 lifting	 it	 from	 the	 wound	 bed	 and	 resulting	 in	 a	 failed	
application.		
Category		 Standardized	thickness	inch;	mm		
Thiersch	 (	 epithelial	 layer	 only-	
rarely	achieved)	
0.008-0.010;	0.2-0.025	
STSGs	 0.012-0.106;	0.3-0.4	
Three	quarter	skin	grafts	 0.018-0.022;	0.45-0.55	
Full	thickness	skin	grafts	 0.030-0.038;	0.75-0.95	
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Table	1:	Initial	classifications	of	thickness	of	skin	grafts	(41).		
1.4.3.2	Meek	Grafting		
	
In	 1958,	 Meek	 an	 American	 Surgeon	 proposed	 the	 development	 of	 a	
dermatome	 that	 allowed	 a	 1	 inch	 square	 of	 skin	 to	 be	 cut	 into	 256	 square	
pieces(45).	Meek	theorized	that	wound	re-epithelization	occurred	from	the	cut	
edges	 of	 the	 small	 squares	 of	 split	 thickness	 skin	 grafts	 therefore	 increasing	
these	 edges	 by	 increasing	 the	 surface	 area	 resulted	 more	 rapid	 wound	 re-
epithelization	rather	than	using	one	large	square.	The	graft	squares	were	placed	
on	prefolded	gauze	to	achieve	an	even	distribution.	This	technique	had	several	
advantages	in	that	there	were	high	rates	of	successful	take	and	the	expansion	
ratio	was	 true	 to	 the	number	desired	 (eg	a	1:4	 ratio	was	actually	1:4)	as	 the	
squares	were	totally	separated	from	each	other	whereas	in	meshed/net	grafts	
the	ratio	is	user	dependent	on	the	amount	of	stretch	applied.	Moreover,	small	
graft	remnants	are	utilized	and	there	is	no	wastage.	As	a	result	there	have	been	
successful	reports	of	its	use	in	the	management	of	major	burns(46)	however	it	
did	not	gain	popularity	in	Burn	Units	in	the	Western	world	as	the	dermatome	
itself	was	expensive	at	that	time,	but	more	so	it	was	labour	intensive	as	each	
skin	 graft	 square	 needed	 to	 be	 placed	 dermis	 side	 down	 (Figure	 1.4a).	 This	
technique	is	not	practical	for	large	burns	where	time	is	a	limiting	factor	in	the	
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initial	 excision	and	 reconstruction.	Over	 the	 years	many	modifications	 to	 the	
Meek	 technique	 have	 been	 explored	 (Figure	 1.4b)	 and	 good	 outcomes	 have	
been	reported	in	the	literature	with	regards	to	time	to	wound	re-epithelization	
leading	to	a	resurgence	 in	 its	usage	(Figure	1.5)(47),(48),(49).	This	principle	of	
keratinocyte	 migration	 in	 Meek	 Grafting	 can	 be	 used	 to	 populate	 the	 skin	
substitute	 with	 a	 patient’s	 own	 cells	 via	 small	 split	 thickness	 skin	 explants	
thereby	 negating	 the	 need	 to	 use	 a	 split	 skin	 graft	 and	 laboratory-expanded	
cells,	which	in	itself	is	associated	with	a	high	cost,	technical	expertise	and	the	
use	of	a	clean	room	environment	which	is	highly	regulated	and	requires	highly	
trained	staff.		Hopefully	this	will	give	the	proposed	construct	the	flexibility	that	
is	required	in	a	dynamic	and	unpredictable	clinical	environment.	
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Figure	1.4:	Meek	Dermatomes.	A:	Original	version	reproduced	with	Permission	
from	 Elsevier.	MEEK	 CP.	 Successful	microdermagrafting	 using	 the	Meek-Wall	
microdermatome.	 Am	 J	 Surg.	 1958	 Oct;	 96(4):	 557-8.	 B:	 Modified	 Meek	
Dermatome	in	current	use.	Reproduced	with	permission	from	Elsevier.	Hsieh	CS,	
Schuong	JY,	Huang	WS,	Huang	TT.	Five	years'	experience	of	the	modified	Meek	
technique	in	the	management	of	extensive	burns.	Burns.	2008	May;	34(3):	350-
4.	
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Figure	1.5:	Method	of	modified	meek	grafting	in	practice.	A:	Grafts	harvested	as	
small	postage	stamped	squares,	laid	onto	gauze;	B:	Application	of	the	graft	onto	
a	debrided	leg	wound;	C:	Graft	check	at	10	days;	D	Long	term	outcome	of	healed	
wound	that	was	treated	with	Meek	Grafting.	Reproduced	with	permission	from	
Elsevier.	Hsieh	CS,	Schuong	JY,	Huang	WS,	Huang	TT.	Five	years'	experience	of	
the	modified	Meek	 technique	 in	 the	management	 of	 extensive	 burns.	 Burns.	
2008	May;	34(3):	350-4.	
	
	
1.4.3.3	Meshed	Grafting		
 
The	main	method	 for	 graft	 expansion	 that	 is	 the	most	 widely	 accepted	 and	
currently	used	in	the	United	Kingdom	was	developed	by	Tanner	in	1964(50).	This	
is	known	as	a	meshed	graft	and	can	achieve	in	theory	ratios	of	expansion	from	
1:1.5	to	1:6.		They	work	well	because	they	have	high	rates	of	take	compared	to	
unmeshed	 grafts,	 they	 allow	 for	 drainage	 and	 are	more	 flexible	when	 being	
A 
C 
B 
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draped	over	areas	with	contours.	The	major	disadvantage	however	is	that	they	
leave	behind	a	 scar	 that	 is	well	 healed	with	 a	net	 like	pattern.	 This	makes	 it	
significantly	cosmetically	inferior	to	a	sheet	(not	meshed)	graft.	Therefore,	many	
patients	opt	for	serial	excision	of	the	meshed	graft	once	healed	if	possible,	which	
leaves	them	with	a	fine	linear	scar.		
	
	1.5			A	review	of	skin	substitutes		
	
1.5.1	Properties	of	an	ideal	skin	substitute	and	current	uptake	of	skin	
substitutes	in	the	United	Kingdom.		
	
Any	model,	which	aims	to	replace	skin,	should	replicate	not	only	the	anatomy	
but	also	 the	physiology	of	 the	organ.	 In	 this	 respect	 skin	 substitutes	need	 to	
possess	 essential	 properties	 for	 them	 to	 be	 used.	 All	 substitutes	 need	 to	 be	
nontoxic,	biocompatible,	non-immunogenic	and	pathogen	free.	Most	biological	
skin	substitutes	have	products	of	animal	origin	eg	bovine	and	porcine.	Although	
disease	transmission	is	rare,	the	advances	in	synthetic	biocompatible	materials	
should	mean	that	we	do	not	have	to	rely	on	animal	based	products.	Efficiency	
of	a	skin	substitute	means	that	they	should	work	and	the	outcome	should	be	
predictable	within	the	realms	of	obvious	known	complications.	This	allows	the	
surgeon	 to	 accurately	 inform	 the	 patient	 about	 the	 product	 in	 order	 to	 gain	
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informed	consent.	Other	desirable	properties	include	reasonable	cost,	long	shelf	
life,	being	readily	available	and	ease	of	handling.	Furthermore,	a	product	being	
off	 the	 shelf	 that	 is	 easy	 to	 use	 are	 also	 desirable	 properties.	 Current	
biomaterials	 are	 not	 infection	 resistant	 and	 are	 actually	more	 susceptible	 to	
infection	than	autologous	skin.	A	study	by	Bargues	et	al(51),	demonstrated	that	
the	popularly	used	 Integra,	was	associated	with	a	42%	 infection	 rate	 in	 their	
series	 which	 was	 higher	 than	 others	 (52).	 They	 reasoned	 that	 delayed	
application	is	a	likely	causative	factor	as	the	most	common	organisms	cultured	
were	Staphylococcus	Aureus	and	Pseudomonas	(51).	Although	this	can	happen	
with	 autologous	 skin	 grafting,	 the	 studies	 performed	 are	 not	 methodically	
robust	 to	definitively	associate	 the	use	of	 Integra	with	an	 increased	 infection	
rate	with	Integra	being	the	causative	factor.	Furthermore,	as	infection	post	skin	
coverage	is	a	multifactorial	process,	it	is	challenging	to	define	which	aspect	of	
the	material	(properties	of	the	material	itself	or	its	application)	are	responsible	
for	this.	
Another	area	that	is	lacking	in	the	current	stock	of	skin	substitutes	is	the		paucity	
of	 composite	 skin	 substitutes	 to	 offset	 the	 need	 to	 use	 either	 laboratory	
expanded	cells	or	thin	split	skin	grafts	on	a	dermal	scaffold.	The	most	commonly	
used	biological	scaffolds	are	dermal	in	origin	which	then	needs	to	be	populated	
with	epithelial	cells.	This	often	requires	planning	and	another	operation.	As	a	
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result,	 it	 was	 felt	 that	 skin	 substitutes	 consisting	 of	 dermal	 and	 epidermal	
components	in	one	sitting,	would	be	a	more	time	effective	approach	to	augment	
wound	 healing.	 An	 example	 of	 this	 is	 Apligraft	 (discussed	 below),	 which	 is	
marketed	for	smaller	wounds	and	limb	ulcers.		
Some	skin	substitutes	require	a	patient	biopsy	to	culture	and	expand	cells	that	
are	then	laid	onto	a	scaffold	or	carrier.		This	means	that	the	product	needs	to	be	
used	within	a	very	defined	and	narrow	timescale,	which	may	not	be	possible	if	
the	patient	is	unfit	for	theatre	at	that	point	in	time.	Furthermore,	purely	dermal	
analogues	 still	 require	a	 split	 skin	graft	 albeit	 a	 thinner	one	but	 this	 requires	
another	trip	to	theatre.	Therefore,	the	ideal	material	would	be	safe,	effective	in	
replacing	 skin	and	have	 reproducible	and	predictable	behaviour	when	placed	
onto	a	wound	bed.	Ideally	it	should	be	free	of	animal	products	and	not	require	
a	clean	room	in	a	laboratory	for	expansion	of	cells	as	this	increases	expense	and	
expertise	required	for	production	of	the	skin.		
	
1.5.2	Skin	Substitutes	in	Current	Clinical	Use		
	
This	has	been	part	of	the	armamentarium	of	the	reconstructive	surgeon	for	over	
three	decades.	They	can	be	divided	into	either	temporary	or	permanent	and	can	
be	further	classified	into	epidermal,	dermal	and	composite	replacements.	There	
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are	a	few	staples	that	have	become	a	permanent	feature	of	theatre	stock	lists,	
despite	 their	 limitations,	 as	 their	 results	 are	 reproducible	 and	 undoubtedly	
beneficial	to	the	patient.	A	survey	conducted	by	Dunne	et	al	in	2015	across	14	
Burns	 in	 the	 UK,	 Australia	 and	 New	 Zealand,	 revealed	 that	 in	 the	 Paediatric	
population,	Biobrane	(	a	temporary	skin	dressing,	discussed	subsequently	in	the	
chapter)	 is	a	popular	temporary	dressing	of	choice	(86%).	Cadaveric	skin,	two	
stage	Integra	and	Matriderm	were	also	commonly	used	in	this	population	for	
resurfacing	larger	TBSA	burns.	For	adults;	Cadaveric	skin,	two	stage	Integra	and	
Matriderm	were	popular	as	well,	with	the	uptake	of	Biobrane	(64%)	less	in	this	
population(53).		
	
1.5.3	Temporary	Skin	Substitutes			
	
Cadaveric	Skin		
One	of	the	most	commonly	used	temporary	skin	substitute	is	cadaveric	skin.	The	
first	documented	use	of	cadaveric	skin	in	covering	burn	wounds	was	in	1881	by	
Girdner	 (54).	 Cadaveric	 skin	 is	 currently	 used	 as	 a	 temporary	 dressing	 on	 a	
freshly	 excised	 burn	 wound.	 It	 prevents	 evaporative	 losses,	 improves	
thermoregulation,	decreases	bacterial	 load	 in	contaminated	wounds	and	may	
provide	dermal	 regeneration	elements,	which	can	persist	once	 it	 is	 removed.	
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There	are	two	main	types	of	cadaveric	skin	allografts	based	on	the	method	of	
processing	 and	 storage:	 cryopreserved	 and	 glycerol	 preserved(55).	 In	 the	
context	 of	 large	 total	 body	 surface	 area	 burn	 excision	 in	 the	 acute	 phase,	 it	
provides	a	stimulus	for	the	release	of	growth	factors	and	cytokines	in	the	wound	
bed.	 It	also	 increases	 the	vascularity	with	enhanced	capillary	 ingrowth	of	 the	
wound	bed.	The	take	rate	of	skin	grafts	following	application	of	cadaveric	skin	
to	prepare	the	wound	bed	can	be	as	high	as	88.4%(55).		It	can	also	be	used	as	a	
definitive	 dressing	 in	 partial	 thickness	 burns,	 which	 is	 associated	 with	 less	
painful	 dressing	 changes.	 This	 is	 particularly	 important	 in	 the	 paediatric	
population	 as	 burns	 dressing	 changes	 are	 associated	 with	 physical	 and	
psychological	distress.	Its	use	however	in	this	population	has	been	superseded	
by	 Biobrane	 which	 is	 popularly	 used	 in	 partial	 thickness	 burns.	 The	 use	 of	
allograft	cadaveric	skin	is	associated	with	a	decrease	in	infection,	fluid	and	heat	
loss,	and	pain	as	well	as	optimal	wound	bed	preparation	prior	to	application	of	
autograft(56).	
Its	main	limitation	revolves	around	donors	and	the	organization	and	funding	of	
tissue	banks	that	prepare	the	skin.	Although	allograft	is	very	much	used	in	many	
plastic	 surgery	 and	 burns	 units	 across	 the	 United	 Kingdom,	 there	 are	 still	
challenges	with	respect	to	its	supply	(57).		The	United	Kingdom	has	centralised	
their	supply	of	allograft	 in	 light	of	 the	decreasing	requirements	 to	cover	very	
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large	TBSA	burns	and	the	increasing	legal	requirements	that	need	to	be	met	in	
order	to	store	human	tissue	on	a	long	term	basis.	As	a	result	xenografts	most	
commonly	porcine	eg	E-Z	Derm®		are	often	used	as	temporary	dressings,	which	
have	 the	 advantage	 of	 low	 cost,	 prolonged	 shelf	 life,	 availability	 and	
convenience	particularly	 	when	allograft	 is	not	available	and	coverage	 is	only	
required	for	a	short	time	(58).	Furthermore	tissue	harvesting	from	the	deceased	
is	 a	 relatively	a	new	concept	 in	many	developing	 countries	as	 some	 religious	
beliefs	 can	 view	 this	 as	 mutilation	 of	 the	 body(59).	 Furthermore,	 despite	
rigorous	screening,	there	remains	the	risk	of	prion	disease	transmission.		
Having	said	this,	the	Euro	skin	bank,	established	by	that	name	in	1992,	formally	
the	 Dutch	 National	 skin	 bank,	 represents	 an	 efficient	 practice	 of	 harvesting,	
storing	 and	 providing	 glycerol	 preserved	 cadaveric	 skin(60).	 Glycerol	 is	
advantageous	 as	 it	 preserves	 the	 architecture	 of	 the	 matrix	 proteins,	 has	
antibacterial	 and	 antiviral	 properties	 and	 it	 is	 thought	 to	 diminish	
antigenicity(61).	Organization	is	the	key	to	the	skin	bank’s	success	as	it	is	hosted	
in	 its	own	 facility	 staffed	with	an	 independent	 team	of	 technicians,	 research,	
managerial	and	medical	personnel.	Additionally,	they	are	in	close	proximity	to	a	
hospital	 that	 treats	major	 burns	which	 allows	 for	 a	 feedback	mechanism	 on	
quality	control	and	assurance(60).	As	a	 result,	 the	uptake	and	use	of	glycerol	
preserved	 cadaveric	 skin	 became	 so	 popular	 in	 the	 early	 1990s,	 that	 the	
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organization	 now	 receives	 skin	 for	 preservation	 and	 storage	 from	 other	
European	Countries	to	meet	demand.	Critically,	they	have	established	their	own	
research	division	supported	financially	by	the	Dutch	burns	Foundation	to	obtain	
a	better	understanding	of	 the	properties	of	glycerol	preserved	skin	 in	wound	
healing.	 The	 centralisation	 of	 the	 skin	 bank	 in	 this	 way	 not	 only	 allows	 an	
amalgamation	 of	 expertise	 but	 benefits	 from	 an	 independent	 administration	
network	to	ensure	that	their	needs	are	met	to	upkeep	with	their	demand.			
	
Xenografts	
The	first	xenograft	to	be	used	as	a	human	skin	substitute	came	from	sheep	in	
1880	(56).	Porcine	products	are	most	widely	used	as	a	substitute	for	allograft	
due	to	the	similarities	with	human	skin.	These	 include	comparable	epidermal	
thickness,	 turnover	 and	migration,	 hair	 distribution,	 dermal	 elastin	 structure	
and	collagen	macrostructure(62)(63).		
There	are	various	preparations	that	are	available	for	clinical	use	and	the	method	
of	 preparation	 influences	 the	 structure	 and	 contents	 of	 the	 product	 that	 is	
ultimately	placed	onto	the	patient.	These	include	fresh,	fresh	frozen,	lyophilized,	
irradiated	and	aldehyde	cross-linked(64)(65).	The	fresh,	fresh	frozen,	lyophilized	
and	irradiated	forms	contain	both	epidermal	and	dermal	components,	however	
the	 aldehyde	 preparation	 results	 in	 removal	 of	 the	 epidermis	 and	 dermal	
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appendages	 leaving	behind	a	sterile	dermal	acellular	matrix	 that	can	be	used	
either	 side	 down	 and	 stored	 at	 room	 temperature(66)(67).	 Xenograft	 skin	
substitutes	are	most	commonly	used	as	a	temporary	dressing	to	aid	wound	bed	
preparation	prior	to	autograft	application	in	full	thickness	burns,	as	a	definitive	
dressing	in	partial	thickness	burns	and	donor	sites	and	in	the	treatment	of	toxic	
epidermal	necrolysis(68).	It	has	been	developed	in	an	attempt	to	meet	the	need	
to	have	a	constant	supply	of	allograft.	One	such	preparation	that	is	in	clinical	use	
is	EZ	Derm®	(Molnlycke	Health	Care,	US,	LLC,	Norcross,	GA).	This	is	an	aldehyde	
cross	linked	porcine	acellular	dermis	that	is	available	for	off	the	shelf	use	as	a	
definitive	dressing	in	partial	thickness	burns(69).	It	has	been	shown	to	reduce	
the	pain	associated	with	dressing	changes	thereby	reducing	the	need	for	them	
to	be	done	under	general	anaesthetic.	It	can	also	be	used	in	patients	who	are	
not	physiologically	fit	for	extensive	skin	reconstruction	or	in	large	burns	with	an	
autograft	shortage.	It	acts	as	a	definitive	barrier	against	evaporative	skin	losses	
and	micro-organisms	 temporarily,	 whilst	 donor	 sites	 are	 regenerating	 or	 the	
patient	is	being	physiologically	optimized	for	further	surgery.	Porcine	products	
form	 fibrin-collagen	 bonds	 with	 the	 underlying	 wound	 bed	 that	 allows	 the	
dressing	 to	 adhere	 readily.	 There	 is	 no	 vascularization	 or	 take	 in	 xenografts,	
unlike	 allograft	 which	 is	 beneficial	 in	 its	 indicated	 use	 as	 a	 temporary	
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dressing(58).	In	these	circumstances	the	dressing	is	left	in	place	until	it	separates	
from	the	underlying	healing	skin	(in	the	case	of	partial	thickness	burns).		
	
Biobrane	(UDL	Laboratories,	Rockford,	IL)	
	
Biobrane	 was	 developed	 in	 1980	 by	 Tavis(70).	 It	 has	 a	 bilaminar	 structure	
consisting	of	a	woven	nylon	membrane	coated	with	silicone	to	which	collagen	is	
chemically	bound.		It	aims	to	prevent	evaporative	fluid	losses	and	development	
of	 infection	when	used	as	a	dressing	 in	 superficial	partial	 thickness	burns.	 Its	
physical	macrostructure	 and	 collagen	 binding	 attracts	 fibrin	 and	 ingrowth	 of	
fibroblasts	from	the	underlying	wound	bed,	so	that	the	product	adheres	tightly	
to	it.	This	is	translated	in	its	use,	as	once	Biobrane	is	applied	to	the	underlying	
wound	it	is	trimmed	away	as	it	separates	from	the	underlying	regenerating	skin	
as	opposed	to	being	peeled	off	the	wound	during	a	dressing	change.	As	a	result	
it	is	advocated	to	provide	painless	dressing	changes	which	reduces	psychological	
and	physical	distress	more	so	in	children	avoiding	the	need	for	another	general	
anaesthetic(71).		It	is	also	used	as	a	dressing	in	toxic	epidermal	necrolysis	and	
for	donor	sites	from	autologous	split	skin	grafting,	especially	when	dealing	with	
the	larger	TBSA	burns(72).		
The	major	limitation	with	the	use	of	Biobrane	is	the	complication	of	infection.	It	
is	not	advocated	for	use	on	an	 infected	or	potentially	 infected	surfaces	or	an	
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eschar.	It	should	also	not	be	used	on	deeper	burns,	where	the	dermis	is	affected.	
This	is	because	fluid	collections	form	between	the	wound	bed	and	the	biobrane	
which	can	go	onto	become	infected.	There	have	been	reports	of	life	threatening	
Staphylococcal	 toxic	 shock	 syndrome	 after	 Biobrane	 use,	 which	 is	 a	 major	
morbidity	 especially	 in	 the	 paediatric	 population	 where	 this	 product	 is	
commonly	 used	 (73)(74).	 However	 careful	 monitoring	 and	 continuous	
assessment	can	avoid	this	for	example	performing	a	dressing	change	within	24	
hours	post	application,	venting	the	Biobrane	above	any	areas	of	fluid	collections	
and	removal	of	any	areas	that	are	not	adherent(75).		
	
1.5.4	Permanent	Skin	Substitutes:	Epidermal	and	Dermal	Replacements.	
	
Epidermal	replacements		
The	 main	 epidermal	 substitute	 that	 is	 clinically	 in	 use	 is	 cultured	 epithelial	
autografts	(CEA)(76).	These	are	used	primarily	as	an	adjunct	to	split	thickness	
grafts	 rather	 than	on	 its	own,	as	 it	 has	been	 reported	 to	provide	 suboptimal	
outcomes	 at	 a	 significant	 expense(77).	 Clinical	 take	 has	 been	 reported	 at	
45%(77).	They	can	be	used	over	widely	meshed	grafts	or	donor	sites	to	expedite	
healing.	 They	 can	 also	 be	 placed	 on	 dermal	 scaffolds	 eg	 Integra	 or	 dermal	
allograft	for	partial	thickness	defects	where	some	residual	dermis	will	allow	for	
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attachment	 of	 keratinocytes.	 The	 real	 difficulty	 occurs	 in	 the	 timing	 of	 the	
production	of	CEA	sheets	to	meet	that	of	the	patient	as	it	takes	on	average	12	
days	to	produce	sheets	with	confluent	cells	before	they	can	be	clinically	used.	
Furthermore,	 these	sheets	are	very	 fragile	and	must	be	handled	with	utmost	
care	 to	 prevent	 fragmentation.	New	methods	 have	 since	 emerged	 to	 deliver	
these	 	 cells	 	 to	patients,	 in	 the	 form	of	 	 specialized	 carrier	dressings	 (78)and	
suspension	sprays(79).		
	
Cell	 suspensions	 contain	 basal	 keratinocytes,	 melanocytes	 and	 papillary	
fibroblasts.	 They	 avoid	 the	 use	 of	 Dispase,	 an	 enzyme	 used	 to	 release	 the	
epidermal	 sheets	 from	 culture,	 which	 removes	 surface	 proteins	 from	
keratinocytes,	 thereby	 reducing	 its	 adhesive	 potential(80).	 Furthermore	 sub-
confluent	cells	can	be	used	which	reduces	the	laboratory	processing	time	and	it	
is	 thought	 that	 keratinocytes	 in	 this	 form	 would	 have	 superior	 proliferative	
potential(79).		
	
Carrier	dressings	 for	sheets	of	keratinocytes	have	also	been	developed	to	aid	
transfer	 of	 sheets	 with	minimal	 damage	 to	 cells.	With	 respect	 to	 its	 clinical	
uptake	MySkin	(CellTran	Ltd,	Sheffield,	UK)	has	been	available	as	a	product	in	
the	UK	since	2004.	From	2004	to	the	present	time,	 the	company	has	worked	
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with	surgeons	to	provide	laboratory	expanded	skin	cells	for	192	patients	at	23	
treatment	centres	in	the	UK.	18	of	these	centres	have	used	MySkin	for	at	least	
3	patients	and	5	centres	have	treated	more	than	10	patients	with	MySkin.	 In	
terms	of	 living	cells	this	 is	the	most	commonly	and	frequently	used	project	 in	
routine	NHS	use	in	the	UK	to	the	best	of	our	knowledge.	
The	 proposed	 benefit	 of	 cultured	 keratinocytes	 is	 the	 potential	 to	 increase	
wound	 epithelization	 due	 to	 the	 presence	 of	 basal	 keratinocytes	 	 and	
transplantation	 of	 melanocytes																																																																																																																		
which	aims	to	maintain	the	colour	of	the	patient’s	skin	as	the	biopsy	to	source	
the	autologous	cells	 is	usually	 taken	 just	adjacent	 to	 the	defect(81).	Multiple	
studies	have	 investigated	 the	use	of	CEA	either	alone	or	 in	combination	with	
other	products	like	Integra.	When	CEA	on	their	own	are	applied	to	excised	burn	
wounds,	 take	 can	 be	 inconsistent.	 For	 example	 one	 case	 series	 reported	 an	
overall	take	of	80%	for	burns	with	a	mean	of	66%	TBSA(82).		Furthermore,	for	
burns	 larger	 than	80%	TBSA	 required	at	 least	 two	applications	of	CEA.	Other	
improved	outcomes	 included	 reducing	donor	 site	 scarring	when	 the	CEA	was	
applied	 to	 these	 areas(83).	 	 One	 of	 the	 fundamental	 problems	 of	 CEA,	 is	 its	
fragility	 both	 at	 the	 time	 of	 application	 and	 after	 take	 occurs.	 The	 most	
commonly	used	application	of	CEA	occurs	in	patients	with	burn	injuries	that	are	
medium	to	large	in	nature	(20-30%	TBSA	depending	on	the	size	of	the	patient)	
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and	can	range	from	partial	thickness	in	which	some	of	the	dermal	regenerative	
elements	 are	 left	 behind	 to	 full	 thickness	 burns	 that	 can	 extend	 beyond	 the	
dermis.	 It	 is	 no	 surprise	 that	 there	 are	 reports	 of	 better	 CEA	 take	 in	 partial	
thickness	 burns.	 However,	 in	 large	 TBSA	 full	 thickness	 injuries,	 it	 has	 been	
reported	that	there	was	60%	reduced	adherence	of	the	CEA	up	to	6	months	post	
application	whereby	 the	 sheets	were	dislodged	with	minimal	 shearing	 forces	
and	these	areas	simply	blistered	and	sloughed	off.	(84).	CEA	provides	epidermal	
cover,	skin	loss	in	large	burns,	of	which	this	application	is	most	used,	can	be	at	
times	mixed	 depth	 or	 full	 thickness.	 In	 these	 cases,	 the	 dermal	 regenerative	
elements	located	at	the	base	of	the	pilosebaceous	unit	have	been	destroyed	and	
as	a	result,	the	dermis	is	not	regenerated.	CEA	applied	to	these	wounds	or	onto	
subcutaneous	fat	or	fascia,	will	not	take.	Studies	have	indicated	that	there	is	a	
lack	of	dermal	attachment	by	way	of	anchoring	fibrils	between	the	applied	CEA	
and	 the	 underlying	 tissue	 some	 of	 which	 will	 be	 native	 dermis(85).	 Other	
reported	challenges	with	the	use	of	CEA	 include	 infection,	blistering	and	cost	
considerations.		
	
The	time,	expense	and	expertise	needed	to	culture	keratinocytes	in	the	lab	as	
part	of	the	application	process	of	CEAs	led	to	the	development	of	an	on	the	spot	
cell	delivery	system	called	ReCell®	(Avital	Medical,	Valencia,	CA,	USA).	
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A	 small	 sample	 of	 split	 thickness	 skin	 is	 obtained	 close	 to	 the	 area	 to	 be	
reconstructed	and	added	to	a	small	container	containing	an	enzyme	(porcine	
origin)	and	heated	for	about	15-	30	minutes	to	and	added	to	a	buffer	solution	to	
obtain	 a	 suspension	 containing	 keratinocytes,	 melanocytes,	 fibroblasts	 and	
Langerhans	cells.	The	suspension	is	then	delivered	either	to	a	debrided	wound	
bed	(with	dermal	components	present-	known	as	mixed	depth)	or	used	on	top	
of	widely	meshed	autograft	in	full	thickness	wounds	using	a	spray	applicator	or	
poured	directly	onto	the	site.		
The	technique	is	designed	to	be	carried	out	in	theatre,	by	clinicians	trained	in	
the	procedure.	The	key	point	in	this	application	is	that	it	does	not	result	in	true	
cellular	expansion	by	numbers-	it	simply	releases	the	cells	from	the	extracellular	
matrix	 from	 the	 skin	 sample	 and	 laid	 over	 an	 expansion	 ratio	 of	 80:1	 in	 an	
attempt	to	aid	epidermal	 regeneration	and	re-epithelization.	 It	has	also	been	
reported	to	treat	conditions	like	rhinophyma	and	congenital	melanocytic	naevi	
where	 in	 both	 these	 cases,	 post	 debridement,	 the	 dermal	 components	 are	
present	(86)(87).	A	study	by	Holmes	et	al	in	2018	comparing	the	use	of	ReCell	
combined	with	widely	meshed	 STS	 vs	 STGs	 alone	 revealed	 that	 donor	 areas	
harvested	combined	with	Re	Cell,	were	superior	in	terms	of	healing	at	weeks	1	
and	 2	 post	 op	 respectively	 compared	 to	 STSGs	 alone(88).	 This	 was	 to	 be	
expected	 as	 used	 thinner	 STSGs	 were	 used	 with	 the	 ReCell	 group	 than	 the	
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control	 versus	 the	 same	 thickness	 and	 evaluation	 of	 time	 to	 healing	 with	
addition	of	Recell	which	was	either	way	found	to	be	not	difference	between	the	
two	groups.	Furthermore	In	2007	Gravante	et	al	compared	ReCell	versus	skin	
grafting	for	deep	partial	thickness	burns	and	found	no	significant	differences	in	
time	 to	 complete	 epithelization,	 postoperative	 pain	 and	 contractures	 (89).	
Procedure	time	was	found	to	be	significantly	longer	in	the	cases	that	used	ReCell	
versus	 skin	 grafting.	 Studies	 have	 also	 investigated	 the	 use	 of	 ReCell	 in	
combination	with	split	 skin	grafting	and	Biobrane(90)	however	 there	was	not	
enough	statistical	analysis	to	accurately	determine	whether	these	combinations	
conferred	 a	 worthwhile	 benefit.	 The	 National	 Institute	 of	 Clinical	 Excellence	
(NICE)	which	provides	recommendations	to	English	health	care	providers	on	use	
of	medicines	and	products	has	not	 supported	 routine	adoption	of	 the	use	of	
ReCell	due	 to	 there	being	 insufficient	evidence	of	 its	 cost	vs	benefit	analysis.	
They	recommended	that	further	robust	studies	were	needed	to	define	its	role	
in	the	surgical	treatment	of	deep	to	full	thickness	burns	and	its	use	is	available	
on	an	NHS	Trust	policy	basis.	Accordingly	at	the	time	of	writing	the	true	uptake	
of	ReCell	in	the	UK	is	not	known	(91).		
	
Dermal	Analogues		
Integra	(LifeScience	Corporation,	Plainsboro,	N.J.)	
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With	 respect	 to	 dermal	 replacement	materials,	 Integra	 is	 currently	 the	most	
widely	accepted	synthetic	dermal	substitute	that	is	used	across	many	areas	of	
skin	reconstruction	(92),(93).	It	is	a	bilaminar	structure	consisting	of	cross-linked	
bovine	collagen	and	glycosaminoglycan	on	one	side	with	a	silicone	membrane	
on	 the	other.	The	pore	size	 in	 the	biological	 layer	 ranges	 from	70-200	μm	to	
allow	 migration	 of	 fibroblasts	 and	 endothelial	 cells,	 which	 is	 needed	 for	
integration(94).	 The	 product	 is	 applied	 with	 the	 biological	 layer	 facing	 the	
wound	bed,	secured	at	the	edges	with	sutures	or	glue	and	dressed	to	facilitate	
regular	inspections.	The	collagen	layer	then	bio	integrates	with	the	wound	bed	
to	 form	 a	 vascular	 neodermis.	 This	 takes	 about	 3-6	weeks.	 At	 this	 point	 the	
patient	is	taken	back	to	theatre	and	a	thin	split	skin	graft	is	applied.	
Integra	has	been	successful	in	the	clinical	environment	as	it	is	readily	available	
(can	be	stored	in	the	hospital	and	used	when	and	as	required),	easy	to	apply,	
has	a	predictable	course	that	is	identifiable,	for	example	the	ability	to	determine	
take	versus	failure	or	infection.	Trials	have	reported	superior	cosmetic	outcomes	
of	 the	 donor	 site	 (more	 thinly	 harvested	 than	 autograft	 alone),	 with	 faster	
healing	times(95).The	longest	published	series	using	Integra	reported	benefits	
such	as	over	80%	 take	 rates	with	no	 severe	hypertrophic	 scar	 formation	and	
excellent	 function	where	 it	has	been	used	over	 involved	 joints(96).	However,	
these	 trials	 are	 flawed	 by	 the	 fact	 that	 outcome	 measurements	 for	 scar	
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assessment	were	subjective	and	not	validated.	Interestingly	histological	studies	
performed	on	areas	with	Integra	over	a	two-year	period	revealed	remodelling	
of	the	dermal	component	over	the	first	month	of	application	with	features	that	
looked	 like	papillary	and	reticular	dermis	but	with	no	rete	ridges(14).	As	with	
any	product	there	are	areas	that	can	be	improved	upon.	These	include	the	fact	
that	it	is	most	commonly	used	as	a	two-stage	procedure	(single	stage	Integra	is	
available),	 requiring	 a	 return	 to	 theatre	 and	 the	 biological	 layer	 contains	
products	of	animal	origin.	Furthermore,	it	is	quite	expensive	which	limits	its	use	
in	 developing	 countries	 that	may	 actually	 need	 it	 the	most	 given	 the	 higher	
incidence	of	larger	burns.		
	
Matriderm	(MedSkin	Solutions	Dr	Suwelack	AG,	Billerbeck,	Germany)	
	
This	is	another	dermal	analogue	consisting	of	single	laminar	matrix	of	collagen	
and	elastin.	The	collagen	matrix	is	isolated	from	bovine	dermis	and	the	elastin	is	
obtained	from	the	bovine	nuchal	ligament	by	hydrolysis(97).	This	is	marketed	as	
a	single	stage	dermal	template,	whereby	it	is	applied	to	the	defect	in	addition	to	
a	very	thin	split	thickness	graft	in	the	same	operation(98).	Matriderm	is	widely	
used	in	skin	reconstruction	in	many	areas	for	example	post	skin	cancer	excisional	
surgery,	burns	(deep	to	full	thickness)	and	traumatic	wounds.	It	handles	easily	
and	acts	as	a	haemostatic	agent	once	placed	on	a	freshly	debrided	wound	bed.	
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A	thinner	than	average	split	thickness	graft	is	then	placed	on	top	as	a	source	of	
epidermal	 cells.	 It	 is	 thought	 that	 the	 combination	 of	 collagen	 and	 elastin	
promotes	vascularization	quicker	and	support	the	ingrowth	of	cells	and	vessels.	
Matriderm	is	used	in	the	management	of	burns	both	in	the	acute	and	chronic	
settings	 for	 burn	 scar	 contracture	 reconstruction.	 Studies	 have	 indicated	 it	
minimises	 scar	 contracture	 and	 increases	 skin	 elasticity	 and	 flexibility	 when	
compared	to	using	autologous	SSG.	Furthermore	a	thinner	split	skin	graft	means	
a	donor	site	containing	much	more	dermal	regenerative	elements,	so	there	is	
less	pain	and	quicker	healing	at	the	donor	site(99).	
	
Composite	Skin	Substitutes	
	
One	 of	 the	 most	 notable	 translated	 composite	 skin	 substitute	 material	 was	
performed	by	Boyce	and	colleagues.	This	consisted	of	creating	a	cultured	split	
skin	(CSS)	graft	in	the	laboratory	and	applying	it	on	debrided	wounds	pre-treated	
with	 allograft	which	 optimized	 vascularization.	 In	 later	 studies	 they	 replaced	
allograft	with	 Integra(100).	 	 A	 biopsy	 of	 the	 patient’s	 skin	was	 taken	 for	 cell	
culture	 and	 expansion	 to	 create	 an	 epidermal	 layer.	 The	 dermal	 analogue	
consisted	 of	 a	 bovine	 collagen-glycosaminoglycan	 (CAG)	 substrate.	 The	
epidermal	cells	once	expanded	were	inoculated	into	the	CAG	substrate	at	high	
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cellular	 density.	 These	 were	 cultured	 until	 keratinocyte	 stratification	 and	
confluence	 were	 found	 to	 be	 optimal	 as	 checked	 by	 light	 microscopy(101).	
Patients	with	>	50%	TBSA	burns	were	used	in	its	evaluation	and	it	was	compared	
to	 the	 gold	 standard	 split	 thickness	 skin	 graft	 by	 using	 both	 techniques	 on	
adjacent	sites	on	the	same	patients.	They	reported	that	areas	treated	with	the	
cultured	skin	substitute	had	superior	appearances	compared	to	autologous	split	
skin	grafting	at	five	months,	due	to	the	lack	of	hypopigmentation	and	meshed	
pattern	which	 are	 common	when	 autologous	 split	 skin	 grafts	 are	 used(102).	
Furthermore,	it	was	reported	that	for	excessively	large	full	thickness	burns	(TBSA	
88%)	complete	coverage	was	achieved	using	Integra	and	CSS	by	55	days.	This	
technique	 combined	 the	 use	 of	 a	 material	 developed	 by	 Burns	 Surgeons	 to	
provide	immediate	wound	cover	with	pioneering	tissue	engineered	biomaterials	
to	achieve	notable	patient	outcomes.	
This	work	highlights	two	key	points,	firstly	that	it	is	possible	to	use	cultured	skin	
in	 large	burns	 in	 a	 relatively	 timely	manner	 and	 the	 importance	of	 achieving	
preparative	 wound	 bed	 vascularisation.	 In	 the	 absence	 of	 a	 well	 debrided	
vascularised	wound	bed,	this	or	any	other	technique	will	not	be	successful.	This	
technique	requires	close	liaison	with	an	appropriate	laboratory	that	can	deliver	
these	cells	to	the	patient	in	a	timely	manner	which	has	always	been	challenging	
to	organize	and	implement	as	part	of	routine	clinical	practice.		
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Apligraf	(Organogenesis,	Canton,	MA)	
	
This	was	 previously	 called	Graftskin	 and	 is	 another	 biological	 composite	 skin	
substitute	 consisting	 both	 of	 epidermal	 and	 dermal	 components(103).	 The	
dermal	aspect	is	mimicked	using	a	scaffold	consisting	of	bovine	type	I	collagen	
and	 human	 derived	 foreskin	 neonatal	 fibroblasts.	 The	 epidermal	 component	
consists	of	human	foreskin	derived	neonatal	epidermal	keratinocytes	that	are	
cultured	onto	the	dermal	scaffold	and	allowed	to	stratify	before	transferring	it	
onto	 the	 patient(104).	 Thus	 this	 is	 based	 on	 allogeneic	 cells	 which	 will	 not	
survive	 long	 term	 in	 patients.	 It	 was	 initially	 approved	 by	 the	 FDA	 for	 the	
treatment	of	venous	ulcers	that	failed	trial	of	conventional	treatment	for	one	
month.		It	has	also	been	evaluated	in	other	clinical	applications	such	as	following	
Moh’s	or	excisional	surgery	 for	cutaneous	cancers	where	 it	was	compared	to	
healing	 via	 secondary	 intention.	 In	 this	 case,	 it	 is	 reported	 that	 Apligraf	was	
associated	with	a	less	vascular	scar	and	a	better	cosmetic	appearance	than	those	
healing	by	secondary	intention(105).	Furthermore,	when	it	is	used	to	aid	donor	
site	wound	healing	 following	grafting	of	 large	burns,	 it	 is	associated	with	 less	
pain	when	compared	to	simple	polyurethane	films(106).	It	was	also	used	in	the	
reconstruction	 of	 small	 full	 thickness	 burn	 injuries	 where	 it	 was	 shown	 to	
expedite	wound	healing(107).	The	evidence	for	 its	successful	use	is	 limited	to	
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level	 IV	 and	 V	 clinical	 studies,	 with	 low	 patient	 numbers	 and	 no	 definitive	
comparison	to	the	clinical	gold	standard	which	is	an	autologous	skin	graft.		
Most	of	 its	advocated	clinical	use	 lies	 in	the	field	of	venous	and	diabetic	 foot	
ulcers	where	it	has	been	shown	to	be	a	cost	effective	option	in	the	long	term	
management	 of	 these	 chronic	 wounds	 as	 it	 offsets	 the	 need	 for	 continuous	
dressing	and	treatment	of	episodic	infections	due	to	its	associated	significantly	
shorter	 healing	 times	 when	 used(108)(109).	 This	 product	 has	 not	 gained	
popularity	 amongst	 reconstructive	 surgeons	 in	 the	 United	 Kingdom	 as	 a	
routinely	used	skin	substitute(53).			
	
1.6	Electrospun	Scaffolds	
	
1.6.1	Introduction		
	
Electrospun	 scaffolds	 have	 been	 at	 the	 forefront	 of	 tissue	 engineering	 with	
many	 uses	 in	 healthcare	 ranging	 from	 tissue	 regeneration	 to	 drug	 delivery	
systems.	Scaffolds	have	been	developed	in	almost	all	areas	where	there	is	lack	
of	 native	 tissue	 and	 current	 clinical	management	 does	 not	 yet	 yield	 optimal	
results	for	example	bone	replacement,	treatment	of	cleft	lip	and	palate	and	skin.	
Scaffolds	 can	 be	 synthetic	 or	 biological.	 Scaffolds	 fabricated	 using	
electrospinning	 have	 a	 wide	 variety	 of	 biomedical	 applications	 due	 to	 the	
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flexibility	in	mimicking	some	of	the	properties		of	the	native	tissue.	Networks	of	
both	 micro	 and	 nanofibres	 can	 be	 made	 separately,	 in	 layers;	 they	 can	 be	
templated	 or	 bioactive	 agents	 eg	 vitamin	 C(110)	 and	 anti-inflammatories	
(111)or	hormones	such	as	oestradiol	(112)can	be	delivered	from		the	fibres.	This	
results	in	a	range	of	scaffolds	consisting	of	various	orientations	of	fibre	size	and	
diameter	 that	 are	 comparable	 to	 the	 structure	 of	 the	 extracellular	matrix	 of	
many	human	tissues.		
	
	
1.6.2	Technique	of	Electrospinning			
	
Many	tissue-engineering	laboratories	across	the	globe	have	been	investigating	
the	use	of	synthetic	electrospun	scaffolds	as	substitutes	for	native	extracellular	
matrix	for	decades.	The	principle	relies	on	a	high	voltage	(e.g.	17000	V)	travelling	
between	a	syringe	driver	and	a	conductive	collector	to	extract	thin	fibres	from	
dissolved	 biodegradable	 polymers.	 	 The	 dissolved	 polymer	 is	 loaded	 into	 a	
needle-tipped	 syringe	 (various	 sizes	 eg	 5,10	or	 60	ml)	 and	 an	 earthed	 target	
collector	is	positioned	at	a	set	distance	from	the	needle	tip.	This	distance	varies	
for	each	polymer	used	and	the	fibre	size	required.	Application	of	a	high	voltage	
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to	the	needle	tip	(eg	17000V)	causes	the	dissolved	polymer	to	charge	and	form	
a	Taylor	cone.		
Once	 the	 charge	 of	 the	 solution	 is	 strong	 enough	 to	 overcome	 the	 surface	
tension	and	viscoelastic	forces	of	the	Taylor	cone,	the	polymer	expels	in	the	form	
of	a	charged	jet.	This	travels	across	an	air	gap	whilst	simultaneously	undergoing	
solvent	evaporation,	stretching	and	thinning.	Once	the	jet	comes	into	contact	
with	the	earthed	collector,	the	process	is	complete,	the	charges	dissipate	and	
networks	of	fibres	are	formed(113).	
	
Fibres	are	randomly	orientated	or	well	aligned	depending	on	the	rate	of	rotation	
of	the	collector.	Randomly	orientated	fibres	are	produced	when	the	collector	is	
left	stationary	i.e.	static	spinning	or	spinning	at	low	speed.	Well	aligned,	ordered	
fibres	are	achieved	using	a	more	rapidly	rotating	mandrel	eg	>	500	rpm,	with	
adjustable	 speeds	 that	 can	 further	 influence	 the	 properties	 of	 the	 fibres.	
Another	 commonly	 used	 speed	 was	 200	 rpm	 to	 create	 the	 initial	 trilayer	
electrospun	 scaffold	 architecture(114).	 The	 diameter	 of	 the	 fibres	 can	 be	
modified	by	changing	any	one	of	many	parameters	in	the	electrospinning	set	up	
(Figure	1.6).	These	 fibres	 form	a	3D	scaffold	onto	which	cells	 can	proliferate,	
migrate	and	function	to	achieve	the	spatial	organization	that	is	required	for	it	to	
form	a	tissue.		
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Figure	 1.6:	 Electrospinning	 Set	 Up:	 A-	 Syringe	 Driver,	 B-	 Electric	 Generator,	 C-	
Mandrel	
	
	
1.6.3	Polymers	used	in	the	Electrospinning	Process		
	
These	 can	 be	 thought	 of	 as	 chemical	 compounds	 that	 have	 the	 ability	 to	
assemble	 in	 simple	 structural	 units	 to	 create	 a	 3-dimensional	 construct	with	
various	applications	in	biological	systems(115).	Polymers	developed	for	use	in	
biomedical	applications	can	be	thought	of	as	natural	or	synthetic	and	permanent	
where	they	remain	in	situ	or	temporary	where	they	degrade	over	a	specific	time	
period.	Their	use	is	flexible	and	variable	ranging	from	structural	proteins	of	the	
extracellular	 matrix	 to	 matrices	 with	 mechanical	 functions	 like	 ligaments,	
cartilage	and	skin.	Furthermore,	they	can	also	serve	to	augment	the	function	of	
A B 
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existing	organ	systems	eg	vascular	grafts	in	occluded	arteries.	Natural	polymers	
have	been	in	use	since	the	dawn	of	time	eg	animal	horn,	hair,	cellulose	and	silk,	
however	with	concerns	of	immunological	reactions	and	variable	batch	to	batch	
reproducibility	 the	 	 focus	 is	 now	 on	 synthetic	 polymers	 that	 have	 biological	
capabilities(115).		
Man-made	biocompatible	synthetic	polymers	are	attractive	materials	for	clinical	
applications.	A	wide	range	of	chemical	and	physical	properties	can	be	achieved	
with	these	compounds	to	fulfil	the	structural	and	mechanical	properties	that	are	
required	 for	 the	 specific	 tissue	 application.	 Polymers	 used	 in	 biomedical	
applications	are	biodegradable	and	can	be	designed	to	stay	in	the	body	for	as	
long	 as	 it	 is	 needed	 and	 then	 disappear	 without	 the	 need	 for	 any	 surgical	
intervention	to	physically	remove	them.	Furthermore,	the	breakdown	products	
are	 non-toxic	 and	 excreted	 in	 a	 predictable	 fashion.	 These	 were	 initially	
developed	for	orthopaedic	applications	like	internal	fixation	of	bone	(116),	but	
have	 now	 extended	 to	 vascular	 stents(117),(118)	 and	 drug	 delivery	
systems(119).		
Synthetic,	hydrolytically	degrading	polymers	are	preferred	for	implants	or	drug	
release	 systems,	 as	 they	 are	 independent	 of	 the	patient	 or	 implantation	 site	
(120).	
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Biodegradable	polyesters	are	just	one	category	of	polymers	employed	in	tissue-
engineered	bioproducts.	The	most	common	ones	consist	of	polyesters	of	small	
aliphatic	glycolic	acid	(PGA),	lactic	acid	(PLLA)	and	polycaprolactone	(PCL)(121).	
PGA	degrades	through	hydrolysis	of	its	ester	bonds	and	is	eliminated	ultimately	
as	water	and	carbon	dioxide.	It	loses	its	strength	in	vitro	within	4	weeks	and	is	
completely	 absorbed	within	 6	months.	As	 a	 result,	 it	 is	 often	 combined	with	
other	polymers	like	PLLA	to	slow	its	rate	of	degradation,	which	can	be	tailored	
to	the	specific	tissue	target(122).	Another	polymer	in	this	group	polydioxanone	
(PDS)	is	a	commonly	used	absorbable	suture	in	current	surgical	practice(123).	
Polylactic	acid	(PLA)	and	polyglycolic	acid	polymers	are	often	chosen	for	dermal	
replacement	as	their	mechanical	properties	and	rates	of	degradation	match	that	
which	 is	 needed	 for	 skin	 wound	 repair.	 Blackwood	 et	 al	 established	 that	 a	
copolymer	of	poly	(D,	L)	 lactide-co-glycolide	(PGLA)	at	a	75:25	ratio	of	PLA	to	
PGA	was	appropriate	for	use	in	human	dermal	replacement	as	it	supported	the	
migration	 and	 proliferation	 of	 keratinocytes	 and	 fibroblasts	 and	 facilitated	
collagen	production	and	deposition.	Additionally	it	did	not	undergo	necrosis	or	
encapsulation	and	degraded	by	50%	within	 three	months	when	 implanted	 in	
rats	(124).This	is	thought	to	be	physiologically	desirable	as	by	the	three-month	
mark,	 the	 wound	 would	 ideally	 be	 at	 the	 stage	 of	 remodelling,	 where	 the	
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patient’s	own	deposited	collagen	III	is	replaced	with	collagen	I	thus	negating	the	
need	for	mechanical	support	or	presence	of	the	scaffold.		
	
1.6.4	Mechanical	Properties	of	electrospun	scaffolds	
	
In	 order	 to	 use	 electrospun	 scaffolds	 in	 biomedical	 applications,	 their	
mechanical	properties	need	to	be	assessed	to	determine	their	suitability.		The	
strength	and	deformability	of	the	fibres	must	match	as	closely	as	possible	the	
tissue	one	 is	 trying	to	replace.	This	 is	especially	 important	for	example	 in	the	
manufacturing	 of	 biosynthetic	 vascular	 grafts,	which	 are	 proposed	 for	 use	 in	
atherosclerotic	arteries.	Any	material	that	aims	to	replace	a	vessel,	must	match	
its	 physical	 and	 mechanical	 properties	 so	 as	 to	 avoid	 the	 disastrous	
consequences	 of	 graft	 failure	 e.g.	 aneurysm	 formation	 if	 the	 walls	 cannot	
withstand	the	blood	flow(125).		Furthermore,	as	most	electrospun	scaffolds	are	
populated	with	cells	and	then	cultured,	 it	 is	also	helpful	to	determine,	 if	post	
culture	 there	are	 any	effects	or	 changes	 to	 the	mechanical	 properties	of	 the	
scaffolds.		
Mechanical	properties	are	measured	using	a	uniaxial	tensile	test	(Figure	1.7)	or	
computational	 analysis	 that	 avoids	 the	 need	 for	 destructive	 testing(126).	
Sample	thickness	is	measured	using	a	micrometer	and	then	clamped	with	two	
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grips	in	a	tensiometer	at	fixed	distance	between	the	grips.	A	small	 load	cell	 is	
selected	 and	a	 ramp	 test	 is	 then	applied.	 The	 first	 failure	point	 or	 plateau	 is	
recorded	as	the	load	at	failure	(or	ultimate	tensile	strength,	UTS)	and	the	slope	
of	this	plot	is	calculated	for	the	Young’s	modulus	both	shown	as	MPa	(N/mm2).	
The	Young’s	modulus	can	be	thought	of	as	a	measurement	of	the	elasticity	of	
the	material.	The	tensile	strength	of	scaffolds	can	be	compared	to	native	tissue	
that	they	are	aiming	to	replace.	Furthermore,	the	mechanical	strength	can	be	
modified	by	the	choice	of	polymer	and	any	of	the	electrospinning	conditions	as	
outlined	above	to	achieve	a	material	that	is	suitable	for	a	particular	application.	
Studies	on	skin	have	shown	that	mechanical	strength	decreases	with	age	and	is	
constant	 in	both	men	and	women.	This	can	be	explained	by	the	fact	that	the	
ratio	of	chondroitin-sulfate	/keratin	sulfate,	the	GAGs	that	absorb	shear	forces	
decrease	in	the	dermis	with	age(127).		
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Figure	1.7:	Bose	Tensiometer	
	
1.6.5	Modifications	of	electrospun	scaffolds		
	
Early	work	in	electrospinning	focused	mainly	on	single	polymers	that	resulted	in	
well-aligned	fibres.	However,	it	is	known	that	most	tissues	are	not	structured	in	
such	a	predictable	and	organized	fashion.	Resident	cells	are	spatially	organized	
depending	on	the	tissues	concerned.	For	example,	in	skin,	cells	are	stratified	and	
its	micro	topography	is	complex	and	variable	depending	on	the	area	of	the	body	
being	studied.	This	lead	to	the	use	of	layered	micro	and	nano	fibrous	scaffolds	
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using	different	polymers	to	support	specific	cells	that	would	better	define	the	
various	 layers	of	skin.	This	 technique	has	been	established	by	Bye	et	al	using	
trilayers	 of	 polyhydroxybutyrate-co-valerate	 (PHBV)	 and	 PLA	 (114).	
Electrospinning	of	PHBV	results	in	nanofibres	that	are	useful	as	a	barrier	layer	
due	 to	 the	 small	 fibre	 and	 pore	 size	 between	 them.	 Scaffolds	 containing	
nanofibres	 facilitate	 cell	 adhesion,	 migration	 and	 proliferation,	 especially	
fibroblasts	 that	 assume	 a	 spindle-type	 shade	 in	 the	 neighbourhood	 of	 the	
nanofibres(128).		Furthermore	these	ultra-fine	fibres	have	similarities	with	the	
extra	 cellular	 matrix	 of	 natural	 tissue	 due	 to	 their	 porosity,	 fibre	 diameter	
orientation	and	mechanical	strength(129).	
Another	 technique	 employed	 to	 improve	 the	 topography	 of	 electrospun	
scaffolds	involves	the	use	of	conductive	templates	onto	which	fibers	are	spun	–	
this	 patterns	 the	 scaffolds	 thereby	 increasing	 the	 chances	 of	 cellular	
proliferation	(Figure	1.8)(130),(131).		
These	templated	scaffolds	have	already	been	developed	for		clinical	application	
in	 the	 area	 of	 corneal	 transplantation.	 Traditionally	 limbal	 biopsies	 from	 the	
functional	cornea	are	 transplanted	onto	 the	contralateral	diseased	cornea	by	
mincing	it	into	very	fine	pieces.	These	are	then	laid	onto	a	scaffold	for	support,	
which	was	initially	amniotic	membrane.		Advances	in	tissue	engineering	resulted	
in	the	use	of	electrospun	biosynthetic	scaffolds	which	have	been	designed	to	
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replace	the	amniotic	membrane(132).	Work	by	Ortega	and	MacNeil	sought	to	
further	improve	these	scaffolds	by	mimicking	the	native	morphology	of	limbal	
stem	 cell	 niches	 by	 templating	 the	 scaffolds	 using	 metal	 collectors	 (Figure	
2.2)(133).		
Within	the	body	almost	no	cell	is	no	more	than	100-200	micrometres	from	the	
nearest	capillary,	within	this	spacing	there	is	the	ability	for	oxygen,	nutrients	and	
waste	 products	 to	 diffuse	 and	 maintain	 the	 viability	 of	 the	 tissues(134).	
Therefore,	it	is	essential	for	any	scaffold	that	is	implanted	in	the	body	to	become	
vascularised	adequately	at	an	early	stage	in	order	for	it	to	survive	and	facilitate	
cellular	migration	and	proliferation.	The	slow	development	of	new	blood	vessels	
after	in	vitro	implantation	of	3D	tissue	engineered	constructs	especially	if	they	
are	1mm	or	thicker	is	a	major	challenge	facing	the	sustainable	translation	to	the	
clinical	 environment.	 Therefore,	 electrospun	 scaffolds	 themselves	 have	 been	
modified	either	physically	or	chemically	to	be	able	to	better	induce	new	blood	
vessel	growth	when	implanted.		
	
One	such	strategy	involves	functionalization	of	electrospun	scaffolds.	This	is	a	
process	whereby	 known	 pro-angiogenic	molecules	 are	 incorporated	 into	 the	
electrospinning	process.	For	example	heparin	is	a	commonly	used	anticoagulant	
that	can	be	linked	to	the	surface	of	the	scaffolds,	this	results	in	a	surface	that	is	
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hydrophilic	 and	 negatively	 charged	 thus	 preventing	 absorption	 of	 molecules	
that	promote	thrombus	formation	(albumin	and	fibrinogen)	 in	scaffolds	to	be	
used	 for	 vascular	 grafts(135).	 Moreover,	 it	 can	 act	 as	 a	 stabilizing	 carrier	
molecule	for	cytokines	like	vascular	endothelial	growth	factor	(VEGF).	Heparin	
binds	to	the	VEGF	thereby	allowing	it	to	be	delivered	in	a	slow	and	predictable	
manner.	VEGF	on	its	own	is	believed	to	be	a	potent	stimulator	of	angiogenesis	
and	by	coating	the	electrospun	scaffold	 initially	with	heparin	to	bind	to	VEGF	
thereafter,	 it	 too	 can	 be	 functionalized	 onto	 scaffolds	 to	 increase	 potential	
neovascularization.	 This	 was	 demonstrated	 by	 Gigliobianco	 et	 al	 where	
electrospun	PLA	scaffolds	coated	with	alternative	 layers	of	polyethylenelmine	
(PEI)	and	heparin	showed	that	this	was	a	superior	technique	to	bind	to	VEGF	as	
compared	 to	 using	 PEI	 and	 Polyacrylic	 acid	 (PAC)	 alone.	 Furthermore	 these	
heparin-coated	scaffolds	were	 then	 implanted	 into	a	chick	chorionic	allantoic	
membrane	 (CAM)	 assays	 which	 revealed	 better	 angiogenic	 activity	 in	 the	
heparin	coated	scaffolds(136).		
	
Another	important	property	of	electrospun	scaffolds	surrounds	their	ability	to	
support	 cellular	 function.	 It	 is	 known	 that	 ascorbic	 acid	 is	 a	 cofactor	 for	 the	
enzyme	 that	 crosslinks	 collagen	 fibrils	 that	 result	 in	 it	 functional	 triple	 helix	
structure(137).	Ascorbic	acid	can	be	incorporated	into	electrospun	scaffolds	to	
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stimulate	the	production	of	collagen	by	fibroblasts.	It	has	been	demonstrated	
that	 by	 producing	 ascorbic	 acid	 releasing	 scaffolds,	 collagen	 production	 is	
increased	significantly	when	they	are	seeded	with	fibroblasts	compared	to	those	
scaffolds	 without	 ascorbic	 acid(110).	 The	 ability	 to	 stimulate	 collagen	
production	 is	 advantageous	property	of	 electrospun	 scaffolds	 in	 the	 fields	of	
skin,	cartilage,	bone	and	soft	tissue	regeneration.			
	
	
Figure	1.8:	Templated	trilayer	electrospun	scaffolds	(	x4	magnification)	
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1.6.6	Clinical	Applications	in	Plastic	and	Reconstructive	Surgery			
	
There	are	many	reasons	why	electrospun	scaffolds	serve	as	an	attractive	option	
for	use	in	plastic	and	reconstructive	surgery.	Firstly	they	are	safe,	non-toxic	and	
biocompatible.	 Scaffolds	 can	be	made	 to	match	 the	physical	 and	mechanical	
profile	of	the	tissue	that	 it	 is	aiming	to	regenerate.	For	example,	the	polymer	
chosen	and	electrospinning	technique	can	be	varied	so	that	it	provides	a	specific	
fibre	size	and	pore	dimension	between	the	fibres	to	best	suit	the	specific	cell	
thereby	 tissue	 type	 that	 it	 aims	 to	 support.	 Furthermore,	 mixing	 polymers	
allowing	 it	 to	 provide	 support	 for,	 as	 long	 it	 is	 needed,	 can	 control	 its	
biodegradation.	 After	 this	 time	 period	 it	 is	 expected	 that	 the	 scaffold	 will	
degrade	into	physiological	by	products	that	are	easily	excreted	leaving	behind	
the	 patient’s	 native	 tissue,	 which	 has	 regenerated,	 similar	 to	 an	 absorbable	
suture	that	disappears	when	the	suture	line	has	healed.		Furthermore,	scaffolds	
can	 be	 textured	 and	moulded	 into	 different	 sizes	 and	 shapes	 to	 aid	 cellular	
attachment	 and	 proliferation.	 	 Advancing	 technology	 has	 resulted	 in	
incorporation	of	various	drugs	and	molecules	that	can	allow	scaffolds	to	be	drug	
releasing	and	stimulate	more	rapid	vascularization	when	implanted.		
	
	
 
 
	 96	
1.7	Tissue	Engineering	Approaches	in	developing	a	dermal	analogue		
 
 
Several	research	groups	have	attempted	to	produce	tissue	engineered	dermal	
matrices	 using	 the	 electrospinning	 process.	 The	 scaffolds	 aim	 to	 match	 the	
tensile	modulus	that	matches	normal	human	skin	and	have	a	porous	matrix	to	
facilitate	the	proliferation	of	skin	cells	throughout	its	structure.	Both	non	organic	
and	biological	polymers	are	used	to	create	materials	which	are	suitable	for	tissue	
engineered	 skin.	One	 such	group	 successfully	used	poly[lactic	 acid-co-glycolic	
acid]	 (PLAGA)	 which	 produced	 appropriate	 electrospun	 scaffolds	 for	 skin	
replacement(138)	Other	groups	are	 trying	 to	 integrate	bioactive	 components	
like	 glycosaminoglycans	 (GAGs)	 (hyaluronan	 and	 chondroitin	 sulphate)	 into	
scaffolds	 which	 has	 the	 effect	 of	 stimulating	 cellular	 proliferation	 and	
accelerated	epidermal-dermal	regeneration(139).	Another	challenge	with	tissue	
engineered	scaffolds	is	the	ability	for	cells	to	adhere	to	the	scaffolds	and	thereby	
migrate	and	proliferate.	As	a	 result,	 techniques	have	developed	which	would	
serve	to	enhance	this.	For	example	PGLA	(75/25)	scaffolds	when	coated	with	
collagen	showed	that	keratinocyte	proliferation	increased	significantly(140).	
	
The	first	potential	use	of	electrospun	scaffolds	is	in	the	field	of	skin	replacement.	
Full	 thickness	 wounds	 are	 by	 definition	 devoid	 of	 the	 dermal	 regenerative	
elements	that	facilitate	healing.	Many	currently	employed	skin	substitutes	are	
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either	dermal	in	origin,	requiring	a	second	procedure	to	obtain	epithelial	cover	
and	are	composed	of	products	of	animal	origin,	which	although	approved	by	the	
FDA	still	carries	the	risk	of	prion	diseases.	Additionally,	many	cultures	are	not	
accepting	 of	 materials	 that	 come	 from	 commonly	 used	 bovine	 and	 porcine	
sources.	Electrospun	scaffolds	in	this	respect	are	desirable	materials	as	they	are	
biocompatible,	 synthetic	 and	 their	 chemical	 and	 physical	 structure	 can	 be	
altered	 to	match	key	 features	 that	are	 required	 in	skin	 reconstruction.	These	
include	prevention	of	 fluid	and	protein	 loss	 from	the	wound	bed,	 removal	of	
exudate,	inhibition	of	microbial	invasion	and	their	fibres	need	to	support	cellular	
attachment,	guide	endogenous	cells	 to	proliferate	and	remodel.	Both	natural	
and	 synthetic	 polymers	 have	 been	 used	 in	 the	 electrospinning	 process	 to	
produce	electrospun	scaffolds	for	skin	regeneration.		Improvements	have	been	
made	 to	 this	 technique	 by	 combining	 synthetic	 polymers	 that	 provide	 the	
mechanical	strength	of	the	scaffold	and	natural	polymers	like	gelatin,	chitosan	
and	 collagen	 to	 facilitate	 cellular	 attachment	 and	 migration.	 For	 example	
PCL/collagen	scaffolds(141)	and	PCL/chitosan(142)	have	shown	good	fibroblast	
proliferation	 and	 adhesion	 which	 are	 	 potential	 applications	 in	 skin	
regeneration.		
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1.8 	Fibrin	
 
1.8.1	Introduction	
Fibrin	is	the	end	result	of	the	coagulation	cascade	which	results	in	activation	of	
thrombin.	Thrombin	in	the	presence	of	calcium	ions	cleaves	fibrinogen	to	form	
fibrin.	 Fibrin	 are	 initially	 peptide	 monomers	 that	 are	 covalently	 cross	 linked	
though	the	action	of	factor	13	to	form	an	insoluble	polymerized	fibrin	clot(143).	
Fibrin	 is	 an	 essential	 component	 of	 the	 blood	 clot	 that	 has	 a	 central	 role	 in	
haemostasis.	 It	 has	 been	 used	 extensively	 as	 a	 biological	 polymer	 in	 tissue	
engineering.	 It	 is	 classed	 as	 a	 hydrogel	 and	 is	 structurally	 similar	 to	 the	
extracellular	matrix	that	is	present	in	tissues.		
	
1.8.2	Clinical	Applications	of	Fibrin		
In	 clinical	 practice	 fibrin	 is	 used	 both	 as	 a	 sealant	 and	 haemostat.	 These	
functions	although	slightly	different	requires	the	fibrin	to	have	a	dense	compact	
structure	in	order	to	plug	the	end	of	bleeding	vessels	and	be	strong	enough	to	
withstand	shear	mechanical	forces	that	are	applied	to	a	wound.	It	is	the	most	
effect	 physiological	 tissue	 adhesive	 that	 is	 commercially	 available.	 The	
concentration	of	fibrinogen	and	thrombin	used	affects	the	structure	of	the	clot	
and	 thereby	 influences	 its	 potential	 applications.	 Higher	 concentrations	 of	
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fibrinogen	renders	the	clot	mechanically	stronger	which	is	ideal	if	it	is	being	used	
as	an	adhesive.	Higher	concentrations	of	thrombin	results	in	a	clot	that	sets	very	
quickly	which	is	useful	in	haemostasis.	Fibrin	itself	is	also	a	chemoattractant	in	
wound	 healing	 cells	 to	 cells	 like	 fibroblasts	 and	 keratinocytes	 and	 their	
associated	growth	factors.	Most	commercial	preparations	of	 fibrin	contain	an	
anti-fibrinolytic	component	to	slow	the	degradation	of	fibrin.	Fibrin	 is	used	in	
various	 specialities	 depending	 on	 need.	 Its	 uptake	 has	 become	 popular	 for	
sealing	dead	spaces	eg	seroma	pockets,	bleeding	wound	beds	when	no	source	
vessel	is	found,	skin	graft	adhesive	and	even	in	solid	organ	lacerations	eg	liver.	
That	being	said,	fibrin	can	be	sourced	from	human	and	bovine	sources	and	as	a	
result	 there	 is	 always	 the	 potential	 risk	 of	 viral	 infection	 or	 foreign	 body	
response.		
	
1.8.3	Use	of	Fibrin	in	tissue	engineered	bioproducts				
Fibrin	can	have	various	applications	in	tissue	engineering.	Firstly,	it	can	be	used	
to	support	cells	on	its	own	i.e.	cells	can	be	suspended	in	the	fibrin	and	cultured	
for	transplantation.	Additionally,	it	can	be	used	with	other	polymers	as	part	of	a	
scaffold.	 This	 is	 advantageous	 as	 it	 utilizes	 the	 strengths	 of	 polymers	 for	
structure	and	mechanical	strength	and	fibrin	which	incorporates	as	much	cells	
as	possible,	 thereby	enabling	good	cell	distribution	which	ultimately	provides	
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coherent	tissue	development.	Finally,	fibrin	can	be	used	as	a	delivery	for	growth	
factors	or	other	therapeutic	agents.	With	regards	to	skin,	fibrin	has	been	used	
as	a	delivery	vehicle	for	keratinocytes	both	in	the	form	of	gel	sheets	(144)	and	
microbeads(145).	It	has	also	been	used	as	a	component	part	of	various	scaffolds.	
This	 is	 advantageous	 as	 fibrin	 has	 been	 shown	 to	 stimulate	 the	migration	 of	
keratinocytes(146)	 and	 fibronectin	 which	 is	 a	 glycoprotein	 in	 fibrin	 does	
enhance	cellular	migration	during	wound	healing(147).		
For	 this	 thesis,	 the	 fibrin	used	 in	 the	experiments	act	 as	an	adhesive	 to	help	
retain	 the	 skin	 explants	 on	 the	 scaffolds	 and	 it	 is	 not	 integrated	 into	 the	
electrospinning	process	formally.	Furthermore,	it	is	not	used	as	a	cell	delivery	
vehicle	as	we	aim	to	use	composite	tissue	pieces	versus	isolated	cells	to	populate	
our	electrospun	scaffolds.	This	can	be	viewed	as	beneficial	 for	many	reasons.	
Firstly,	it	allows	for	fibrin	to	be	used	as	part	of	the	application	rather	than	adding	
fibrin	 to	 the	electrospinning	process	changes	 the	mechanical	 structure	of	 the	
electrospun	 scaffold	 which	 has	 already	 been	 established	 in	 the	 MacNeil	
laboratory	 for	 skin	 replacement.	 Moreover,	 by	 using	 fibrin	 on	 top	 of	 the	
scaffolds,	 its	 properties	 of	 both	 an	 adhesive	 and	 a	 chemoattractant	 to	
keratinocytes	are	used.	By	fixing	the	explants	to	the	scaffolds	thereby	increasing	
the	contact	time	of	the	explants	to	the	scaffolds,	 facilitates	cellular	migration	
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from	the	explants	onto	the	scaffolds	which	is	essential	if	explants	are	to	be	used	
as	a	cell	source.		
	
1.9	Aims,	Objectives	and	Rationale		
	
1.9.1	Aims	
The	aim	of	this	project	is	to	design	and	evaluate	a	novel	biodegradable	dermal	
alternative	(composed	of	medical	grade	PGLA	(75:25)	and	PHBV)	to	be	combined	
with	skin	explants	for	use	as	a	one-step	approach	in	theatre	for	reconstruction	
of	full	thickness	skin	defects.		
	
The	following	are	the	hypotheses	to	be	tested:	
1. Culturing	skin	pieces	on	a	trilayer	scaffold	consisting	of	micro/nano	fibres	
will	lead	to	better	epithelial-stromal	organization	than	would	be	achieved	
on	a	scaffold	consisting	of	microfibers	alone		
2. Inclusion	of	features	that	approximate	the	dimensions	of	the	rete	ridges	
will	help	in	the	outgrowth	of	epithelial	cells	into	the	electrospun	scaffolds.	
3. The	inclusion	of	fibrin	as	tissue	glue	will	act	as	a	stimulant	for	epithelial	
outgrowth	into	these	synthetic	scaffolds.		
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4. The	 presence	 of	 fibroblasts	 precultured	 in	 synthetic	 scaffolds	 help	
stimulate	the	outgrowth	of	epithelial	cells	from	skin	explants		
	
1.9.2	Experimental	Objectives		
	
To	achieve	the	above,	the	project	was	divided	into	the	following	experimental	
objectives:		
	
1. Evaluation	 of	 how	 a	 novel	 method	 for	 spinning	 a	 basement	 membrane	
substitute	can	encourage	epithelial-stromal	organisation.		
	
2. Investigation	 of	 whether	 the	 inclusion	 of	 features	 that	 approximate	 the	
dimensions	of	 rete	 ridges	will	 help	 in	 the	outgrowth	of	 epithelial	 cells	 into	
epithelial	cells	into	the	electrospun	scaffolds.	
	
3. Assessment	 of	 whether	 the	 inclusion	 of	 fibrin	 as	 tissue	 glue	 will	 act	 as	 a	
stimulant	for	epithelial	outgrowth	into	these	synthetic	scaffolds.	
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4. Evaluation	of	whether	inclusion	of	fibroblasts	in	the	templated	trilayer	PGLA	
75:25	/	PHBV		electrospun	scaffolds	will	promote	epithelial	cell	outgrowth	in	
the	presence	and	absence	of	fibrin.	
	
1.9.3	Rationale	
	
Traditional	reconstructive	plastic	surgery	techniques	rob	Peter	to	pay	Paul.		Skin	
grafting	remains	the	gold	standard	for	resurfacing	full	thickness	burns	and	later	
functional	reconstruction	of	scars	and	contractures.	This	poses	problems	in	large	
burns	(>	30%	TBSA)	where	lack	of	donor	sites	results	in	multiple	theatre	sessions	
utilizing	remaining	unburnt	skin	sites	and	resulting	in	donor	site	morbidity.		
	 	The	 aim	 of	 this	 project	 is	 to	 bring	 the	 use	 of	 a	 one	 stage	 reconstructive	
technique	using	tissue-engineered	scaffolds	closer	to	clinical	use.	This	promises	
to	be	a	viable	economical	alternative,	which	uses	the	patient’s	own	skin	in	the	
form	 of	 a	 biopsy,	 thereby	 avoiding	 the	 need	 to	 culture	 cells	 in	 the	 lab	 in	
combination	with	the	use	of	biodegradable	synthetic	FDA	approved	polymers,	
already	in	clinical	use,	free	from	products	of	animal	origin.		
This	 model	 of	 combining	 scaffolds	 with	 small	 tissue	 explants	 is	 clinically	
successful	in	the	treatment	of	scarred	corneas.	Ocular	disease	resulting	in	limbal	
stem	deficiency	results	 in	the	 inability	 to	use	corneal	 transplants.	A	biopsy	of	
	 104	
limbal	 tissue	 harvested	 from	 the	 contralateral	 healthy	 eye	 was	 minced	 into	
several	pieces	and	spread	onto	amniotic	membrane.	Using	fibrin	glue	to	hold	
the	pieces	in	place,	this	was	grafted	onto	surgically	prepared	corneas	in	a	single	
theatre	session(132).	At	6	week	follow	up	stable	epithelized	corneas	were	seen.	
This	study	highlights	that	it	is	possible	to	combine	tissue	biopsies	to	regenerate	
new	epithelium	in	situ.	This	is	what	we	are	aiming	to	achieve	for	skin	epithelium	
regeneration.	
We	aim	to	have	a	similar	model	for	skin.	Clinically	this	would	translate	as	follows:	
a	 small	 biopsy	 of	 the	 patient’s	 skin	 is	 minced	 into	 very	 fine	 explants	 and	
combined	with	electrospun	scaffolds	and	secured	onto	the	surgically	prepared	
wound	bed.		It	is	expected	that	fibroblasts	and	keratinocytes	will	migrate	along	
the	 fibres	 of	 the	 scaffold	 to	 enhance	 wound	 healing	 without	 the	 need	 for	
culturing	cells	in	a	laboratory	and	further	theatre	sessions.	The	current	project	
seeks	to	develop	this	further	through	the	development	of	more	sophisticated	
electrospun	 biodegradable	membranes,	 containing	 3D	 features	 to	mimic	 the	
micro	topography	of	the	basement	membrane	and	rete	ridges.		
	 Furthermore,	we	aim	to	assess	the	role	of	fibrin	as	a	biological	stimulator	of	the	
migration	of	skin	cells	from	the	explants	onto	the	scaffolds.	Fibrin	is	component	
of	 haemostasis	 and	 used	 surgically	 as	 sealant.	 It	 can	 be	 prepared	 from	
autologous	 plasma	 and	 is	 available	 as	 an	 FDA	 approved	 product	 for	 clinical	
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applications(148).	The	approach	we	describe	could	become	a	key	addition	to	the	
plastic	surgeon’s	armamentarium	in	treating	full-thickness	skin	defects	and	 in	
helping	manage	patients	with	burns	that	ideally	require	reconstruction	using	full	
thickness	skin	grafts	but	lack	available	donor	sites.		
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Chapter	2	
	
Materials	and	Methods	
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2.1	Ethical	Permission	for	use	of	human	skin	
	
Ethical	 Permission	 was	 obtained	 from	 the	 NHS	 Health	 Research	 Authority,	
Yorkshire	 and	 Humber,	 Sheffield	 for	 the	 use	 of	 excess	 unwanted	 skin	 from	
reconstructive	cases	being	undertaken	in	the	plastic	and	reconstructive	surgery	
department	sited	both	at	the	Royal	Hallamshire	Hospital	and	Northern	General	
Hospital	under	a	research	tissue	bank	license	(number	15/YH/0017)	(Appendix	
2).	This	allowed	us	to	obtain	skin	from	any	operative	case	that	resulted	in	excess	
skin	 +/-	 subcutaneous	 fat	 that	would	 normally	 be	 incinerated.	 Patients	were	
consented	preoperatively	using	both	the	standard	Sheffield	Teaching	Hospitals	
Trust	consent	 form	in	addition	to	that	produced	by	Professor	Sheila	MacNeil,	
approved	 by	 the	 Sheffield	 Research	 and	 Ethics	 Committee	 (Appendix	 1).	 	 An	
honorary	clinical	contract	was	obtained	from	the	human	resources	department	
at	the	Sheffield	Teaching	Hospitals	in	order	to	facilitate	this	activity.	As	part	of	
the	consent	process,	it	was	a	requirement	to	provide	the	patient	with	a	written	
patient	information	leaflet,	which	contained	a	detailed	explanation	of	why	and	
how	the	skin	was	collected,	its	general	use	and	storage.	Furthermore,	it	provided	
essential	contact	details	of	the	research	team	in	case	the	patient	had	any	queries	
at	a	later	date	(Appendix	1).		Patient	anonymity	was	maintained	throughout	in	
accordance	 with	 the	 General	 Medical	 Council’s	 (GMC)	 Good	 Medical	
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Practice(149).	 The	 tissue	 was	 labelled	 and	 stored	 in	 an	 approved	 facility	 in	
keeping	with	the	guidelines	laid	out	by	the	Human	Tissue	Act	(HTA)	2004(150).		
	
2.1.1	Harvesting	Donor	Skin	
	
A	 Watson	 knife	 was	 procured	 from	 York	 Medical	 Technologies	 Limited	 and	
disposable	blades	were	obtained	from	Swann	Morton	Ltd,	Sheffield,	England.		
Skin	 was	 obtained	 in	 theatre	 from	 breast	 specimens	 (breast	 reductions	 or	
mastectomies)	or	brought	into	the	lab	for	harvesting	in	cases	of	free	flap	breast	
reconstruction.	 The	 method	 used	 at	 either	 site	 was	 the	 same.	 Skin	 was	
harvested	under	aseptic	conditions.	One	side,	the	specimen	was	secured	onto	a	
Styrofoam	 board	 with	 multiple	 21G	 hypodermic	 needles,	 (Fisher	 Scientific,	
Loughborough,	UK).	The	board	was	made	aseptic	by	covering	it	with	two	layers	
of	a	sterile	plastic	covering.	The	other	end	of	the	tissue	was	manually	stretched	
to	tension	the	specimen	appropriately.	A	sterile	No.	22	blade	(Swann	Morton,	
Sheffield,	UK)	was	mounted	on	a	scalpel	and	placed	into	the	space	between	the	
blade	 and	 the	 Watson	 knife	 handle	 to	 set	 the	 appropriate	 thickness	
(approximately	2mm).	Once	the	skin	was	harvested	it	was	placed	into	a	100mls	
universal	 sterile	pot	containing	a	mixture	of	phosphate	buffered	saline	 (PBS),	
penicillin/streptomycin	(50	i.u/ml	and	50μg/ml)	and	fungizone	(313μg/l)	(Sigma-
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Aldrich,	Dorset,	UK).	All	 specimens	were	 then	 labelled	with	a	unique	number	
that	was	anonymous	and	not	traceable	to	the	patient.	The	skin	collected	was	
recorded	 in	a	human	 tissue	 log	with	 the	 following	details:	date	of	 collection,	
tissue	collected	and	person	collecting	 it.	All	authorized	users	 thereafter	were	
required	 to	 complete	 the	user	 section	 in	 the	 log	before	 taking	 the	 tissue	 for	
further	use.	Specimens	were	stored	in	a	refrigerator	at	4°C.		After	3	weeks,	any	
unused	skin	+/-	subcutaneous	fat	was	sent	for	 incineration	as	per	the	Human	
Tissue	Authority	(HTA)	requirements.	Skin	explants	used	from	these	specimens	
were	 prepared	 on	 the	 day	 of	 skin	 harvest	 and	 cell	 isolation	 was	 performed	
within	four	days.		
	
2.2	Culture	Media		
	
2.2.1	Materials	
	
The	 following	 reagents	were	made	up	 in	 the	 lab	 for	use	 in	both	500mls	10%	
serum	Green’s	media	 and	 10%	 serum	 (Dulbecco’s	Modified	 Eagle’s	Medium,	
Sigma-Aldrich,	Dorset,	UK)	DMEM	respectively.		
• Penicillin/streptomycin	 (Sigma-Aldrich,	 Dorset,	 UK)	 consisted	 of	 10,000	
i.u/ml	 penicillin	 and	 10,000μg/ml	 Streptomycin.	 Final	 media	
concentration:	100	i.u/ml	penicillin	and	100	μg/ml	streptomycin	
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• Fungizone	 (Sigma-Aldrich,	 Dorset,	 UK):	 Amphotericin	 B	 250μg/ml,	 final	
media	concentration:	0.625μg/l	
• Adenine	(Sigma-Aldrich,	Dorset,	UK):	2g	of	adenine	powder	was	added	to	
280	ml	of	sterile	distilled	water	and	then	acidified	in	1M	hydrochloric	acid	
(HCL)	until	dissolved.	This	was	made	up	to	320	ml	using	distilled	water.	It	
was	then	filtered	to	sterilize.	Final	media	concentration:	184	μM	
• Insulin	(human	recombinant)	(Sigma-Aldrich,	Dorset,	UK)	1mg/ml:	250mg	
of	 human	 recombinant	 insulin	 was	 weighed	 out	 and	 to	 this	 25mls	 of	
0.01M	HCL	was	added	to	dissolve	the	powder.		225	ml	of	distilled	water	
was	 then	 added.	 It	 was	 then	 filtered	 to	 render	 it	 sterile.	 Final	 media	
concentration:	5μg/ml		
• 3,3,5	 –Tri-iodo-L-thyronine	 (T3)/Apo-Transferrin	 (TT)	 (Sigma-Aldrich,	
Dorset,	UK):	13.6mg	T3	was	dissolved	in	0.02M	sodium	hydroxide	(NaOH).	
The	volume	was	then	made	up	to	100ml	using	distilled	water	and	filtered	
to	render	it	sterile.	100mg	of	apo-transferrin	was	dissolved	in	12	mls	of	
distilled	water	over	30-60	minutes.	0.2ml	T3	was	then	added	and	volume	
made	up	to	20ml	using	distilled	water,	this	was	again	filtered	to	render	it	
sterile.	Final	media	concentration:	T3:	1.36	μg	/l	and	transferrin	5mg/l	
• Hydrocortisone	(Sigma-Aldrich,	Dorset,	UK):	50mg	of	hydrocortisone	was	
dissolved	in	2ml	sterile	distilled	water	and	to	this	18mls	of	sterile	PBS	was	
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added.	It	was	further	sterilized	using	a	filter.	Final	media	concentration:	4	
μg/ml	
• Epidermal	 Growth	 Factor	 (Human	 recombinant)	 (EGF)	 (R&D	 systems,	
Biotechne):	20μl	foetal	calf	serum	was	added	to	2mls	acetic	acid	(10mM).	
1ml	of	this	was	added	to	a	vial	containing	200μg	EGF	powder	and	mixed	
to	 dissolve.	 25μl	 aliquots	 were	 used	 in	 making	 media.	 Final	 media	
concentration:	10μg/l	
• Cholera	 Toxin	 (Sigma-Aldrich,	 Dorset,	 UK):	 1mg	 Cholera	 Toxin	 was	
dissolved	 in	1.18ml	distilled	water.	0.1ml	of	 this	 solution	was	added	to	
10ml	 medium	 with	 serum	 to	 form	 8.47pg/l	 stock.	 Final	 media	
concentration:	8.47	pg/l.	
	
2.2.2	10%	Serum	Green’s	Media		
	
This	was	used	for	keratinocyte	culture	and	used	in	all	experiments.	It	was	made	
under	 sterile	 conditions	 by	 combining	 the	 following	 components	 at	 room	
temperature	in	a	Class	II	laminar	flow	hood:	108mls	Nutrient	Mixture	F-12	HAM,	
(Sigma-Aldrich,	Dorset,	UK)	330	mls	of	DMEM,	5mls	of	penicillin/streptomycin,	
1.25mls	of	 fungizone,	50	mls	of	 foetal	calf	serum	(Sigma-Aldrich,	Dorset,	UK),	
2mls	adenine,	2.5	mls	 insulin,	0.5mls	TT,	0.08ml	hydrocortisone,	0.025ml	EGF	
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and	 0.5mls	 of	 cholera	 toxin.	 This	was	 labelled,	 dated	 and	 stored	 in	 a	 sterile	
500ml	Duran	bottle	at	4°C	in	between	uses.		
	
2.2.3	10%	serum	DMEM	
	
This	 was	 used	 for	 fibroblast	 culture	 and	 was	 made	 and	 stored	 in	 the	 same	
conditions	as	above	by	combining	 the	 following	 reagents:	440	mls	of	DMEM,	
5mls	 of	 penicillin/streptomycin,	 1.25mls	 of	 fungizone,	 50	 mls	 of	 foetal	 calf	
serum,	2mls	adenine,	2.5	mls	insulin,	0.5mls	TT,	0.08ml	hydrocortisone,	0.025ml	
EGF	and	0.5mls	of	cholera	toxin.		
	
	
2.2.4	Serum	free	Media	
	
10%	 serum	 free	 Green’s	media	 and	 10%	 serum	 free	 DMEM	was	 used	when	
labelling	fibroblasts	and	keratinocytes	with	the	fluorescent	markers	CellTracker	
green	(CMFDA)	and	CellTracker	red	(CMTPX)	(Invitrogen,	USA)	respectively.	The	
conditions	for	producing	and	storing	the	media	were	the	same	as	above.	The	
reagents	for	10%	serum	free	Green’s	media	were:	120mls	Nutrient	Mixture	F-12	
(HAM),	367	mls	of	DMEM,	5mls	of	penicillin/streptomycin,	1.25mls	of	fungizone,	
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2mls	adenine,	2.5	mls	bovine	insulin,	0.5mls	TT,	0.08ml	hydrocortisone,	0.05ml	
EGF	 and	 0.5mls	 of	 cholera	 toxin.	 For	 10%	 serum	 free	 DMEM,	 the	 following	
reagents	were	combined:	489	mls	of	Dulbecco’s	Modified	Eagles’	Medium,	5mls	
of	penicillin/streptomycin	and	1.25mls	of	fungizone.	
	
	
2.3	Cell	Culture	
	
2.3.1	Materials	
	
The	following	reagents	were	prepared	in	the	laboratory	for	use	in	cell	culture:		
• Difco-Trypsin	 0.1%	 (w/v)	was	 prepared	 by	 adding	 0.5g	 of	Difco	 trypsin	
powder	(Difco,	West	Molesey,	Surrey,	UK)	to	0.5	g	D-glucose	and	500-μl	
phenol	red	and	topped	up	to	500mls	PBS.	The	pH	was	made	to	7.45	using	
2M	NaOH	 and	 sterilized	 by	 filtering.	 It	was	 stored	 and	 used	 in	 10	mls	
aliquots	for	cell	culture	purposes.		
• Collagenase	A	from	the	bacterium	Clostridium	histolyticum	was	made	by	
dissolving	 100mg	 collagenase	 A	 powder	 (Roche	 Laboratories,	 West	
Sussex,	U.K)	in	180mls	10%	serum	free	DMEM.	This	was	then	filtered	to	
sterilize	 and	 20mls	 of	 foetal	 calf	 serum	 (FCS)	 was	 then	 added.	 This	
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resulted	in	a	0.05%	(w/v)	solution.	The	solution	was	used	in	10ml	aliquots	
for	fibroblast	isolation.		
	
2.3.2	Preparation	of	 irradiated	mouse	3T3	 (i3T3)	 fibroblast	 feeder	 layers	on	
T75	flasks	
	
Green’s	media	containing	10%	serum	was	warmed	and	a	Class	II	tissue	culture	
cabinet	was	prepared.	Using	the	appropriate	safety	gear,	the	required	number	
of	 cryovials	 containing	 i3T3	 cells	 (irradiated	 with	 a	 dose	 of	 60	 Greys)	 were	
removed	from	the	liquid	nitrogen	dewar	and	placed	in	a	37°C	incubator	until	just	
thawing.	 The	 thawed	 cells	were	 transferred	 to	 a	 sterile	 30	ml	universal	 tube	
containing	10%	serum	Green’s	media.	This	was	then	centrifuged	at		1000	rpmfor	
five	 minutes.	 The	 supernatant	 was	 discarded	 and	 isolated	 cell	 pellet	 was	
resuspended	in	5mls	of	10%	serum	Green’s	Media.	The	cells	were	counted	using	
the	method	outlined	below.		If	needed	more	media	was	added	to	the	cells	to	
obtain	 a	 concentration	 of	 1	 x	 106	 cells/ml.	 	 An	 appropriate	 volume	 of	 cell	
suspension	 was	 then	 transferred	 to	 T75	 flasks	 to	 obtain	 a	 final	 seeding	
concentration	of	1	x106	cells.	Media	was	then	topped	up	to	10	mls	and	this	was	
incubated	at	37°C,	humidified	atmosphere	5%	CO2	overnight.	 	 The	 cells	were	
inspected	the	following	day	to	observe	for	confluence	and	to	exclude	infection.		
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2.3.3	Keratinocyte	Isolation	from	human	skin	
	
On	the	day	of	skin	harvest,	a	sterile	forceps	was	used	to	place	the	split	thickness	
skin	sample	in	a	90mm	petri	dish	containing	a	small	volume	of	PBS.	A	sterile	No.	
22	blade	was	used	to	cut	the	skin	in	1cm2	square	pieces.		The	skin	pieces	were	
then	transferred	to	a	sterile	30	ml	universal	container	containing	15mls	of	Difco	
–trypsin	and	incubated	overnight	at	4°C.		After	12-20	hours,	the	skin	suspension	
was	removed	from	the	refrigerator	and	a	sterile	 forceps	was	used	to	remove	
one	piece	of	skin	from	the	Difco-trypsin,	rinsed	in	sterile	PBS	then	placed	in	a	
dry	petri	dish	with	the	dermis	side	down.	A	few	drops	of	PBS	were	added	to	keep	
the	skin	moist.	The	sterile	 forceps	was	then	used	to	peel	the	epidermis	away	
from	the	dermis.	If	this	occurred	easily,	the	Difco-trypsin	was	poured	away	into	
a	waste	pot	without	disturbing	the	skin.	10-15	mls	of	FCS	was	added	to	the	bottle	
to	negate	the	action	of	 the	Difco-	 trypsin.	 If	 the	epidermis	did	not	peel	away	
easily	 from	 the	dermis	 then	 the	 skin	 suspension	 containing	 the	Difco-Trypsin	
was	returned	to	4°C	until	the	epidermis	was	easily	removed.		
The	process	of	peeling	away	the	epidermis	was	repeated	for	all	the	skin	squares.		
A	sterile	No.	22	blade	was	then	used	to	very	gently	scrape	the	cells	from	both	
the	 papillary	 surface	 of	 the	 dermis	 and	 the	 underside	 of	 the	 epidermis.	 The	
epidermis	was	then	placed	in	a	labelled	petri	dish	for	incineration	and	the	dermis	
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was	kept	aside	for	later	use	in	fibroblast	culture.	As	the	cells	are	scraped	from	
these	surfaces	 the	PBS	became	 increasingly	cloudy.	 	A	sterile	Pasteur	pipette	
was	used	 to	 collect	 the	PBS	 containing	 the	 cells,	which	was	 then	added	 to	 a	
sterile	30	mls	universal	tube	containing	10-15ml	of	10%	serum	Green’s	media.		
	
2.3.4	Keratinocyte	Culture		
	
Once	 the	 keratinocytes	 were	 harvested	 from	 all	 the	 skin	 pieces,	 the	 30	 ml	
Universal	tube	was	centrifuged	at	1000	rpm	for	5	minutes.	The	supernatant	was	
decanted	and	the	cell	pellet	was	broken	by	tapping	the	tube	on	the	base	of	the	
culture	cabinet.	The	cells	were	re-suspended	in	10	mls	of	10%	serum	Green’s	
media	and	mixed	thoroughly.	The	cells	were	then	counted	(see	cell	count	and	
viability	assessment	below).	Depending	on	the	cell	count,	 the	volume	of	10%	
serum	 Green’s	 media	 was	 adjusted	 to	 give	 a	 final	 concentration	 of	 1	 x	 106	
cells/ml.	 	 A	 sterile	 plastic	 pipette	was	 then	 used	 to	 dispense	 an	 appropriate	
volume	of	cell	suspension	into	T75	flasks	containing	a	feeder	layer	of	i3T3	cells	
(see	section	on	preparing	a	feeder	layer	of	i3T3	cells).	As	a	guide,	primary	(p1)	
keratinocytes	were	seeded	not	less	than	1.5	x	106	cells	per	flask.	The	volume	was	
made	up	to	10-13	mls	per	flask	by	adding	10%	serum	Green’s	as	appropriate.	
The	cells	were	spread	gently	across	the	flasks	by	gently	sliding	the	flasks	from	
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side	to	side	and	then	placed	in	an	incubator	at	37°C,	humidified	atmosphere	5%	
CO2	overnight.	After	48	hours	in	culture,	the	flasks	were	examined	under	a	light	
microscope	for	confluence	and	to	exclude	infection.	The	media	was	changed	as	
appropriate.	This	continued	until	cells	were	60-70%	confluent.	At	this	point	they	
were	either	passaged,	subjected	to	freezing	or	used	in	experiments.		
2.3.5	Passage	of	Keratinocytes	
	
This	occurred	when	the	keratinocytes	were	about	60-70%	confluent.	24	hours	
prior	to	passaging	the	keratinocytes	for	expansion,	feeder	layers	of	i3T3	cells	in	
T75	 flasks	 were	 prepared.	 10%	 serum	 Green’s	 media,	 0.02%	 EDTA	 solution	
(Sigma-Aldrich,	 Dorset,	 UK)	 and	 5mls	 of	 trypsin-EDTA	 (Sigma-Aldrich,	 Dorset,	
UK)	were	warmed	to	37°C	in	the	incubator	before	use.	A	sterile	plastic	pipette	
was	used	to	remove	all	the	culture	medium	from	the	T75	flask.	The	flasks	were	
then	washed	three	times	with	PBS.	5mls	of	0.02%	EDTA	solution	was	added	to	
each	flask	and	returned	to	the	37°C	incubator	for	five	minutes.	After	this	time	
the	flasks	were	removed	from	the	incubator,	the	sides	were	gently	tapped	and	
they	were	viewed	under	the	light	microscope	to	assess	for	evidence	of	detached	
i3T3	 cells.	 If	 necessary,	 the	 flasks	were	 returned	 to	 the	 37°C	 incubator	 for	 a	
further	five	minutes.	Once	the	i3T3s	were	detached	the	EDTA	was	removed	and	
discarded.		2mls	of	trypsin-	EDTA	was	then	added	to	the	flask,	gently	swirled	and	
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incubated	at	37°C	for	10	minutes.	After	this	time,	they	were	removed	from	the	
incubator,	 the	 sides	gently	 tapped	and	viewed	under	 the	 light	microscope	 to	
ensure	that	all	keratinocytes	were	detached.	Once	confirmed,	the	trypsin-	EDTA	
cell	suspension	was	placed	into	a	sterile	30	ml	universal	tube.	To	this	an	equal	
volume	of	10	%	serum	Green’s	was	added.	It	was	then	centrifuged	at	200	g	(1000	
rpm)	for	5	minutes.	The	supernatant	was	decanted	and	the	pellet	was	dislodged	
by	tapping	the	tube	on	the	base	of	the	culture	cabinet.	The	cells	were	then	re-
suspended	 in	5	mls	of	10	%	Green’s	medium	and	mixed	thoroughly	and	then	
counted.	If	needed	more	10%	serum	Green’s	medium	was	added	to	give	a	final	
concentration	of	1	x	106	cells	per	ml.	A	sterile	pipette	was	then	used	to	dispense	
an	appropriate	volume	of	the	cell	suspension	into	a	T75	flask	containing	a	feeder	
layer	of	i3T3	cells.	As	a	guide,	p2	and	p3	keratinocytes	were	seeded	at	2	x	106	
cells	per	T75	flask.	The	flasks	were	topped	up	with	an	appropriate	volume	of	
10%	 serum	 Green’s	 media	 and	 placed	 in	 an	 incubator	 at	 37°C,	 humidified	
atmosphere	 5%	 CO2	 overnight.	 The	 cells	 were	 inspected	 daily	 under	 the	
microscope	and	 the	media	changed	every	2	 -3	days	 thereafter.	At	60	–	70	%	
confluence	 the	 cells	 were	 passaged,	 frozen	 or	 used	 for	 seeding.	 For	 these	
experiments	p1-p3	keratinocytes	were	used.		
	
2.3.6	Fibroblast	Isolation	from	Human	Epidermis	
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Using	the	small	squares	of	split	thickness	dermis	that	was	denuded	of	epidermis	
from	keratinocyte	isolation,	a	sterilized	No.	22	blade	was	used	to	mince	it	into	
very	fine	pieces	(2-3mm2).	A	sterilized	forceps	was	used	to	transfer	the	pieces	of	
dermis	 into	 a	 sterile	 petri-dish	 containing	 10mls	 of	 Collagenase	 A.	 This	 was	
incubated	 in	 37°C,	 humidified	 5%	 CO2	 overnight.	 The	 following	 day,	 the	
Collagenase	A/dermis	suspension	was	 inspected	to	ensure	that	all	 the	dermis	
was	digested	(cloudy	appearance).	Any	pieces	of	residual	dermis	were	removed	
using	 a	 sterile	 forceps	 and	 discarded	 into	 a	 labelled	 30ml	 universal	 tube	 for	
incineration.		
	
2.3.7	Fibroblast	Culture		
	
The	fibroblast	suspension	was	decanted	into	a	sterile	30	ml	universal	tube,	and	
centrifuged	at	400g	(2000	rpm)	for	ten	minutes.	The	supernatant	was	discarded	
carefully	and	the	remaining	cell	pellet	was	dislodged	by	tapping	the	tube	on	the	
base	of	the	culture	cabinet.	The	cells	were	then	resuspended	in	5	mls	of	serum	
10%	DMEM.	They	were	then	counted	(see	counting	cells)	and	if	needed	further	
10%	serum	DMEM	was	added	to	obtain	a	concentration	of	1	x	106	cells	per	ml.	
The	cell	suspension	was	then	transferred	into	T25	flasks	(25	cm2),	as	a	guide	0.5-
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1	x	106	primary	(p1)	fibroblasts	were	seeded	per	flask.	The	media	volume	in	each	
flask	was	made	up	 to	7	ml.	The	cells	were	spread	across	 the	 flasks	by	gently	
sliding	the	flasks	and	incubated	at	37°C,	in	a	humidified	atmosphere	of	5%	CO2.		
The	cells	were	inspected	daily	under	the	light	microscope	for	confluence	and	to	
exclude	infection.	The	first	media	changed	occurred	at	48	hours	and	three	times	
a	week	thereafter.	This	was	continued	until	the	cells	became	60-70	%	confluent	
(usually	5-7	days).		
	
	
	
2.3.8	Passage	of	fibroblasts	
	
This	 was	 performed	 when	 the	 cells	 were	 60-70	 %	 confluent.	 The	 flasks	 of	
fibroblasts	 were	 removed	 from	 the	 incubator,	 media	 discarded	 and	 washed	
three	times	with	sterile	PBS.	3mls	of	Trypsin-EDTA	was	added	to	each	flask	and	
incubated	at	37°C,	in	a	humidified	atmosphere	of	5%	CO2	for	five	to	ten	minutes.	
They	were	then	removed	from	the	incubator	and	the	sides	of	the	flasks	were	
gently	tapped	to	aid	cellular	dislodging.	The	flasks	were	inspected	under	 light	
magnification	 to	 confirm	 that	 all	 the	 cells	 had	 detached.	 Once	 this	 was	
confirmed	the	fibroblast-	trypsin	EDTA	suspension	was	placed	into	a	sterile	30	
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ml	universal	tube.	To	this	an	equal	volume	of	10%	serum	DMEM	was	added.	It	
was	then	centrifuged	for	400g	(2000	rpm)	for	10	minutes.	The	supernatant	was	
discarded	and	the	cell	pellet	dislodged	by	tapping	the	base	of	the	tube	against	
the	tissue	culture	cabinet.	The	cells	were	resuspended	in	5	mls	of	10%	serum	
DMEM,	mixed	 thoroughly	 and	 counted.	 If	 needed	 further	10%	 serum	DMEM	
was	added	to	obtain	a	final	concentration	of	1	x	106	cells	per	ml.	The	cellular	
suspension	was	then	placed	into	newly	labelled	T75	flasks	and	topped	up	to	10-
12	mls	of	10%	serum	DMEM.	As	a	guide	p2	and	p3	fibroblasts	were	seeded	at	3	
x	 105	 cells	 per	 T75	 flask.	 The	 cells	 were	 then	 spread	 across	 the	 flasks	 and	
incubated	at	37°C,	humidified	5%	CO2	overnight.	Cells	were	inspected	daily	to	
observe	for	confluence	and	to	exclude	infection	with	media	changes	every	2-3	
days.		
	
2.3.9	Cell	count	and	viability	assessment.		
	
This	was	performed	using	Trypan	blue	(mixture	of	0.4%	trypan	blue	and	PBS,	
Sigma-Aldrich,	Dorset,	UK).	Once	the	cell	suspension	was	centrifuged	and	the	
supernatant	discarded	the	resultant	cell	pellet	was	mechanically	dislodged	by	
tapping	it	against	the	side	of	the	tissue	culture	hood.	To	this	a	known	volume	of	
either	 10%	 serum	 DMEM	 (for	 fibroblasts)	 or	 10%	 serum	 Green’s	 (for	
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keratinocytes)	 was	 added	 and	 mixed	 thoroughly.	 A	 200μl	 micropipette	 and	
sterile	tip	was	used	to	remove	50	μl	of	the	cell	suspension	and	added	to	50μl	of	
trypan	blue	in	a	sterile	7ml	bijou.	This	was	then	mixed	thoroughly	by	pipetting	
up	and	down	2-3	times.		50μl	of	this	trypan	blue-	cell	suspension	was	then	added	
into	 the	 two	 counting	 chambers	 of	 a	 Neubauer	 haemocytometer	 (Fisher	
Scientific,	Loughborough	UK)	and	placed	under	a	 light	microscope.	The	viable	
cells	(unstained)	were	counted	in	each	chamber	and	averaged	for	the	two.	This	
was	then	multiplied	by	the	volume	in	mls	of	the	resuspended	cells	and	multiplied	
by	105	to	obtain	the	number	of	cells	in	that	volume	of	cell	suspension.		
2.3.10	Cell	cryopreservation	
	
Flasks	containing	cells	were	removed	from	the	incubator,	media	discarded	and	
washed	twice	with	PBS.	5mls	of	trypsin/EDTA	was	then	added	to	each	flask	and	
incubated	 at	 37°C,	 in	 a	 humidified	 atmosphere	 of	 5%	 CO2	 for	 ten	 to	 fifteen	
minutes.	After	this	time,	they	were	gently	tapped	against	the	sides	of	the	culture	
cabinet	to	aid	cellular	detachment	and	inspected	under	the	light	microscope	to	
confirm	this.	The	cell/trypsin	EDTA	suspension	was	transferred	to	a	sterile	30	ml	
universal	tube	and	the	trypsin	deactivated	by	adding	an	equivalent	amount	of	
either	10%	serum	DMEM	(fibroblasts)	or	10%	serum	Green’s	(keratinocytes).		It	
was	then	centrifuged	at	200	g	(1000	rpm)	for	5	minutes.	The	supernatant	was	
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discarded	and	cells	resuspended	in	5mls	of	media.	The	cells	were	then	counted.	
Freezing	media	was	made	by	adding	3mls	of	dimethyl-sulphoxide	(DMSO,	Alfa	
Aesar,	USA)	 to	 30	mls	 of	 FCS	 to	make	 a	mixture	of	 10%	DMSO	 in	 FCS.	Once	
counted	the	cells	were	again	centrifuged	at	200g	(1000	rpm)	for	5	minutes.		The	
supernatant	 was	 discarded	 and	 the	 cellular	 pellet	 was	 resuspended	 in	 an	
appropriate	volume	of	the	freezing	medium	to	obtain	a	cell	count	of	1x	106	cells	
per	ml.	A	sterile	pipette	was	used	to	add	1	ml	of	this	cell/freezing	medium	to	
labelled	cryovials	(CryoPure	Tubes,	Sarstedt	AG	&Co.)	These	were	then	placed	
in	a	Mr	Frosty	(Sigma-Aldrich,	Dorset	UK)	freezing	container	and	into	the	-80°C	
freezer	for	2-4	hours.		Following	this	the	cryovials	were	transferred	into	liquid	
nitrogen	(-196°C)	for	long-term	storage.	
	
2.3.11	Thawing	of	cells	
	
The	 required	numbers	of	vials	containing	cells	were	 removed	 from	the	 liquid	
nitrogen	left	to	defrost	at	room	temperature.	They	were	then	transferred	to	a	
sterile	30	ml	universal	tube	containing	10	mls	of	the	appropriate	pre-warmed	
media	 depending	 on	 the	 cell	 type.	 The	mixture	was	 the	 centrifuged	 at	 200g	
(1000	rpm)	for	five	minutes.	The	supernatant	was	discarded	and	the	cell	pellet	
was	resuspended	in	5	mls	of	the	appropriate	media	and	counted	using	trypan	
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blue.	 Cells	 were	 then	 re-centrifuged	 or	 more	 media	 added	 to	 obtain	 a	
concentration	depending	on	the	need.		
	
2.4	Preparation	of	Skin	Explants	
 
On	the	day	skin	harvest,	5	x	5	mm2	square	pieces	of	skin	were	cut	using	a	sterile	
No.	22	Scalpel	in	a	sterile	petri	dish	in	a	few	drops	of	PBS	to	keep	the	skin	moist.	
These	 were	 then	 finely	 minced	 into	 approx.	 16-20	 squares.	 To	 this,	 a	 small	
amount	of	10%	serum	Green’s	media	was	added	 to	 create	a	 suspension.	 For	
each	experimental	construct	mince	from	one	square	was	used.		
	
	
2.5	Preparation	of	Euro	Skin	
	
This	was	obtained	 from	 the	Euro	 Skin	Bank,	 Zeestraat,	Netherlands.	 This	 is	 a	
national	 tissue	bank	 that	collects	and	preserves	split	 thickness	human	skin	 in	
glycerol.	Clinically	it	serves	as	a	temporary	wound	dressing	for	wounds.		
To	 prepare	 the	 Euro	 Skin,	 they	 were	 firstly	 rehydrated	 in	 a	 sterile	 100ml	
universal	pot	using	sterile	PBS	for	24	hours.	Following	this	the	PBS	was	discarded	
and	the	rehydrated	skin	was	immersed	in	an	excess	1M	sodium	chloride	(NaCl)	
solution	and	incubated	overnight	at	37°C,	in	a	humidified	atmosphere	of	5%	CO2.	
At	this	point	the	epidermis	was	visibly	separated	from	the	dermis.	This	made	it	
easier	to	remove	any	remaining	adherent	epidermis	with	a	sterile	No.	22	blade.	
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The	de-epithelized	dermis	(DED)	was	then	washed	twice	with	PBS.	At	this	point,	
the	DED	was	 incubated	with	Green’s	media	to	remove	any	remaining	sodium	
chloride	for	at	least	48	hours	before	use.		For	experiments	15	x	15	mm2	square	
pieces	of	skin	was	used	in	constructs.		
		
2.5.1	Mechanical	testing	of	Euro	Skin	and	human	skin	used	for	explants		
	
Mechanical	 testing	was	carried	out	 in	 the	MacNeil	 laboratory	using	the	same	
method	for	electrospun	scaffolds.	Prior	to	mechanical	testing,	the	Euro	Skin	was	
left	to	warm	to	room	temperature.		A	sterile	No.	22	blade	was	used	to	remove	
the	epidermis	and	cut	 into	15	x	14mm	rectangular	 strips.	These	were	placed	
again	 in	 sterile	 PBS	 to	 ensure	 that	 they	 were	 hydrated.	 Thickness	 was	 then	
measured	using	a	digital	micrometer.	Uniaxial	tensile	testing	was	performed	in	
air	 at	 room	 temperature	 set	 at	 a	 rate	 of	 0.1	 mm/sec	 with	 a	 maximum	
displacement	of	10	mm	in	the	direction	of	the	long	axis	of	the	samples.		Analysis	
followed	the	method	outlined	below	for	electrospun	scaffolds.		
	
2.6	Preparation	of	Electrospun	Scaffolds	
	
2.6.1	Polymer	Preparation	
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For	 these	 experiments	 electrospun	 scaffolds	 were	 made	 from	 two	
biodegradable	 synthetic	 polymers.	 The	 first	 one	 was	
Polyhydroxybutyrate/Polyhydroxyvalerate	 (PHBV)	 12%	 biopolymer	
(Goodfellow,	Cambridge	limited,	Huntingdon,	England)	which	was	used	as	the	
middle	 layer	 of	 the	 trilayer	 scaffold.	 Poly	 (D,	 L-lactide-co-glycolide)	 lactide:	
glycolide	75:25	(PGLA)	 (Sigma-Aldrich,	Dorset,	UK)	was	used	on	either	side	of	
the	PHBV	to	complete	the	trilayer	construct.	PHBV	was	weighed	out	into	a	glass	
bottle.	To	this	an	appropriate	quantity	of	10	%	wt./volume	methanol	and	80%	
wt.	 dichloromethane	 (solvent	 ratio	 88.8:11.1	 DCM-MeOH	 (Sigma-Aldrich,	
Dorset	 UK)	 was	 added	 using	 a	 glass	 pipette	 to	 obtain	 10	 %	 wt.	 /v	 PHBV.	 The	
mixture	was	placed	onto	a	stirrer	and	kept	overnight	for	dissolving.	10	%	wt.	/v	
PGLA	(75:25)	polymer	solutions	were	similarly	made	by	dissolving	the	polymer	
in	 the	appropriate	volume	of	dichloromethane	 (DCM)	 (Sigma-Aldrich,	Dorset,	
UK)	depending	on	the	volume	of	the	polymer	that	was	required.		
	
	
2.6.2	Electrospinning	Conditions		
	
The	electrospun	scaffolds	used	in	these	experiments	were	trilayer	consisting	of	
a	middle	core	of	PHBV	and	on	either	side	PGLA	(75:	25).		
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They	were	also	templated	with	niches	to	mimic	the	rete	ridges	or	the	stem	cell	
niches	 found	 in	 the	 dermal-epidermal	 junction	 of	 skin.	 These	 niches	 were	
templated	onto	the	scaffolds	using	a	textured	metal	collector	(Figure	2.1).	
The	first	polymer,	PHBV	was	loaded	into	4	x	5ml	syringes	(1	ml	in	each	syringe)	
and	 fitted	with	 a	 blunt	 tipped	 needle,	 0.8cm	 internal	 diameter	 (Intertronics,	
Kidlington,	UK).	All	four	syringes	were	placed	into	a	single	syringe	driver	(Genie	
Plus,	Kent	Scientific,	Connecticut,	USA)	with	a	fitted	plastic	backing	to	facilitate	
driving	all	four	syringes	at	the	same	time.		
The	copper	board	collector	was	wrapped	in	one	layer	of	aluminium	foil	with	the	
shiny	side	facing	the	syringe	driver.	The	metal	templates	were	attached	to	the	
middle	 of	 the	 copper	 board	 using	 carbon	 conductive	 tape	 (Agar	 Scientific,	
Stanstead,	UK)	(Figure	2.2).		
Adhesive	tape	was	used	to	attach	the	prepared	collector	to	a	mandrel	20	cm	
wide	and	10	cm	in	diameter.	The	spinning	occurred	under	static	conditions.		
A	perforated	6x6	cm	copper	plate	was	fitted	over	all	4	needles	and	a	crocodile	
tip	 from	a	metal	 generator	was	attached	 to	one	of	 the	needles.	 The	needles	
were	positioned	11cm	from	the	copper	collecting	board	when	PHBV	was	used.	
The	metal	collector	was	then	connected	to	a	voltage	generator	set	at	17kV	and	
earthed.	The	syringe	driver	was	turned	on	at	a	rate	of	4mls/hour,	ensuring	that	
the	diameter	was	set	to	12.06mm.	The	voltage	generator	was	then	switched	on	
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(Figure	2.3).	The	Taylor	cones	were	removed	with	a	wooden	collector.	Once	the	
syringes	of	PHBV	were	finished,	four	new	syringes	containing	the	PGLA	(75:25)	
were	then	loaded	onto	the	syringe	driver	and	fitted	with	the	same	blunt	needle	
tips.	 The	 tip	of	 the	needle	was	now	positioned	17	 cm	 from	 the	 foil	wrapped	
copper	 collector.	 The	 syringe	 driver	 had	 the	 same	 settings	 as	 the	 PHBV.	 The	
syringe	driver	was	then	turned	on	followed	by	the	generator	set	at	17kV.	Once	
the	 syringes	 containing	 PGLA	 (75:25)	were	 empty,	 the	 scaffold	was	 removed	
from	 the	 collector,	 turned	 over	 and	 re-attached	 to	 the	 copper	 board	 using	
adhesive	tape.	A	further	4	x	5	ml	syringes	containing	PGLA	75:25	were	loaded	
onto	the	syringe	driver	and	electrospun	to	 form	the	final	 layer	of	 the	trilayer	
scaffold.	Once	completed,	the	scaffolds	were	stored	in	a	sterile	plastic	bag	and	
placed	in	a	freezer	at	-12°C	until	use.	In	order	to	make	non-templated	scaffolds,	
the	conditions	were	the	same	apart	from	omitting	the	use	of	the	textured	metal	
templates.			
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Figure	2.1:	Top:	Metal	template	with	coin	next	to	it	for	scaling	purpose,	Bottom:	
illustration	of	the	pattern	of	the	metal	templates	to	illustrate	the	small	square	
structures	used	to	imprint	the	template	to	aid	creation	of	the	niches.		
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Figure	2.2	Conductive	 copper	board	wrapped	 in	 foil	with	 the	metal	 collectors	
attached	using	carbon	conductive	tape	
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Figure	2.3:	Electrospinning	process	demonstrating	the	set	up.			
A:	 loaded	 syringes	 with	 polymer,	 B:	 Copper	 Plate	 fitted	 to	 the	 Blunt	 tipped	
needles,	 C:	 Crocodile	Clip	 connected	 to	 the	17kV	Generator,	D:	Collector	with	
Metal	templates	attached	
	
2.6.3	Selective	Laser	Melt	Collectors	
	
These	were	obtained	from	Dr	Ilida	Ortega’s	research	group	based	in	the	School	
of	Clinical	Dentistry	at	 the	University	of	Sheffield.	 	These	were	manufactured	
using	a	Renishaw	SLM	125	machine	(Renishaw,	Gloucestershire,	UK)	
	and	 316L	 stainless	 steel.	 The	 plates	 were	made	 using	 a	 range	 of	 niche	 like	
morphologies	 designed	 using	 the	 computer	 aided	 software	 Solidworks,	
A B 
C 
D 
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(Dassault	Systèmes	SOLIDWORKS	Corp).	The	specific	processing	parameters	for	
the	 fabrication	 of	 the	 collectors	 were	 as	 follows:	 laser	 power	 200W;	 speed:	
480nm/s;	point	distance:	50	μm	and	exposure	time	70μs.		
	
2.6.4	Sterilization	of	electrospun	scaffolds		
	
All	scaffolds	were	sterilized	before	use,	by	methods	previously	established	in	the	
MacNeil	Laboratory.	Once	the	squares	of	scaffolds	were	cut	to	the	desired	size	
(usually	1.5x	1.5	cm2	pieces)	for	use	in	experiments,	they	were	placed	in	a	sterile	
100ml	 universal	 pot	 containing	 70%	 ethanol	 (Fisher	 Scientific,	 Loughborough	
UK)	 for	15	minutes.	Following	this	they	were	washed	three	times	with	sterile	
PBS	and	left	to	air	dry	in	a	tissue	culture	hood	overnight.		They	were	then	used	
in	experiments	or	stored	in	sterile	plastic	bags	for	later	use	in	a	freezer	at	-12°C.	
	
2.6.5	Mechanical	Testing	of	Electrospun	Scaffolds		
	
Mechanical	properties	were	measured	using	a	uniaxial	tensile	test.	The	device	
used	 in	 the	 laboratory	 to	 conduct	 this	 test	was	 a	 uniaxial	 tensiometer	 (Bose	
Electroforce	 test	 instrument,	 Bose,	 Minnesota,	 USA).	 The	 calibration	 of	 the	
selected	22N	load	cell	was	checked	before	using	the	instrument	and	was	found	
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to	be	satisfactory	using	linear	regression	analysis	(R2	=	0.9997).	Samples	were	
cut	 into	rectangular	pieces	of	at	 least	15mm	by	4	mm,	and	measurements	of	
width	and	thickness	were	obtained	using	a	digital	micrometer.	Samples	were	
clamped	with	two	grips	in	the	tensiometer,	ensuring	10	mm	in	distance	between	
the	grips	(Figure	2.4),	and	the	device	was	pre-tuned	to	the	particular	scaffold	
that	was	being	tested.		A	ramp	test	was	applied	at	a	rate	of	0.1	mm/sec	with	a	
maximum	 displacement	 of	 10	 mm	 on	 the	 direction	 of	 the	 long	 axis	 of	 the	
samples.	Stress	was	normalized	by	the	area	(width	x	thickness)	and	the	strain	by	
the	tested	length	of	the	samples	(all	10	mm).	The	values	were	analysed	using	an	
OriginPro	8	Software	(obtained	from	the	University	of	Sheffield).	The	first	failure	
point	or	plateau	was	recorded	as	the	load	at	failure	(or	ultimate	tensile	strength,	
UTS)	and	the	slope	of	this	plot	was	later	calculated	for	the	Young’s	modulus	(YM)	
both	 shown	 as	 MPa	 (N/mm2).	 The	 displacement	 at	 the	 failure	 point	 was	
recorded	as	the	Strain	at	the	UTS	(%	of	displacement	from	its	original	size).		
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Figure	2.4	Clamp	Stretching	Electrospun	Scaffold	during	Mechanical	Testing		
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2.7	Fibrin	Preparation	
	
2.7.1	Materials	
Fibrin	was	made	by	combining	human	fibrinogen	with	human	thrombin.		
18.75mg	of	Fibrinogen	(human	plasma;	50-70%	protein,	Sigma-Aldrich,	Dorset,	
UK)	was	weighed	out	and	added	to	1ml	of	0.9%	NaCl	(w/v).		
To	make	0.9%	Normal	Saline,	0.9g	of	NaCl	salt	was	weighed	out	and	added	to	
100mls	of	distilled	water.	The	fibrinogen/	Saline	mixture	was	placed	into	a	water	
bath	at	37°C	for	4	hours	to	aid	dissolving.	This	was	then	sterilized	by	filtering.		
1	KU	of	Thrombin	from	human	plasma	(Sigma-Aldrich,	Dorset)	was	dissolved	in	
4mls	of	distilled	water	 to	obtain	a	concentration	of	250	 IU/ml.	This	was	then	
filtered	to	sterilize.		These	were	then	aliquoted	into	100	μl	portions	for	later	use.		
	
2.7.2	Methods	
In	order	to	create	fibrin	during	experiments,	the	constituent	components	were	
defrosted	 in	 a	 water	 bath	 slowly	 over	 2	 hours	 until	 they	 were	 at	 room	
temperature.	Depending	on	the	concentration	of	fibrinogen	and	thrombin	being	
used,	 the	 desired	 quantities	 were	 pipetted	 out-	 fibrinogen	 first	 followed	 by	
thrombin	and	mixed	on	the	scaffolds.	The	explants	were	added	and	manipulated	
to	allow	for	an	even	spread	before	the	fibrin	could	set.		
	 136	
2.8	Experiments		
	
2.8.1	Preparation	of	tissue	engineered	skin	composites	Using	DED.		
	
These	constructs	were	used	as	controls.	Medical	grade	stainless	steel	rings	(1cm	
external	diameter,	0.79cm2	area)	and	grids	(Figure	2.5)	were	obtained	from	the	
Department	of	Medical	Physics,	Royal	Hallamshire	Hospital,	Sheffield.	A	sterile	
No.	22	scalpel	was	used	to	cut	the	prepared	Euro	Skin	into	15	x15	mm2	pieces.	
The	 epidermis	 was	 gently	 scraped	 off,	 leaving	 the	 papillary	 dermis	 exposed.	
These	were	placed	into	6	well	plates	with	the	reticular	dermal	side	uppermost	
and	the	stainless	steel	metal	ring	was	placed	on	top	of	it.	To	this,	1x105	CMFDA	
fluorescently	labelled	fibroblasts	(between	passage	4	to	9)	were	placed	in	the	
centre	of	the	metal	ring	suspended	in	0.5mls	of	10%	serum	DMEM.	2	mls	of	10%	
serum	DMEM	was	used	to	top	up	the	surrounding	Euro	Skin	outside	the	steel	
ring	 and	 these	were	 incubated	at	 37°C,	 humidified	5%	CO2	for	 48	hours.	 The	
constructs	 were	 then	 removed	 from	 the	 incubator	 and	 the	 presence	 of	
fibroblasts	 were	 verified	 by	 observing	 for	 CMFDA	 using	 an	 Olympus	 IX73	
Epifluroscent	Microscope.	The	media	was	then	discarded	and	the	scaffolds	were	
then	turned	over	with	the	papillary	side	uppermost.	New	sterilized	metal	rings	
were	then	placed	onto	the	centre	of	the	square	pieces	of	skin	and	fluorescently	
labelled	keratinocytes	CMTPX	were	now	seeded	 into	 the	centre	of	 the	metal	
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rings.	 For	 this	 3x	 105	 keratinocytes	 were	 used	 between	 passage	 one	 to	 four	
suspended	in	0.5mls	of	10%	serum	Green’s	media.	2mls	of	Green’s	media	was	
then	added	outside	 the	 ring	 and	 this	 construct	was	 again	 incubated	at	37°C,	
humidified	5%	CO2	for	48	hours.	At	the	end	of	this	time,	the	6-well	plates	were	
removed	 from	 the	 incubator	 and	 the	 presence	 of	 both	 keratinocytes	 and	
fibroblasts	were	 assessed	observing	 for	CMFDA	and	CMTPX.	Once	 cells	were	
confirmed	to	be	present,	 the	metal	 rings	were	removed	and	the	DED	seeded	
with	fibroblasts	and	keratinocytes	were	raised	to	an	air	liquid	interface	using	the	
metal	grids.	These	were	then	cultured	for	7,	14	and	21	days	respectively	with	
media	changes	occurring	three	times	a	week.		
	
	
	
	
	
	
	
Figure	2.5:	Metal	rings	and	grids	used	in	constructs obtained	from	the	medical	
workshop	of	the	Royal	Hallamshire	Hospital,	Sheffield.	Scale	bar=	1cm.		
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2.8.2	Preparation	of	isolated	keratinocytes	and	fibroblasts	seeded	on	trilayer	
electrospun	scaffolds.		
	
A	sterile	No.	22	scalpel	was	used	to	cut	sterilized	trilayer	electrospun	scaffolds	
into	 15	 x15	 mm2	 pieces.	 These	 were	 placed	 into	 6	 well	 plates	 followed	 by	
stainless	 steel	metal	 rings	placed	on	 top.	 To	 this,	 1x105	CMFDA	 fluorescently	
labelled	fibroblasts	(between	passage	4	to	9)	were	placed	in	the	centre	of	the	
metal	ring	suspended	in	0.5mls	of	10%	serum	DMEM.	2	mls	of	DMEM	was	used	
to	 top	 up	 the	 surrounding	 scaffold	 outside	 the	 steel	 ring	 and	 these	 were	
incubated	at	37°C,	humidified	5%	CO2	for	48	hours.	The	constructs	were	then	
removed	from	the	 incubator	and	the	presence	of	 fibroblasts	were	verified	by	
observing	for	CMFDA.	The	media	was	discarded	and	the	electrospun	scaffolds	
were	turned	over.	New	sterilized	stainless	steel	metal	rings	were	then	placed	
onto	the	centre	of	the	square	pieces	of	fibroblast	seeded	electrospun	scaffolds	
and	 fluorescently	 labelled	 CMTPX	 keratinocytes	 were	 now	 seeded	 into	 the	
centre	 of	 the	 metal	 rings.	 For	 this	 3x	 105	 keratinocytes	 were	 used	 between	
passage	one	to	four	suspended	in	0.5mls	of	10%	serum	Green’s	media.	2mls	of	
10%	serum	Green’s	media	was	then	added	outside	the	ring	and	this	construct	
was	again	incubated	at	37°C,	humidified	5%	CO2	for	48	hours.	At	the	end	of	this	
time	 period,	 the	 6-well	 plates	 were	 removed	 from	 the	 incubator	 and	 the	
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presence	of	both	keratinocytes	and	fibroblasts	were	confirmed	by	observing	for	
CellTracker	green	and	CellTracker	red.	Once	cells	were	found	to	be	present,	the	
metal	rings	were	removed	and	electrospun	scaffolds	containing	fibroblasts	and	
keratinocytes	were	raised	to	an	air	liquid	interface,	with	the	side	containing	the	
seeded	keratinocytes	uppermost	using	the	metal	grids	for	support.	These	were	
then	 cultured	 for	 7,	 14	 and	 21	 days	 respectively.	Media	 changes	 using	 10%	
serum	Green’s	occurred	three	times	a	week	
	
2.8.3	Preparation	of	trilayer	scaffolds	combined	with	skin	explants.		
	
A	sterile	No.	22	scalpel	was	used	to	cut	sterilized	trilayer	electrospun	scaffolds	
into	15	x15	mm2	pieces.	These	were	placed	into	6	well	plates	with	stainless	steel	
metal	rings	were	on	the	top.	To	this,	the	prepared	skin	explants,	suspended	in	
0.5	mls	of	10%	serum	Green’s	Media	was	added	to	the	centre	of	each	metal	ring.	
2	mls	of	10%	serum	Green’s	media	was	used	to	top	up	the	surrounding	scaffold	
outside	the	steel	ring	and	these	were	incubated	at	37°C,	humidified	5%	CO2	for	
48	hours.	At	the	end	of	this	time	period,	the	constructs	were	raised	to	an	air	
liquid	 interface	 using	 the	 metal	 grids	 to	 support	 the	 skin	 explant	 seeded	
scaffolds.	 These	 were	 then	 cultured	 for	 7,	 14	 and	 21	 days	 respectively	 with	
media	changes	using	10%	serum	Green’s	three	times	a	week.	
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2.8.4	 Preparation	 of	 skin	 explants	 on	 trilayer	 scaffolds	 with	 varying	
concentrations	of	fibrin	and	Tisseel	(Baxter,	Deerfield,	IL,	USA)	
		
A	sterile	No.	22	scalpel	was	used	to	cut	sterilized	trilayer	electrospun	scaffolds	
into	 15	 x15	 mm2	 pieces.	 These	 were	 placed	 into	 6	 well	 plates	 to	 this,	 the	
prepared	skin	explants,	suspended	in	0.5	mls	of	10%	serum	Green’s	Media	was	
added.	 This	 was	 followed	 by	 adding	 30µml	 of	 fibrinogen	 (concentrations	
18.75mg/ml,	67mg.ml	and	86.5	mg/ml)	and	10µml	of	thrombin	(concentrations	
2.5	I.	U,	4.5	I.	U,	6.5	I.	U)	to	create	a	fibrin	clot,	which	was	mixed	with	the	explants	
to	allow	even	distribution.	For	experiments	with	Tisseel	(FDA	approved	product	
for	 clinical	 use	 consisting	 of	 fibrinogen	 and	 thrombin	 in	 concentrations	 that	
combine	to	give	a	dense	fibrin	clot-see	chapter	6	for	further	details),	this	was	
allowed	to	reach	room	temperature	over	a	two-hour	period	before	assembling	
the	kit,	which	facilitated	simultaneous	ejection	of	fibrinogen	and	thrombin	onto	
the	skin	explants.	Following	this,	2	mls	of	10%	serum	Green’s	media	was	used	to	
top	up	the	surrounding	scaffold	these	were	incubated	at	37°C,	humidified	5%	
CO2	for	48	hours.	At	the	end	of	this	time	period,	the	constructs	were	raised	to	
an	air	liquid	interface	using	the	metal	grids	to	support	the	skin	explant	seeded	
scaffolds.	 These	 were	 then	 cultured	 for	 7,	 14	 and	 21	 days	 respectively	 with	
media	changes	using	10%	serum	Green’s	three	times	a	week.	
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2.8.5	 Preparation	 of	 split	 thickness	 skin	 with	 variable	 dermal	 thickness	 to	
determine	its	effect	on	outward	skin	cell	migration	
	
Skin	of	variable	dermal	thickness	were	prepared	by	altering	the	settings	of	the	
Watson	knife	that	was	used	to	create	the	split	thickness	skin.	Once	the	skin	was	
harvested,	it	was	cut	into	5x5	mm2	pieces	and	a	digital	micrometer	was	used	to	
determine	the	thickness	of	the	sample.		The	epidermal	thickness	was	assumed	
to	be	the	same,	as	all	samples	for	this	experiment	came	from	the	same	patient	
using	 the	same	block	of	 skin.	The	squares	of	 skin	were	 finely	minced	 into	16	
smaller	pieces	and	placed	in	the	centre	of	a	6	well	plate.		2	mls	of	10%	serum	
Green’s	media	was	added	and	samples	were	incubated	at	37°C,	humidified	5%	
CO2	for	7	days.	Each	day,	the	skin	cells	were	stained	with	Rose	Bengal	and	the	
distance	of	the	stain	from	the	edge	of	the	skin	explants	were	plotted	against	the	
thickness	of	the	skin.		
	
	
2.8.6	The	sandwich	technique-	placing	skin	explants	between	two	squares	of	
electrospun	scaffold	to	aid	cellular	migration.		
	
	 142	
Templated	PHBV/PGLA	(75:25)	trilayer	electrospun	scaffolds	were	prepared	as	
above	in	addition	to	skin	explants.	The	scaffolds	were	placed	into	6	well	plates.	
To	this,	the	prepared	skin	explants,	suspended	in	0.5	mls	of	10%	serum	Green’s	
media	 was	 added	 to	 the	 centre	 of	 the	 scaffold.	 Another	 layer	 of	 trilayer	
electrospun	 scaffold	 was	 placed	 on	 top	 of	 the	 skin	 explants	 followed	 by	 a	
stainless	steel	ring	to	hold	the	construct	in	place.	2	mls	of	10%	serum	Green’s	
media	was	used	to	top	up	the	surrounding	scaffold	outside	the	steel	ring	and	
these	were	incubated	at	37°C,	humidified	5%	CO2	for	48	hours.	At	the	end	of	this	
time	period,	the	constructs	were	raised	to	an	air	liquid	interface	using	the	metal	
grids	to	support	the	skin	explant	seeded	scaffolds.	These	were	then	cultured	for	
7,	14	and	21	days	 respectively	with	media	changes	using	10%	serum	Green’s	
three	times	a	week.	
	
	
	
	
	
2.8.7	 Preparation	 of	 skin	 explants	 with	 fibroblast	 co-cultured	 electrospun	
scaffolds	with	and	without	fibrin.		
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A	sterile	No.	22	scalpel	was	used	to	cut	sterilized	trilayer	electrospun	scaffolds	
into	 15	 x15	 mm2	 pieces.	 These	 were	 placed	 into	 6	 well	 plates	 followed	 by	
stainless	 steel	metal	 rings	placed	on	 top.	 To	 this,	 1x105	CMFDA	 fluorescently	
labelled	fibroblasts	(between	passage	4	to	9)	were	placed	in	the	centre	of	the	
metal	ring	suspended	in	0.5mls	of	10%	serum	DMEM.	2	mls	of	DMEM	was	used	
to	 top	 up	 the	 surrounding	 scaffold	 outside	 the	 steel	 ring	 and	 these	 were	
incubated	at	37°C,	humidified	5%	CO2	for	48	hours.	The	constructs	were	then	
removed	from	the	 incubator	and	the	presence	of	 fibroblasts	were	verified	by	
observing	for	CMFDA.	The	media	was	discarded	and	the	electrospun	scaffolds	
were	turned	over.	New	sterilized	stainless	steel	metal	rings	were	then	placed	
onto	the	centre	of	the	square	pieces	of	fibroblast	seeded	electrospun	scaffolds	
and	skin	explants	prepared	as	above,	were	placed	in	the	centre	of	the	ring.	For	
experiments	including	fibrin,	30	µml	of	18.75mg/ml	of	fibrinogen	was	placed	in	
the	centre	of	the	skin	explants	followed	by	10µml	of	2.5	I.	U	of	thrombin.	Once	
the	 fibrin	clot	 set,	2mls	of	10%	serum	Green’s	media	was	placed	 in	 the	well.		
These	were	incubated	at	37°C,	humidified	5%	CO2	for	48	hours.	At	the	end	of	
this	time	period,	the	constructs	were	raised	to	an	air	liquid	interface	using	metal	
grids	to	support	the	skin	explant	seeded	scaffolds.	These	were	then	cultured	for	
7,	14	and	21	days	 respectively	with	media	changes	using	10%	serum	Green’s	
three	times	a	week.	
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2.9	Outcome	Measurements	
	
2.9.1	Cell	Tracker	TM	Fluorescent	Probes		
CMFDA	 and	 CMTPX	 (Invitrogen,	 USA)	 were	 used	 to	 stain	 fibroblasts	 and	
keratinocytes	respectively	to	ensure	that	they	were	present	on	scaffolds	before	
they	 were	 raised	 to	 an	 air	 liquid	 interface.	 These	 are	 non-toxic	 probes	 that	
monitor	 cell	 movement,	 location	 and	 proliferation.	 	 They	 cross	 the	 cell	
membrane	 and	 stay	 within	 that	 cell	 for	 several	 daughter	 generations.	 They	
display	 florescence	 for	 at	 least	 72	hours	 to	 a	maximum	of	 7days.	 Fibroblasts	
were	stained	with	CellTracker	green.	Flasks	containing	fibroblasts	were	removed	
from	the	 incubator	and	media	discarded,	 followed	by	 three	washes	of	 sterile	
PBS.	CMFDA	10	mM	was	prepared	by	adding	 the	required	amount	 to	DMSO.	
This	was	then	added	to	10	mls	of	10%	serum	free	DMEM.	The	flasks	were	then	
incubated	at	37°C,	in	a	humidified	atmosphere	of	5%	CO2	for	45	minutes.	After	
this	time	the	media	was	discarded	followed	by	three	washes	of	sterile	PBS.	3mls	
of	Trypsin/EDTA	was	then	added	to	each	flask	and	once	again	incubated	at	37°C,	
in	a	humidified	atmosphere	of	5%	CO2	for	10	minutes	until	cells	were	detached	
from	the	bottom	of	the	flask.	The	cell/Trypsin	EDTA	suspension	was	then	placed	
into	a	sterile	30	ml	universal	pot	together	with	7	mls	of	10%	serum	DMEM	to	
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stop	the	action	of	trypsin.	This	was	then	centrifuged	at	200g	(1000	rpm)	for	5	
minutes.	The	supernatant	was	discarded	and	the	cell	pellet	resuspended	in	5	mls	
of	10%	serum	DMEM.	The	cells	were	counted	using	the	standard	method.	The	
media	was	then	adjusted	to	ensure	that	there	were	1x105	fibroblasts	per	0.5	ml	
which	 was	 the	 number	 used	 for	 seeding	 onto	 scaffolds.	 The	 labelling	 of	
keratinocytes	followed	the	same	method.	CMTPX	was	used	at	a	concentration	
of	 10mM.	 The	 cells	 once	 labelled	 were	 harvested	 by	 the	 same	method	 and	
resuspended	in	the	required	amount	of	serum	10%	Green’s	media	to	ensure	that	
a	concentration	of	3	x105	cells	was	present	in	0.5	mls	of	media.	Once	seeded	the	
cells	 could	were	 imaged	 in	Olympus	 IX73	 Epifluroscent	Microscope	 (KeyMed	
Medical	&	 Industrial	 Equipment	 Ltd.	 Essex,	 UK)	 at	 570	 nm	 λex–620	 nm	 λem	
(CellTracker	red)	and	480	nm	λex–533	nm	λem	(CellTracker	green).		
	
2.9.2	Alamar	BlueTM	assay	(AbD,	serotec,	Kiddlington,	UK).		
	
This	 is	a	quantitative,	non-toxic	assay	 that	can	be	performed	during	 the	time	
course	of	an	experiment,	as	it	does	not	result	in	cell	lysis.	The	active	reagent	is	a	
blue	dye	called	resuzarin,	which	 is	cell	permeable	and	non-fluorescent.	Upon	
entering	the	cells	 it	 is	reduced	to	resofurin,	which	produces	a	bright	red/pink	
fluorescence	(Figure	2.6).	Viable	cells	continuously	reduce	resuzarin	to	resofurin	
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thereby	the	amount	of	florescence	produced	is	proportional	to	the	number	of	
living	 cells	 in	 the	 sample.	 This	 generates	 a	 quantitative	 picture	 of	 cellular	
viability.			
Samples	were	washed	 three	 times	with	sterile	PBS.	Alamar	Blue	powder	was	
weighed	out	and	dissolved	in	PBS	to	obtain	a	10%	dilution.	A	filter	was	then	used	
to	sterilize	the	solution.	10%	Alamar	Blue	solution	was	added	to	constructs	to	
ensure	that	they	were	completely	covered	with	the	dye.	The	plates	were	then	
incubated	for	60	minutes	at	37°C,	in	a	humidified	atmosphere	of	5%	CO2.		At	this	
time,	 it	was	usual	 to	observe	some	colour	change	 in	 the	samples,	confirming	
cellular	viability.		200µl	of	dye	from	each	sample	was	pipetted	into	a	labelled	96	
well	 plate.	 They	were	 then	 read	 at	 570nm	 (manufacturer’s	 instructions)	 in	 a	
colorimetric	plate	reader	(BIOTEK,	NorthStar	Scientific	LTD,	Leeds,	UK).	This	was	
performed	 at	 various	 time	 checkpoints	 for	 each	 experiment.	 	 The	 data	 was	
analysed	to	obtain	%	absorbance.		
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Figure	 2.6:	Alamar	 Blue	 cellular	 viability	 assay.	 A:	 Pre	 incubation	 cell	 seeded	
samples.	B:	Post	incubation	cell	seeded	samples		
	
2.9.3	Rose	Bengal	Staining		
	
Cellular	outgrowth	from	skin	explants	onto	scaffolds	or	on	tissue	culture	plastic	
were	assessed	using	1%	Rose	Bengal	(Sigma	Aldrich,	Dorset,	U.K)	for	5	min.	The	
samples	were	washed	several	times	with	PBS	to	remove	any	excess	Rose	Bengal.	
These	 stained	 areas	 were	 then	 photographed	 to	 obtain	 an	 image	 that	 was	
A 
B 
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assessed	 quantitatively	 using	 Image	 J	 (NIH,	 USA)	 to	 estimate	 the	 extent	 of	
outgrowth	from	explants	onto	the	membranes.	The	difference	in	the	areas	were	
averaged	and	the	data	expressed	as	mean	±	SEM.		
	
2.9.4	Fixation	of	Constructs	
	
This	 was	 done	 using	 3.7%	 Formaldehyde	made	 by	 adding	 10	 PBS	 tablets	 to	
900ml	of	water	followed	by	100ml	of	stock	37%	formaldehyde	(Sigma-Aldrich,	
Dorset,	UK).	Prior	to	fixation,	media	was	discarded	from	each	construct	and	they	
were	washed	three	times	with	sterile	PBS.	To	each	well	plate	3.7%	formaldehyde	
was	 added	 to	 ensure	 that	 each	 construct	 was	 completely	 submerged	 in	 the	
liquid.	This	was	incubated	for	at	least	2	hours	at	4°C	before	conducting	further	
tests	or	stored	at	4°C	until	required.		
	
2.9.5	DAPI	Staining	
	
DAPI	(4’,	6-diamindino-2-phenylindole	dihydrochloride)	(Sigma-Aldrich,	Dorset,	
UK)	 is	 a	 blue	 fluorescent	 stain	 that	 preferentially	 binds	 to	 nuclear	DNA.	 This	
produces	 a	 x	 20-fluorescence	 enhancement	 once	 bound	 to	 the	 DNA.	 It	
penetrates	 the	 cell	 membrane	 optimally	 if	 the	 cells	 are	 fixed	 therefore	 all	
	 149	
constructs	were	fixed	using	3.7%	formaldehyde	as	above	before	performing	the	
stain.	Stock	vials	of	DAPI	were	made	to	a	concentration	of	1mg/ml	by	diluting	in	
DMSO	and	aliquots	of	10μl	were	made.	These	were	 then	diluted	 in	10mls	of	
sterile	PBS	to	obtain	a	final	working	concentration	of	1μg	per	ml.	This	was	then	
added	 to	 each	 construct	 just	 enough	 to	 cover	 it	 completely.	 It	 was	 then	
incubated	at	37°C,	in	a	humidified	atmosphere	of	5%	CO2	for	45	minutes.	The	
excess	DAPI	was	 then	discarded	and	each	construct	was	washed	 three	 times	
with	sterile	PBS.	The	presences	of	the	stain	in	the	constructs	were	studied	using	
the	Olympus	IX73	Epifluroscent	Microscope	at	λex385nm/λem461nm	imaging	
along	the	whole	length	of	the	scaffold	strips.		
2.9.6	Total	Collagen	Quantification:	Sirius	Red	staining		
	
This	is	both	a	quantitative	and	qualitative	outcome	measure.	It	is	assumed	that	
functional	fibroblasts	will	produce	collagen	on	the	constructs.	Sirius	red	is	a	well-
known	stain	 that	 is	used	 in	 collagen	histochemistry.	 It	binds	 to	and	 stains	all	
forms	of	collagen	fibrils	thereby	quantifying	the	amount	of	collagen	in	a	given	
area	of	the	construct.		0.1%	Sirius	red	stain	(Direct	red	80,	Sigma-Aldrich,	Dorset,	
UK)	 was	 prepared	 by	 weighing	 out	 the	 desired	 quantity	 and	 adding	 it	 to	
saturated	 Picric	 Acid	 0.9-1.1%	 (Sigma-Aldrich,	 Dorset,	 UK).	 	 This	 stain	 was	
performed	on	fixed	constructs.	The	3.7%	formaldehyde	was	removed	from	each	
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well	plate	and	the	samples	were	washed	three	times	with	sterile	PBS.		Sirius	red	
was	then	added	to	each	well	plate	ensuring	that	the	constructs	were	completely	
covered	 by	 the	 stain.	 They	 were	 placed	 onto	 a	 shaking	 platform	 and	 left	
overnight.	The	following	day,	the	constructs	were	washed	at	least	three	times	
in	distilled	water	to	remove	any	excess	stain.	They	were	then	left	to	air	dry	in	a	
laminar	 flow	 hood	 for	 48	 hours.	 Each	 construct	 was	 weighed	 and	 this	 was	
recorded.	Following	this	3mls	of	0.2M	NaOH:	Methanol	1:1	solution	was	added	
to	each	well	plate	 to	elute	 the	absorbed	Sirus	 red	and	placed	on	 the	 rocking	
platform	for	15	minutes	to	allow	the	methanol	to	evaporate.	200µl	of	the	eluted	
dye	was	then	pipetted	into	a	new	96-well	plate.	The	absorbance	was	then	read	
at	490nm	in	a	spectrophotometer	(BIOTEK,	NorthStar	Scientific	LTD,	Leeds,	UK).		
The	absorbance	of	stain	per	gram	of	dry	construct	was	calculated.	Furthermore,	
the	difference	between	absorbance	per	gram	of	constructs	with	seeded	cells	or	
explants	and	those	with	no	seeded	cells	or	explants	were	calculated	to	assess	
the	amount	of	collagen	deposited	by	functioning	cells	on	scaffolds.		
	
2.9.7	Histology	
	
Samples	after	being	 fixed	 in	3.7%	 formaldehyde	were	 cryopreserved	prior	 to	
staining	 with	 Carazzi’s	 Haematoxylin	 and	 Eosin	 Staining.	 This	 method	 was	
	 151	
chosen,	 as	 it	 does	not	 result	 in	 destruction	of	 the	 scaffold	 compared	 to	wax	
embedding.	 These	 stains	 were	 chosen	 to	 highlight	 the	 cellular	 architecture/	
location	 within	 the	 scaffold.	 Haematoxylin	 is	 a	 dark	 blue/violet	 stain	 that	 is	
alkaline	in	nature	and	stains	cellular	nuclei	blue.	Eosin	is	a	pink	acidic	stain	that	
binds	 to	 cytoplasmic	 structures	 resulting	 in	 shades	 of	 red,	 pink	 and	 orange.	
Together	they	give	an	indication	of	the	location	of	cells	within	the	scaffold	and	
any	 protein/	 extracellular	 matrix	 produced	 by	 viable	 cells	 eg.	 keratin	 and	
collagen.		
	
2.9.7.1	Cryopreservation	
	
The	3.7%	formaldehyde	was	removed	from	the	samples	and	they	were	washed	
three	times	with	sterile	PBS.	Samples	were	then	placed	in	a	plastic	cassette	and	
embedded	 with	 Optimal	 Cutting	 Temperature	 O.C.T	 TM	 (Tissue-Tek®	 4583,	
Sakura	Finetek,	Netherlands,	Europe)	compound.		
A	 pair	 of	metal	 forceps	was	 used	 to	 gently	 and	 slowly	 submerge	 the	 plastic	
cassette	in	liquid	nitrogen	(-197°C).	Once	the	sample	was	completely	frozen,	it	
was	 removed	 from	the	 liquid	nitrogen	and	 the	plastic	 cassette	very	gently.	A	
sterile	No.	 22	blade	was	used	 to	 cut	 the	 sample	 in	half.	 It	was	 then	 fixed	 to	
mounting	device	 the	O.C.T	 as	 an	 adhesive	 and	 left	 to	 solidify	 in	 the	 cryostat	
(Leica	CM1860	U.V,	Leica	Biosystems,	Germany).	The	sample	was	then	sectioned	
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using	a	cryostat	 into	7μm	slices	and	mounted	on	 frosted	 labelled	glass	 slides	
(Fisher	Scientific,	Loughborough,	UK)	and	left	to	air-dry	overnight.	
	
	
2.9.7.2	Haematoxylin	and	Eosin	Staining	
	
The	slides	were	soaked	in	distilled	water	for	2	minutes	before	they	were	stained	
with	Harris	Haematoxylin	(Sigma-Aldrich,	Dorset,	UK)	for	1.5	minutes.	After	two	
washes	 in	running	tap	water	for	a	total	of	four	minutes,	the	slides	were	then	
stained	with	 eosin	 (Sigma-Aldrich,	 Dorset,	 UK)	 for	 five	minutes.	 The	 samples	
were	 then	washed	 in	 tap	 water	 again	 for	 1.5	minutes	 and	 then	 dehydrated	
through	70%	alcohol	(IMS;	Industrial	Methylated	Spirit,	Fisher	Scientific,	UK	Ltd.)	
by	dunking.	This	was	followed	by	100%	alcohol	for	30	seconds	and	finally,	they	
were	 cleaned	 in	 two	 changes	 of	 xylene	 (Fisher	 Scientific,	 UK	 Ltd)	 lasting	 one	
minute	each.	They	were	then	mounted	with	a	coverslip	using	a	DPX	mounting	
medium	(Fisher	Scientific,	UK	Ltd.)	and	left	to	air-dry	overnight.	The	following	
day	 images	 were	 taken	 of	 each	 slide	 using	 a	 light	 microscope:	 Motic	 B5	
Professional	and	the	software	used	for	analysis	was	Motek	Images	Advanced	3.2	
(Motek	 CME	 group	 ltd).	 Scale	 bars	 and	 final	 adjustment	 of	 the	 images	were	
performed	 using	 ImageJ	 software	 (US	 National	 Institutes	 for	 Health,	 NIH	
Bethesda,	Maryland).			
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2.10	Immunohistochemistry		
	
Electrospun	 scaffold	 cultured	 with	 isolated	 cells	 and	 co-culture	 with	 skin	
explants	 were	 assessed	 in	 both	 2D	 and	 3D	 culture	 immunostaining	 using	
Antibodies	against	proliferating	cells	(Ki67),	keratinocytes	(pancytokeratin)	and	
collagen	(collagen	IV).		
Templated	and	non-templated	trilayer	PHBV/PGLA	75:25	and	monolayer	PGLA	
75:25	 electrospun	 scaffolds	 that	 were	 cultured	 with	 isolated	 fibroblasts	 and	
keratinocytes	for	14	days	at	air	liquid	interface	were	fixed	in	3.7%	formaldehyde	
for	 at	 least	 30	minutes.	 They	were	 then	 cryopreserved	 using	 the	method	 as	
outlined	 above.	 Slices	 of	 7	 μm	 were	 made	 onto	 glass	 slides	 and	 left	 to	 dry	
overnight.	Immunostaining	was	also	performed	on	fixed	14	day	samples	where	
fibroblasts	were	 used	 to	 culture	 the	 templated	 trilayer	 electrospun	 scaffolds	
before	adding	skin	explants.	Due	to	the	3d	nature	of	these	scaffolds,	we	elected	
to	 immunostain	 the	 entire	 fixed	 sample	 followed	 by	 confocal	microscopy	 to	
analyse	 the	 resulting	 images.	 Once	 these	 samples	 were	 fixed	 with	 3.7%	
formaldehyde	for	at	least	30	mins,	the	fixative	was	removed	and	samples	were	
washed	with	PBS	three	times.	The	method	from	this	point	is	the	same	for	both	
sample	preparations.	100%	ethanol	was	added	to	samples	for	two	minutes	and	
left	to	air	dry	at	room	temperature.	Following	this,	the	samples	were	incubated	
with	 Triton	 X100	 (0.25%)	 for	 thirty	 minutes.	 After	 three	 washes	 of	 PBS,	
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quenching	was	performed	using	ammonium	chloride	(50mM)	for	ten	minutes.	
This	 was	 followed	 by	 adding	 fish	 gelatin	 (0.2%)	 as	 a	 blocking	 buffer	 for	 30	
minutes.	Samples	were	then	incubated	overnight	using	the	following	dilutions:		
	
• Ki67-	 monoclonal	 antibody	 (e	 fluoro	 570;	 eBioscience,	 ThermoFisher	
Scientific,	Renfrew);	stock	0.5mg/ml	unconjugated;	Cat	14.5698.82.	1	μml	
of	the	antibody	was	added	to	1000	microml	of	fish	gelatin(0.2%)	to	obtain	
a	dilution	of	1	in	100.		
• Pancytokeratin	(ThermoFisher	Scientific,	Renfrew)	-	monoclonal	antibody	
AE1/AE3	Alex	fluro-488;	e	bioscience;	stock	0.5mg/ml	(conjugated).	Cat	
53.9003.82.	Dilution	used	was	1	in	300.		
• Collagen	 IV	 (Alexa	 Fluor	 488,	 e	 Bioscience,	 Thermofisher	 Scientific,	
Renfrew);	stock	0.5mg/ml	(conjugated).	Dilution	used	was	1	in	100.		
The	 following	day	 samples	were	washed	 three	 times	with	PBS	and	DAPI	was	
added	 (1	 :1000	 dilution	 in	 PBS)	 for	 30	 minutes.	 The	 samples	 were	 then	
rehydrated	and	dehydrated	by	adding	distilled	water	for	10	minutes	to	samples	
followed	by	100%	ethanol	for	one	minute.	Samples	that	were	prepared	on	glass	
slides	were	then	mounted	using	a	coverslip	and	DPX	mounting	medium	and	left	
to	air	dry	for	two	hours	in	the	dark.		
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2D	images	were	obtained	using	an	Olympus	IX73	Epifluroscent	Microscope	using	
the	following	excitation	and	emission	wavelengths:		
• DAPI:	λex	385	nm/λem	461	nm.	
• TRITC:	λex	545/25	nm/λem	605/70	nm.	
• FITC:	λex	488	nm/λem	519	nm.	
	
2.11	Scanning	Electron	Microscopy	
		
This	 was	 used	 to	 visualize	 scaffolds	 before	 and	 after	 seeding	 cells	 and	 skin	
explants.	Furthermore,	it	was	able	to	demonstrate	the	presence	of	the	3	distinct	
layers	of	polymers	and	stem	cell	niches	templating	on	the	scaffolds.	
	
	
2.11.1	Sample	Preparation	
	
All	samples	containing	cells	and	skin	explants	were	fixed	in	3.7%	formaldehyde.	
After	 three	 washes	 in	 PBS,	 2	 mL	 0.1	 M	 cacodylate	 buffer	 was	 added	 and	
incubated	for	5	min.	This	was	followed	by	2	mL	2.5%	gluteraldehyde	in	distilled	
water	and	incubated	for	30	min.		
The	gluteraldehyde	was	removed	and	2	mL	of	cacodylate	buffer	was	again	added	
to	rinse	any	remaining	gluteraldehyde.	500	μL	of	osmium	tetraoxide	was	then	
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added	and	incubated	for	2	hours.	The	osmium	tetraoxide	was	then	removed	and	
2	 mL	 cacodylate	 buffer	 added	 and	 incubated	 for	 15	 min.	 Subsequently	 the	
samples	were	 incubated	 for	 15	min	 each	with	 75,	 95	 and	 100%	ethanol	 and	
freeze	dried	for	16	hours.	
	
2.11.2	Sample	Imaging		
Samples	were	cut	into	2x2mm2	square	pieces	and	mounted	onto	12.5mm	stubs	
(Agar	Scientific,	Stanstead,	UK)	using	carbon	conductive	tape.		
They	were	first	painted	with	silver	dag	(Agar	Scientific,	Stanstead,	UK)	and	then	
sputter	coated	with	gold	for	2	minutes	at	15	mA	current	(Gold	coater;	Edwards	
sputter	coater	S150B,	Crawley,	England).	Samples	were	imaged	using	a	scanning	
electron	microscope	 (Inspect	 F,	 FEI,	 Netherlands,	 Europe)	 at	 an	 accelerating	
voltage	of	between	10-15	kV	and	a	SPOT	size	of	3.		
	
2.12	Statistical	Analysis		
	
All	tests	that	resulted	in	quantitative	data,	P	values	are	calculated	for	differences	
between	 samples	 using	 a	 two-sample	 t-test	 with	 no	 assumption	 of	 equal	
variance.		
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Chapter	3	
	
Design	and	Production	of	Candidate	
Scaffolds	for	Dermal	Replacement	
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3.1	Introduction	
	
The	aim	of	this	chapter	is	to	detail	the	design	and	production	of	an	electrospun	
biodegradable	scaffold	designed	to	be	used	with	finely	dissected	pieces	of	split	
thickness	 skin	 as	 a	 one	 stage	 approach	 to	 full	 thickness	 skin	 defect	
reconstruction.	The	scaffold	is	designed	as	a	trilayer,	templated	membrane	like	
structure	with	 the	aim	of	encouraging	 fibroblast	entry	 into	 the	 lower	dermal	
layer	and	keratinocyte	production	of	an	epithelial	barrier	layer	separated	by	a	
pseudo-basement	membrane.	Human	 skin	 cannot	be	 viewed	 simplistically	 as	
two	layers	(Figure	1.2),	it	is	a	complex	homeostatic	system	in	which	its	anatomy	
plays	a	significant	role	in	its	ability	to	continuously	regenerate,	be	stable	when	
subject	to	shear	forces	and	most	importantly	maintain	its	barrier	function.		
The	basement	membrane	 to	 recap,	 is	 a	 thin	 layer	of	 specialized	extracellular	
matrix	onto	which	the	epidermis	is	attached.		It	links	the	epidermis	to	the	dermis	
and	 provides	 a	 barrier	 against	 epidermal	 migration(4).	 It	 is	 morphologically	
distinguished	into	four	layers:	the	plasma	membrane	of	the	basal	keratinocytes;	
lamina	 lucida;	 lamina	densa	and	 sublamina	densa.	 These	 layers	 augment	 the	
keratinocyte	to	dermis	attachment(5).	The	 lamina	densa	provides	mechanical	
strength	and	the	middle	 layer	 that	 forms	a	sheet	 like	structure	comprising	of	
type	 IV	 collagen,	 nidogens	 and	 perlecan(7).	 The	 sublamina	 densa	 (lamina	
fibroreticularis)	is	the	deepest	layer	of	the	basement	membrane	which	contains	
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collagen	VII	that	extends	through	fibrils	and	insert	into	plaques	in	the	reticular	
dermis(8).The	basement	membrane	is	topographically	organized	into	peaks	and	
troughs	in	post-natal	skin.	These	develop	mid-gestation	where	prior	to	this;	the	
dermal	epidermal	junction	is	flat(9).These	structures	referred	to	as	rete	ridges,	
range	 from	 50-400	 micrometres	 in	 width	 and	 50-200	 micrometres	 in	
depth(10),(11)	Epidermal	stem	cells	lie	in	specific	locations	relative	to	the	rete	
ridges	depending	on	their	location	in	the	body.	The	rete	ridges	are	an	important	
feature	 in	 the	 topography	 of	 the	 dermal-epidermal	 junction.	 It	 provides	
structural	integrity	for	the	epidermal-dermal	interface	and	defines	the	cellular	
microenvironments,	which	 then	 determines	 the	 functioning	 of	 the	 basal	 and	
suprabasal	keratinocytes	in	these	regions(14).	
To	achieve	structures	which	would	support	epidermal	keratinocytes	and	dermal	
fibroblasts	and	yet	keep	them	separated	while	securely	attached	to	each	other	
we	designed	a	trilayer	structure.	This	was	composed	of	two	layers	of	microfibres	
of	biodegradable	PGLA	 (75:2%)	separated	by	a	very	 thin	 layer	of	nanofibrous	
PHBV.	The	latter	was	designed	so	that	cells	could	attach	to	these	fibres	but	the	
spaces	between	 them	were	 so	 compact	 that	 cells	 could	not	migrate	 through	
them.	In	producing	this	trilayer	it	was	also	necessary	to	produce	the	three	layers	
so	that	they	did	not	delaminate	when	cells	were	placed	on	them.	Further	the	
	 161	
nano	fibre	layer	was	also	spun	over	a	template	designed	to	mimic	the	folds	of	
the	rete	ridges.	This	is	illustrated	in	cartoon	form	in	Figure	3.1	
	
	
	
Figure	 3.1:	 Cartoon	 demonstrating	 structure	 of	 the	 templated	 trilayer	 of	
nanoporous	PHBV	between	two	layers	of	microporous	electrospun	fibres.				
	
PGLA	 (75:25)	 fibres	 were	 spun	 to	 be	 microfibres	 with	 relatively	 large	 pores	
between	 them	 to	 allow	 cell	 entry	while	 PHBV	were	 spun	 as	 nanofibres	with	
relatively	compact	pores	between	them	to	prevent	cell	migration	through	this	
layer.		The	ability	to	achieve	microfibers	using	PGLA	(75:25)	and	nanofibres	using	
PHBV	to	create	this	trilayer	structure	was	established	by	Bye	et	al(114),	not	only	
by	using	different	polymers	but	also	by	varying	the	distance	between	the	tip	of	
the	needle	and	the	collector	(	10cm	for	PHBV	and	17cm	for	PGLA	75:25).		
PGLA	(75:25)	is	a	linear	amorphous	co-polymer	composed	of	poly	(lactic	acid)	
PLA	and	poly	(glycolic	acid)	(PGA).	They	belong	to	the	group	of	saturated	poly	
(α-hydroxy	 esters).	 These	 polymers	 degrade	 via	 hydrolysis	 through	 de-
esterification.	 Under	 physiological	 conditions	 PGA	 is	 a	 rigid	 thermoplastic	
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material	with	a	high	crystallinity	 (46-50%)	as	a	result	 it	 is	not	soluble	 in	most	
organic	solvents.	It	has		glass	transition	and	melting	temperatures	of	36°C	and	
225	°C	respectively(151).	PGA	undergoes	hydrolysis	and	may	also	be	degraded	
by	surrounding	enzymes	that	have	esterase	activity.	The	breakdown	product	is	
glycolic	acid,	which	then	enters	the	tricarboxylic	acid	cycle.	Following	this	it	is	
excreted	as	water	and	carbon	dioxide.	This	makes	PGA	a	very	attractive	option	
for	clinical	applications	as	its	degradation	products	are	non-toxic	and	conform	
to	a	known	excretion	pathway.				
	
Poly	(lactic	acid)	(PLA)	is	present	in	three	isomer	forms	d	(-),	(l+)	and	racimi	(d.l).		
The	d,	l	form	is	a	popular	source	of	polymer	for	drug	releasing	scaffolds.	PLA	is	
hydrophobic,	semi-crystalline	and	has	a	glass	transition	temperature	between	
60-65°C	and	a	melting	temperature	of	around	170	°C.		It	degrades	via	hydrolysis	
into	lactic	acid,	which	then	enters	the	Krebs’s	cycle(152).		
PGLA	 can	 be	 prepared	 using	 various	 ratios	 of	 the	 constituent	monomers	 i.e.	
lactic	acid	(LA)	and	glycolic	acid.	PGLA	is	therefore	identified	by	its	constituent	
monomer	ratios.	Therefore,	PGLA	(75:25)	reflects	a	copolymer	consisting	of	75%	
lactic	acid	and	25%	glycolic	acid.	This	ratio	strongly	influences	the	physical	and	
chemical	properties	of	the	resultant	co-polymer.		PGLA	is	advantageous	over	its	
constituent	monomers	in	that	it	dissolves	in	a	wider	range	of	solvents	including	
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chlorinated	 solvents	 and	 acetone.	 	 PGLA	 is	 available	 in	 two	 forms,	 which	 is	
dependent	on	the	isomer	of	the	lactide	that	it	 is	made	of	(D,	L	and	L,	D).	The	
PGLA	used	in	this	thesis	was	of	the	(D,	L)	form.		
PHBV	is	a	biodegradable	co-polymer	made	from	units	of	hydroxybutyrate	with	
anywhere	 between	 0	 and	 24%	 of	 hydroxyvalerate	 units	 appearing	 randomly	
throughout	the	polymer	chain(153).	Polyhydroxybutyrate	(PHB)	is	produced	in	
nature	by	a	variety	of	bacteria,	which	store	it	as	a	source	of	carbon	and	energy.	
However,	this	material	itself	is	brittle	and	has	deficiencies	in	thermal	stability,	
which	limits	its	ability	to	be	used	as	a	manufacturing	material.	The	addition	of	
polyhydroxyvalerate	to	the	polymer	chains	leads	to	a	reduction	in	melting	point	
and	crystallinity	of	the	copolymer	and	enables	milder	processing	conditions	to	
be	used(154).	PHBV	can	be	manufactured	by	fermentation	of	a	wide	range	of	
microorganisms.	The	PHB	is	produced	during	the	first	fermentation	process	and	
PHBV	is	obtained	when	the	bacteria	are	fed	a	controlled	amount	of	organic	acid	
during	 a	 second	 stage	 of	 fermentation.	Once	 the	 polymer	 is	made	 it	 is	 then	
separated	from	bacterial	cells	using	solvent	extraction	after	breaking	down	the	
bacterial	 cell	 wall(153).	 PHBV	 is	 more	 stable	 than	 polyesters	 and	 is	 more	
resistant	 to	 hydrolytic	 degradation(155).	 This	 property	 can	 be	 exploited	 in	 a	
variety	of	biomaterials	that	require	 longer	periods	of	mechanical	stability	e.g.	
bone	regeneration.	It	was	selected	as	a	polymer	to	make	the	pseudo-basement	
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membrane	because	of	 its	biocompatibility,	 its	ability	 to	be	 reproducibly	 spun	
into	nano	fibres	and	it's	known	route	of	breakdown.	It	provides	a	large	surface	
area	of	nanofibres	for	extra	cellular	matrix	deposition	and	degrades	at	a	slower	
rate	 than	 PGLA,	 which	 provides	 a	 small	 amount	 of	 additional	 support	 for	
proliferating	cells	during	the	remodelling	phase	of	wound	healing.		
Electrospinning	is	one	of	several	methods	that	are	used	to	produce	porous	3D	
biodegradable	 scaffolds	 for	 tissue-engineering	 applications.	Other	 fabrication	
techniques	have	been	well	described.	These	can	be	divided	into	those	that	use	
porogens	in	biomaterials	(solvent	casting,	particulate	leaching,	gas	foaming	and	
freeze-drying	 and	 phase	 separation),	 solid	 free-form	 or	 rapid	 prototyping	
technologies	(selective	 laser	sintering,	stereolithography	and	3D	printing)	and	
techniques	that	develop	woven	and	non-woven	fibres	(use	of	thermal	energy	or	
adhesives	 to	 result	 in	 a	 porous	 fibrous	 network)(156).	 Electrospinning	 is	 our	
chosen	 technique	 to	 produce	 these	 porous	 scaffolds,	 as	 it	 is	 cost	 effective,	
reproducible	and	easily	up	scaled	to	increase	production	for	wide	spread	clinical	
use.	Furthermore,	it	provides	desirable	scaffold	architecture	with	a	large	surface	
area	for	cellular	attachment,	migration	and	proliferation	that	can	closely	mimic	
the	collagen	scaffold	of	the	dermis.		
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3.2	Properties	of	a	dermal	scaffold	
 
Any	scaffold	for	tissue	engineering	applications	for	human	use	must	have	
certain	features	that	make	it	compatible	for	use	in	patients.	These	can	be	
divided	into	essential	and	desirable.	All	scaffolds	at	a	minimum	must	be	
biocompatible.	They	need	to	be	safe	for	use	in	man	with	negligible	
inflammatory	and	immunological	reaction	from	the	host(157).	Scaffolds	should	
also	act	as		a	support	matrix	for	cells	to	adhere	to	and	function	to	regenerate	
the	underlying	tissue(158).	Once	the	patient’s	own	cells	have	regenerated	the	
tissue	components	the	scaffold	should	degrade	into	known	by	products	that	
are	excreted	via	established	pathways.	Scaffolds	in	tissue	engineered	
applications	aim	to	be	temporary	support	matrices	as	opposed	to	a	permanent	
implant.	By	modifying	the	choice	of	polymers	used	in	production	of	the	
scaffold	then	scaffolds	can	be	designed	to	degrade	within	a	time	frame	to	
match	the	expected	regeneration	period	of	that	tissue	for	example	in	skin	this	
would	ideally	be	at	the	2-3	month	mark	when	the	wound	is	in	the	remodelling	
phase,	and	the	patient’s	own	collagen	is	being	remodelled	from	type	1	to	type	
3.	Furthermore,	the	scaffold	should	have	similar	or	close	enough	mechanical	
properties	to	accommodate	the	deformational	forces	that	are	expected	to	be	
present	in	the	tissue	into	which	it	is	being	implanted.	The	different	parts	of	the	
skin	are	also	expected	to	experience	varying	mechanical	forces.	Geerligs	et	al. 
(159)	found	the	Young’s	modulus	for	the		epidermis	to	be	1.1 ± 0.2 MPa	and	
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Crichton	et	al	(160)reported	the	Young’s	modulus	of	dermis	to	be	7.33–
13.48 MPa.	 
	
This	 mechanical	 integrity	 should	 last	 from	 implantation	 to	 integration-	
essentially	for	as	long	as	it	is	required(161).	Importantly	also	scaffolds	should	be	
able	to	withstand	surgical	manipulation	and	handling	and	the	deforming	forces	
that	will	occur	during	the	implantation	process.		
In	order	for	scaffolds	to	act	as	a	structural	support	for	tissue	regeneration	the	
underlying	 architecture	 is	 of	 great	 importance.	 	 Scaffolds	 should	 possess	 an	
appropriate	 porosity	 that	 facilitates	 cellular	 penetration	 and	 diffusion	 of	
nutrients	and	oxygen	to	facilitate	cellular	proliferation.	Furthermore	porosity	is	
also	important	in	ensuring	that	waste	products	of	cellular	metabolism	are	able	
to	diffuse	out	of	the	structure(157).	Additionally,	apart	from	supporting	cells	and	
their	by-products,	they	should	also	be	able	to	support	a	vascular	tree	which	is	
needed	if	the	material	is	going	to	engraft	successfully.	These	features	outlined	
above	can	be	considered	as	essential	and	need	to	be	present	to	implant	these	
materials	into	man.		
Other	features	can	be	considered	desirable,	which	can	be	directed	to	the	tissue	
that	the	material	is	aiming	to	mimic.	For	skin	tissue	engineering,	scaffolds	made	
from	natural	polymers	like	collagen	and	chitosan	naturally	possess	ligands	that	
	 167	
are	needed	for	cells	to	interact	and	attach	to	the	fibres	of	the	scaffolds.	These	
ligands	 are	 often	 not	 present	 in	 scaffolds	 that	 are	 made	 from	 completely	
synthetic	substances.	These	 ligands	can	be	 incorporated	 into	the	scaffolds	by	
means	 of	 protein	 adsorption,	 however	 even	 if	 they	 are	 not	 deliberately	
incorporated	once	a	biomaterial	comes	into	contact	with	any	biological	fluid	eg	
blood	or	tissue	fluid,	proteins	-primarily	fibronectin	-will	begin	to	adhere	to	the	
fibres	 via	 protein	 adsorption.	 When	 cells	 are	 ultimately	 seeded	 onto	 the	
scaffolds	the	material	will	already	have	been	coated	in	protein	hence	ultimately	
cellular	attachment	will	depend	on	the	affinity	of	the	cells	to	bind	to	the	dynamic	
protein	layer(162).		
Moreover	in	order	for	a	scaffold	or	any	tissue	engineered	construct	to	become	
clinically	and	commercially	viable	it	needs	to	be	cost	effective	and	should	be	able	
to	be	seamlessly	up	scaled	from	single	unit	to	batch	production(163).	This	is	the	
ideal	and	it	is	appreciated	that	many	tissue	engineered	applications	will	have	a	
significant	cost	attached	to	production	for	clinical	use	however,	keeping	costs	to	
a	minimum	will	always	be	desirable	especially	for	widespread	clinical	uptake	in	
developing	countries.		Another	critical	issue	in	the	manufacturing	process	is	the	
shelf	life,	storage	conditions	and	delivery	of	the	scaffold	to	the	clinic	such	that	
there	is	no	change	to	the	architecture	and	integrity	of	the	scaffolds.		
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For	use	in	the	clinic	it	is	always	desirable	to	have	an	off	the	shelf	product,	which	
is	 available	 as	 and	 when	 needed.	 It	 has	 to	 be	 noted	 that	 clinicians	 use	
biomaterials	on	a	case	by	case	basis	which,	in	the	case	of	traumatic	wounds	or	
burn	injuries	are	unpredictable.	This	dictates	the	need	for	flexibility(164).		
Another	key	issue	in	tissue	engineered	applications	is	the	source	of	cells	that	are	
used	to	populate	the	scaffolds.	To	be	successful	all	scaffolds	ultimately	need	to	
be	populated	with	 cells	 that	 are	present	 in	 the	 tissue	 that	 they	are	 trying	 to	
replace.	 This	 is	 so	 that	 the	 cells	 can	 proliferate	 and	deposit	 the	 extracellular	
matrix	that	will	allow	structure	to	effectively	regenerate	and	reform.	These	cells	
most	 commonly	 autologous	 (from	 the	 patient)	 or	 less	 commonly	 allogeneic	
(sourced	 from	 donor	 patients).	 When	 cells	 are	 sourced	 from	 the	 patient	
themselves,	 they	 need	 to	 be	 cultured	 onto	 the	 scaffolds	 until	 they	 become	
suitable	 for	 implantation.	 This	 requires	 time,	 clean	 room	 facilities	 and	 the	
expertise	to	undertake	this	process.		
As	a	result,	although	this	approach	has	been	clinically	successful	even	within	this	
group	 (78)	 uptake	 of	 these	 autologous	 therapies	 has	 not	 been	 extensive.	
Furthermore	using	biomaterials	that	require	animal	sources	either	as	part	of	the	
dermal	scaffold	eg	porcine	or	bovine	collagen	or	in	the	process	of	culturing	cells	
(media	 contains	 serum	obtained	 from	 fetal	 calves)	 still	 carries	 a	 small	 risk	of	
infection	and	immunological	responses	which	can	be	immediate	or	delayed	for	
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years(165).	This	includes	the	risk	of	bovine	spongiform	encephalitis,	which	can	
be	transmitted	from	the	FCS	which	is	a	vital	component	of	cell	media.	Although	
the	 serum	 is	 obtained	 from	animals	 in	 countries	 free	of	 the	 condition,	 these	
prion	diseases	can	be	challenging	and	difficult	to	detect(166).	Furthermore,	the	
use	of	porcine	products	in	man	(xenotransplantation)	is	associated	with	hyper	
acute	rejection	due	to	the	presence	of	a	cell	membrane	antigen	called	the	Gal	
epitope(167).		
	
Table	 2:	 	 Ideal	 and	 Desirable	 Properties	 of	 Electrospun	 Scaffolds	 for	 Dermal	
Replacement		
	
3.3	Developing	a	suitable	electrospun	scaffold	for	dermal	replacement		
 
The	candidate	scaffold	used	in	this	thesis	to	be	evaluated	as	a	dermal	analogue	
is	 a	 continuation	 of	 the	 work	 by	 the	 MacNeil	 group	 in	 the	 field	 of	 skin	
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regeneration.	Foundation	work	performed	by	Blackwood	et	al	compared	PLLA,	
PGLA	 50:50,	 PGLA	 75:25	 and	 PGLA	 85:15.	 	 In	 vitro	 degradation	 studies	
performed	 here	 revealed	 that	 the	 PLLA	 degraded	 the	 slowest	 with	 it	 being	
largely	intact	after	one	year	and	the	PGLA	50:50	degraded	the	fastest	within	2	
weeks(124).	Given	that	a	healing	dermal	wound	has	most	of	its	tensile	strength	
between	60-90	days,	 it	would	be	desirable	 for	 the	 scaffold	 to	be	 structurally	
intact	for	this	period	of	time.	This	was	found	to	be	the	case	for	the	PGLA	75:25,	
which	lost	half	 its	strength	at	the	3-month	mark.	As	a	result,	PGLA	75:25	was	
chosen	 to	be	 the	 top	and	bottom	 layer	of	 this	 scaffold,	as	 it	will	 support	 the	
migration	and	proliferation	of	both	keratinocytes	and	 fibroblasts.	Building	on	
this,	work	by	Bye	et	al	we	proposed	the	use	of	a	trilayer	scaffold	consisting	of	
layers	of	PLA	microfibres	on	either	side	of	PHBV	nanofibers	that	was	successful	
in	supporting	the	proliferation	and	segregation	of		fibroblasts	and	keratinocytes	
for	tissue	engineered	applications(126).	
A	trilayer	scaffold	for	a	dermal	replacement	could	provide	a	synthetic	basement	
membrane	 that	 would	 provide	 a	 framework	 around	 which	 cells	 could	 be	
stimulated	 to	produce	an	extracellular	matrix.	The	polymer	chosen	 for	 this	 is	
PHBV,	 which	 produced	 a	 scaffold	 which	 with	 pores	 large	 enough	 to	 allow	
fibroblasts	 to	 cross	 into	 the	 layer	 intending	 to	be	 the	dermis	 and	 later	 allow	
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signalling	 molecules	 to	 cross	 from	 the	 dermis	 into	 the	 epidermis	 which	 is	
essential	for	skin	regulation.		
Furthermore,	as	previously	discussed,	the	dermal	epidermal	interface	is	not	flat	
but	has	undulated	regions	where	the	epidermis	projects	deep	into	the	dermis	
which	is	called	the	rete	ridges.	These	develop	mid	gestation	and	prior	to	this	the	
interface	 is	 flat25.	 The	 height	 and	 overall	 dimensions	 of	 the	 rete	 ridges	 vary	
according	 to	 skin	 location	 on	 the	 body,	 age,	 and	 any	 acquired	 or	 congenital	
proliferative	disorders.	For	example,	the	height	of	the	rete	ridges	declines	as	we	
age(169)	and	increases	in	disorders	which	as	psoriasis	which	are	associated	with	
high	 epidermal	 turnover(170).	 Furthermore,	 the	 concentration	 of	 rete	 ridges	
varies	depending	on	the	anatomical	location	the	skin	that	is	being	assessed.	The	
palms	 and	 soles,	 which	 have	 different	 epidermal	 and	 dermal	 structures	
compared	to	the	rest	of	the	body,	contains	a	higher	concentration	of	rete	ridges.		
Presumably	this	is	due	to	the	higher	epidermal	cells	turnover,	thicker	epidermis	
and	the	need	for	a	strong	anchor	between	the	epidermis	and	dermis	to	prevent	
shear	as	these	two	areas	are	subjected	to	the	greatest	number	of	external	forces	
compared	to	any	other	skin	location.	Stem	cells	which	renew	the	epidermal	cells	
lie	in	clusters	outside	the	rete	ridges	just	where	the	epidermal	basal	layer	is	most	
superficial	 and	 closest	 to	 the	 skin	 surface(13).	 	 Previous	 products	 that	 have	
successfully	 translated	 into	 clinical	 practice	 for	 example,	 CEA	 sheets	without	
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consideration	for	the	microstructure	of	skin	have	worked	to	some	extent	as	the	
stem	cells	self-organise	into	clusters	and	their	numbers	become	auto	regulated.	
However,	 these	materials	 require	 cultured	 cells	which	 demand	 the	 time	 and	
facilities	for	cells	to	become	confluent	before	transfer.		
Our	 model	 relies	 on	 the	 migration	 of	 skin	 cells	 from	 the	 cut	 edges	 of	 skin	
explants,	which	 in	our	opinion	 should	be	optimised	as	much	as	possible.	We	
hypothesize	that	by	mimicking	the	microstructure	of	skin,	we	can	encourage	not	
only	cellular	migration	but	cellular	adhesion	and	organization	so	as	to	improve	
take,	a	problem	which	is	seen	not	infrequently	with	epidermal	skin	substitutes	
eg	 CEA	 sheets.	 CEA	 sheets	 that	 are	 in	 clinical	 use,	 requires	 enzymatic	
detachment	of	the	sheet	from	the	culture	vessels	prior	to	transplantation.	This	
results	in	the	loss	of	keratinocyte	basement	membrane	proteins	and	integrins	
which	are	cell	surface	receptors	which	are	responsible	for	the	attachment	of	the	
sheet	 to	 the	 underlying	 wound	 bed(171).	 Moreover,	 when	 keratinocytes	
achieve	confluence	they	rapidly	become	differentiated	cells	which	is	associated	
with	 alteration	 of	 their	 integrin	 expression,	 this	 may	 explain	 the	 poor	 take	
observed	by	CEA	sheets(172).		
Additionally,	undulations	in	the	electrospun	scaffolds	can	provide	the	construct	
with	stem	cell	niches	which	aims	to	direct	the	stem	cells	to	organize	into	their	
clusters	around	the	niches.		Feeding	on	this	the	MacNeil	group	then	undertook	
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successful	work	in	using	stereolithography	to	fabricate	templated	scaffolds	for	
corneal	 regeneration	 to	 provide	 these	 stem	 cell	 niches	 –it	 was	 felt	 that	 this	
concept	could	be	applied	to	a	potential	dermal	analogue29.		
There	 is	 little	 data	 on	 the	 significance	 of	 the	 rete	 ridges	 as	 firstly	 they	 vary	
significantly	 between	 individuals	 and	 also	 between	 the	 anatomical	 area	 that	
they	have	been	taken	from.	Furthermore,	the	most	used	animal	model	for	skin	
research,	the	mouse,	has	no	rete	ridges.	Tissue	engineered	skin	made	using	the	
traditional	 techniques	 of	 seeding	 isolated	 keratinocytes	 onto	 decellularized	
dermis	has	the	issue	of	the	collapse	of	the	dermal	topography	which	leads	to	cells	
migrating	into	empty	hair	follicles,	creating	false	rete	ridges(174).	
Many	electrospun	scaffolds	have	been	evaluated	for	dermal	replacement	using	
a	combination	of	natural	and	synthetic	biodegradable	polymers	in	addition	to	
various	 adjuncts	 to	 the	 electrospinning	 process	 eg	 plasma	 treatment	 and	
electrical	stimulation	of	 the	 fibres	to	produce	a	candidate	scaffold	 fit	 for	skin	
regeneration.	For	example,	Poly	(ε-caprolactone)	(PCL)/gelatin	was	shown	to	be	
able	to	support	the	migration	and	proliferation	of	fibroblasts	when	seeded	on	
both	sides	of	the	scaffold.	 It	was	felt	 that	seeding	fibroblasts	on	two	sides	as	
opposed	 to	 one	 would	 increase	 the	 capacity	 of	 cells	 to	 be	 loaded	 into	 the	
scaffold	 structure	 and	 also	 engage	 cellular	 adhesion	 and	 proliferation(175).		
Polyurethane/	polyvinylidene	electrospun	 scaffolds	have	also	been	evaluated	
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for	skin	regeneration.	Fibroblasts	cultured	on	these	scaffolds	showed	enhanced	
migration,	 adhesion	 and	 secretion	 of	 collagen(176).	 Poly	 (L-lactic	 acid)-co-
poly(ε-caprolactone)	 (PLACL)	 and	 PLACL/gelatin	 complexes	 were	 made	 and	
plasma	 treated	 to	 improve	 their	 hydrophilic	 properties.	 After	 seeding	 these	
scaffolds	 with	 fibroblasts	 it	 was	 shown	 that	 the	 expression	 and	 secretion	 of	
collagen	were	significantly	increased	in	plasma-treated	PLACL/gelatin	scaffolds	
compared	to	PLACL	nanofibrous	scaffolds(177).		
Other	groups	have	recognized	the	value	of	the	trilayer	construct.	For	example,	
Lin	et	al	used	trilayer	chitosan	electrospun	scaffolds	to	replicate	the	striation	of	
full	thickness	of	skin	more	accurately(178).	They	were	able	to	create	discernible	
dermal,	 basement	 membrane	 and	 epidermal	 layers	 which	 maintained	 their	
structure	even	after	seeding	with	keratinocytes	and	fibroblasts.		
Our	scaffolds	are	novel	in	that	we	are	evaluating	the	incorporation	of	features	
of	 the	 fine	micro	 topography	of	 the	 skin	 like	basement	membranes	and	 rete	
ridges	 on	 cellular	 attachment,	 proliferation	 and	 migration.	 Moreover,	 the	
methods	of	production	of	these	scaffolds	are	easily	reproducible	and	convertible	
to	 small	 scale	 manufacturing	 for	 clinical	 applications.	 The	 methodology	 of	
producing	 templated	 scaffolds	 was	 recently	 published	 from	 the	 MacNeil	
laboratory,	 using	 expanded	 cells	 to	 assess	 the	 initial	 performance	 of	 these	
scaffolds(179).		
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3.4	Evaluation	of	the	characteristics	of	PGLA	(75:25)	and	PHBV	scaffolds.		
	
To	 undertake	 this,	 we	 assessed	 morphological,	 physical	 and	 mechanical	
properties	of	these	polymers	when	spun	into	scaffolds.		
Morphological	properties	included	the	assessment	of	pore	and	fibre	diameter	
size	using	ImageJ	software	of	the	SEM	images	of	the	polymers	that	constituted	
the	electrospun	scaffold.	This	was	undertaken	for	three	different	pictures	of	the	
same	area	of	scaffold,	measuring	the	pore	and	fibre	size	diameter	for	at	least	
(n=100)	fibres	and	pores	(n=100).		
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Figure	3.2a:	Pore	diameter	and	fibre	diameter	distribution	calculated	from	100	
fibres	(n=3)	for	PHBV.		
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Figure	3.2b:	SEM	images	of	PHBV	scaffolds	used	in	calculations.		
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Figure	3.3a:	Pore	diameter	and	fibre	diameter	distribution	calculated	from	100	
fibres	(n=3)	for	PGLA.		
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Figure	3.3b:	SEM	images	of	PGLA	(75:25)	scaffolds	used	to	calculate	pore	and	
fibre	diameter	size			
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As	 shown	 in	 the	 SEM	 images,	 PHBV	 scaffolds	 consist	 of	 randomly	orientated	
fibres	with	a	mean	diameter	of	1.89	µm	and	with	an	average	pore	size	of	4.161	
µm	(Figure	3.2).	PLGA	(75:25)	scaffolds	consisted	of	randomly	orientated	fibres	
with	a	mean	diameter	2.22	µm	of	and	a	mean	pore	size	of	8.062	µm	(Figure	3.3).	
This	difference	 is	expected	and	reflects	 the	design	of	 the	scaffolds.	The	PGLA	
(75:25)	 has	 larger	 fibres	 and	 pore	 sizes	 which	 facilitate	 the	 movement	 of	
keratinocytes	and	fibroblasts	and	has	a	large	surface	area	for	deposition	of	their	
bioproducts.	PHBV	has	a	smaller	fibre	diameter	with	smaller	pores	to	mimic	the	
basement	membrane	which	although	is	not	a	defined	anatomical	structure,	it	is	
a	distinct	layer	that	separates	the	keratinocyte	filled	epidermis	from	the	dermis	
but	at	the	same	time	allow	signalling	proteins	to	move	in	between	the	two	layers	
which	is	essential	for	development	and	renewal.		
Scaffolds	 with	 pore	 sizes	 that	 are	 <	 200	 µm	 facilitate	 the	 development	 of	
vascular	networks	with	 small	 vessels	at	high	density	and	shallow	penetration	
which	is	suitable	for	skin	substitutes	as	they	are	relatively	thin	compared	to	solid	
organ	 constructs(180).	 	 In	 line	 with	 this	 it	 is	 no	 surprise	 that	 clinically	 used	
dermal	matrices	like	Integra	and	Matriderm	have	pore	sizes	of	20-125	µm	and	
20-150	µm	respectively(181).	
Mechanical	properties	of	the	scaffolds	were	measured	using	an	uniaxial	tensile	
test.	The	length,	width	(cut	to	be	all	the	same)	and	thickness	of	all	the	samples	
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were	measured	to	aid	normalisation	of	results	as	these,	if	not	constant	would	
affect	the	mechanical	properties	measured.	Parameters	obtained	from	this	test	
include	 the	 ultimate	 tensile	 strength	 (maximum	 stretch	 of	 the	 material),	
maximum	elongation	and	the	Young’s	modulus.	This	allows	comparison	of	the	
biomechanical	properties	of	our	scaffold	to	skin	itself,	which	is	the	material	that	
we	are	trying	to	match	as	closely	as	possible.	Furthermore,	it	is	known	that	the	
mechanical	properties	of	skin	is	affected	by	patient	factors	such	as	age,	smoking	
and	use	of	steroids,	so	for	these	measurements,	samples	were	repeated	from	
one	patient.	Due	to	patient	confidentiality	we	were	unable	to	map	these	factors	
onto	the	skin	hence	the	use	of	one	sample.	
The	Young’s	modulus	(YM)	is	also	known	as	the	elastic	modulus,	as	elongation	
of	 the	material	 during	 this	 linear	 slope	 is	 known	 as	 elastic	 deformation.	 The	
material	will	recoil	to	its	original	size	once	the	force	stops.	YM	is	the	first	linear	
slope	when	a	material	is	stretched	which	is	obtained	from	a	stress	strain	plot.	It	
reflects	 the	 relationship	 between	 stress	 (force	 per	 unit	 area)	 and	 strain	
(proportional	deformation)	in	a	material.	It	is	calculated	by	dividing	the	tensile	
stress	by	the	exertional	strain	in	the	elastic	(initial	linear)	portion	of	the	stress-
strain	curve	that	is	obtained	from	the	uniaxial	tensile	test.	The	steeper	the	slope,	
the	 stiffer	 the	 material.	 Once	 this	 portion	 of	 the	 curve	 is	 past,	 all	 further	
elongation	observed	is	plastic	deformation.		Another	parameter	often	measured	
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is	 the	Ultimate	 tensile	 strength	 (UTS)	which	 is	 the	maximum	 strength	 of	 the	
material	 and	 the	 strain	 at	 ultimate	 tensile	 strength	 which	 is	 the	 maximum	
elongation	of	the	material	before	it	starts	to	snap.		
All	 samples	 assessed	 in	 this	 project	 for	 the	uniaxial	 tensile	 test	were	 initially	
measured	for	size.	The	stress	strain	data	for	each	sample	was	normalized	before	
plotting	the	three	above	parameters	described:	YM,	UTS	and	strain	at	UTS.		This	
was	done	by	dividing	the	stress	by	the	area	of	the	scaffold	(width	of	scaffold	x	
thickness)	and	dividing	the	strain	by	the	length	between	the	two	grids	on	the	
tensiometer	(effectively	the	length	of	the	scaffold)	to	obtain	a	%	of	elongation	
from	its	original	length.		
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Figure	3.4:	Mechanical	properties	of	human	skin,	Euroskin,	 templated	 trilayer	
PGLA	 (75:25)/PHBV,	 non-templated	 PGLA	 (75:25)/PHBV	 trilayer	 and	 PGLA	
(75:25)	monolayer	electrospun	scaffolds.	Mean±SEM	(n=3).	A=Ultimate	tensile	
strength,	B=Strain	at	Ultimate	tensile	strength	and	C=Young’s	Modulus.		
	
The	 non-templated	 trilayer	 scaffolds	 exhibited	 a	 significantly	 higher	 Young’s	
Modulus	 compared	 to	 monolayer	 PGLA	 (75:25),	 skin	 and	 Euroskin,	 which	
highlighted	 its	 stiffness	 (Figure	 3.4).	 Templated	 scaffolds	 had	 no	 significant	
differences	in	YM	compared	to	skin	and	monolayer	PGLA	(75:25).	Alternatively,	
the	non-templated	scaffolds	had	a	significantly	lower	strain	at	ultimate	tensile	
Sk
in
Eu
ros
kin
Tem
pla
ted
 PG
LA
/PH
BV
 sc
aff
old
s 
No
n T
em
pla
ted
 PG
LA
/PH
BV
 Sc
aff
old
s 
PG
LA
(75
:25
) M
on
ola
ye
r S
ca
ffo
ld
0
5
10
15
20
Material
Yo
un
g’s
 M
od
ul
us
 (M
Pa
)C 
	 185	
strength	 compared	 to	 templated	 scaffolds,	 fresh	 skin	 and	 Euroskin	 but	 not	
significantly	 different	 to	 monolayer	 PGLA	 (75:25)	 scaffolds.	 	 The	 templated	
scaffolds	had	similar	tensile	properties	to	skin	and	Euroskin	apart	from	Ultimate	
tensile	 strength,	 which	 is	 significantly	 higher	 in	 skin	 and	 Euroskin.	 However,	
when	comparing	templated	scaffolds	to	non-	templated	and	monolayer	PGLA	
(75:25),	the	UTS	was	significantly	higher	in	the	templated	samples.	To	conclude,	
adding	the	undulating	features	to	the	electrospun	scaffold,	resulted	in	material	
that	was	overall	stronger	and	less	stiff	than	non-templated	scaffolds.				
	
3.5	Evaluation	of	the	stem	cell	niche	in	templated	scaffolds		
 
The	 middle	 layer	 of	 our	 electrospun	 scaffolds	 are	 templated,	 to	 mimic	 the	
undulations	present	in	the	interface	between	the	dermis	and	epidermis.	These	
templates	 are	 modelled	 on	 those	 scaffolds	 used	 for	 a	 similar	 application	 in	
corneal	regeneration	at	the	MacNeil	 laboratory	based	on	a	similar	undulating	
pattern	termed	the	Palisades	of	Vogt.	Although	there	is	published	work	on	the	
dimensions	of	the	rete	ridges,	it	is	challenging	to	exactly	replicate	this,	as	a	result	
these	templates	were	used	 in	an	attempt	to	assess	the	effect	of	proliferating	
cells	in	response	to	the	undulations	rather	than	having	an	exact	replica.	We	used	
three	metal	templates	(figure	6)	all	created	in	the	same	manner	to	produce	the	
middle	 layer	of	PHBV	for	all	electrospun	scaffolds	used	 in	the	experiments	as	
shown	in	figure.	The	templates	can	be	seen	to	consist	of	a	regular	honeycomb	
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pattern	where	the	average	diameter	of	the	template	feature	was	found	to	be	
1.43mm	(figure	7).	A	side	view	revealed	the	depth	of	 the	templates	to	be	on	
average	566	µm	(Figure	3.5).	
	
	
Figure	 3.5:	 Light	 micrograph	 of	 the	 templates	 in	 the	 stainless	 steel	 metal	
collectors	illustrating	the	diameter	and	depth	of	the	template.		
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Figure	3.6	Macroscopic	and	SEM	images	of	the	templated	trilayer	scaffold.		
These	 templates	 were	 translated	 into	 PHBV	 scaffolds	 where	 the	 undulating	
pattern	was	present	both	macroscopically	and	microscopically.		
	
3.6	Modification	of	Electrospun	Scaffolds.		
 
Vascularization	of	electrospun	scaffolds	can	be	viewed	as	one	of	the	challenges	
to	clinical	 translation.	 Inorganic	polymers	are	attractive	as	 they	are	 inert	and	
non-reactive	with	predictable	breakdown	products	that	are	excreted	in	known	
physiological	 pathways.	 However,	 failure	 to	 develop	 and	 support	 a	 vascular	
system	will	result	in	failure	of	the	material	to	integrate	into	the	patient’s	own	
tissues.	As	a	result,	a	lot	of	research	has	focussed	on	increasing	the	angiogenic	
properties	 of	 scaffolds.	 Table	 3	 summarizes	 some	 of	 the	 current	 published	
vascularization	strategies	for	dermal	scaffolds.		
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Strategy	 Mechanism	 Reference	
Innate	 properties	 of	
the	scaffold	
Pore	 size	 and	
interconnectivity	(180)	
Allows	space	for	infiltration	
of	vessels	of	varying	sizes			
Treatment	 of	
scaffolds		
Plasma	 treatment	
(182)	
Proposed			
Alternative		
polymers	 that	 are	
proangiogenic		
Example:	 PolyN	
acetlyglucosamine	
NAG	(183)	
	
Additives	to	scaffolds		 	 	
Molecular		 Vascular	 Endothelial	
Growth	 Factor	 (184),	
(185)	
Directly	influences	new	and	
existing	 vessel	 growth	 by	
endothelial	 cell	
proliferation	
	 VEGF	 and	 Heparin	
(136)	
Heparin	 allows	 for	 better	
binding	of	VEGF	to	enhance	
its	effect	
	
	
Basic	 Fibroblast	
Growth	factor	(186)	
Chemoattractant	 to	
fibroblasts	 –	 this	 releases	
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factors	that	promote	angio	
and	vasculogenesis		
	 Platelet	 derived	
growth	factor	(184)	
Stimulates	 proliferation	 of	
endothelial	cells		
	 Alginate	 +	 Basic	
Fibroblast	 Growth	
Factor	(187)	
Chemoattractant	 to	
fibroblasts	 which	 secrete	
factors	 to	 stimulate	 blood	
vessel	ingrowth		
	 Ascorbic	Acid	(110)	 Co	 factor	 in	 collagen	 cross	
linking	 –	 thought	 to	
increase	 collagen	 which	 in	
turn	increases	the	ingrowth	
of	 blood	 vessels	 into	
scaffolds		
	 Oestrodiol	(112)	 This	 is	 proangiogenic-	
thought	to	stimulate	blood	
vessel	 ingrowth	 into	
scaffold.		
	 2	Deoxyribose	(188)	 As	 for	 oestrodiol,	 good	
alternative	to	VEGF	
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Cell	Based		 Human	 dermal	
microvascular	
endothelial	cells	(189)	
Proangiogenic		
	 Umbilical	 vein	
endothelial	cells	(190)	
Progangiogenic		
	 Endothelial	 progenitor	
cells	(191)	
Proangiogenic		
	 Mesenchymal	 stem	
cells	from:	
Adipose	tissue	.	(192)	
Bone	marrow	(193)	
Umbilical	cord		(194)	
	
	
Proangiogenic,	 thought	 to	
differentiate	 into	 desired	
cell	 type	 depending	 on	
conditions.		
	
Table	3:		Summary	of	current	strategies	to	induce	vascularity	into	scaffolds.		
	
	
As	observed	there	have	been	many	substances	added	to	electrospun	scaffolds	
to	 enhance	 their	 vasculogenesis.	 Several	 such	 approaches	 have	 been	
investigated	 in	 the	 MacNeil	 group.	 One	 such	 is	 the	 addition	 of	 estradiol	 to	
electrospun	 scaffolds.	 This	was	 investigated	by	Mangir	 and	 colleagues	where	
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they	used	PLA	containing	various	concentrations	of	oestradiol	and	evaluated	its	
angiogenic	 potential	 using	 a	 chick	 chorionic	 membrane	 assay(112).	 Their	
research	 revealed	 that	 these	 scaffolds	 increased	 ECM	 production	 and	
stimulated	angiogenesis.	The	proposed	use	of	this	scaffold	was	for	pelvic	floor	
repair	in	females.		
Possible	issues	with	this	would	be	the	effect	of	systemic	oestradiol	absorption,	
although	the	dose	of	oestradiol	used	in	the	scaffold	is	likely	to	be	very	small,	the	
clinical	effects	of	 this	 is	 yet	unknown.	 	 	Another	 strategy	 investigated	adding	
ascorbic	acid	in	two	forms	l-ascorbic	acid	(AA)	and	ascorbate-2-phopshate	(A2P)	
to	 PLA	 scaffolds.	 This	 resulted	 in	 an	 increase	 in	 collagen	 production	 by	
fibroblasts(110).	 Although	 ascorbic	 acid	 is	 not	 a	 hormone	 and	 a	 vitamin,	 its	
proposed	use	as	part	of	a	scaffold	is	not	what	it	 is	 licensed	for	 in	humans	i.e.	
topical	and	oral,	as	a	result,	this	would	also	have	to	be		approved	before	being	
allowed	 into	 the	clinic.	Other	strategies	 include	the	addition	of	products	 that	
indirectly	 increases	 scaffold	vascularity.	For	example,	heparin	when	added	 to	
scaffolds	 stimulate	 the	 formation	 of	 new	 blood	 vessels.	 In	 order	 to	 use	 this	
property	of	heparin	on	scaffolds	efficiently,	chemicals	like	chitosan	are	added	to	
the	scaffold	used	to	increase	its		heparin	binding	capacity	5150.		
Our	model	did	not	 include	any	additives	hormonal	or	otherwise	 to	 stimulate	
neovascularization	specifically	as	ultimately	this	would	have	to	undergo	rigorous	
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certification	 for	 human	use.	Addition	of	 chemicals	 inorganic	 or	 organic	 alike,	
converts	an	electrospun	scaffold	from	a	medical	device	e.g.	like	biodegradable	
sutures	or	a	metal	plate	for	bony	fixation	or	a	joint	replacement	unit	to	a	drug	
releasing	device.		
Any	structure	that	contains	or	releases	a	chemical	that	can	potentially	react	will	
contend	with	a	significantly	lengthy	and	challenging	regulatory	process,	to	get	
these	to	the	clinic.	As	expected	there	will	be	the	need	to	demonstrate	via	way	
of	animal	studies	and	then	a	clinical	trial	that	these	additives	do	not	have	any	
adverse	 effects	 on	 the	 physiology	 of	 the	 patient.	 Also	 there	 is	 a	 need	 to	
demonstrate	that	this	is	significantly	better	than	the	current	materials	that	are	
being	used	to	tackle	the	clinical	problem	in	question.		
Vascularization	 is	 essential	 for	 any	wound	 to	 heal,	 however	 the	 skin	 has	 the	
ability	 to	 revascularize	 as	 a	 part	 of	 wound	 healing	 process	 given	 the	 right	
conditions	 (free	 of	 infection	 and	 the	 absence	 of	 excessive	 inflammation)	 are	
met.	This	is	because	signalling	proteins	are	concentrated	at	the	wound	edges,	
which	act	as	a	strong	drive	 for	endothelial	cells	 to	migrate	across	 the	wound	
bed.	 We	 have	 therefore	 focused	 on	 the	 ultrastructure	 of	 the	 electrospun	
scaffolds	and	used	only	two	polymers	which	are	known	to	facilitate	and	support	
the	migration	of	skin	cells	without	any	additives.	This	approach	is	based	on	the	
fact	that	the	microstructure	of	skin	is	key	to	cellular	organization	and	cell/cell	
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communication	creating	a	homeostatic	loop	of	continuous	regeneration	as	and	
when	needed.	Once	polymer	provides	the	right	scaffold	for	the	patient’s	cells	to	
proliferate	and	migrate,	endothelial	cells	and	vasculogenesis	should	occur.		
In	summary	we	have	described	in	depth	the	polymers	chosen	for	our	scaffold	
and	the	reasoning	behind	seeking	to	provide	the	microstructure	of	a	templated	
trilayer	construct.	We	have	outlined	the	various	strategies	that	many	research	
groups	 have	 published	 for	 optimizing	 tissue	 engineered	 dermal	 scaffolds.	
Furthermore,	we	have	outlined	the	properties	both	essential	and	desirable	of	a	
dermal	scaffold	for	clinical	use	and	the	strategies	used	to	vascularize	scaffolds.	
We	 have	 emphasized	 that	 for	 the	 purpose	 of	 this	 application	 to	 be	 used	 in	
medium	sized	(cannot	directly	close)	full	thickness	defects,	we	aimed	to	keep	
the	scaffolds	free	from	chemical	or	hormonal	additives	which	would	convert	the	
scaffold	from	being	a	medical	device	to	a	potential	drug	releasing	device.	
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Chapter	4	
 
Evaluation	of	how	a	novel	method	of	
spinning	a	basement	membrane	
substitute	will	encourage	epithelial	
stromal	organization:	Monolayer	vs	
Trilayer	Electrospun	Scaffolds	
	
	
	
	
	
4.1	Introduction		
	
Basement	membranes	are	thin	sheets	of	extracellular	proteins	situated	in	close	
proximity	to	cells.	They	function	to	influence	tissue	compartmentalization	and	
cellular	 phenotypes.	 The	 main	 constituents	 of	 all	 basement	 membranes	 are	
collagen	 IV	 and	 laminin.	 These	 are	 connected	 by	 nidogens	 (sulphated	
monomeric	glycoproteins).	Cells	are	connected	to	the	basement	membrane	via	
glycoprotein	 integrin	 receptors.	 Collagen	 type	 IV	 is	 the	 most	 widespread	
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basement	 membrane	 component,	 its	 structure	 and	 arrangement	 confers	
mechanical	stability	(196)(197).	Laminins	(several	heterotrimeric	forms:	laminin	
1	 to	 7)	 also	 make	 up	 a	 significant	 proportion	 of	 the	 basement	 membrane.	
Proteoglycans	are	another	important	basement	membrane	constituent	of	which	
perlecan	is	the	most	abundant	(198).			
These	proteins	allow	 the	membrane	 to	adjust	 function	at	 specific	anatomical	
sites.	For	example,	thin,	continuous,	extended	sheets	of	basement	membrane	
that	 maintain	 integrity	 and	 stability	 are	 needed	 over	 long	 distances	 in	 the	
vascular	system.		Additionally,	sufficient	mechanical	stability	is	needed	to	resist	
the	 high	 shear	 forces	 at	 the	 dermal-epidermal	 junction	 in	 the	 skin.	 These	
proteins,	by	subtle	phenotypical	changes	based	on	their	anatomical	 locations	
are	able	to	provide	these	properties	to	the	basement	membrane,	the	integrity	
of	which	is	crucial	for	the	survival	of	any	organ	system(199).		
The	extracellular	matrix	consists	of	structural	and	functional	proteins	arranged	
in	a	unique	3D	structure	and	occupies	the	spaces	between	cells(167).	The	ECM	
of	the	basement	membrane	contains	a	mixture	of	extracellular	proteins	which	
include:	laminin,	collagen	type	IV	and	entactin(200).			
Collagen	type	VII	is	a	structural	basement	membrane	component	which	forms	
fibrils,	 anchoring	 the	 basement	 membrane	 to	 the	 underlying	 dermis.	 Both	
keratinocytes	 and	 fibroblasts	 contribute	 to	 the	 formation	 of	 the	 basement	
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membrane	 in	 the	 skin(201).	 The	 basement	 membrane	 and	 the	 underlying	
dermis	regulate	keratinocyte	growth	and	terminal	differentiation,	and	thereby	
influence	 the	 structure	 of	 the	 overlying	 epidermis	 and	 its	 crucial	 barrier	
function(202).	 Therefore,	 it	 is	 desirable	 in	 organ	 regeneration	 to	 consider	
including	a	feature	that	can	mimic	or	act	like	a	basement	membrane	to	further	
simulate	the	structure	that	is	being	engineered.			
The	use	of	electrospun	scaffolds	as	a	dermal	regenerative	template	consisting	
of	 single	 polymers	 is	 an	 accepted	 technique	 (203).	 Simple	 monopolymer	
electrospun	scaffolds	provide	a	surface	for	cellular	attachment	and	proliferation	
with	eventual	organization	of	cells	and	their	products	into	dermis	and	epidermis.	
However,	cells	in	the	organ	systems	that	we	are	trying	to	replicate	exist	in	3D	
structures	within	their	respective	tissues	and	environments.	Culturing	cells	on	a	
monolayer	eg	tissue	culture	plastic	or	a	single	polymer	electrospun	scaffold	does	
not	replicate	this	environment	or	provide	a	true	potential	for	multi	layered	cell	
culture(204).	 Skin	 has	 two	main	 layers	 separated	 by	 a	 specialized	 basement	
membrane.	It	would	be	desirable	to	create	a	scaffold	which	has	the	capacity	to	
support	 different	 cells	 to	 proliferate	 and	 migrate	 and	 simultaneously	
communicate	with	each	other	in	order	to	function	as	a	unit.		
We	 hypothesise	 that	 incorporating	 this	 into	 our	 scaffolds	 will	 encourage	
epithelial-stromal	organization	which	is	seen	very	clearly	in	native	human	skin.	
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In	order	to	do	this,	we	propose	to	use	the	electrospinning	technique	to	combine	
two	 different	 polymers	 in	 three	 distinct	 layers	 thereby	 creating	 a	 trilayer	
electrospun	 scaffold.	 The	 PHBV	 or	 the	 basement	 membrane	 mimic	 will	 be	
sandwiched	 in	between	 two	 layers	of	 PGLA	75:25	which	will	 support	 cellular	
growth	(Figure	4.1).	
	
	
Figure	4.1:	Illustration	of	the	trilayer	electrospun	scaffold,	consisting	of	a	middle	
layer	of	PHBV,	in	between	two	layers	of	PGLA	75:25.		
	
This	method	has	been	previously	established	 in	 the	MacNeil	group	using	PLA	
and	PHBV(205).	A	key	feature	of	this		technique	when	spinning	two	polymers	at	
the	same	time	is	a	method		to	prevent	delamination	of	the	different	layers	post	
spinning,	which	can	occur		given	the	different	properties	of	the	polymers.	To	do	
this	we	used	8mls	of	PHBV	in	4	syringes	(	2mls	each)	to	create	the	first	layer	on	
the	template.	The	second	layer	was	a	hybrid	consisting	of	4mls	of	PHBV	and	4	
mls	of	PGLA	75:25,	the	third	layer	consisted	of	8mls	of	PGLA	75:25.	Once	this	
was	complete,	the	templates	were	removed	and	the	scaffolds	were	flipped	over	
to	then	add	another	hybrid	of	4mls	of	PHBV	and	4	mls	of	PGLA	75:25	on	the	
PGLA(75:25) 
PGLA(75:25) 
PHBV 
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other	side	of	the	middle	layer	of	PHBV,	and	finally	8	mls	of	PGLA	75:25	to	create	
the	outer	surface	of	the	scaffold.	This	is	illustrated	below.		
	
	
	
Figure	4.1b:	Cartoon	to	illustrate	the	process	of	spinning	the	polymers	to	
prevent	delamination	during	experimentation.	The	hybrid	layer	was	essential	
where	both	polymers	were	mixed	to	facilitate	this.		
	
	In	this	chapter	we	aim	to	create	electrospun	scaffolds	with	a	central	 layer	of	
nano-porous	and	nanofibrous	PHBV	securely	placed	 in	between	two	layers	of	
microporous	and	microfibrous	PGLA	(75:25).	PHBV	was	chosen	because	it	has	
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been	shown	to	restrict	cellular	movement	between	two	layers	of	different	cells	
but	 still	 be	 porous	 enough	 to	 allow	 communication	 via	 chemical	 signalling	
between	 the	 two	 cell	 types(126).	 This	 is	 essential	 as	 the	 structure	 of	 the	
epidermis	 is	dependent	on	the	signalling	 factors	produced	by	 the	cells	of	 the	
epidermis	and	the	dermis	in	addition	to	the	underlying	basement	membrane.		
PGLA	75:25	was	chosen	based	on	previous	work	 that	aimed	at	establishing	a	
suitable	 polymer	 that	 would	 sustain	 the	 attachment	 and	 proliferation	 of	
fibroblasts	and	keratinocytes.	Most	importantly,	it	degrades	with	a	decline	in	its	
mechanical	 strength	 at	 	 about	 five	 months	 post	 implantation	 which	 is	 an	
appropriate	time	match	for	wound	healing	and	skin	regeneration	(124).		
The	experiments	 in	this	chapter	compare	the	performance	of	a	monolayer	of	
PGLA	75:25	to	a	trilayer	electrospun	PHBV/PGLA	75:25	electrospun	scaffolds	in	
supporting	 the	 migration	 and	 proliferation	 of	 isolated	 human	 dermal	
keratinocytes	 and	 fibroblasts.	 We	 also	 aim	 to	 investigate	 the	 effect	 of	 the	
trilayer	scaffolds	if	any,	on	the	migration	of	skin	cells	from	skin	explants	and	their	
spatial	organisation	compared	to	monolayer	scaffolds.		
	
4.2	 Quantitative	 analysis	 of	 activity	 of	 cultured	 cells	 on	 monolayer	 versus	
trilayer	electrospun	scaffolds.		
 
4.2.1 Alamar	Blue		assay		
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Absorbances	 for	cells	and	skin	explant	seeded	on	monolayer	PGLA	75:25	and	
trilayer	PHBV/PGLA	75:25	electrospun	scaffolds	were	read.	The	absorbance	for	
scaffolds	of	each	type	seeded	without	cells	and	explants	were	subtracted	from	
these	values	for	each	time	checkpoint	at	day	7,	14	and	21	(Figure	4.2.1).	It	was	
demonstrated	that	cellular	constructs	were	viable	throughout	the	21-day	testing	
period	on	both	scaffolds	types.		Metabolic	activity	in	the	monolayer	electrospun	
scaffold	constructs	progressively	increased	from	day	7	to	day	21.	There	were	no	
significant	 differences	 in	 cellular	 metabolic	 activity	 when	 isolated	 cells	 were	
seeded	on	monolayer	vs	trilayer	electrospun	scaffolds	apart	from	day	7	with	the	
monolayer	 constructs	 having	 significantly	 higher	 metabolic	 activity	 versus	
trilayer	 at	 this	 time	 checkpoint.	 Although	 in	 absolute	 terms,	 the	 trilayer	
constructs	had	lower	metabolic	activity	going	forward	to	21	days,	this	was	not	
statistically	 significant.	With	 regards	 to	 constructs	 with	 skin	 explants,	 it	 was	
found	that	there	was	significantly	higher	metabolic	activity	in	those	seeded	on	
monolayer	scaffolds	compared	to	those	seeded	on	trilayer	scaffolds	throughout	
the	experimental	period	(Figure	4.2.2).		
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Figure	 4.2.1	Metabolic	 activity	 of	 isolated	 human	 dermal	 keratinocytes	 and	
fibroblasts	on	monolayer	PGLA	75:25	electrospun	scaffolds	and	non-templated	
trilayer	 (	PGLA	75:25/PHBV)	electrospun	scaffolds	over	a	21-day	experimental	
period	of	culture,	as	determined	by	absorbance	of	AlamarBlue	stain	(mean±SEM	
(n=3).		
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Figure	 4.2.2	 Metabolic	 activity	 of	 skin	 explants	 on	 monolayer	 PGLA	 75:25	
electrospun	 scaffolds	 compared	 to	 	 non-templated	 PGLA	 75:25/PHBV		
electrospun	 scaffolds	 over	 a	 21-day	 experimental	 period	 of	 culture,	 as	
determined	by	absorbance	of	AlamarBlue	stain	(mean±SEM)	(N=3).		
	
	
4.2.2	Sirius	Red	Assay	
 
At	day	7,	14,	and	21	post	seeding,	Sirius	red	assays	were	undertaken	to	estimate	
the	total	collagen	produced	overtime	by	the	isolated	human	dermal	fibroblasts	
and	keratinocytes	seeded	on	the	monolayer	and	trilayer	electrospun	scaffolds	
(Figure	4.2.3).		
The	 aim	 was	 to	 quantify	 the	 ability	 of	 the	 electrospun	 scaffolds	 to	 support	
cellular	 proliferation	 and	 function	 by	 measuring	 the	 collagen	 production	 by	
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fibroblasts.	We	also	wanted	to	determine	if	there	were	any	differences	between	
the	monolayer	PGLA	75:25	and	trilayer	PHBV/PGLA	(75:25)	constructs.		
With	 regards	 to	 the	 cellular	 constructs,	 collagen	 production	 increased	 in	 the	
monolayer	scaffolds	over	the	21-day	experimental	period	and	was	significantly	
greater	compared	to	collagen	production	in	the	trilayer	constructs	only	on	days	
14	and	21.		
	
	
	
	
	
Figure	4.2.3		Sirius	red	staining	after	7,14	and	21	days	of	cultured		isolated	
human	fibroblasts	and	keratinocytes		on	monolayer	and	trilayer	electrospun	
scaffolds.	(N=3±SEM).	
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4.3	Qualitative	evidence	of	cellular	migration	within	monolayer	PGLA	75:25	
electrospun	scaffolds.		
	
4.3.1	DAPI	Staining	
	
This	was	undertaken	for	both	cell	and	skin	explant	constructs	fixed	at	day	7,	
14,	and	21	to	demonstrate	cellular	attachment	and	migration	along	fibres	of	
monolayer	PGLA	75:25	and	trilayer	PHBV/PGLA	75:25	electrospun	scaffolds.	
Both	layers	were	imaged	such	that	the	top	surface	is	shown	in	the	pictures	for	
the	trilayers	to	see	the	migration	of	keratinocytes,	for	the	monolayers	the	
orientation	made	no	difference.	We	also	wanted	to	detect	whether	there	were	
any	differences	observed	between	the	two.		Good	cell	attachment	and	
migration	were	demonstrated	along	the	fibres	on	both	monolayer	PGLA	75:25	
and	trilayer	electrospun	scaffolds,	which	were	comparable	to	each	other	in	
pattern	and	distribution	(Figure	4.3.1)	when	isolated	cells	were	seeded.	
However,	when	comparing	constructs	with	skin	explants	,	cells	were	seen	to	be	
migrating	from	the	cut	edge	of	the	skin	explants	onto	the	surface	of	the	
monolayer	scaffolds	most	predominantly	at	day	21	compared	to	trilayer	
constructs,	which	had	the	best	evidence	of	cellular	migration	at	day	14.		
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Figure	4.3.1	DAPI	staining	of	constructs	(monolayer	scaffolds	and	trilayer	
scaffolds)	cultured	with	isolated	human	fibroblasts	and	keratinocytes.	Scale	
bar	=0.2mm.	
	
	
																							Day	7	 	 	 	 	 							Day	14	 	 	 																																		Day	21 		
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Figure	4.3.2	DAPI	staining	of	constructs	(monolayer	scaffolds	and	trilayer	
scaffolds)	cultured	with	skin	explants.	Scale	bar	=0.2mm.	
	
4.3.2	Haematoxylin	and	Eosin	Staining	
	
For	 these	 experiments,	 confluent	 dermal	 fibroblasts	 were	 seeded	 on	 both	
Monolayer	 75:25	 PGLA	 and	 non-	 templated	 trilayer	 PGLA	 75:25/PHBV	
electrospun	 scaffolds	 respectively	 and	 cultured	 for	 48	 hours	 followed	 by	
confluent	isolated	keratinocytes.	These	experiments	were	repeated	using	skin	
explants	instead	of	isolated	cells	and	fixed	at		days	7,	14,	and	day	21.	Specimens	
were	cryosectioned	and	stained	with	H&E	according	to	the	protocol	outlined	in	
the	methods.	The	aim	here	was	to	obtain	a	quantitative	assessment	by	way	of	
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images	to	determine	if	there	was	any	difference	in	the	migration	and	integration	
of	 cells	 versus	 skin	 explants	 on	 both	monolayer	 and	 trilayer	 scaffolds..	 	 The	
cellular	 nuclei	 appear	 as	 blue/black	 and	 the	 cytoplasm	 and	 surrounding	
connective	tissue	appears	pink.	H&E	stained	constructs	containing	cell	seeded	
monolayer	 and	 trilayer	 electrospun	 scaffolds	 demonstrated	 confluent	 cell	
populations	on	both	scaffolds(Figure	4.3.4).	A	distinct	difference	was	seen	in	the	
architectures	 whereby	 the	 trilayer	 scaffolds	 had	 a	 defined	 layer	 consisting	
predominantly	of	 keratinocytes.	 The	PHBV	basement	membrane	 layer	 is	 also	
visible	 in	 these	 constructs	 which	 is	 largely	 devoid	 of	 cellular	 material	 as	
intended.	The	 fibroblast	 seeded	 layer	 is	also	 seen	 in	 the	H&E	sections	of	 the	
trilayer	constructs.	Compared	to	the	monolayer	scaffolds,	which	consist	of	both	
cell	types	in	one	polymer	layer	(Figure	4.3.3),	the	trilayer	construct	has	a	more	
similar	architecture	to	that	of	human	skin	(Figure	4.3.4	and	Figure	4.3.5).	H&E	
sections	 of	 monolayer	 and	 trilayer	 electrospun	 scaffolds	 with	 explants	
demonstrate	 that	 there	was	 less	 cellular	migration	 from	 the	 cut	 edge	of	 the	
explants	and	thereby	less	cellular	proliferation	along	the	fibres	of	the	scaffold	
compared	to	using	isolated	cells	(Figure	4.3.6).		
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Figure	4.3.3.	Annotated	light	microscopy	H&E	stained	section	of	isolated	human	
dermal	fibroblasts	and	keratinocytes	cultured	on	monolayer	scaffolds.	Scale	bar	
of	 0.2	 mm	 (10X	 magnification).	
	
	
Figure	4.3.4	Representative	 light	microscopy	H&E	stained	 sections	of	 isolated	
human	dermal	fibroblasts	and	keratinocytes	cultured	on	monolayer	and	trilayer	
electrospun	scaffolds.	Scale	bars	of	0.2	mm	(10X	magnification).	
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Figure	4.3.5	Representative	 light	microscopy	H&E	stained	 sections	of	 isolated	
human	dermal	fibroblasts	and	keratinocytes	cultured	for	14	days	on	monolayer	
(x200)(A)	 and	 trilayer	 electrospun	 scaffolds	 (x40)(C)	 compared	 to	 human	
skin(x100)	 (B.	 These	 figures	 illustrates	 the	 definable	 layers	 of	 epidermis	 and	
dermis	created	by	the	trilayer	electrospun	scaffold	technique	when	cultured	with	
isolated	fibroblasts	and	keratinocytes.		
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Figure	 4.3.6	 Representative	 light	 microscopy	 H&E	 stained	 sections	 of	 skin	
explants	 cultured	 on	 monolayer	 PGLA	 75:25	 (top)	 and	 non-templated	 PGLA	
75:25/PHBV	trilayer	electrospun	scaffolds	(bottom),	illustrating	poor	contact	of	
skin	explants	on	scaffold	at	day	..	Scale	bars	of	0.2	mm	(100X	magnification).		
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4.4	Scanning	electron	microscopy		
	
These	were	undertaken	to	demonstrate	cellular	migration	and	proliferation	along	
the	fibres	of		both	isolated	fibroblasts	and	keratinocytes		and	skin	explant	seeded	
monolayer	PGLA	75:25	scaffolds	respectively	after	14	days	in	culture.	We	chose	
representative	 images	 at	 this	 time	 point	 as	 we	 would	 expect	 some	 cellular	
migration	and	proliferation	from	the	edge	of	the	skin	explant	onto	the	scaffold	by	
14	days.		These	images	clearly	illustrate	cellular	infiltration	and	proliferation	on	
the	fibres	of	the	electrospun	scaffolds	(Figure	4.4.1).	Furthermore,	the	production	
of	 extracellular	 proteins	 and	 collagen	 fibrils	 that	 have	 been	 deposited	 by	 the	
proliferating	fibroblasts	are	visible	on	the	surface	of	the	scaffolds	(Figure	4.4.2).	
Imaging	 was	 also	 undertaken	 for	 the	 skin	 explant	 seeded	 constructs	 to	
understand	 if	 there	 was	 any	 cellular	 migration	 at	 this	 time	 point.	 The	 image	
(4.4.3)	shows	very	little	in	the	way	of		cellular	migration	and	proliferation	in	these	
constructs	especially	in	the	area	surrounding	the	skin	explants.	
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Figure	4.4.1	SEM	images	of	isolated	human	dermal	fibroblasts	and	keratinocytes	
cultured	on	monolayer	electrospun	scaffolds	(x4000	and	x200	Magnification	(A	
and	 B).	 C	 shows	 monolayer	 PGLA	 75:25	 scaffolds	 without	 seeded	 cells	 for	
comparison	(x100	magnification)).		
	
	
	
Figure	 4.4.2	 SEM	 image	 of	 isolated	 fibroblasts	 and	 keratinocytes	 cultured	 on	
trilayer	PGLA	75:25/	PHBV	electrospun	scaffolds	at	day	7(left).	The	figure	shows	
deposition	of	extracellular	material	on	the	scaffold	by	proliferating	cells.	(	x2000	
magnification).	The	figure	on	the	right	is	an	SEM	image	of	the	same	magnification	
of	the	non-templated	trilayer	scaffolds	without	cells	for	comparison.		
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Figure	 4.4.3	 SEM	 image	 of	 skin	 explants	 cultured	 on	monolayer	 (PGLA	 75:25)	
electrospun	scaffolds(left)	 (x200	Magnification).	SEM	image	of	plain	monolayer	
75:25	electrospun	scaffolds	without	cultured	skin	explant	for	comparison	(right)			
(	x100	magnification)	
	
	
4.5	Collagen	IV	Immunohistochemistry	
	
This	was	undertaken	on	day	14	 for	monolayer	and	trilayer	constructs	seeded	
with	isolated	fibroblasts	and	keratinocytes.	The	aim	of	this	was	to	determine	if	
there	was	any	organization	of	the	collagen	into	a	defined	layer	close	to	the	PHBV	
polymer	middle	layer	which	acted	as	a	nanofibrous/porous	structure	similar	to	
that	of	the	ECM	of	the	basement	membrane.	Figure	4.5.1	demonstrates	that	in	
the	monolayer	constructs	collagen	is	distributed	randomly as	deposited	by	the	
fibroblasts.	However,	in	the	trilayer	constructs	there	is	a	distinct	organization	of	
the	 collagen	 confined	 to	 the	 layer	 that	 contained	 the	 fibroblasts	 and	 just	
adjacent	to	the	PHBV	layer.	A	comparison	of	collagen	IV	immunohistochemistry	
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of	stained	human	skin	made	with	H&E	stained	human	skin	is	demonstrated	in	
Figure	4.5.2	to	orientate	the	epidermis	and	the	dermis.		
	
	
	
 
Figure	 4.5.1	 Immunohistochemistry	 staining	 of	 	 collagen	 IV	 (	 seen	 as	 green	 )	
produced	by		cultured	isolated	dermal	fibroblasts	and	keratinocytes	comparing	
the	collagen	organization	on	monolayer	PGLA	75:25	(	B	and	C)	and	trilayer	PGLA	
75:25/PHBV	 electrospun	 scaffolds(E	 and	 F).	 Scale	 bars	 =	 0.2mm	 (x100).	 H&E	
staining	of	the	same	constructs	(A	and	D)	are	inserted	for	orientation.		
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Figure	4.5.2		Immunohistochemistry	for	collagen	IV	on	human	skin	
demonstrating	the	collagen	organization	in	the	dermis	(left).	H&E	stained	slide	
of	human	skin(right)	placed	as	a	reference	to	orientate	the	image	on	the	left.	
Scale	bars	of	0.2mm	(x10).		
	
	
 
 
4.6	Discussion	
	
The	experiments	in	this	chapter	aim	to	evaluate	a	novel	method	of	spinning	a	
basement	membrane	substitute	to	promote	epithelial/stromal	organization.	In	
order	to	do	this,	we	fabricated	electrospun	scaffolds	consisting	of	two	different	
polymers	 in	 three	 distinct	 layers.	 The	 two	 layers	 of	 PGLA	 75:25	 are	 cell	
supportive	encouraging	the	growth	of	skin	cells	and	the	PHBV	nanofibrous	layer	
is	meant	to	act	like	a	basement	membrane	to	aid	definition	of	the	neo	epidermis	
and	neo	dermis.			
	
It	is	known	that	PGLA	75:25	supports	cellular	growth	and	proliferation(124).	Its	
microporous	 characteristics	 facilitate	 cellular	movement	 through	 the	 scaffold	
and	 its	microfibrous	 nature	 facilitates	 cellular	 proliferation,	 and	 ECM	protein	
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and	 collagen	 deposition	 due	 to	 its	 high	 surface	 area.	 Constructs	 containing	
monolayers	of	PGLA	75:25	only	therefore	exhibited	superior	ability	to	support	
both	 isolated	 skin	 cells	 and	 skin	explants	 in	 this	 regard	when	compared	with	
trilayer	constructs.	This	is	supported	by	AlamarBlue	and	Sirius	Red	analyses	as	
demonstrated	above.	This	could	be	explained	by	the	fact	that	the	nanofibrous	
layer	of	PHBV	in	the	centre	of	the	trilayer	scaffolds	is	impermeable	to	cellular	
movement	 compared	 to	 the	 	 PGLA	75:25	on	 either	 side.	 This	 layer	 is	 almost	
devoid	of	cells	as	a	result	,		it	serves	to	create	a	barrier	between	the	neo	dermis	
consisting	mainly	of	collagen	and	a	neo	epidermis	consisting	of	keratinocytes	
and	keratin.	However	the	middle	PHBV	layer	is	still	porous	enough	for	chemical	
signals	from	the	fibroblasts	to	reach	the	keratinocytes	in	order	to	stimulate	them	
to	 migrate,	 proliferate,	 and	 differentiate.	 This	 process	 takes	 time,	 whereas	
constructs	with	monolayer	scaffolds,	having	all	the	cells	mixed	together	will	not	
have	this	lag	as	the	cells	are	next	to	each	other	in	the	same	area.	As	a	result,	the	
quantitative	analyses	reflect	this,	with	significantly	higher	metabolic	activity	and	
collagen	production	in	these	monolayer	constructs.	This	is	the	same	for	scaffolds	
seeded	 with	 skin	 explants.	 Furthermore,	 the	 DAPI	 images	 at	 21	 days	 of	
constructs	 containing	 skin	 explants	 seeded	 on	 monolayers,	 show	 significant	
cellular	 migration	 from	 the	 skin	 explants	 onto	 the	 electrospun	 scaffolds	
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comparable	to	that	of	isolated	cells	seeded	on	scaffolds.	These	results	therefore	
support	the	use	of	PGLA	75:25	as	one	of	the	polymers	in	the	trilayer	constructs.		
However,	when	analysing	the	actual	structure	of	the	composites	at	day		14,	it	is	
clearly	 demonstrated	 that	 this	 alternative	 method	 of	 spinning	 a	 basement	
membrane	 into	the	scaffold	defines	the	 layers	of	the	skin	to	a	greater	extent	
compared	to	monolayer	constructs.	Collagen	deposition	is	more	organized	into	
a	distinct	layer	with	keratin,	made	by	proliferating	keratinocytes	is	also	found	in	
the	 opposite	 layer.	 	 As	 a	 result,	 the	 cellular	 organization	 of	 these	 trilayer	
constructs	are	more	similar	to	that	of	human	skin	as	illustrated	in	Figure	4.7.2	
compared	to	their	monolayer	counterparts.		
Another	difference	between	using	these	scaffolds,	which	is	very	relevant	to	
clinical	translation,	is	its	handling	ability	when	undertaking	the	experiments.	 
The	PGLA	75:25	monolayer	scaffolds		were	very	adherent	to	the	foil	onto		which	
they	were	electrospun.	They	required	prolonged	soaking	in	PBS	to	release	the	
scaffolds	from	the	foil.	Although	this	can	be	tackled	by	soaking	 in	PBS	before	
being	used		in	the	lab	a	better	solution	is	most	definitely	required	in	order	to	
upscale	up	for	future	clinical	use.	`Furthermore	despite	using	the	same	volume	
of	polymer	in	both	the	trilayer	and	monolayer	scaffolds,	the	monolayers	were	
very	 thin	 and	 did	 not	 support	 the	 skin	 explants	 well.	 They	 were	 almost	
transparent	and	tore	very	easily	when	handled.		
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We	have	demonstrated	 that	 it	 is	possible	 to	spin	a	basement	membrane	 like	
layer	 into	 an	 electrospun	 construct	 and	 use	 a	 combination	 of	 polymers	 to		
simulate	the	various		layers	of	the	skin.	This	work	is	only	part	of	the	emerging	
techniques	of	using	multiple	polymers	as	part	of	the	same	scaffold	construct	to	
provide	more	definable	anatomical	and	functional	 layers.	Other	combinations	
using	this	principle	of	polymer	blending	have	been	used	for	tissue	engineered	
skin.	 For	 example	 poly	 (caprolactone)	 (PCL)	 was	 blended	 with	 collagen	 to	
improve	 its	 mechanical	 properties	 for	 tissue	 engineered	 dermis(206).	
Additionally	 in	 vascular	 tissue	 engineering,	 synthetic	 polymers	 like	 PDS	 are	
blended	with	organic	proteins	like	gelatin	and	elastin	to	create	the	appropriate	
fibrous	 and	 porous	 network	 that	 will	 support	 endothelial	 cell	 development	
(207).		
In	 summary	 we	 have	 created	 a	 trilayer	 electrospun	 scaffold	 consisting	 of	 a	
basement	membrane	like	 layer	that	has	the	ability	to	support	organization	of	
cells	 and	 extracellular	 matrix	 which	 appear	 more	 like	 native	 human	 skin	
compared	 to	monolayer	 PGLA	 75:25	 scaffolds.	 The	 current	 results	 based	 on	
laboratory	expanded	cells	suggest	this	structure	has	some	benefit	to	offer	with	
respect	to	spatial	organisation	of	these	cells.	
There	was	not	however	any	benefit	to	be	seen	to	outgrowth	of	cells	from	tissue	
explants	in	this	in	vitro	model.	
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Chapter	5	
	
	
Evaluating	split	thickness	skin	interaction	
with	dermal	replacement	scaffold	
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5.1	Introduction	
In	developing	any	tissue	engineered	skin	substitute	attention	must	be	paid	to	
the	cell	source	that	is	going	to	be	used	to	populate	the	scaffold.	In	this	regard,	
both	 scaffold	 and	 cell	 source	need	 to	be	 synergistic	 in	order	 to	have	 an	end	
product	that	is	analogous	histologically	and	physiologically	to	human	skin.	Skin	
replacement	 can	 be	 thought	 of	 as	 epidermal,	 dermal	 and	 composite	 (both	
epidermis	and	dermis	present).	When	creating	a	dermal	equivalent	to	be	placed	
on	a	full	thickness	wound	bed,	a	clear	mechanism	of	epithelial	cell	source	and	
attachment	 must	 be	 identified.	 	 For	 example,	 the	 commonly	 used	 Integra,	
requires	a	very	thin	split	thickness	skin	graft	(5-6/1000	inches)	to	be	placed	on	
it,	either	at	the	time	of	surgery	(one	stage	Integra)	or	2-3	weeks	later	(traditional	
Integra)	which	is	attached	to	the	Integra	using	skin	staples,	sutures	or	glue.	In	
fact,	 all	 clinically	 available	dermal	 replacements	will	 require	 an	epithelial	 cell	
source	 usually	 from	 the	 patient	 themselves.	 This	 can	 be	 challenging	 if	 the	
patient	has	no	available	sites.	 In	this	case	a	small	sample	of	their	skin	can	be	
taken	to	the	lab	where	the	epithelial	cells	can	be	isolated	and	cultured	in	sheets	
which	are	then	transferred	onto	the	prepared	dermal	wound	bed.		However,	the	
use	of	isolated	cells	to	populate	a	bioengineered	dermis	has	been	fraught	with	
challenges	and	as	a	result	its	clinical	uptake	has	remained	low	despite	this	being	
a	 breakthrough	 technique	 since	 the	 1980s(1).	 The	 most	 documented	 used	
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approach	for	isolated	skin	cells	clinically	is	CEA(208)(100).	The	principle	of	using	
CEA	is	as	follows:	these	are	integrated	sheets	of	cultured	keratinocytes	that	are	
grown	in	clean	room	facilitates	from	the	patient’s	skin	as	a	cell	source.	Once	the	
biopsy	is	taken,	cells	are	isolated	and	cultured	until	confluent	sheets	of	cells	are	
formed	to	be	transferred	back	to	the	patient	onto	an	appropriately	vascularized	
wound	bed.	This	wound	bed	should	ideally	have	a	dermal	matrix	-which	may	be	
the	patient’s	own	dermis	(mixed	depth	burn	where	the	burn	has	been	excised	
to	mid	dermis	depth),	 cadaveric	dermis,	or	an	artificial	dermal	 template.	The	
process	 in	 itself	of	producing	CEA	 is	successful	 it	 is	a	 long	standing,	 tried	and	
tested	 technique	of	 cell	 culture.	 	However,	 there	are	 significant	barriers	 that	
have	 resulted	 in	 a	 low	 clinical	 uptake.	 Firstly,	 its	 production	 has	 to	 be	 cost	
effective.	Although	cell	culture	itself	is	affordable,	for	human	use,	there	needs	
to	be	clean	room	facilitates	and	trained	staff	in	order	for	this	to	be	approved	for	
human	use	by	local	ethics	committees.	There	are	very	few	laboratories	that	can	
therefore	accommodate	this	not	just	with	respect	to	facilitates	and	personnel	
but	 also	 having	 the	 appropriate	 HTA	 licensing	 which	 allows	 this	 work	 to	 be	
carried	out	in	the	facility.	Not	only	does	this	reflect	the	increased	cost	of	using	
such	 products	 but	 also	 transport	 and	 delivery	 costs	 is	 considered	 when	
departments	decide	on	a	product	for	clinical	use	especially	if	they	need	to	be	
sourced	nationally.		Furthermore,	the	timing	of	delivery	of	cells	need	to	be	exact,	
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once	cells	reach	confluence	if	there	are	not	used	within	2-3	days	they	will	not	
attach	 to	 a	wound	 bed.	 As	 a	 result,	 the	 product	 in	 itself	 does	 not	meet	 the	
flexibility	 that	 is	 demanded	 with	 a	 product	 that	 is	 suitable	 for	 routine	 use	
clinically,	ideally	it	should	be	off	the	shelf.	This	is	aptly	demonstrated	by	Hernon	
et	a,	where	they	reported	in	a	10-year	audit	of	CEA	use	in	burns,	nearly	50%	of	
the	sheets	were	wasted	between	CEA	production	and	delivery	to	patients(78).	
Flexibility	 in	 a	 product	 is	 one	 of	 the	 key	 features	 that	 contribute	 to	 routine	
clinical	uptake	and	explains	why	dermal	regenerative	templates	like	integra	and	
Matriderm	have	enjoyed	 long	standing	clinical	success	as	they	do	not	require	
cultured	cells	but	very	thin	epithelial	autografts.	Furthermore,	tissue	engineered	
products	are	often	only	used	in	the	context	of	larger	areas	of	skin	resurfacing,	
be	it	burns,	or	large	skin	lesions	when	there	are	not	enough	autologous	donor	
sites	 to	 safely	 resurface.	 For	 acute	 burns	 by	 and	 large	 these	 patients	 are	
physiologically	 unstable	 and	 their	 suitability	 for	 operative	 intervention	 are	
determined	 by	 daily	 clinical	 reviews.	 As	 a	 result,	 any	 change	 in	 the	 patient’s	
physiology	may	offset	surgical	intervention	which	may	result	in	wastage	of	the	
product.	 In	 addition	 the	 outcome	 of	 using	 CEA	 has	 been	 described	 as	
inconsistent	in	published	case	series	throughout	the	years.(209)	Take	is	a	visual	
objective	outcome	measure	used	to	determine	if	application	of	a	skin	substitute	
or	a	graft	has	been	successful.	It	is	mainly	denoted	by	adhesion	to	the	wound	
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bed	 and	 a	 lack	 of	 infection.	 The	 take	 of	 CEA	 sheets	 is	 inconsistent	 and	 this	
actually	is	reflective	of	any	large	burn	as	several	factors	influence	take,	namely	
the	vascularity	of	the	wound	bed,	and	the	extent	of	the	immunological	hit	the	
patient	 has	 had.	 These	 factors	 are	 not	 easily	 influenced	 or	 predictable	 by	
objective	measures	(e.g.	a	blood	test)	therefore	using	CEA	sheets	may	well	have	
not	 have	 been	 inferior	 to	 split	 skin	 grafts	 however	 in	 order	 for	 a	 product	 to	
assume	 routine	clinical	use,	 it	has	 to	be	 seen	as	 superior	 to	 the	current	gold	
standard,	which	in	the	case	of	skin	resurfacing	is	an	autologous	skin	graft.	The	
bias	here	lies	in	the	fact	that	there	are	few	robust	measures	in	assessment	of	
autologous	skin	grafts	or	skin	substitute	use.	Most	published	work	consists	of	
cases	 series	 and	 expert	 opinions	 which	 actually	 maybe	 the	 highest	 level	 of	
evidence	that	one	may	obtain	in	this	field	of	reconstructive	surgery.	Successful	
outcome	is	also	affected	by	the	experience	of	the	team	treating	the	patient	in	
firstly	making	 the	most	appropriate	 judgement	of	 the	material	 to	use,	 timing	
and	technique	application.	As	a	result,	it	is	not	surprising	that	some	groups	who	
may	have	more	clinical	experience	and	access	 to	close	 laboratory	 facilities	 to	
produce	 CEA	 sheets	 have	 reported	 better	 than	 average	 results	 in	 their	
experience	with	CEA(208).	In	addition,	these	sheets	are	fragile,	and	not	easy	to	
handle.	This	technical	feature	is	a	minor	deterrent	as	there	have	been	carrier	
mechanisms	that	have	developed	to	successfully	overcome	this(78).	Therefore,	
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one	 can	 consider	 the	 need	 to	 steer	 away	 from	 laboratory	 expanded	 cells	 to	
populate	scaffolds	and	use	an	alternate	cell	source	with	respect	to	developing	a	
tissue	engineered	biodegradable	substitute.	Ideally	this	should	come	from	the	
patient	 themselves	 which	 reduces	 the	 immunogenicity	 associated	 with	 the	
process	 and	 thereby	 increase	 the	 chances	 of	 successful	 take.	 Our	 proposal	
therefore	used	the	concept	of	Meek	Grafting	as	a	source	of	cells	to	populate	the	
scaffold.	The	principle	of	wound	healing	here	is	the	same	as	a	meshed	graft,	in	
that	epithelial	cells	undergo	conformational	change,	migrate	to	the	wound	edge	
until	they	meet	other	epithelial	cells	and	then	recreate	epithelial	connections.	
This	 principle	 is	 also	 used	 in	 the	 technique	 of	 fibroblast	 culture	 from	 skin	
explants.	Here	instead	of	using	an	enzymatic	process,	a	skin	sample	is	taken	as	
soon	as	it	is	harvested,	it	is	minced	into	fine	pieces	and	placed	into	6	well	plates	
containing	10%	DMEM.	Attachment	and	outgrowth	of	 keratinocytes	occur	at	
day	3	and	 fibroblasts	at	day	7(31).	This	 is	advantageous	 in	 that	 in	cases	with	
small	 amount	 of	 tissue,	 it	 is	 a	more	 reproducible	 technique,	 it	 is	 technically	
simpler	 and	avoids	over	digestion,	 reduction	of	 cell	 viability,	 and	 subsequent	
attachment	of	cells	when	not	handled	properly.	Therefore,	the	principle	of	using	
skin	 explants	 as	 a	 cell	 source	 to	 populate	 the	 trilayer	 templated	 electrospun	
scaffolds	in	principle	should	result	in	skin	cells	leaving	the	cut	edge	of	the	skin	
explants,	and	migrating	along	the	fibres	of	the	electrospun	scaffold.		
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This	concept	of	explant	use	as	a	cell	source	has	been	established	in	the	MacNeil	
laboratory	 and	 translated	 into	 clinical	 practice	 in	 the	 area	 of	 corneal	
regeneration.	In	brief,	damaged	corneas	are	regenerated	by	excising	the	non-
viable	 tissue,	 and	 using	 an	 amniotic	membrane	 scaffold	with	 small	 pieces	 of	
limbal	explants	from	the	contralateral	normal	eye.	The	explants	are	held	in	place	
with	fibrin	glue.	At	1.5	years,	76%	of	patients	had	an	epithelized,	stable	corneal	
surface(132).		Therefore,	the	aim	of	the	experiments	in	this	chapter	is	to	assess	
the	ability	for	skin	explants	to	be	used	as	a	cell	source	to	populate	the	trilayer,	
templated	PGLA	(75:25),	and	PHBV	electrospun	scaffolds	to	create	a	composite	
skin	 substitute.	 To	 do	 this,	 we	 needed	 to	 establish	 a	 control	 group	 with	 a	
standard	to	which	we	would	be	aiming	for	with	regards	to	cellular	proliferation	
and	migration.	The	first	set	of	experiments	establishes	the	ability	of	the	trilayer	
electrospun	 scaffolds	 to	 support	 isolated	 human	 dermal	 fibroblasts	 and	
keratinocytes.	To	do	this,	we	used	as	a	control,	the	original	tissue	engineered	
skin,	consisting	of	a	dermal	scaffold	of	DED,	to	which	we	populated	fluorescently	
labelled	 isolated	 human	 dermal	 fibroblasts	 and	 keratinocytes	 on	 either	 side.	
Additionally,	 we	 seeded	 the	 same	 cells	 on	 the	 trilayer	 electrospun	 scaffolds	
using	the	same	technique,	and	raised	all	constructs	to	an	air	liquid	interface	after	
3	days.	They	were	cultured	for	a	further	7,	14,	and	21	days	respectively.	Previous	
work	 conducted	 in	 the	 MacNeil	 lab	 has	 already	 established	 the	 ability	 of	
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electrospun	 scaffolds	 using	 various	 polymers	 to	 support	 the	 migration	 and	
proliferation	of	isolated	human	dermal	fibroblasts	and	keratinocytes(124)(205).	
However,	it	was	important	to	establish,	as	a	control	the	ability	for	the	templated	
trilayer	scaffolds	to	support	epithelial	cells.	Once	this	was	completed	we	then	
used	skin	explants	laid	onto	the	scaffolds	as	a	cell	source.	They	were	cultured	
for	3	days	with	Green’s	media	and	raised	to	ALI,	continuing	for	another	7,14,	and	
21	days.	The	data	therefore	represents	a	comparison	using	both	qualitative	and	
quantitative	methods	to	determine	the	ability	for	skin	explants	to	be	used	as	a	
cell	source	to	populate	the	electrospun	scaffolds.		
	
5.2	 Culture	 of	 isolated	 keratinocytes	 and	 fibroblasts	 on	 templated	 versus	
scaffolds	compared	to	tissue	engineered	composites	using	DED	
	
CellTracker	Fluorescence	Staining	
This	 was	 undertaken	 at	 48	 hours	 following	 seeding	 of	 both	 isolated	 human	
dermal	 fibroblasts	 and	 keratinocytes	 on	 electrospun	 scaffolds	 and	 DED	 to	
confirm	 their	 presence.	 Fibroblasts	 were	 used	 between	 passage	 4-9	 and	
keratinocytes	between	1-3.	The	images	seen	demonstrate	green	fibroblasts	and	
red	keratinocytes	were	successfully	seeded	on	scaffolds	before	raising	it	an	air	
liquid	 interface	 and	 also	 the	 differing	 architectures	 of	 the	 scaffolds	 used	 in	
experiments	(Figure	5.1).			
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Figure	 5.1:	 	 Representative	 images	 of	 cell	 tracker	 fluorescence	 for	 isolated	
human	 fibroblasts	 (top	 3	 rows)	 between	 passage	 4-9	 and	 isolated	 human	
keratinocytes	(Bottom	3	rows)	between		passage	1-4	seeded	on	non-templated	
and	templated	electrospun	scaffolds	and	DED.	Scale	bar	=	0.2	mm.	
	
AlamarBlue		assay		
Absorbances	 for	 AlamarBlue	 treated	 cells	 seeded	 on	 templated	 and	 non-
templated	scaffolds	were	read	and	the	absorbance	 for	scaffolds	of	each	type	
seeded	 without	 cells	 were	 subtracted	 from	 these	 values	 for	 each	 time	
checkpoint	 of	 day	 0,	 7,	 14,	 and	 21	 (Figure	 5.2).	 Furthermore,	 the	 change	 in	
absolute	 values	 is	 represented	 as	 a	 percentage	 change	 in	 metabolic	 activity	
relative	to	day	0	from	day	7,	14,	and	21	(figure	5.2).	This	was	done	by	subtracting	
the	absorbance	for	cell	seeded	scaffolds	after	accounting	for	absorbance	from	
plain	scaffolds,	from	values	obtained	at	day	0,	which	was	performed	after	two	
hours	following	seeding	of	cells	onto	scaffolds.		Additionally,	we	compared	the	
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seeded	with	Fibroblasts 
Templated	Scaffolds	seeded	
with	Fibroblasts 
DED	seeded	with	Fibroblasts 
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with	Keratinocytes 
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Keratinocytes 
	 228	
metabolic	 activity	 of	 the	 cells	 seeded	 on	 the	 electrospun	 scaffolds	 to	 those	
seeded	on	tissue	engineered	skin	composites	using	DED	as	a	standard.	 It	was	
demonstrated	that	cellular	constructs	were	viable	throughout	the	21-day	testing	
period	 both	 on	 the	 scaffolds	 and	 the	 DED.	 	 Cellular	 metabolic	 activity	 in	
constructs	containing	electrospun	scaffolds	 initially	decreased	from	day	0	but	
then	steadily	increased	from	day	7	through	to	day	21.	There	were	no	significant	
differences	 in	 cellular	metabolic	 activity	when	 isolated	 cells	were	 seeded	 on	
templated	versus	non-templated	electrospun	scaffolds.	There	was	however	a	
significant	difference	in	metabolic	activity	seen	in	cells	seeded	on	DED	compared	
to	those	seeded	on	templated	and	non-templated	scaffolds	from	day	7	to	day	
21.	
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Figure5.2	 Metabolic	 activity	 of	 isolated	 keratinocytes	 and	 fibroblasts	 on	
templated	 and	 non-templated	 electrospun	 scaffolds	 and	 DED	 over	 a	 21-day	
experimental	 period.	 	 Absolute	 change	 in	 metabolic	 activity	 over	 21	 days	 of	
culture,	as	determined	by	absorbance	of	AlamarBlue	stain	(Mean±SEM)	(N=3)	
	
	
	
DAPI	Staining	
This	was	undertaken	for	constructs	at	day	7,	14,	and	day	21	to	demonstrate	the	
cellular	 attachment,	 proliferation	 and	migrate	 along	 the	 fibres	 of	 templated	
trilayer	electrospun	scaffolds	and	whether	there	were	any	differences	observed,	
with	the	non-templated	scaffolds.	DAPI	imaging	was	also	undertaken	for	seeded	
scaffolds	as	the	negative	control	and	tissue	engineered	skin	composites	using	
DED	and	isolated	cells	as	the	positive	control	at	the	above	time	check	points.	
Good	cell	attachment	was	demonstrated	on	both	templated	and	non-templated	
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electrospun	 trilayer	 scaffolds,	 which	 were	 comparable	 in	 pattern	 and	
distribution	to	DED	constructs	(Figure	5.3).	
	
	
	
Figure	 5.3	 DAPI	 staining	 of	 constructs	 (non-templated	 scaffolds,	 templated	
scaffolds	and	DED)	with	isolated	human	fibroblasts	and	keratinocytes.	Top	row	also	
demonstrates	scaffolds	without	cells	as	a	negative	control.		Scale	bar=0.2mm	
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Haematoxylin	and	Eosin	Staining.	
This	was	undertaken	on	formaldehyde	fixed	constructs	at	day	7,	14,	and	day	21	
to	demonstrate	consecutive	cellular/scaffold	architectures	and	any	evidence	of	
integration	between	the	two.	The	cellular	nuclei	appear	as	blue	black	and	the	
cytoplasm	and	surrounding	connective	 tissue	appear	pink.	 Frozen	sections	of	
constructs	 containing	 cell	 seeded	 templated	 and	 non-templated	 scaffolds	
demonstrated	 with	 H&E	 staining,	 confluent	 cell	 populations	 on	 the	 scaffold,	
most	predominantly	seen	on	day	14.	Furthermore,	there	was	a	distinct	middle	
layer	of	PHBV	that	was	seen	as	an	interface	between	the	neo	epidermis	the	area	
seeded	with	keratinocytes	and	the	fibroblast	populated	dermis	(Figure	5.4	and	
5.4.1).		
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Figure	 5.4	 Annotated	 light	 microscopy	 H&E	 stained	 sections	 of	 isolated	
keratinocytes	 and	 fibroblasts	 seeded	 on:	 A:	 DEDs,	 B:	 non-templated	 trilayer	
scaffolds	and	C:	templated	trilayer	scaffolds	over	14	days	in	culture.	Scale	bars	
of	0.2	mm	(100x	magnification).	
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Figure	 5.4.1	 Representative	 light	 microscopy	 H&E	 stained	 sections	 of	 cells	
seeded	on	non-templated,	templated	and	DED	scaffolds.	Scale	bars	of	0.2	mm	
(100x	 magnification)	 applies	 to	 all	 images.	 A=neoepidermis;	 B=dermal	 layer	
made	of	electrospun	scaffold	or	DED,	C=template	on	electrospun	scaffold.		
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Sirius	Red	Assay	
At	day	7,	14,	and	21	Sirius	 red	assays	were	undertaken	 to	estimate	 the	 total	
collagen	produced	overtime	by	 the	 human	dermal	 fibroblasts	 seeded	on	 the	
templated	 and	 non-templated	 trilayer	 electrospun	 scaffolds	 (Figure	 5.5).	 The	
aim	was	to	quantify	the	ability	of	the	electrospun	scaffolds	to	support	cellular	
function	using	collagen	production	by	fibroblasts	as	a	marker	and	to	compare	
this	 to	 tissue	 engineered	 skin	 constructs	 containing	 DED	 as	 a	 standard.	 The	
absorbance	 of	 Sirus	 red	 is	 plotted	 in	 Figure	 5.5.1	 minus	 the	 absorbance	 of	
constructs	containing	scaffolds	without	cells.	There	was	no	significant	difference	
in	 total	collagen	produced	per	gram	of	scaffold	between	templated	and	non-
templated	 electrospun	 scaffolds.	 There	were	 however	 significant	 differences	
between	the	collagen	produced	in	DED	constructs	versus	templated	and	non-
templated	scaffolds	respectively,	with	the	former	producing	the	highest	amount	
of	collagen	per	gram	of	dry	scaffold	(table	8).		
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Figure	5.5	Examples	 of	 Sirius	 red	 staining	after	 7,	 14,	 and	21	days	 culture	of	
isolated	human	fibroblasts	and	keratinocytes	on	templated	(top	row	of	6	well	
plates),	non-templated	(bottom	row	of	6	well	plates)	electrospun	scaffolds	and	
DED.	
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Figure	 5.5.1	 Sirius	 red	 staining	 after	 7,14,	 and	 21	 days	 of	 isolated	 human	
fibroblasts	and	keratinocytes	cultured	on	templated,	non-templated	electrospun	
scaffolds	and	DED.	(N=3±SEM).	
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Day	 Comparison	 N	 2	tailed	P	value		
7	 DED	vs.	Templated	
Scaffolds		
3	 0.0033	
	 DED	 vs.	 Non-
templated	
Scaffolds	
3	 0.0040	
14	 DED	vs.	Templated	
Scaffolds	
3	 0.0020	
	 DED	 vs.	 Non-
templated	
Scaffolds	
3	 0.0020	
21	 DED	vs.	Templated	
Scaffolds	
3	 0.0178	
	 DED	 vs.	 Non-
templated	
Scaffolds	
3	 0.0190	
Table	4:	Results	of	unpaired	T	test	for	Sirus	Red	absorbance	values	comparing	
cell	seeded	constructs	on	DED	and	electrospun	scaffolds	at	day	7,	14,	and	21.	
Significance	was	taken	as	p<0.05.		
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5.3	 Culture	 of	 Skin	 Explants	 on	 Templated	 versus	 Non-templated	 Trilayer	
Electrospun	Scaffolds		
	
This	 experiment	 involved	 culturing	 skin	 explants	 onto	 templated	 and	 non-
templated	 trilayer	 electrospun	 scaffolds	 to	 determine	 if	 cells	 would	 migrate	
from	the	cut	edges	of	the	explants	onto	the	fibres	of	the	scaffolds.		A	fixed	area	
(5x5	mm2)	piece	of	split	thickness	skin	was	minced	very	finely	to	create	these	
skin	explants.	The	idea	here	was	to	increase	the	surface	area	of	the	cut	edges	
giving	 the	 epithelial	 cells	more	 opportunity	 to	migrate	 from	 the	 skin	 pieces.	
Furthermore,	we	also	aimed	to	compare	if	there	was	any	difference	between	
cellular	 migration	 and	 proliferation	 on	 templated	 versus	 non-templated	
scaffolds.	After	48	hours,	the	skin	explant-scaffold	constructs	were	raised	to	an	
air	liquid	interface	and	cultured	for	7,	14,	and	21	days	respectively.		
	
AlamarBlueTM	assay		
Absorbance	 for	 skin	 explants	 cultured	 on	 templated	 scaffolds	 and	 non-
templated	scaffolds	were	read	and	the	absorbance	 for	scaffolds	of	each	type	
with	no	skin	explants	were	subtracted	from	these	values.	The	change	in	absolute	
values	 is	represented	as	a	percentage	change	 in	metabolic	activity	relative	to	
the	control	at	every	time	check	point	namely	day	7,	14,	and	21.	Furthermore	the	
metabolic	activity	of	the	skin	explants	seeded	on	the	electrospun	scaffolds	were	
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compared	to	tissue	engineered	skin	composites	using	DED	as	the	standard.	 It	
was	 demonstrated	 that	 the	 skin	 explants	were	 viable	 throughout	 the	 21-day	
testing	period	both	templated	and	non-templated	scaffolds.			
Cellular	metabolic	 activity	 in	 constructs	 containing	 both	 templated	 and	 non-
templated	 electrospun	 scaffolds	 like	 those	 of	 the	 cell-seeded	 constructs	
decreased	from	day	0	to	day	7	but	then	steadily	 increased	through	to	day	21	
(Figure	5.6).	 There	was	no	 significant	difference	metabolic	 activity	when	 skin	
explants	 were	 seeded	 on	 templated	 versus	 non-templated	 electrospun	
scaffolds.	There	was	however	a	significant	difference	in	metabolic	activity	seen	
in	 cells	 seeded	 on	 DED	 compared	 to	 those	 seeded	 on	 templated	 and	 non-
templated	 scaffolds	 respectively	 (table	 9).	 Furthermore,	 there	 were	 no	
significant	differences	in	%	metabolic	change	from	day	0	to	day	21	between	skin	
explants	cultured	on	templated	and	non-templated	electrospun	scaffolds.		
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Figure	5.6	Metabolic	activity	of	skin	explants	cultured	on	templated	and	non-
templated	 electrospun	 scaffolds	 and	DED	over	 a	 21-day	 experimental	 period.	
Absolute	change	in	metabolic	activity	over	21	days	of	culture,	as	determined	by	
absorbance	of	AlamarBlue	stain	(mean±SEM)	(n=3)	
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Day	 Comparison	 N	 2	tailed	P	value		
7	 DED	vs.	Templated	
Scaffolds		
12	 <0.0001	
	 DED	 vs.	 Non-
templated	
Scaffolds	
12	 <0.0001	
14	 DED	vs.	Templated	
Scaffolds	
9	 <0.0001	
	 DED	 vs.	 Non-
templated	
Scaffolds	
9	 <0.0001	
21	 DED	vs.	Templated	
Scaffolds	
3	 <0.0001	
	 DED	 vs.	 Non-
templated	
Scaffolds	
3	 <0.0001	
Table	5:	Results	of	unpaired	T	test	for	AlamarBlue	absorbance	values	comparing	
skin	explant	cultured	constructs	on	DED	and	electrospun	scaffolds	at	day	7,	14,	
and	21.	Significance	was	taken	as	p<0.05.		
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DAPI	Staining.	
This	was	undertaken	for	constructs	fixed	at	day	7,	14,	and	day	21	to	determine	
firstly	if	cells	were	able	to	leave	the	cut	edge	of	the	skin	explants	and	migrate	
along	 fibres	 of	 the	 electrospun	 scaffolds	 and	 whether	 there	 were	 any	
differences	observed,	if	any	with	the	non-templated	scaffolds.	DAPI	imaging	was	
also	undertaken	for	tissue	engineered	skin	composites	using	DED	the	above	time	
check	points	as	a	comparison.	Cells	were	seen	to	be	leaving	the	surrounding	area	
around	 the	 skin	explant	pieces,	however	compared	to	 tissue	engineered	skin	
constructs	using	DED	there	was	not	as	much	cellular	migration	and	proliferation	
observed.	It	is	appreciated	that	the	cells	would	take	time	to	leave	the	explants	
and	migrate	along	fibres;	 therefore,	a	comparison	at	day	21	was	undertaken.	
These	images	still	do	not	demonstrate	a	significant	amount	of	cellular	migration	
compared	to	day	21	DED	samples	(Figure	5.7).		
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Figure	5.7	DAPI	staining	of	constructs	(non-templated	scaffolds(left),	templated	
scaffolds	 (right)	 cultured	with	 skin	 explants	 at	 day	 14	 illustrating	 little	 to	 no	
cellular	nuclei	of	cells	migrating	from	the	skin	explant	onto	the	scaffold.	Scale	
bar	=0.2mm.	
	
Haematoxylin	and	Eosin	Staining.		
	
These	 were	 undertaken	 on	 fixed	 constructs	 at	 day	 7,	 14,	 and	 day	 21	 to	
demonstrate	 consecutive	 cellular/scaffold	 architectures.	 The	 cellular	 nuclei	
appear	 as	 blue	 black	 and	 the	 cytoplasm	 and	 surrounding	 connective	 tissue	
appear	pink.	Frozen	sections	of	constructs	containing	skin	explant	cultured	on	
non-templated	(Figure	5.8.)	and	templated	(5.8.1)	scaffolds	demonstrated	with	
H&E	 staining,	 very	 little	 cellular	 outgrowth	 from	 the	 cut	 edges	 of	 the	 skin	
explant.	Due	to	the	lack	of	cellular	migration	and	integration	within	fibres	of	the	
scaffold	it	can	be	observed	that	the	scaffolds	are	visibly	devoid	of	these	and	in	
most	cases	have	lost	their	distinctive	trilayer	architecture	during	the	process	of	
H&E	staining.		There	is	also	a	very	obvious	difference	in	cellular	integration	and	
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ECM	 production	 between	 constructs	 seeded	 with	 isolated	 cells	 (both	
electrospun	scaffolds	and	DED)	and	those	cultured	with	skin	explants	with	the	
former	 having	 definitive	 evidence	 of	 an	 epidermal	 and	 dermal	 layer	 (figure	
5.4.1).		
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Figure	 5.8	 Annotated	 panoramic	 light	microscopy	 H&E	 stained	 sections	 of	 skin	
explants	seeded	on	non-templated	trilayer	scaffolds	over	21	days	in	culture.	Scale	
bars	of	0.07	mm	(100X	magnification).	
Figure	5.8.1	Annotated	panoramic	 light	microscopy	H&E	stained	sections	of	skin	
explants	seeded	on	templated	trilayer	scaffolds	over	21	days	in	culture.	Scale	bars	
of	0.07	mm	(100X	magnification).	
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Sirius	Red	Assay	
	
At	day	7,	14,	and	21	Sirius	 red	assays	were	undertaken	 to	estimate	 the	 total	
collagen	produced	overtime	by	the	skin	explants	seeded	on	trilayer	electrospun	
scaffolds	(Figure	5.9).	The	aim	was	to	quantify	the	amount	of	collagen	deposited	
by	 fibroblasts	 that	 have	 migrated	 and	 proliferated	 along	 the	 fibres	 of	 the	
electrospun	scaffolds	from	the	skin	explants.	This	was	compared	to	constructs	
containing	DED	and	 isolated	cells.	There	was	no	significant	difference	 in	total	
collagen	produced	per	gram	of	scaffold	between	templated	and	non-templated	
electrospun	 scaffolds	 (Figure	 5.9.1).	 However,	 comparing	 skin	 explant	
constructs	to	isolated	cell	seeded	with	DED		tissue	engineered	skin)		there	were	
significant	differences	 in	collagen	produced	with	the	 latter	being	higher	at	all	
time	checkpoints	(table	10).			
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Figure	5.9	Examples	of	Sirius	red	staining	after	7,	14,	and	21	days	culture	of	skin	
explants	on	templated	(top	row	of	6	well-	plates)	and	non-templated	(bottom	
row	of	6	well	plates)	electrospun	scaffolds.		
	
	
	
	
Figure	5.9.1	Sirius	red	staining	after	7,	14,	and	21	days	of	skin	explants	cultured	
on	templated,	non-templated	electrospun	scaffolds	and	tissue	engineered	skin	
constructs	containing	DED.	(N=9±SEM).	
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Day	 Comparison	 N	 2	tailed	P	value		
7	 DED	vs.	Templated	
Scaffolds		
3	 0.0033	
	 DED	 vs.	 Non-
templated	
Scaffolds	
3	 0.0037	
14	 DED	vs.	Templated	
Scaffolds	
3	 0.0012	
	 DED	 vs.	 Non-
templated	
Scaffolds	
3	 0.0010	
21	 DED	vs.	Templated	
Scaffolds	
3	 0.0149	
	 DED	 vs.	 Non-
templated	
Scaffolds	
3	 0.0113	
Table	6:	Results	of	unpaired	T	test	for	Sirus	Red	absorbance	values	comparing	
skin	explant	cultured	constructs	containing	DED	and	electrospun	scaffolds	at	day	
7,	14,	and	21.	Significance	was	taken	as	p<0.05.		
	
	
	
	 250	
5.4			Summary		
	
The	 aims	 of	 the	 first	 set	 of	 the	 experiments	 in	 this	 chapter	 were	 to	 firstly	
determine	if	cells	would	be	able	to	proliferate	along	the	fibres	of	the	templated	
scaffolds	and	function	so	as	to	start	 formation	of	an	extracellular	matrix.	 It	 is	
known	 that	 electrospun	 scaffolds	 are	 cell	 conductive,	 however	 the	 idea	 of	
investigating	the	effect	of	templating	scaffolds	so	as	to	provide	a	stem	cell	niche	
is	 novel.	 Furthermore,	we	wanted	 to	 extend	 this	 idea	 to	 investigate	 if	 these	
modified	electrospun	scaffolds	had	any	effect	on	the	migration	of	cells	from	the	
cut	edges	of	skin	explants.	Fluorescence	staining	using	cell	tracker	green	and	red	
confirmed	that	isolated	human	keratinocytes	and	fibroblasts	cells	were	present	
on	each	scaffold	prior	to	raising	them	to	an	air	liquid	interface.	In	general,	no	
significant	 differences	 were	 noted	 in	 the	 ability	 for	 templated	 electrospun	
scaffolds	 to	support	cellular	migration	and	proliferation	as	compared	 to	non-
templated	 trilayer	 scaffolds.	 	 For	 both	 templated	 and	 non-templated	
electrospun	scaffolds	it	was	noted	that	there	was	a	significant	drop	in	cellular	
viability	as	demonstrated	by	AlamarBlue	absorbance	readings	from	day	0	to	day	
7.	This	could	be	explained	by	the	fact	that	on	Day	0,	cells	are	most	populous	on	
the	scaffolds	whereas	on	day	7,	some	would	have	died	and	not	been	supported	
on	the	fibres.	This	contrasts	the	native	human	dermal	scaffold	provided	for	by	
the	DED,	which	supports	the	cells	from	the	start	of	seeding.	Furthermore,	some	
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cells	would	have	 fallen	between	 the	micropores	 of	 the	PGLA	 fibres	 onto	 the	
bottom	of	 the	 6	well	 plate	 between	 day	 0	 and	 day	 7	 hence	 account	 for	 the	
reduction	 in	numbers	of	cells	and	overall	metabolic	activity	of	 the	constructs	
containing	electrospun	scaffolds.	Following	day	7	it	is	observed	that	metabolic	
activity	increases	until	day	21	in	the	constructs	containing	both	templated	and	
non-templated	scaffolds.	There	were	no	significant	differences	between	these	
two	scaffolds	during	 this	 time	however	constructs	containing	DED	showed	as	
expected	significantly	higher	amounts	of	metabolic	activity.	Interestingly	when	
%	metabolic	activity	of	scaffolds	is	compared	relative	to	day	0,	there	seemed	to	
be	 a	 significant	 difference	 in	 templated	 versus	 non-templated	 scaffolds	
suggesting	that	over	time	and	longer	culture	periods,	this	scaffold	architecture	
was	more	conductive	to	cellular	migration	and	proliferation.		
Furthermore,	 it	 was	 demonstrated	 that	 cells	 were	 confluent	 over	 -and	
distributed	 along	 the	 fibres	 of	 both	 the	 templated	 and	 non-templated	
electrospun	scaffolds,	which	were	comparable	to	those	on	DED	constructs.	This	
finding	was	also	supported	by	H&E	staining	of	histology	sections.	Additionally,	
this	technique	allowed	us	to	better	visualize	the	topography	of	the	electrospun	
dermal	analogue,	which	included	the	basement	membrane	and	the	niches.		It	is	
shown	 that	 keratinocytes	 populated	 the	 microporous	 side	 containing	 PGLA	
(75:25)	and	produced	strands	of	keratin	whereas	the	fibroblasts	occupied	the	
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other	side	of	the	PHBV	basement	membrane	layer.	Additionally,	there	were	no	
notable	differences	in	the	ability	of	the	electrospun	scaffold	be	it	templated	or	
non-templated	to	support	the	production	of	an	extracellular	matrix	containing	
collagen.	This	ability	remained	significantly	higher	in	constructs	containing	DED	
however	there	was	evidence	of	some	fibroblast	migration	and	proliferation	to	
produce	 collagen	 in	 constructs	 containing	 electrospun	 scaffolds.	 The	 data	
presented	thus	far	highlights	the	fact	that	the	templated	scaffolds	supports	the	
proliferation	 and	migration	 of	 isolated	 human	 fibroblasts	 and	 keratinocytes.	
Another	aim	of	the	latter	experiments	in	this	chapter	was	to	determine	if	cells	
from	the	cut	edge	of	skin	explants	would	migrate	and	proliferate	along	the	fibres	
of	the	trilayer	templated	electrospun	scaffolds.	This	is	in	keeping	with	trying	to	
develop	a	sustainable	off	the	shelf	technique	for	dermal	substitution	that	does	
not	rely	on	expanding	isolated	patient’s	cells	in	the	lab.	The	use	of	isolated	cells	
as	part	of	a	skin	substitute	is	a	tried	and	tested	technique	in	skin	reconstruction,	
which	has	never	made	it	into	the	routine	of	reconstructive	reach	for	the	plastic	
surgeon.	The	results	demonstrate	that	there	were	no	significant	differences	in	
the	metabolic	activity	of	 constructs	 containing	 templated	and	non-templated	
trilayer	 scaffolds	when	 cultured	with	 skin	explants.	 	 There	was	a	decrease	 in	
metabolic	activity	from	day	0	to	day	7,	which	slowly	increased	until	day	21.	This	
was	a	similar	picture	for	the	cell-seeded	constructs	however	the	decreases	 in	
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cellular	proliferation	in	the	skin	explant	samples	were	more	pronounced.	This	
finding	 was	 supported	 by	 the	 fluorescent	 images	 using	 DAPI	 staining	 that	
illustrated	 very	 little	 outward	 migration	 of	 cells	 from	 the	 cut	 edges	 of	 the	
explants	 in	 comparison	 to	 cell	 seeded	 constructs	 and	 the	 standard	 tissue	
engineered	skin	constructs	containing	DED.		Additionally,	the	skin	explants	did	
not	show	convincing	evidence	that	cells	from	their	cut	edges	integrated	with	the	
electrospun	scaffolds	as	demonstrated	by	H&E	staining.	Furthermore	because	
of	 the	 lack	of	cellular	proliferation	and	ECM	deposition	on	these	skin	explant	
constructs,	 as	 expected	 the	 histology	 process	 resulted	 in	 destruction	 of	
electrospun	 scaffold	 architecture	 and	 topography.	 	 This	 finding	 was	 also	
reflected	 in	 the	 assessment	 of	 collagen	 deposition	 quantified	 by	 Sirius	 Red	
Assays.	Although	there	was	some	collagen	production,	we	postulate	that	 this	
was	 mainly	 due	 to	 the	 natural	 collagen	 contained	 in	 the	 skin	 explants	
themselves	 as	 opposed	 to	 fibroblast	 integration	 and	 function	 on	 the	 trilayer	
scaffolds,	one	limitation	of	our	study	was	that	it	was	very	difficult	to	determine	
the	amount	of	collagen	that	were	present	in	the	skin	explants	as	a	control.	This	
would	 involve	 undertaking	 Sirus	 red	 on	 a	 fixed	 sample	 and	 assume	 that	 this	
sample	was	 representative	 of	 all	 the	 repeats	 used,	 however	 there	would	 be	
significant	variation	in	the	various	batches	of	skin	with	regards	to	the	amount	of	
collagen	 in	 the	 dermis	 and	 in	 between	 patients	 to	 use	 this	 technique	 as	 a	
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standard.	.	This	is	evidenced	in	Figure	5.9	which	highlights	a	concentration	of	the	
Sirius	red	stain	on	the	actual	skin	explants	as	opposed	confluent	staining	on	the	
dermal	scaffold	which	was	observed	in	the	cell	seeded	electrospun	constructs	
and	 tissue	 engineered	 skin	 models	 containing	 DED	 (Figure	 5.5).	 The	 data	
presented	here	also	suggests	that	the	use	of	isolated	cells	on	trilayer	electrospun	
scaffolds	 resulted	 in	 constructs	 with	 significantly	 better	 overall	 cellular	
proliferation,	integration	and	function	as	opposed	to	using	skin	explants	as	a	cell	
source.	 	 The	 cells	 contained	 in	 the	 skin	 explants	 are	 viable	 throughout	 the	
experimental	time	period	and	in	theory	have	the	ability	to	migrate	from	the	cut	
edge	 of	 the	 skin	 explants	 onto	 the	 fires	 of	 the	 electrospun	 scaffold.	 This	
technique	as	mentioned	in	the	introduction	is	taken	from	the	principles	of	Meek	
Grafting,	where	small	squares	are	cut	from	split	thickness	skin	and	placed	onto	
a	wound	bed.	 This	 results	 in	 cellular	migration	 from	 the	 edge	of	 the	 grafted	
squares	of	split	thickness	skin	and	re-epithelisation	of	the	wound	bed.	However,	
using	 that	 same	 principle,	 replacing	 the	 wound	 bed	 with	 the	 electrospun	
scaffold	reveals	that	there	is	not	enough	migration	of	cells	from	the	cut	edges	
of	the	skin	explants	along	the	fibres	of	the	electrospun	scaffolds	which	would	
ultimately	serve	to	augment	wound	healing.	During	the	experimental	process,	
from	a	practical	viewpoint,	it	was	very	challenging	to	keep	the	finely	dissected	
skin	explants	in	contact	with	the	scaffold	at	all	times,	which	is	needed	for	cellular	
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migration.	Firstly,	there	was	a	tendency	for	some	of	the	pieces	to	float	 in	the	
media.	Furthermore,	media	changes	and	assessment	of	cellular	viability	using	
AlamarBlue	assays	would	often	disturb	the	explants.	Despite	these	disturbances	
being	only	3	times	per	week	and	performed	in	a	slow	and	careful	manner	so	as	
to	not	disturb	the	constructs,	there	were	many	instances	where	the	quantity	of	
skin	explants	was	noted	to	be	less	compared	to	the	start	of	the	experiment.	As	
this	 technique	 is	modelled	on	 the	 successful	 clinical	 application	of	meek	 skin	
grafting,	this	led	us	to	believe	that	our	skin	explant	model	needed	to	be	refined.	
There	 should	 be	 a	 reasonable	 explanation	 for	 this	 lack	 out	 outward	 cellular	
growth.	Therefore,	we	postulated	that	there	were	two	main	factors	that	could	
contribute	to	this	lack	of	outward	cellular	migration,	firstly	the	properties	of	the	
skin	 explant	 themselves	 and	 the	 interaction	 between	 the	 skin	 explants	 and	
scaffolds.		
With	regards	to	the	skin	explants	themselves,	it	is	known	that	the	keratinocytes	
and	 fibroblasts	 without	 the	 appropriate	 chemical	 signalling	 will	 not	 be	
stimulated	 to	 leave	 the	 skin	 explant	 and	 migrate	 onto	 the	 fibres	 of	 the	
electrospun	 scaffold.	 To	 migrate	 over	 a	 wound	 site,	 the	 keratinocytes	 must	
disengage	their	desmosome/hemidesmosomes	junctions	and	re-organize	their	
cytoskeleton.	 As	 re-epithelization	 continues	 keratinocytes	 once	 again	 by	
receiving	 the	 correct	 signalling	 result	 in	 a	 cessation	 of	 this	 migration	 and	
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reversion	to	their	normal	phenotype,	using	hemidesmosomes	to	attach	to	the	
basement	membrane	and	the	underlying	dermis	through	collagen	fibrils(210).		
Foundation	work	in	cell	biology	revealed	the	necessity	to	co-culture	fibroblasts	
with	 keratinocytes	 in	 order	 to	 stimulate	 growth	 and	 proliferation(211).	
Keratinocytes	 whilst	 in	 culture	 instruct	 fibroblasts	 to	 synthesize	 and	 secrete	
growth	 factors	 and	 cytokines	 like	 keratinocyte	 growth	 factor	 (KGF)/fibroblast	
growth	 factor-7	 (FGF7),	 IL-6,	 and	 GM-CSF(212).	 	 This	 in	 turn	 stimulates	 the	
migration	 and	 proliferation	 of	 keratinocytes	 and	 ultimately	 wound	
epithelization	resulting	 in	 this	double	paracrine	 loop.	 In	 the	absence	of	 these	
signalling	 proteins	 migration	 of	 these	 cells	 does	 not	 occur.	 This	 could	 be	 a	
possible	explanation	of	the	lack	of	migration	of	keratinocytes	and	fibroblasts	in	
our	 novel	 tissue	 engineered	 skin	model	 containing	 electrospun	 scaffolds	 and	
skin	explants.	Additionally,	cells	will	only	migrate	out	of	the	explants	where	it	is	
in	 direct	 contact	 with	 the	 fibres	 of	 the	 electrospun	 scaffolds.	 This	 will	 be	
increased	 in	 constructs	 in	which	 isolated	 cells	 are	 used	 as	 compared	 to	 skin	
explants	as	there	will	be	greater	number	of	contact	points	between	the	scaffold	
fibres	 and	 isolated	 cells	 versus	 skin	 explant	 and	 fibres	 as	 the	 cells	 are	 still	
retained	 in	 the	block	of	 tissue.	Additionally,	 the	 interaction	between	the	skin	
explants	and	electrospun	scaffolds	in	vivo	is	very	different	to	that	which	occurs	
with	the	model	of	meek	grafting	in	the	clinical	environment,	which	this	concept	
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is	based	on.	Meek	grafts	when	placed	on	wound	beds	are	often	secured	to	 it	
using	 tissue	 glue	 and	 layers	 of	 initially	 non-adherent,	 absorbent	 and	 elastic	
dressings	to	ensure	that	the	grafts	are	held	in	place	and	in	the	right	orientation.	
These	wounds	are	not	disturbed	for	five	days	initially	to	allow	good	contact	to	
occur	between	the	meek	graft	squares	and	the	wound	bed	and	thereby	cellular	
migration	 and	 proliferation.	 In	 our	 in	 vitro	 constructs	 the	 skin	 explants	 are	
simply	placed	on	top	of	the	electrospun	scaffolds	without	any	method	to	secure	
their	contact.	Furthermore,	media	changes	which	are	required	result	in	physical	
disturbances	 to	 this	 contact.	 Therefore,	 we	 need	 to	 refine	 this	 in	 vitro	 skin	
explant	model	to	allow	for	a	more	secure	contact	between	the	skin	explants	and	
the	 electrospun	 scaffolds	 and	 investigate	 potential	 strategies	 to	 increase	 the	
cellular	migration	and	proliferation	from	the	cut	edges	of	the	skin	explants.		
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Chapter	6	
	
Investigation	of	approaches	to	achieve	
adhesion	of	skin	pieces	to	scaffolds	to	
increase	the	outgrowth	of	cells	into	the	
scaffolds.	
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6.1	Introduction	
	
		Experiments	from	Chapters	3	and	4	illustrate	that	simply	placing	skin	explants	
directly	 onto	 an	 electrospun	 scaffold	 in	 vitro	 does	 result	 in	 some	 skin	 cell	
migration	from	the	cut	edges	of	skin	explants	however	not	at	a	rate	that	would	
be	appropriate	for	use	of	this	product	in	the	clinical	environment.		The	ultimate	
goal	is	for	the	electrospun	scaffold	is	to	form	part	of	a	new	dermis,	which	is	to	
be	populated	by	cellular	outgrowth	from	the	skin	explants.			This	chapter	aims	
to	 assess	 potential	 strategies	 to	 aid	 retention	 of	 the	 skin	 explants	 onto	 the	
electrospun	 scaffolds	 and	 to	 improve	 the	 migration	 of	 skin	 cells	 along	 the	
scaffold	fibres.		
	
		The	strategies	tested	were:		
1. The	use	of	 fibrin,	a	clinically	used	adhesive	 to	aid	 retention	of	 the	skin	
explants	onto	the	electrospun	scaffolds.		
2. The	use	of	explants	with	less	dermis	to	determine	is	this	has	an	effect	on	
cellular	migration	onto	the	scaffolds		
3. The	 use	 of	 an	 additional	 scaffold	 overlying	 the	 skin	 explants	 to	 aid	
retention	of	the	pieces	on	the	scaffold.		
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The	aim	 is	 to	 achieve	 a	 level	 of	 cellular	migration	 similar,	 or	 close	 to	 that	of	
seeding	 isolated	 cells	 on	 electrospun	 scaffolds.	 In	 terms	 of	 wound	 healing,	
fibroblasts	 begin	 proliferating	 to	 form	 type	 III	 collagen	 from	 the	 fourth	 day	
following	injury	for	up	to	2-4	weeks	thereafter	to	replace		dermal	breaches(213).	
At	 the	 same	 time,	 keratinocytes	 also	 begin	 to	 migrate.	 Therefore,	 these	
constructs	should	have	some	evidence	of	migrating	and	proliferating	cells	from	
at	least	the	7	to	14-day	time	checkpoints.			
As	outlined	in	the	introduction,	the	use	of	skin	explants	as	a	source	of	skin	cells	
to	aid	wound	healing	is	a	successful	technique	employed	in	Meek	grafting.	This	
is	 due	 to	 the	 technique	 itself	 and	 the	 presence	 of	 a	 suitable	 wound	 bed	
containing	 the	 appropriate	 architecture	 and	 signalling	 molecules	 that	 are	
essential	 for	 fibroblast	 and	 keratinocyte	 migration	 and	 proliferation.	 The	
surgical	technique	of	Meek	grafting	has	been	refined	over	time,	but	its	principle	
remains	 the	 same	 to	 ensure	 clinical	 success	 and	 reproducibility	 i.e.	 re-
epithelization	of	the	wound	bed.	 In	this	method,	the	skin	explants	are	placed	
onto	the	wound	bed	and	secured	with	either	glue	or	sutures	followed	by	layers	
of	dressings.	This	is	needed	to	prevent	shear	forces	that	can	disrupt	the	fibrin	
that	is	formed	between	the	grafts	and	the	wound	bed	as	part	of	the	initial	phase	
of	graft	take.	This	adhesion	to	the	wound	bed	is	a	vital	part	of	skin	graft	take,	as	
only	when	this	occurs,	the	keratinocytes	in	the	basal	layer	of	the	epidermis	show	
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high	proliferation	rates	which	serves	to	stimulate	growth	factor	excretion	and	
conversely	 further	 proliferation	 of	 cells(213).	 Furthermore,	 fibrin	 acts	 as	 a	
scaffold	for	skin	cells	to	migrate	along	and	thereby	re-epithelize.	 	As	outlined	
previously,	it	was	found	that	due	to	the	in	vitro	conditions	of	the	construct,	skin	
explants	were	lost	during	media	changes	and	AlamarBlue	measurements	during	
the	experimental	time	period.	We	postulated	therefore	that	one	of	the	reasons	
why	there	was	lack	of	migration	of	skin	cells	onto	the	fibres	of	the	electrospun	
scaffold	was	because	the	explants	were	not	in	contact	with	the	scaffolds	at	all	
times.	Furthermore,	 fibrin	was	not	present	between	the	skin	explant	and	the	
electrospun	 scaffold,	which	 is	what	would	normally	 occur	when	explants	 are	
placed	onto	a	wound	bed.	In	order	to	address	these,	this	chapter	aims	to	assess	
various	 strategies	 to	 aid	 retention	 of	 the	 skin	 explants	 onto	 the	 electrospun	
scaffolds	thereby	optimizing	the	migration	of	skin	cells	along	the	scaffold	fibres.		
The	 first	 strategy	 assessed	 the	 use	 of	 fibrin	 to	 fix	 the	 skin	 explants	 onto	 the	
electrospun	scaffold.	We	investigated	this	using	both	laboratory	made	fibrin	gels	
of	 varying	 fibrin	 concentrations,	 and	 a	 clinically	 available	 product	 TISSEEL™:	
(Baxter	 Healthcare	 Corp,	 Deerfield,	 IL,	 USA).	 Furthermore,	 we	 aimed	 to	
determine	whether	or	not	 the	dermal	 thickness	of	 the	 skin	explants	had	any	
influence,	 if	 any,	 in	 determining	 how	 quickly	 skin	 cells	migrate	 from	 the	 cut	
edges	of	the	skin	explants.	Finally,	as	our	last	optimization	strategy	we	placed	
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the	skin	explants	between	two	layers	of	electrospun	scaffold.	The	second	layer	
acted	somewhat	 like	a	dressing	 that	would	normally	be	put	onto	a	skin	graft	
once	it	has	been	applied	to	the	wound	bed	to	keep	the	skin	explants	in	place	
during	the	21-day	experimental	time	period.		
	
6.2	Fibrin		
	
Fibrin	is	a	meshwork	of	insoluble	protein	fibres	that	is	formed	as	a	result	of	the	
activation	of	the	coagulation	cascade.	The	end	point	of	the	coagulation	cascade	
is	the	production	of	a	serine	protease	called	thrombin	from	its	precursor	form	
prothrombin.	 Thrombin	 converts	 fibrinogen	 to	 fibrin.	 Fibrinogen	 is	 a	 soluble	
glycoprotein,	which	when	exposed	to	thrombin	results	in	cleavage	of	two	small	
peptides	(fibrinopeptides	A	and	B).	This	results	in	the	formation	of	protofibrils	
that	 aggregate	 to	 form	 insoluble	 fibrin	 fibres.	 	 The	 fibrin	 network	 is	 further	
stabilized	by	activated	factor	XIII,	as	the	network	can	undergo	early	degradation	
by	a	serine	protease	called	plasmin(214)(148).	This	fibrin	network	has	multiple	
functions.	 Firstly,	 it	 reinforces	 the	 initial	 platelet	 plug	 by	 trapping	 platelets,	
erythrocytes,	 and	 other	 proteins	 to	 stop	 bleeding.	 It	 also	 serves	 as	 an	 initial	
template	 for	promoting	cellular	migration	and	proliferation	as	 it	 is	 filled	with	
cytokines	 and	 growth	 factors	 which	 promote	 re-epithelization,	 angiogenesis,	
and	 collagen	 deposition(215).	 Furthermore,	 fibroblasts	 from	 surrounding	
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uninjured	tissue	are	stimulated	both	by	growth	factors	 from	within	the	 fibrin	
network	 and	 the	 network	 itself	 to	 migrate	 towards	 the	 matrix.	 Fibroblasts	
express	 integrin	 receptors,	 proliferate,	 and	 produce	 extracellular	 matrix	
components	 to	 replace	 the	 temporary	 fibrin	 network.	 Keratinocytes	 are	 also	
stimulated	by	 the	 fibrin	network	 to	detach	 themselves	 from	 the	 surrounding	
healthy	 wound	 edges	 and	 migrate	 towards	 it-	 instituting	 the	 process	 of	 re-
epithelization(216)(16).		
	
The	 concentration	 of	 thrombin	 at	 the	 time	 of	 fibrin	 clot	 formation	 has	 a	
significant	influence	on	fibrin	clot	structure(217).	Extremely	low	concentrations	
of	thrombin	(<1nM,	<	0.1	U/mL)	produce	turbid	clots	composed	of	thick,	loosely	
woven	 fibrin	 strands.	 Higher	 concentrations	 of	 thrombin	 produce	 relatively	
thinner	 fibrin	 clots	 composed	of	 tightly	packed	 fibrin	 strands(218).	 Thrombin	
becomes	inactivated	once	the	fibrin	clot	has	formed.	Fibrin	is	attractive	for	use	
in	 tissue-engineered	 skin.	 Firstly,	 it	 serves	 as	 a	 stimulus	 to	 promote	 cell	
adhesion,	migration	and	proliferation.	Additionally,	fibrin	precursors	thrombin	
and	 fibrinogen	can	be	easily	 isolated	 from	patient’s	blood	 thereby	creating	a	
custom	autologous	treatment.	In	this	regard,	the	fibrin	clot	should	have	a	porous	
structure	to	facilitate	cellular	movement	and	function	but	at	the	same	time	be	
mechanically	 strong	 to	 combat	 shear	 forces	 that	 can	occur	between	 the	 skin	
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explants	and	the	electrospun	scaffolds.	Furthermore	increasing	the	fibrinogen	
concentration	 results	 in	 a	 clot	 with	 an	 increased	 tensile	 and	 adhesion	
strength(219).	
	
We	 tested	 three	 concentrations	 of	 thrombin	 and	 three	 concentrations	 of	
fibrinogen.	The	first	concentrations	tested	were	based	on	that	used	in	previous	
studies	performed	in	the	MacNeil	laboratory	on	corneal	explants.	Ortega	et	al	
used	 a	 1:1	 mixture	 of	 fibrinogen	 at	 a	 concentration	 of	 18.75mg	 /ml	 and	
thrombin	at	a	concentration	of	2.5	U/ml,	which	was	found	to	adhere	the	limbal	
explants	onto	the	electrospun	scaffold	and	at	the	same	time	facilitated	outward	
cellular	migration.	Fibrin	as	mentioned	in	the	introduction	is	used	clinically	as	a	
haemostat,	sealant,	and	an	adhesive.	The	clinical	applications	of	sealants	and	
adhesives	were	 chosen	 as	models	 for	 our	 concentrations.	 Fibrin	 is	 used	 as	 a	
haemostat	 in	 cases	 of	 bleeding	 which	 is	 not	 controllable	 by	 suturing	 or	
cauterization	of	vessels	e.g.	solid	organ	 lacerations.	 In	 this	case	the	thrombin	
concentration	used	is	often	greater	than	500	I.U/ml,	this	high	concentration	of	
thrombin	would	result	in	a	tightly	compact	fibrin	clot	that	sets	instantly,	which	
is	a	requirement	of	 its	 function	as	a	haemostat.	 	However,	 this	would	not	be	
suitable	for	our	in	vitro	studies.	Other	thrombin/fibrinogen	concentrations	used	
are	 based	 on	 the	 approximate	 concentrations	 from	 these	 clinical	 products.	
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Thrombin/fibrinogen	concentration	of	2.5-6.5	 I.U	/	67-86.5mg/ml	 is	based	on	
the	 use	 of	 fibrin	 as	 an	 adhesive	 for	 skin	 graft	 attachment	 at	 burn	 wound	
debridement	sites.	This	is	marketed	commercially	as	Artiss(220).		
The	key	feature	that	makes	it	a	useful	adhesive	is	the	relatively	low	thrombin	
concentration	of	4.5	IU	(range	2.5	to	6.5)	that	allows	at	least	up	to	60	seconds	
to	 position	 the	 grafts	 or	 flaps	 before	 the	 fibrin	 starts	 to	 set.	 The	 fibrinogen	
concentration	in	this	product	ranged	from	67	to	106	mg/ml	with	an	average	of	
86.5mg/ml.	 The	 fibrinogen	 concentrations	 that	 we	 chose	 (67mg/ml	 and	
86.5mg/ml)	reflect	the	lower	and	average	concentrations	of	fibrinogen	present	
in	this	product.	These	concentrations	were	postulated	to	be	beneficial	in	our	in	
vitro	studies,	as	it	would	allow	some	time	to	manipulate	the	skin	explants	onto	
the	electrospun	scaffold	fibres	before	they	were	adhered	in	place.				
Tisseel	is	another	product	that	we	tested	in	its	ability	to	fix	skin	explants	onto	
the	electrospun	scaffold	and	facilitate	cellular	migration	from	the	cut	edge	of	
the	skin	explants.	This	 is	marketed	both	as	a	sealant	 for	vascular	and	cardiac	
procedures	and	as	a	haemostat	for	cases	where	suture	or	cautery	of	vessels	are	
not	appropriate.	This	product	has	a	thrombin	concentration	ranging	from	400		
–	 625	 units/mL	 and	 a	 fibrinogen	 concentration	 ranging	 from	 67	 –	 106	
mg/mL(221).	As	 this	preparation	 is	FDA	approved,	widely	available,	and	used	
within	 the	United	 Kingdom,	 it	was	 felt	 that	 it	would	 be	 beneficial	 to	 test	 its	
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suitability	in	our	in	vitro	constructs	as	this	would	make	clinical	translation	using	
fibrin	more	realistic.		
Additionally,	we	wanted	 to	 assess	 the	effect	of	 dermal	 thickness	on	 skin	 cell	
migration	from	the	cut	edges	of	skin	explants.	The	earliest	studies	that	examined	
the	effect	on	dermal	thickness	on	successful	skin	graft	take	were	undertaken	by	
an	American	surgeon	called	Earl	Padgett	(50).		He	divided	skin	grafts	into	four	
standardized	 thicknesses:	 Thiersch	 grafts	 (0.008–0.010	 inches;	 0.2–0.25mm),	
STSGs	 (0.012–0.016inches;	 0.3–0.4mm),	 three-quarter	 skin	 grafts	 (0.018–
0.022inches;	0.45–0.55mm),	and	full	thickness	skin	grafts	(0.030	–0.038	inches;	
0.75–0.95mm)(50).		
He	 concluded	 that	 using	 grafts	with	 less	 dermis	was	 suitable	 for	 granulating	
wound	bases	and	grafts	with	more	dermis	for	wounds	that	would	require	more	
substantial	coverage	to	avoid	contractures	e.g.	over	joint	surfaces.	The	dermal	
thickness	 of	 a	 graft	 is	 dependent	 on	 the	 technique	 used,	 the	 quality	 of	 the	
patient’s	skin	(age,	drugs	and	other	co-morbidities),	and	the	chosen	donor	site.	
Areas	like	the	inner	arm	and	thigh	have	thinner	dermis	and	result	in	such	grafts	
being	 thinner	 than	grafts	 from	donor	sites	 like	 the	abdomen,	back	and	outer	
thigh.		
Furthermore,	 the	 use	 of	 an	 air-powered	 dermatome	 has	 standardized	 graft	
thickness	to	some	extent	as	the	desired	thickness	can	be	set	in	thousandths	of	
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an	inch.	However,	the	pressure	placed	on	the	instrument	by	the	surgeon	has	an	
influence	as	well	on	overall	dermal	thickness.	In	these	experiments	the	skin	was	
obtained	 from	either	 the	breast	 or	 the	 abdomen.	 The	method	used	 in	 these	
experiments	to	create	the	skin	explants	was	the	manual	Watson	knife,	in	which	
the	thickness	is	set	by	adjusting	the	gap	between	the	blade	and	the	knife.	The	
manual	pressure	applied	by	the	user	influences	the	dermal	thickness	to	an	even	
greater	extent	when	compared	to	using	an	air	driven	dermatome.		
	In	 our	 experiment	 we	 divided	 the	 skin	 explants	 into	 two	 groups	 based	 on	
varying	dermal	thickness	measured	with	a	digital	micrometer,	as	the	epidermal	
thickness	 from	 one	 sample	 was	 assumed	 to	 be	 constant	 throughout.	 We	
hypothesized	that	dermal	thickness	should	not	influence	the	migration	of	skin	
cells	from	the	explants	as	this	in	theory	should	only	occur	from	the	cut	edges	
and	should	not	be	influenced	by	dermal	thickness.	Therefore,	we	hypothesized	
that	 there	 should	 be	 similar	 amounts	 of	migration	when	 thicker	 and	 thinner	
samples	were	compared.		
	
Finally,	as	a	last	strategy	we	tried	to	model	our	constructs	on	other	aspects	of	
the	skin	grafting	technique	that	is	practiced	clinically.	Once	skin	grafts	are		
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secured	onto	a	wound	bed	dressings	are	applied	over	the	graft	and	are	often	
secured	with	a	tie	over	suture.	This	is	all	aimed	at	reducing	the	disruptive	shear	
forces	that	occur	between	the	graft	and	the	wound	bed	which	result	in	
breakage	of	the	fibrin	bonds	and	graft	failure.	In	our	constructs	we	postulated	
that	putting	another	layer	of	electrospun	scaffold	on	top	of	the	skin	explants	
would	act	as	a	dressing	and	prevent	the	displacement	of	skin	explants	in	the	
media.	Given	that	we	know	the	scaffolds	support	skin	cell	migration	and	are	
porous	in	nature,	media	would	still	be	able	to	diffuse	through	the	scaffolds	to	
nourish	the	skin	explants	(Figure	6.1).		
 
Figure	6.1:	Schematic	illustrating	skin	explant	between	two	layers	of	
electrospun	scaffolds	
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6.3	The	effect	of	varying	the	concentration	of	fibrin	on	cellular	migration	
from	skin	explants.	
	
These	experiments	aimed	to	assess	the	effect	of	varying	the	concentrations	of	
the	constituent	components	of	fibrin	on	outward	cellular	migration	from	the	
skin	explants.	This	was	assessed	quantitatively	by	using	Rose	Bengal	Staining	at	
0,	7,	and	14	days	respectively	to	map	the	outgrowth	of	cells	from	the	skin	
explants	that	were	mixed	with	fibrin	on	tissue	culture	plastic.		Furthermore,	at	
14	days	we	undertook	DAPI	staining	to	confirm	that	presence	of	skin	cells	from	
the	cut	edge	of	the	skin	explant	pieces.	Additionally,	we	repeated	these	
experiments	using	trilayer	electrospun	scaffolds	instead	of	tissue	culture	
plastic,	which	enabled	us	to	obtain	H&E	images	of	the	explant-fibrin-scaffold	
interface.		
	
Rose	Bengal	Staining	
	
Rose	Bengal	is	a	derivative	of	fluorescein	and	stains	by	localizing	primarily	in	
cellular	nuclei	and,	to	a	lesser	degree,	in	other	organelles(222).	It	can	be	used	
to	quantify	the	amount	of	cellular	outgrowth	from	skin	explants	without	
affecting	their	viability.	This	allows	for	a	continuous	in	vitro	analysis	of	the	
effect	of	varying	the	concentration	of	fibrinogen	and	thrombin	on	outward	
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cellular	migration	from	the	cut	edges	of	skin	explants.	The	various	
combinations	of	thrombin	and	fibrinogen	used	in	the	experiments	are	detailed	
in	Table	11.		
	
Experiment	 Concentration	of	
Thrombin	(I.U)	/ml	
Concentration	of	Fibrinogen	mg/ml	
A	 2.5		 18.75	 67	 86.5		
B	 4.5	 18.75	 67	 86.5		
C	 6.5	 18.75	 67	 86.5		
Table	7:	Various	concentrations	of	thrombin	and	fibrinogen	used	in	constructs	
to	test	their	effect	on	the	cellular	outgrowth	from	skin	explants.		
	
	
For	these	experiments	the	split	thickness	skin	explants	were	placed	in	the	
centre	of	each	well	in	a	six	well	plate.	To	this	varying	concentrations	of	
thrombin	and	fibrinogen	were	added	on	top	of	the	skin	explants	as	outlined	in	
table	1	that	resulted	in	a	fibrin	clot.	Rose	Bengal	was	then	added	according	to	
the	methods	outlined	in	chapter	2	and	photographed	as	a	day	0	record.	
Following	this,	the	constructs	were	cultured	in	10%	serum	Green’s	and	stained	
at	day	7	and	14.	The	total	areas	stained	by	the	Rose	Bengal	at	each	of	these	
time	checkpoints	were	measured	in	mm2	using	ImageJ	software	(Figure	6.2).		
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There	was	a	progressive	increase	from	day	0	to	day	14	in	the	Rose	Bengal	
stained	area	the	thrombin	groups	2.5	and	4.5	for	all	concentrations	of	
fibrinogen.	Constructs	with	a	thrombin	concentration	of	6.5,	reflected	a	
decrease	in	the	stained	area	from	day	7	to	day	14	at	all	fibrinogen	
concentrations	apart	from	86.5mg.		
	
	
Group	Analysis	
	
Thrombin	2.5		
Constructs	containing	thrombin/fibrinogen	2.5mg/18.75mg	showed	
significantly	greater	stained	areas	at	day	7	and	day	14	compared	to	the	other	
two	fibrinogen	concentrations	(p=0.0041	at	day	7	and	p=	0.0005	at	day	14)	
(Figure	6.2a).		
	
Thrombin	4.5		
Although	constructs	containing	fibrinogen	86.5mg	had	a	greater	area	stained	
by	Rose	Bengal	at	day	14	this	was	not	statistically	significant	compared	to	the	
other	two-fibrinogen	concentrations	(Figure	6.2b).	
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Thrombin	at	6.5	
These	constructs	had	significant	differences	in	the	Rose	Bengal	area	stained	at	
day	7	and	14	(table	12).	This	group	demonstrated	that	with	a	fibrinogen	
concentration	of	18.75mg	at	day	7	there	was	significantly	more	outward	Rose	
Bengal	staining	than	the	other	fibrinogen	concentrations	at	this	time	point.	
Furthermore,	constructs	with	fibrinogen	concentration	of	86.5mg	had	
significantly	larger	stained	areas	compared	to	the	other	fibrinogen	(	67mg	and	
18.75	mg	respectively)	concentrations	at	14	days	(Figure	6.2c).		
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Figure	6.2:	Area	of	Rose	Bengal	Staining	over	a	14-day	culture	period	using	
constructs	containing	various	concentrations	of	thrombin	and	fibrinogen	with	
skin	explants.	A:	thrombin	2.5	I.	U/ml;	B:	thrombin	4.5	I.	U/ml;	C:	thrombin	6.5	
I.	U/ml.	(Mean±SEM).	
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DAPI	Staining	
	
This	was	undertaken	for	fixed	constructs	at	day	14	to	demonstrate	cellular	
migration	from	the	cut	edges	of	the	skin	explants	when	combined	with	varying	
concentrations	of	thrombin	and	fibrinogen	on	tissue	culture	plastic.	The	results	
indicate	that	cellular	migration	surrounding	the	skin	explants	were	the	most	for	
the	thrombin	2.5	groups	when	all	concentrations	of	fibrinogen	were	evaluated.	
The	migration	of	skin	cells	from	the	cut	edges	of	skin	explants	seemed	to	
decrease	as	the	fibrinogen	concentration	increased.	There	was	negligible	to	
absent	migration	of	skin	cells	from	the	skin	explants	in	the	other	
thrombin/fibrinogen	group	combinations	as	demonstrated	in	Figure	6.3	apart	
from	thrombin/fibrinogen	4.5/86.5	which	clearly	illustrates	cellular	migration	
from	the	edge	of	the	skin	explant	on	tissue	culture	plastic.			
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Figure	6.3:	DAPI	fluorescence	staining	of	varying	concentrations	of	thrombin	
and	fibrinogen	combined	with	skin	explants	on	tissue	culture	plastic.		
	
Hematoxylin	and	Eosin	Staining.	
These	were	undertaken	on	fixed	constructs	on	day	14.	Skin	explants	were	
cultured	on	templated	trilayer	PHBV/PGLA	75:	25	scaffolds	with	varying	
concentrations	of	fibrin	constituents	for	14	days	as	noted	in	Table	1.	These	
visually	highlight	the	electrospun	scaffold/skin	explant/fibrin	architectures	and	
evidence	of	integration,	if	any	between	the	two.	Figure	6.4	illustrates	that	the	
Thrombin	2.5 
Thrombin	
4.5 
Thrombin	
6.5 
Fibrinogen:	18.75mg	 Fibrinogen:	67mg	 Fibrinogen:	86.5mg	 
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skin	explants	were	closely	applied	to	the	scaffolds	in	the	thrombin	2.5	group,	
at	all	concentrations	of	fibrinogen.	Increasing	the	concentration	of	thrombin	to	
4.5	and	6.5	results	in	a	significant	gap	between	the	skin	explants	and	the	
electrospun	scaffolds.	This	was	mostly	obvious	at	fibrinogen	concentrations	of	
86.5mg/ml.	There	were	very	little	visible	cellular	structures	present	on	the	
electrospun	scaffolds	that	migrated	from	the	cut	edge	of	the	skin	apart	from	
some	material	just	adjacent	to	the	skin	explants	in	the	thrombin	2.5	group.	
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Figure	6.4:	Representative	light	microscopy	H&E	stained	sections	of	skin	
explants	seeded	on	templated	trilayer	electrospun	scaffolds	with	various	
concentrations	of	fibrinogen	and	thrombin	cultured	over	14	days.			Scale	bars	of	
0.2	mm	(100X	magnification).	
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6.4	Investigating	the	effect	Tisseel	on	skin	explant	handling	and	cellular	
migration	along	fibres	of	trilayer	electrospun	scaffolds	
	
These	experiments	aimed	to	assess	the	ability	to	use	Tisseel,	a	commercially	
available	fibrin	sealant	that	is	already	in	clinical	use,	to	fix	skin	explants	onto	
electrospun	scaffolds.	We	also	wanted	to	assess	if	there	was	any	difference,	if	
any	when	Tisseel	was	used	with	templated	versus	non-templated	PHBV/PGLA	
(75:25)	electrospun	scaffolds.	Constructs	containing	trilayer	templated	and	
non-templated	electrospun	scaffolds	were	cultured	with	skin	explants	mixed	
with	Tisseel.	They	were	cultured	for	7,14	and	21	days	respectively.		
	
AlamarBlueTM	assay		
Absorbance	for	skin	explants	and	Tisseel	cultured	on	trilayer	templated	
scaffolds	and	non-templated	scaffolds	were	read	and	the	absorbance	for	
scaffolds	of	each	type	with	no	skin	explants	and	Tisseel	were	subtracted	from	
these	values.	The	absolute	values	are	represented	at	days	7,	14,	and	21.	It	was	
demonstrated	that	the	skin	explants	with	Tisseel	were	viable	throughout	the	
21-day	testing	period	on	both	templated	and	non-templated	scaffolds	(Figure	
6.5).			
Cellular	metabolic	activity	in	constructs	were	similar	to	those	without	Tisseel	
where	a	decrease	was	noted	from	day	7	to	day	14	followed	by	an	increase	in	
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metabolic	activity	steadily	through	today	21.	There	was	no	significant	
difference	in	metabolic	activity	when	skin	explants	with	Tisseel	were	seeded	
on	templated	versus	non-templated	electrospun	scaffolds	(p=0.7928).		
.		
	
	
	
	
	
	
Figure	6.5	Metabolic	activities	of	skin	explants	with	Tisseel	on	templated	and	
non-templated	trilayer	electrospun	scaffolds	over	a	21-day	experimental	period	
as	determined	by	absorbance	of	AlamarBlue	stain	(Mean±SEM).	
	
	
DAPI	Staining	
	
This	was	undertaken	for	constructs	fixed	at	day	7,	14,	and	21	to	determine	if	
cells	from	the	cut	edges	of	the	skin	explants	were	now	able	to	migrate	along	
the	fibres	of	the	electrospun	scaffolds	in	the	presence	of	Tisseel.	We	also	
wanted	to	assess	if	there	were	any	differences	between	templated	and	non-
templated	scaffolds.	Cells	were	seen	to	be	leaving	the	surrounding	area	around	
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the	skin	explant	pieces	that	progressively	increased	over	time	and	was	most	
visible	on	day	21.	This	level	of	cellular	migration	was	much	more	than	that	
observed	when	skin	explants	were	simply	placed	on	scaffolds	with	no	Tisseel.	
However,	when	compared	to	tissue	engineered	skin	constructs	using	DED	at	
the	same	time	checkpoints	as	a	positive	control,	there	was	not	as	much	cellular	
migration	and	proliferation	observed	even	in	the	presence	of	Tisseel.		
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Figure	6.6:	DAPI	staining	of	constructs	consisting	of	non-templated	scaffolds	
and	templated	scaffolds	cultured	with	skin	explants	and	Tisseel.	Scale	
bar=0.2mm	
	
	
	
	
	
	
Non-Templated	scaffolds Templated	scaffolds 
Day	7 
Day	14 
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Haematoxylin	and	Eosin	Staining.		
	
This	was	undertaken	on	fixed	constructs	at	day	7,	14,	and	day	21	to	
demonstrate	consecutive	skin	explant/Tisseel/scaffold	architectures.	Frozen	
sections	of	constructs	stained	with	H&E	demonstrated	some	cellular	
outgrowth	from	the	cut	edges	of	the	skin	explants	onto	the	fibres	of	the	
electrospun	scaffolds.	There	was	more	integration	of	the	skin	explants	with	the	
scaffolds	in	the	presence	of	Tisseel	compared	to	skin	explants	cultured	without	
Tisseel.	This	however	did	not	hold	for	non-templated	scaffolds	cultured	with	
skin	explants	on	day	21,	as	the	Tisseel	seemed	to	have	set	in	between	the	skin	
explants	and	the	scaffold	creating	a	dense	clot	between	the	skin	cells	and	the	
scaffold	fibres	(Figure	6.6).		
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Figure	6.7:	Representative	light	microscopy	H&E	stained	sections	of	skin	
explants	seeded	on	templated	and	non-templated	trilayer	electrospun	scaffolds	
with	Tisseel	and	cultured	over	14	days.		Scale	bars	of	0.2	mm	(100X	
magnification).	
	
	
	
Day	14	
Day	7	
Day	21	
Non-Templated	scaffolds	 Templated	scaffolds	
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Sirius	Red	Assay	
	
At	day	7,	14,	and	21	Sirius	red	assays	were	undertaken	to	estimate	the	total	
collagen	produced	overtime	by	the	skin	explants	seeded	on	trilayer	
electrospun	scaffolds	with	Tisseel	(Figure	6.7).	The	aim	was	to	compare	the	
amount	of	collagen	deposited	by	proliferating	fibroblasts	from	the	skin	
explants	compared	to	those	from	tissue-engineered	skin	using	DED	as	a	
positive	control.	Furthermore,	we	aimed	to	compare	Tisseel/skin	explant	
constructs	to	those	without	Tisseel.	There	was	no	significant	difference	in	total	
collagen	produced	per	gram	of	scaffold	when	Tisseel	was	used	between	
templated	and	non-templated	electrospun	scaffolds.	However,	comparing	
these	skin	explant/Tisseel	constructs	to	DED	there	were	significant	differences	
in	collagen	produced	with	the	latter	being	significantly	more	at	day	7	
compared	to	non-templated	scaffolds	with	Tisseel	and	at	day	14	for	all	
constructs	containing	Tisseel	(Figure	6.8).	However,	at	day	21,	although	total	
collagen	produced	per	gram	was	more	in	the	DED	samples,	this	was	not	
significantly	different	to	those	constructs	containing	Tisseel	(Table	13).	
Furthermore,	templated	constructs	containing	skin	explants/	Tisseel	had	
significantly	more	collagen	produced	per	gram	compared	to	those	constructs	
containing	skin	explants	alone	at	day	14.	
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Figure	6.8:	Sirius	red	staining	after	7,	14,	and	21	days	comparing	a:	non-
templated	and	templated	with	skin	explants	and	Tisseel;	b:	skin	explants	on	
scaffolds,	skin	explants	with	Tisseel	and	DED.	(N=3±SEM).	
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Construct	A	 Construct	B	 P	Value		
Non	templated	
scaffolds	with	Tisseel	
Day	7	
DED	Day	7	 0.0255	
	
Non	templated	
scaffolds	with	Tisseel	
Day	14	
DED	Day	14	 0.0055	
	
Templated	scaffolds	
with	Tisseel	Day	14	
DED	Day	14	 0.0025	
	
Templated	scaffolds	
with	explants	no	
Tisseel	
Templated	scaffolds	
with	Tisseel	Day	14	
0.0104	
	
Table	8:	Illustrating	significant	P	values	comparing	Sirius	Red	Staining	of	
various	constructs	using	Unpaired	Student’s	T	test.		
	
Section	Discussion	
The	aim	of	these	experiments	was	to	determine	if	a	clinically	used	sealant	like	
Tisseel	would	be	suitable	to	adhere	the	skin	explants	onto	the	electrospun	
scaffolds	and	at	the	same	time	facilitate	cellular	migration.	Tisseel	is	widely	
used	in	hospitals	across	many	specialties	in	the	United	Kingdom.	In	plastic	
surgery,	it	is	used	mainly	as	a	haemostat	when	there	are	no	identifiable	vessels	
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to	be	sutured	or	coagulated	on	a	bleeding	wound	bed.	As	Tisseel	is	marketed	
mainly	as	a	haemostat	and	a	sealant,	the	concentration	of	thrombin	is	very	
high	which	facilitates	prompt	coagulation,	but	also	a	fibrin	clot	with	thin	tightly	
packed	fibrin	strands.		
	
The	experiments	in	the	previous	section	tested	fibrin	clots	produced	by	low	
thrombin	concentrations	which	usually	are	found	in	adhesives.	These	products	
are	used	infrequently	in	the	hospital	environment	to	adhere	skin	grafts	or	flaps	
to	wound	beds	as	it	is	more	expensive	than	suturing.	Therefore,	we	wanted	to	
assess	if	Tisseel,	which	is	already	part	of	theatre	stock	lists,	would	facilitate	
cellular	migration	from	skin	explants.		
	
Adding	Tisseel	to	constructs	did	not	adversely	affect	the	viability	of	the	cells	as	
their	metabolic	activity	increased	progressively	throughout	the	experimental	
period.		Qualitative	analysis	using	DAPI	showed	that	there	was	more	cellular	
migration	from	skin	explants	in	constructs	containing	Tisseel	compared	to	skin	
explants	cultured	without	Tisseel.	Furthermore,	when	assessing	total	collagen	
produced,	it	was	found	that	constructs	containing	Tisseel	showed	more	
collagen	production	than	those	without,	which	was	significant	at	the	14-day	
culture	period	for	templated	constructs.	Although	DED	constructs	had	
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significantly	higher	amounts	of	collagen	at	day	7	and	day	14	compared	to	
Tisseel	constructs,	by	21	days	this	difference	became	insignificant.	This	
suggests	that	over	time,	the	fibroblasts	from	the	skin	explants	that	are	
adherent	to	the	scaffold	with	the	help	of	Tisseel,	were	able	to	proliferate	and	
start	producing	collagen.	This	is	one	of	the	key	steps	in	wound	healing	as	
proliferating	fibroblasts	produce	signals	to	stimulate	the	further	migration	and	
proliferation	of	keratinocytes.	
	
There	were	however	a	few	challenges	encountered	when	handling	Tisseel.	The	
most	significant	one	is	that	it	sets	quickly;	as	the	jet	of	thrombin	and	fibrinogen	
exits	the	syringe	it	forms	a	ball	of	fibrin	that	is	quite	tough.	There	was	about	5-
6	seconds	to	manipulate	skin	explants	onto	the	scaffold	before	the	fibrin	began	
to	set	into	a	solid	clot.		Furthermore,	because	it	was	a	very	dense	clot,	some	of	
explants	were	bunched	together	rather	than	being	flat	onto	the	surface	of	the	
electrospun	scaffold	which	is	needed	for	outward	cellular	migration	onto	the	
scaffolds.	We	were	able	to	achieve	correct	positioning	of	the	skin	explants	on	
the	scaffolds	when	thrombin/fibrinogen	concentrations	of	2.5	I.	U/18.75	mg	
were	used	and	like	the	Tisseel	clot	was	stable	(still	structurally	visible	with	the	
skin	explants	present)	throughout	the	21-day	experimental	period.		
	
	 289	
6.5	Investigating	the	effect	of	varying	dermal	thickness	on	cellular	migration	
from	the	cut	edges	of	skin	explants.		
	
The	aim	of	these	experiments	was	to	investigate	the	effect	of	varying	dermal	
thickness	on	cellular	migration	from	the	cut	edge	of	skin	explants.	It	aimed	to	
determine	if	thinner	(with	respect	to	the	dermis)	skin	explants	had	more	
outward	cellular	migration	versus	samples	containing	thicker	dermis.	There	is	
no	consensus	on	a	thin	vs	a	thick	skin	explant.	As	a	result,	we	used	the	thinnest	
setting	on	the	Watson	knife	for	the	thin	explants	which	were	all	less	than	
0.3mm	and	the	thickest	setting	on	the	Watson	knife	for	a	thick	skin	explant	–	
all	>	0.7mm.	Split	thickness	skin	of	varying	dermal	thickness	were	categorized	
into	two	groups:	thick	and	thin	after	measuring	each	square	piece	of	skin	
explant	with	a	digital	micrometer.	As	all	samples	in	the	experiment	came	from	
the	same	source	skin,	it	was	assumed	that	the	epidermis	was	of	a	constant	
thickness	and	the	variability	in	the	readings	resulted	from	the	varying	amounts	
of	dermis	present.	Squares	of	skin	explants	were	then	minced	into	fine	pieces	
and	placed	in	the	centre	of	a	six	well	plate.	They	were	cultured	for	a	period	of	
7days.	The	dermal	thicknesses	of	the	2	groups	are	summarized	in	Table	14		
below.		
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Group	A:	
thin	dermis	
/mm	
0.282	 0.220	 0.154	 0.256	
Group	B:	
thick	
dermis/mm	
2.031	 1.030	 1.761	 0.716	
Table	9	Various	thickness	of	skin	explants	used	in	experiments	(mm).		
	
Rose	Bengal	Staining	of	skin	explants	of	varying	dermal	thickness.		
	
This	stain	was	able	to	evaluate	ongoing	cellular	migration	from	the	skin	
explants	outwards	from	day	0	to	day	7	(Figure	6.9).	Figure	6.9A	shows	the	area	
occupied	by	the	stain	after	a	few	hours	of	being	in	culture	as	a	baseline.	The	
blue	bars	indicate	the	explants	that	belonged	to	the	samples	with	thin	dermis	
and	the	red	bars	those	with	thick	dermis.		At	this	point,	the	area	of	stain	
surrounding	the	explants	in	both	the	groups	were	very	similar	as	equal	squares	
of	explants	were	used	with	the	same	amount	of	rose	bengal	staining.	The	Rose	
Bengal	stain	was	removed	and	the	explants	were	returned	to	culture	for	7	
days.	At	day	7	(Figure	6.9B)	there	is	a	significant	increase	in	the	stained	area	
surrounding	the	skin	explants	with	thin	dermis	compared	to	those	with	thicker	
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dermis	(p=	0.0026	Kruk	shall	Wallis	test	for	multiple	groups	assuming	non	
parametric	distribution)	
This	is	better	illustrated	in	Figure	6.9C	where	the	mean	of	each	replicate	value	
of	the	area	of	rose	bengal	stain	per	skin	explant	has	been	plotted	at	day	0	and	
day	7	respectively.	This	clearly	illustrates	that	the	explants	with	thinner	dermis,	
overtime	results	in	more	outward	cellular	migration	of	skin	cells	onto	scaffolds	
versus	thicker	skin	explants.		
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Figure	6.9:	Rose	Bengal	stained	area	in	mm2	illustrating	cellular	migration	
from	skin	explants.	A:	Skin	both	thick	and	thin	at	day	0,	B:	Skin	explants	at	day	
7;	C:	The	mean	of	the	area	staining	per	explant	thickness	at	day	0	and	day	7.		
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Section	Discussion	
	
The	aim	of	this	work	was	not	only	to	produce	a	biodegradable	membrane,	but	
also	to	develop	a	technique	whereby	skin	explants	from	the	patient	would	be	
used	as	a	cell	source	to	populate	the	fibres	of	the	scaffold	in	a	reproducible	
manner.	In	that	regard,	we	needed	to	scrutinize	the	properties	of	the	skin	
explants	both	in	terms	of	thickness	and	placement	onto	the	electrospun	
scaffold	to	assess	if	any	of	these	factors	influenced	outward	cellular	migration.		
Many	groups	have	published	tissue-engineered	models	using	isolated	cultured	
autologous	cells	as	skin	substitutes(223).	However	as	discussed	in	the	
introduction	these	have	not	made	a	sustained	impact	on	the	reconstructive	
options	available	to	surgeons	and	hence	patients.	The	advantage	of	using	skin	
explants	is	that	they	contain	fibroblasts,	which	serve	to	stimulate	the	migration	
and	proliferation	of	keratinocytes.	We	have	shown	that	our	scaffolds	facilitate	
the	migration	and	proliferation	of	both	these	cells.	Therefore,	the	idea	here	is	
to	use	skin	explants	in	one	step,	as	a	cell	source	to	populate	the	fibres	of	the	
electrospun	scaffolds.		
In	order	to	translate	a	technique	clinically,	it	has	to	be	easily	reproducible	to	
reduce	the	effect	of	patient	variability	on	a	successful	outcome.	The	less	
precise	the	requirements	for	the	technique,	the	more	chance	of	it	becoming	
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successful	in	the	clinical	environment	due	to	the	unavoidable	influence	of	
human	error	and	patient	physiology.	One	of	the	oldest	and	most	common	skin	
reconstructive	techniques	used	in	clinical	practice	is	the	skin	graft.	It	is	a	
reliable	method	of	reconstruction	as	the	technique	is	easily	reproducible.	
There	are	no	recommended	dermal	thickness	ranges	for	skin	grafts	apart	from	
clinical	indications	–	for	example	in	burn	contracture	reconstruction	full	
thickness	grafts	are	preferred	as	they	have	less	secondary	contraction	
compared	to	split	thickness	skin	grafts.	The	dermal	thickness	often	influences	
the	method	of	fixation	used	for	the	graft	on	the	wound	bed.	Split	thickness	
grafts	with	less	dermis	have	less	primary	contracture	(elastic	recoil	at	the	time	
of	harvesting	due	to	the	amount	of	elastin	in	the	dermis)	and	as	a	result	they	
are	able	to	lay	flat	on	a	wound	bed	without	having	to	suture	the	edge.	Tissue	
glue	can	be	used	and	a	tie	over	dressing.	This	is	not	the	case	for	full	thickness	
grafts,	where	there	is	significantly	more	primary	contracture.	The	piece	of	skin	
tends	to	therefore	curl	in	and	not	lay	flat	on	the	wound	bed	compared	to	grafts	
with	thinner	dermis.		
In	these	experiments	a	Watson	knife	was	used	to	harvest	the	skin	into	grafts	
and	by	adjusting	the	blade	we	were	able	to	obtain	skin	samples	containing	
variable	amounts	of	dermis.	This	explains	the	variation	in	the	thickness	of	skin	
explants	that	were	obtained	in	each	group.	The	Watson	knife	is	not	commonly	
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used	to	harvest	skin	grafts	as	a	matter	of	routine	as	it	has	been	superseded	by	
the	air	driven	dermatome,	which	results	in	grafts	with	a	more	consistent	
dermal	thickness.	Our	data	supports	the	use	of	skin	explants	with	less	dermis	
for	our	proposed	technique	as	there	was	a	significant	increase	in	the	stained	
area	around	the	explants	with	less	dermis	compared	to	those	with	more	
dermis.	This	reflects	increased	cellular	migration	from	the	cut	edges	of	the	skin	
explants.	Furthermore,	thinner	explants	handle	easier	than	thicker	ones,	due	
to	less	elastic	recoil	which	results	in	more	contact	between	the	fibres	of	the	
scaffold	and	the	overlying	cells,	increasing	their	chances	of	migrating	out	of	the	
explant	and	onto	the	scaffold.	Furthermore,	previous	unpublished	work	from	
our	group	demonstrated	that	the	skin	explants	did	not	need	to	be	orientated	
specifically	on	the	underlying	scaffold	as	skin	cells	tend	to	migrate	from	the	cut	
edge	of	the	explants	as	long	as	the	skin	explant	is	in	contact	with	the	fibres	of	
the	electrospun	scaffold.	Therefore,	increasing	the	surface	area	of	these	edges	
by	mincing	the	squares	of	skin	facilitates	increased	contact	with	fibres	of	the	
scaffold	and	consequently	increased	cellular	migration	throughout	the	
scaffold.			
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6.6	The	sandwich	technique	to	increase	cellular	migration	from	the	cut	edges	
of	skin	explants.		
	
The	aim	of	these	experiments	was	to	determine	whether	the	placement	of	the	
skin	explants	between	two	layers	of	electrospun	scaffold	would	aid	cellular	
migration	along	the	fibres	of	the	scaffold	onto	which	the	explants	were	placed.	
Skin	explants	were	placed	in	the	centre	of	a	1.5	cm	x	1.5	cm	square	piece	of	
electrospun	scaffold.	Onto	this,	a	further	1.5	x	1.5	cm	square	piece	of	scaffold	
was	placed	on	top	of	the	skin	explants	in	order	to	keep	them	in	place.	
Constructs	were	then	raised	to	an	air	liquid	interface	and	cultured	for	7,	14,	
and	21	days.		
	
AlamarBlue	assay		
Absorbance	for	skin	explants	cultured	between	two	layers	of	electrospun	
scaffold,	both	templated	and	non-templated	were	read,	the	absorbance	
obtained	from	control	scaffolds	with	no	skin	explants	was	subtracted	from	
these	values.	The	absolute	values	are	represented	from	days	7,	14,	and	21.	It	
was	demonstrated	that	the	skin	explants	cultured	between	two	layers	of	
electrospun	scaffold	were	viable	throughout	the	21-day	testing	period	for	both	
templated	and	non-templated	scaffolds	(Figure	6.10)	
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Cellular	metabolic	activity	in	constructs	similar	to	those	of	skin	explants	
cultured	on	a	single	layer	of	electrospun	scaffold	increased	from	day	7	through	
today	21.	There	were	no	significant	differences	in	metabolic	activity	when	
comparing	templated	and	non-templated	at	any	of	the	time	checkpoints	of	day	
7	(p=0.3471),	day	14	(p=0.7995)	and	day	21	(p=0.3391).					
	
	
Figure	6.10:	Metabolic	activities	of	skin	explants	seeded	between	two	layers	of	
electrospun	scaffolds	over	a	21-day	period	as	determined	by	absorbance	of	
AlamarBlue	stain	(Mean±SEM).	
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Haematoxylin	and	Eosin	Staining.		
	
This	was	undertaken	on	constructs	fixed	in	formaldehyde	at	day	7,	14,	and	21	
to	demonstrate	consecutive	skin	explant/scaffold	architectures.	Frozen	
sections	of	constructs	containing	skin	explants	between	two	layers	of	
electrospun	scaffolds	both	templated	and	non-templated	were	stained	with	
H&E.	The	images	clearly	demonstrate	the	position	of	the	skin	explants	
between	the	two	layers	of	electrospun	scaffolds.	There	was	evidence	of	some	
cellular	material	on	the	scaffolds,	which	increased	especially	between	the	14	to	
21-day	culture	period	(Figure	6.11)		
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Figure	6.11:	Representative	light	microscopy	H&E	stained	sections	of	skin	
explants	seeded	in	between	two	layers	of	electrospun	scaffold	both	templated	
and	non-templated.		Scale	bars	of	0.2	mm	(100X	magnification).	
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Sirius	Red	Assay	
At	day	7,	14,	and	21	Sirius	red	assays	were	undertaken	to	estimate	the	total	
collagen	produced	overtime	by	the	skin	explants	placed	in	between	the	two	
layers	of	trilayer	electrospun	scaffolds	(Figure	6.12).	The	aim	was	to	quantify	
and	compare	the	amount	of	collagen	deposited	by	proliferating	fibroblasts	in	
electrospun	scaffold	sandwich	from	the	skin	explants	to	constructs	containing	
tissue	engineered	skin	using	DED	as	a	positive	control.	Furthermore,	we	aimed	
to	compare	skin	explant/bilayer	electrospun	scaffold	constructs	to	those	
cultured	on	monolayers	of	electrospun	scaffold.	There	were	no	significant	
differences	in	total	collagen	produced	per	gram	of	scaffold	when	two	layers	of	
electrospun	scaffold	were	used	when	comparing	templated	and	non-
templated	scaffolds	(Figure	6.12a).	However,	comparing	these	skin	
explant/bilayer	constructs	to	DED	tissue	engineered	skin	there	were	significant	
differences	in	collagen	produced	with	the	latter	being	significantly	more	at	7	
and	14	days	(Figure	6.12b)	(table	6).	Interestingly	at	day	21	although	in	
absolute	values	the	amount	of	collagen	produced	by	the	DED	constructs	were	
more,	there	were	not	significantly	different	from	templated	and	non-
templated	bilayer	constructs	respectively	(p=	0.1003;	p=	0.2288)		
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Furthermore,	although	skin	explants/	bilayer	constructs	had	more	collagen	
produced	per	gram	compared	to	those	constructs	containing	skin	explants	
alone	in	absolute	terms	this	was	only	significant	at	day	21	(table	15).		
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Figure	6.12:	Sirius	red	staining	after	7,	14,	and	21	days	comparing	a:	non-
templated	and	templated	scaffolds	used	to	create	a	sandwich	construct	with	
skin	explants	in	the	centre;	b:	skin	explants	on	scaffolds,	skin	explants	in	
between	2	layers	of	scaffolds	and	DED.	(N=3±SEM).	
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Construct	A	 Construct	B	 P	Value		
Non	templated	bilayer	
Day	7	
DED	Day	7	 0.0078	
	
Templated	bilayer	Day	7	 DED	Day	7	 0.0256	
	
Non	templated	bilayer	
day	14	
DED	Day	14	 0.0037	
	
Templated	bilayer	day	14	 DED	Day	14	 0.0051	
	
Non	templated	skin	
explants	D	21	
	
Non	Templated	bilayer	Day	
21	
0.0108	
	
Templated	skin	explants	
D21	
	
Non	Templated	bilayer	Day	
21	
0.0170	
	
Table	10:		illustrating	significant	P	values	comparing	various	constructs	from	
Sirius	Red	Staining	using	the	Unpaired	Student’s	T	test.		
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Section	Discussion	
This	experiment	aimed	to	optimize	the	migration	of	skin	cells	from	the	skin	
explants	onto	scaffolds	by	adding	another	layer	of	electrospun	scaffold	to	act	
as	a	dressing	on	top	of	the	skin	explants.	We	felt	this	was	an	easy,	reproducible	
technique	to	promote	retention	of	the	skin	explants	during	media	changes	and	
in	vitro	AlamarBlue	testing.	Furthermore,	placing	scaffolds	on	top	of	the	skin	
explants	would	not	limit	diffusion	of	nutrients	and	oxygen	from	media	as	it	is	
porous	and	facilitates	free	movement	of	these	molecules.		
This	idea	is	simply	mimicking	what	would	actually	happen	if	this	technique	
were	to	be	transferred	to	an	in	vivo	model.	Once	the	skin	explants	are	laid	onto	
the	scaffold,	there	would	be	a	requirement	for	some	dressing	or	material	to	
protect	it	during	the	course	of	the	experiments	from	shear	forces.	This	would	
be	the	case	even	if	fibrin	were	to	be	used.	Clinically	even	if	grafts	are	sutured	
or	glued	onto	a	wound	bed,	a	layered	compressive	dressing	is	placed	over	the	
graft.	This	serves	a	number	of	purposes.	Firstly,	it	reduces	the	amount	of	shear	
force	that	is	transmitted	to	the	graft	during	movement.	It	is	also	acts	to	absorb	
blood	and	tissue	fluid	from	the	wound	bed	to	prevent	it	from	accumulating	
between	it	and	the	graft,	which	would	prevent	direct	graft	to	wound	bed	
contact	and	thereby	graft	take.		The	results	have	indicated	overall	that	these	
constructs	were	viable,	and	had	more	proliferating	fibroblasts	producing	more	
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collagen	than	skin	explant/scaffold	constructs	without	the	additional	layer	of	
scaffold	on	the	top.		Although	there	was	not	a	lot	of	cellular	migration	onto	the	
scaffolds	at	the	start	of	the	experiments,	this	progressively	increased	to	day	
21.	This	suggests	that	given	time,	cells	contained	in	the	skin	explants	would	
migrate	out	onto	the	scaffold	and	populate	the	fibres.		
	
6.7	Chapter	Discussion	
	
The	aim	of	this	chapter	was	to	optimize	the	migration	of	skin	cells	from	the	cut	
edges	of	skin	explants	onto	the	electrospun	scaffolds.	Previous	chapters	have	
demonstrated	that	given	time,	cells	will	migrate	and	populate	the	scaffold,	
however	in	the	context	of	wound	healing	this	should	usually	occur	in	
approximately	two	weeks.	A	product	that	has	a	primary	aim	of	augmenting	
wound	healing	must	achieve	this	in	a	timely	fashion.	Skin	and	soft	tissue	cover	
of	a	wound	is	one	of	the	fundamental	aspects	of	plastic	surgery,	and	most	
techniques	revolve	around	trying	to	achieve	this	in	a	safe	and	effective	
manner.	It	significantly	improves	the	patient’s	quality	of	life,	as	having	to	
continuously	dress	a	wound	left	to	heal	by	secondary	intention	requires	time,	
expertise,	and	a	limitation	of	activities	of	daily	living.		In	reality,	wounds	left	
open	to	heal	by	secondary	intention	take	anywhere	from	6	weeks	to	3	months	
to	achieve	re-epithelization,	and	at	times	even	longer	depending	on	the	
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underlying	pathology	and	patient	factors.	Furthermore,	a	break	in	the	skin’s	
barrier	albeit	large	or	small	always	carries	the	risk	of	infection.	Therefore,	
although	culturing	skin	explants	on	electrospun	scaffolds	result	in	eventual	
cellular	migration,	we	are	observing	that	this	starts	most	definitively	from	the	
14-	21-day	mark.	Thereafter	the	cells	would	then	need	more	time	to	populate	
the	scaffold	and	start	proliferating	to	produce	an	extracellular	matrix.		
Therefore,	we	identified	areas	of	improvement	that	could	refine	our	technique	
of	using	skin	explants	combined	with	trilayer	templated	electrospun	scaffolds.		
The	first	being	our	construct	and	the	second	introducing	an	in	vitro	wound	
bed.		This	chapter	focused	on	modifications	of	our	technique	by	capturing	
some	aspects	of	clinical	practice.		
Fibrin	was	shown	to	be	an	appropriate	adhesive	for	the	skin	explants.	The	
structure	of	the	fibrin	clot	at	low	thrombin	concentrations	facilitates	cellular	
migration	and	movement	through	the	clot	structure	(Figure	6.13).	
Furthermore,	lower	concentrations	of	thrombin	allowed	for	some	
manipulation	of	skin	explants.	Although	Tisseel	is	a	commonly	used	product	in	
the	clinical	area	as	a	sealant	and	haemostat,	the	thrombin	concentration	
required	for	this	function	maybe	too	high	for	our	application	-although	over	
time,	cells	may	eventually	migrate,	the	aim	of	the	fibrin	application	is	to	
accelerate	this.		Nevertheless	there	are	other	commercially	available	FDA	
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approved	fibrin	products	that	can	be	used	for	this	purpose(224).	As	a	result,	
we	have	chosen	to	use	a	thrombin/fibrinogen	concentration	of	2.5/18.75mg	as	
our	fibrin	constituents	for	the	purpose	of	our	experiments	in	the	forthcoming	
chapters.		
	
	
Figure	6.13:	The	thrombin	concentration	present	at	the	time	of	gelation	
dictates	the	fibrin	clot	structure.	Scanning	electron	micrographs	of	fibrin	clots	
formed	by	adding	thrombin	(0.5–20	nM)	to	solutions	of	purified	fibrinogen	
(2	mg/mL).	The	scale	bars	indicate	10	μm	(top	row),	2	μm	(middle	row),	and	
1	μm	(bottom	row).	Reproduced	with	permission	from	Elsevier	(218).		
	
Furthermore,	we	were	able	to	demonstrate	that	skin	explants	with	less	dermis	
resulted	in	significantly	increased	cellular	migration	onto	the	scaffolds	
compared	to	those	with	more	dermis.	This	is	an	important	finding	as	we	are	
able	to	define	the	characteristics	of	the	skin	explants	that	are	required	for	the	
technique	to	have	the	best	chance	of	success.	Additionally,	clinically	skin	
explants	with	less	dermis	is	a	preferred	option	especially	in	patients	with	few	
donor	areas.		
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Dermis	retention	in	wounds	is	essential	for	wound	healing	and	donor	
regeneration.	Keratinocyte	stem	cells	live	in	the	bulge	area	of	the	hair	follicle,	
and	migrate	upwards	when	stimulated	to	form	basal	keratinocytes	and	
eventually	re-epithelization	the	skin.	These	hair	follicles	are	located	within	the	
reticular	dermis	and	ensuring	that	this	part	remains	on	the	patient	facilitates	
eventual	wound	healing	of	donor	sites(225).		
Finally,	we	were	able	to	demonstrate	that	adding	another	layer	of	electrospun	
scaffold	to	constructs	on	top	of	the	skin	explants,	does	not	inhibit	cellular	
migration	from	them.		This	is	an	important	finding,	as	any	skin	replacement	
technique,	apart	from	the	technical	aspects	of	its	application	will	need	an	
outline	as	to	how	it	is	to	be	dressed.	Dressings	form	an	integral	part	of	wound	
care	and	follows	a	specific	sequence.	In	simplistic	terms	the	first	layer	is	usually	
a	non-adherent	layer	that	does	not	disrupt	ay	developing	wound	islands	on	
removal	for	inspection,	the	second	layer	is	an	absorbent	layer	that	allows	
egress	of	exudate	and	the	last	aids	to	bind	the	first	two,	holding	it	in	place,		
	
	Our	work	has	shown	that	by	using	another	layer	of	electrospun	scaffold	in	the	
sandwich	technique	to	ensure	the	skin	explants	are	not	displaced	does	not	
result	in	inhibition	of	cellular	migration.	This	can	be	one	method	via	which	this	
technique	is	translated	clinically.		The	first	layer	of	electrospun	scaffold	will	
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form	part	of	the	new	dermis	and	integrate	with	the	underlying	wound	and	be	
populated	by	cells	from	the	skin	explants.	This	can	safely	be	protected	by	
another	layer	of	electrospun	scaffold	on	top	of	the	skin	explants.		This	top	layer	
of	electrospun	scaffold	is	advantageous	as	due	to	its	porosity	will	allow	wound	
exudate	to	be	released,	which	prevents	fluid	accumulation	and	build	up	which	
can	lead	to	failure	of	the	technique.	Furthermore,	this	top	layer	of	scaffold	can	
be	designed	using	fast	dissolving	PGLA	50:50	which	would	degrade	to	allow	
inspection	within	5-7	days	to	ensure	that	the	technique	has	been	successful	
and	as	a	result,	does	not	have	to	physically	be	removed	which	would	facilitate	
the	least	amount	of	disruption	to	the	underlying	wound.		
	
This	chapter	aimed	to	refine	our	technique	of	using	skin	explants	to	be	
combined	with	electrospun	scaffolds	as	a	one-step	approach	for	wound	
healing.	We	applied	some	clinical	principles	to	aid	this,	and	overall	have	
fulfilled	the	aim	of	retention	of	skin	explants	on	scaffolds.	However,	these	
experiments	have	all	illustrated	that	time	is	a	key	factor	in	the	migration	of	
cells	when	skin	explants	are	placed	on	electrospun	scaffolds.	The	in	vitro	model	
still	does	not	reflect	the	exact	surface	that	the	scaffolds	will	be	placed	on	in	
vivo.		
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Any	wound	bed,	be	it	full	thickness	where	all	of	the	dermis	is	damaged	or	
disrupted	or	partial	thickness	where	some	of	the	dermis	is	left	behind	will	have	
a	microenvironment	consisting	of	inflammatory	cells,	cytokines,	and	growth	
factors	that	will	facilitate	the	migration	and	proliferation	of	skin	cells.	These	
often	come	from	the	edges	of	the	wound	and	the	blood	that	is	present	on	the	
wound	bed,	even	if	it	is	a	full	thickness	defect.	This	explains	why	tissues	that	
are	well	vascularized	make	for	better	wound	beds	for	skin	substitutes	and	
grafts	e.g.	muscle	compared	to	those	that	are	not	e.g.	bone	without	
periosteum.	Despite	the	steps	that	we	have	taken	in	this	chapter	to	optimize	
our	construct,	the	skin	explants	are	still	not	in	the	environment	of	a	
vascularized	wound	bed.	As	a	result,	migration	and	proliferation	of	cells	takes	
too	long	a	time	than	would	be	clinically	acceptable	for	augmented	wound	
healing.		
	
The	following	chapter	aims	to	address	this	by	creating	an	in	vitro	wound	bed	in	
order	to	test	how	readily	cells	from	the	skin	explants	will	migrate	onto	
electrospun	scaffolds	in	an	environment	that	would	be	similar	more	to	that	of	
a	debrided	wound.		
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Chapter	7	
	
Investigating	the	contribution	of	
fibroblasts	in	the	scaffold	to	epithelial	
cell	outgrowth	from	skin	explants	
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7.1	Introduction	
	
Thus	far	we	have	outlined	the	process	undertaken	of	developing	a	tissue	
engineered	skin	substitute	consisting	of	a	templated	trilayer	dermal	scaffold	to	
be	cultured	with	skin	explants	as	a	cell	source.	Initial	experiments	
demonstrated	that	the	cells	will	migrate	from	the	cut	edges	of	the	skin	explant	
onto	the	fibres	of	the	electrospun	scaffold.	Following	this,	various	strategies	
were	outlined	to	optimize	the	migration	of	skin	cells	out	of	the	skin	explants	
onto	scaffold.	These	included	using	fibrin,	altering	the	dermal	thickness	of	the	
skin	explants	and	using	two	layers	of	the	electrospun	scaffold	with	the	explants	
in	the	middle.		
	
These	experiments	were	all	conducted	in	vitro,	and	it	was	felt	that	it	would	be	
appropriate	if	the	constructs	better	represented	an	in	vivo	wound	bed	model.	
The	dermis	has	a	central	role	to	play	in	wound	healing,	and	this	is	largely	due	
to	the	extra	cellular	matrix	(ECM)	and	the	resident	fibroblasts.	The	ECM	can	be	
thought	of	as	a	conglomeration	of	fibres	forming	molecules	which	provide	a	3D	
framework	of	rigid	proteins,	non-fibre	forming	molecules	which	creates	a	
charged	osmotically	active	space	and	matricellular	proteins	that	influence	cell	
interactions(226).		Collagen	accounts	for	77%	of	the	fibre	forming	molecules	in	
the	skin,	others	include	fibrin,	fibronectin,	vitronectin,	elastin	and	fibrillin(227).	
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The	main	non	fibre	forming	molecules	are	proteoglycans	and	GAGs,	the	most	
common	being	hyaluronon,	followed	by	decorin,	versican,	and	
dermatopontin(228).	The	matricellular	proteins	do	not	contribute	to	ECM	
structure	as	do	the	other	two,	but	are	critical	to	cell	signalling.	In	the	healing	
wound,	fibroblasts	produce	most	of	these	components,		and	in	turn	they	
influence	the	function	of	the	keratinocyte(229).		As	a	result,	this	autocrine-type	
interaction	between	the	fibroblast	and	the	ECM	can	be	viewed	as	a	crucial	
aspect	of	wound	healing.		
	
	
In	all	our	experiments	thus	far,	we	have	shown	that	the	trilayer	templated	
electrospun	scaffolds	will	support	the	migration	and	proliferation	of	epithelial	
cells.	We	have	established	a	technique	of	skin	explant	preparation,	laying	of	
skin	explants	onto	scaffolds	and	using	fibrin	as	an	adhesive	to	facilitate	the	
contact	of	the	skin	explants	with	the	scaffold.	Nevertheless,	the	skin	explants	
were	still	being	cultured	directly	onto	sterile	electrospun	scaffolds,	with	no	
external	or	surrounding	cell	signalling	proteins	to	stimulate	migration	and	
proliferation	of	cells,	the	importance	of	which	is	outlined	above.	It	was	felt	that	
this	did	not	mimic	the	in	vivo	micro-environment	of	a	dermal	wound,	as	the	
eventual	aim	would	be	to	use	this	technique	in	vivo,	on	a	clean,	prepared	
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wound	bed	which	would	contain	the	stimulus	to	propagate	epithelial	cell	
migration	and	proliferation.		
In	an	attempt	to	do	this,	we	therefore	opted	to	culture	the	electrospun	
scaffolds	for	48	hours	with	confluent	isolated	fibroblasts	to	allow	for	a	prior	
fibroblast	presence	and	release	of	the	appropriate	signalling	factors	on	the	
electrospun	scaffold.	This	aim	of	this	was	to	create	a	micro	environment	which	
better	represents	the	wound	bed	to	further	assess	the	performance	of	skin	
explants	as	a	cell	source	on	the	electrospun	scaffolds.		
Additionally	apart	from	the	crucial	role	in	wound	healing,	the	use	of	
precultured	dermal	scaffolds	with	isolated	fibroblasts	has	been	shown	to	be	
associated	with	the	formation	of	more	mature	collagen	bundles	in	the	
regenerating	wound(230).	The	practice	of	preculturing	fibroblasts	on	
electrospun	scaffolds	has	always	been	viewed	as	a	method	to	aid	optimisation	
of	tissue	engineered	bioproducts	for	skin	replacement.	There	are	different	
approaches	to	this	technique	from	culturing	both	sides	of	a	scaffold	with	
fibroblasts	and	keratinocytes(231)	to	culturing	fibroblasts	only	on	the	under	
surface	of	co-polymer	scaffolds	and	keratinocytes	at	the	top	(232).	In	this	
method,	we	propose	the	use	of	fibroblasts	to	simulate	the	wound	bed	
conditions	that	our	scaffolds	would	be	placed	on.	Even	if	a	wound	is	devoid	of	
dermis,	there	will	still	be	some	background	inflammatory	process,	which	will	
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act	as	a	stimulus	to	aid	the	integration	of	the	scaffolds.	Without	these	signals,	
it	is	very	challenging	to	judge	the	true	extent	of	cellular	migration	that	would	
occur	in	vitro.		These	experiments	aim	to	firstly	produce	a	more	accurate	
mimic	of	the	wound	bed	and	also	use	the	knowledge	from	the	previous	
chapters	to	optimise	the	cellular	migration	from	skin	explants	on	these	
electrospun	scaffolds.	As	outlined	previously,	the	use	of	isolated	cultured	cells	
is	fraught	with	challenges	in	the	clinical	setting	and	we	want	to	determine	if	a	
small	skin	explant,	readily	available	in	theatre	would	have	a	similar	effect	in	a	
similar	time	frame.	To	do	this,	we	isolated	human	dermal	fibroblasts	from	
donated	skin	as	outlined	in	the	methods.	Once	the	cells	were	confluent,	they	
were	then	seeded	onto	the	PGLA	(75:25)	surface	of	the	templated	trilayer	
electrospun	scaffolds.	These	were	kept	in	culture	for	48	hours	to	enable	to	the	
fibroblasts	to	adhere	to	the	scaffolds	and	start	proliferation.	Once	this	was	
complete,	the	minced	pieces	of	skin	explants	were	added	to	the	centre	of	the	
scaffold	with	fibrin	(at	a	thrombin	concentration	of	2.5	I.	U	and	fibrinogen	at	
18.75mg).		These	were	cultured	for	another	48	hours	before	raising	to	an	air	
liquid	interface.	Once	raised,	the	culture	media	was	changed	every	48	hours	
and	kept	for	a	total	of	14	days.	Interim	measurements	were	taken	at	day	7	for	
all	samples.	Quantitative	analysis	included	Alamar	blue	and	Sirus	red	for	
assessment	of	metabolic	activity	and	collagen	deposition.	Qualitative	analysis	
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included	confocal	immunohistochemistry	to	test	for	evidence	of	keratin	from	
proliferating	keratinocytes	combined	with	DAPI	to	illustrate	the	the	location	of	
the	cells	in	relation	to	the	keratin	deposited.	Furthermore,	we	used	
fluorescence	microscopy	to	obtain	images	of	the	constructs	after	incubating	
them	with	Ki67	which	is	a	marker	of	proliferation	to	assess	the	location	of	
these	cells	on	the	electrospun	scaffold.	The	aim	of	this	was	to	determine	the	
location	of	these	cells	that	were	actively	proliferating	and	determine	if	there	
was	tendency	to	occupy	the	niches	of	the	electrospun	scaffold	that	were	
templated	on	them	for	this	purpose.	Furthermore,	we	stained	the	constructs	
for	collagen	4,	as	another	assessment	to	visualize	the	location	of	the	collagen	
deposited	by	the	proliferating	fibroblasts.		
	
7.2	Use	of	AlamarBlue	assay		to	demonstrate	cell	outgrowth	from	explants	
 
Absorbances	for	skin	explants	combined	with	fibrin	and	those	without	fibrin	
seeded	on	fibroblast	impregnated	templated	electrospun	scaffolds	were	read	
and	the	absorbance	for	plain	scaffolds	were	subtracted	from	these	values	for	
each	time	checkpoint	of	day	0,7	and	14	(Figures	7.1	and	7.2).	Additionally,	we	
compared	the	metabolic	activity	of	these	constructs	to	templated	scaffolds	
cultured	with	explants	over	a	14-day	period	with	no	fibrin	or	pre	culture	with	
fibroblasts.	Furthermore,	as	a	positive	control	we	used	tissue	engineered	skin	
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(isolated	fibroblasts	and	keratinocytes	cultured	on	DED)	to	determine	the	
impact,	if	any	of	pre	culturing	fibroblasts	and	using	fibrin	made	to	the	outward	
migration	of	skin	cells	from	the	cut	edge	of	the	skin	explants.		
	
It	was	demonstrated	that	skin	explants	combined	with	fibrin	cultured	on	
fibroblast	impregnated	scaffolds	were	viable	throughout	the	14-day	testing	
period.		Cellular	metabolic	activity	in	constructs	precultured	with	fibroblasts	
and	fibrin	demonstrated	significantly	increased	metabolic	activity	compared	to	
using	co-culture	scaffolds	without	fibrin	and	when	the	explants	were	simply	
laid	onto	the	scaffolds	without	preculturing	them	with	fibroblasts.	
Furthermore,	it	was	also	noted	that	co-culture	of	scaffolds	with	fibrin	and	
explants	gave	a	significantly	increased	amount	of	cellular	metabolic	activity	
compared	to	using	DED	scaffolds	seeded	with	isolated	cells.	As	demonstrated	
in	earlier	chapters,	constructs	where	the	explants	were	simply	seeded	on	the	
plain	scaffolds	resulted	in	the	least	amount	of	metabolic	activity	as	
demonstrated	in	Figure	7.1.		
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	Figure	7.1	Metabolic	activities	of	skin	explants	combined	without	fibrin	
(orange	bars)	and	fibrin	(Purple	bars)	on	fibroblast	impregnated	scaffolds	
compared	to	skin	explants	cultured	on	plain	templated	electrospun	without	
fibrin	over	a14-day	experimental	period	as	determined	by	absorbance	of	
AlamarBlue	stain	(Mean±SEM).	
 
 
 
	
7.3	Use	of	Sirius	red	assay	to	assess	collagen	production		
	
At	day	7,	14	Sirius	red	assays	were	undertaken	to	estimate	the	total	collagen	
produced	overtime	by	the	co-culture/fibrin	constructs	compared	to	skin	
explants	seeded	on	plain	scaffolds.	The	aim	was	to	quantify	the	ability	of	the	
electrospun	scaffolds	to	support	cellular	function	using	collagen	production	by	
fibroblasts	as	a	marker.	The	absorbance	of	Sirus	red	is	plotted	in	Figure	7.3	
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minus	the	absorbance	of	plain	scaffolds.	Although	at	all	time	checkpoints,	the	
amount	of	collagen	produced	was	more,	this	was	not	statistically	significant	
(P=0.2)	because	of	the	considerable	variation	between	the	replicates.	
	
	
	
Figure	7.3:	Sirius	red	staining	after	14	days	comparing	a:	Skin	explants	cultured	
with	fibroblast	impregnated	electrospun	scaffolds	and	fibrin	(purple)	and	b	Skin	
explants	cultured	on	plain	scaffolds.	(N=3±SEM).	
	
	
7.4	Identification	of	keratinocyte	outgrowth	using	immunohistochemistry	for	
pancytokeratin	and	confocal	microscopy.		
	
At	the	end	of	the	14-day	culture	period,	constructs	containing	skin	explants	
seeded	with	fibrin	on	fibroblast	impregnated	scaffolds	were	stained	for	
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pancytokeratin	as	outlined	in	the	methods	above.	In	previous	experiments,	
H&E	stains	were	used	to	visualize	the	migration	of	the	epithelial	cells	along	the	
scaffold,	however	given	that	the	wound	bed	model	demonstrates	a	significant	
amount	of	cellular	migration	from	the	cut	edges	of	the	electrospun	scaffold,	it	
was	thought	that	further	cellular	characterisation	using	immunohistochemistry	
would	be	of	benefit.	The	aim	of	this	assessment	was	firstly	to	determine	if	the	
keratinocytes	were	proliferating	on	the	electrospun	scaffold	and	producing	
keratin,	which	is	the	main	protein	of	the	epidermis.	The	only	source	of	
keratinocytes	in	these	constructs	were	from	the	skin	explant	seeded	on	the	
scaffolds.	We	hypothesized	that	by	pre-culturing	fibroblasts	onto	the	scaffolds,	
this	would	aid	the	outward	migration	of	keratinocytes	from	the	skin	explants	
to	populate	the	scaffolds.	Simultaneously	we	stained	the	same	constructs	
using	DAPI	to	visualize	the	cellular	nuclei	around	the	areas	stained	with	
pancytokeratin.		
Confocal	imaging	was	chosen	as	the	templated	scaffolds	were	not	flat	2D	
structures,	but	had	an	undulating	pattern	in	the	middle	layer.	This	technique	
allowed	for	varying	depths	of	the	middle	layer	of	the	electrospun	scaffold	to	be	
imaged.		
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7.4.1	Assessment	of	cellular	migration	by	staining	nuclei	for	DAPI	and	
imaging	using	confocal	microscopy	
	
Figure	7.4	demonstrates	the	various	depths	that	the	cells	extend	to	in	the	
template	as	illustrated	by	the	blue	stained	nuclei.	Figure	7.4	B	demonstrates	
the	depth	in	detail,	which	illustrates	that	the	cells	penetrated	the	entirely	of	
the	scaffold.	Furthermore,	we	were	able	to	visualise	the	outward	migration	of	
cells	from	the	cut	edge	of	the	explants	(Figure	7.5)	which	provides	further	
evidence	of	the	outward	migration	of	cells	from	the	explant.		
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Figure	7.4	A:	Confocal	imaging	of	14	day	old	constructs	of	skin	explants	with	
fibrin	cultured	on	fibroblast	impregnated	templated	scaffolds	using	DAPI	which	
illustrates	from	left	to	right	the	presence	of	nucleated	cells	throughout	the	
thickness	of	the	scaffold,	left	being	the	most	superficial	aspect	and	the	far	most	
right	being	the	deepest	aspect.	B:	Magnified	view	of	Figure	A	illustrating	the	
vertical	penetrance	of	the	epithelial	cells	through	the	templated	scaffolds.		
	
 
 
	
A 
B 
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Figure	7.5	(A)	Confocal	imaging	of	14	day	old	constructs	of	skin	explants	with	
fibrin	cultured	on	fibroblast	impregnated	templated	scaffolds	using	DAPI	which	
illustrates	from	left	to	right	the	presence	of	nucleated	cells	throughout	the	
thickness	of	the	scaffold,	left	being	the	most	superficial	aspect	and	the	far	most	
right	being	the	deepest	aspect.	These	images	also	demonstrate	the	skin	explant	
(labelled)	and	the	cells	that	are	migrating	from	the	edge	(B).	
	
	
A 
Skin	explant	
on	corner	of	
scaffold	 
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7.4.2	Pancytokeratin	Staining	combined	with	Confocal	Imaging		
The	above	constructs	were	stained	using	pancytokeratin	and	imaged	to	
confirm	the	deposition	of	keratin	in	areas	just	adjacent	to	the	implant,	which	is	
an	indicator	of	keratinocyte	migration	and	proliferation.	This	was	an	important	
stain	as	it	proves	that	keratinocytes,	the	cells	that	make	up	the	epidermis	will	
proliferate	on	the	templated	trilayer	electrospun	scaffold.	Figure	7.6	illustrates	
that	the	area	just	adjacent	to	the	skin	explants	contained	cells	that	have	
migrated	onto	the	electrospun	scaffold	that	overlap	the	areas	stained	for	the	
pancytokeratin	(green).	It	also	demonstrates	that	keratinocytes	proliferated	
the	depth	of	the	scaffold	which	increased	its	surface	area.	Figure	7.6	C	
illustrates	this	more	closely,	which	further	confirms	that	the	cells	are	producing	
pancytokeratin,	just	beyond	the	explant.		
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Legend	
1. Green	areas	of	pancytokeratin	staining	adjacent	to	the	explant	
2. Skin	explant	stained	green	with	pancytokeratin	
3. Blue	areas	of	DAPI	staining	of	cellular	nuclei	adjacent	to	the	explant	
4. Skin	explant	stained	Blue	with	DAPI		
 
	
Figure	7.6	14	day	cultured	samples	with	skin	explants	combined	with	fibrin	on	
scaffolds	cultured	with	fibroblast	impregnated	trilayer	electrospun	scaffolds	
stained	for	pancytokeratin	and	imaged	using	the	confocal	microscope.	A	shows	
the	stain	distribution	throughout	the	depths	of	the	trilayer	scaffold,	B	shows	
area	of	cellular	staining	and	migration	just	adjacent	to	the	skin	explant.	Scale	
bar	=	200µm.	
2 
1 3 
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7.5	Scanning	Electron	Microscopy		
	
These	images	were	taken	for	fixed	samples	at	day	14	of	the	pre-cultured	
scaffolds	with	fibroblasts	/fibrin	/skin	explant	constructs.	The	images	clearly	
show	the	skin	explant	on	the	templated	scaffold	(Figure	7.7A).	On	further	
magnification	(Figure	7.7B)	the	fibrin	strands	randomly	orientated	on	the	
surface	of	the	scaffold	is	seen,	together	with	adjacent	areas	of	deposition	of	
products	of	cellular	migration	and	proliferation	from	cells	just	adjacent	to	the	
skin	explant	on	the	scaffold.	This	provides	further	evidence	that	the	cells	are	
not	only	able	to	leave	the	explants	and	migrate	along	the	fibres	of	the	scaffold	
but	also	proliferate	and	manufacture	essential	proteins	like	keratin	and	
collagen,	which	are	the	key	materials	that	make	up	the	epidermis	and	dermis	
respectively.		
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Figure	7.7	A	SEM	image	of	skin	explant	with	fibrin	on	precultured	scaffolds	with	
fibroblasts	illustrating	the	edge	of	the	explant	on	the	templated	scaffolds.	
Figure	7.7	B	shows	higher	magnification	of	an	area	just	adjacent	to	the	skin	
explant	containing	fibrin	stands	and	extracellular	matrix	material	deposited	by	
the	proliferating	fibroblasts.		
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7.6	Immunohistochemistry	for	Collagen	IV	and	Ki67	using	Epifluroscent	
microscopy.		
	
The	aim	of	these	experiments	was	to	observe	the	deposition	of	collagen	on	the	
electrospun	scaffold	as	another	method	to	prove	that	fibroblasts	were	able	to	
migrate	and	proliferate	along	the	fibres	of	the	scaffold.	For	these	experiments	
we	seeded	isolated	cells	on	either	side	of	the	trilayer	templated	PGLA	(75:25)	
and	PHBV	scaffolds	and	kept	the	constructs	in	culture	at	an	air	liquid	interface	
for	14	days.	In	addition	to	this	we	also	assessed	the	scaffolds	that	were	
cultured	with	isolated	fibroblasts	for	48	hours	prior	to	application	of	skin	
explants	cultured	for	the	same	two-week	period	at	an	ALI.	At	the	end	of	the	
culture	period	samples	were	fixed	in	3.7%	formaldehyde	and	cryopreserved.	7	
μm	slices	were	glass	mounted	and	stained	with	collagen	IV	(details	outlined	in	
methods).	After	24	hours’	samples	were	stained	with	DAPI	to	visualize	adjacent	
cell	nuclei	and	then	rehydrated.	For	collagen	IV,	2D	images	were	obtained	
using	an	Olympus	IX73	Epifluroscent	Microscope	using	the	following	excitation	
and	emission	wavelengths:		
• DAPI:	λex	385	nm/λem	461	nm.	
• TRITC:	λex	545/25	nm/λem	605/70	nm.	
• FITC:	λex	488	nm/λem	519	nm.	
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Our	images	revealed	firstly	that	collagen	was	present	on	the	fibres	of	the	
electrospun	scaffold	when	stained	with	collagen	IV.	DAPI	staining	showed	the	
concurrent	nuclei	of	fibroblasts	along	the	collagen	stained	electrospun	scaffold	
fibres.	The	trilayer	constructs	were	not	visible	in	these	images	as	the	process	
and	solvents	of	cryofixation	and	sectioning,	damaged	some	of	the	inherent	
trilayer	structure.	Nevertheless,	we	were	able	to	visualize	areas	of	collagen	
deposition	along	the	scaffold,	where	the	fibroblasts	were	seeded	(Figure	7.8)	
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Figure	7.8	Collagen	immunohistochemistry	of	templated	electrospun	scaffold	
illustrating	collagen	deposition	along	the	top	and	middle	layers	of	the	
electrospun	scaffolds.	Scale	bar	x	0.2mm	(x100). 	
	
Furthermore,	we	wanted	to	assess	the	effect	if	any,	of	changing	the	
topography	of	the	scaffold,	whether	going	from	being	straight	to	undulating	
had	on	the	organization	and	distribution	of	cells.	Specifically,	we	wanted	to	
assess	its	effect	on	the	proliferating	cells,	as	the	design	intended	to	stimulate	
the	rete	ridges,	which	is	one	of	the	areas	that	cells	with	proliferative	capacity	
in	the	skin	tend	to	occupy	in	vitro.	To	do	this,	we	cultured	isolated	fibroblasts	
and	keratinocytes	on	either	side	of	the	templated	trilayer	scaffold	as	above	
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and	performed	immunohistochemical	staining	using	Ki67	of	formalin	fixed	7μm	
sections	followed	by	imaging	using	the	Epifluroscent	microscope	as	described	
earlier.	Ki67	is	a	nuclear	protein	that	is	expressed	in	the	cell	throughout	the	
various	stages	of	the	cell	cycle	but	is	maximally	expressed	during	the	G2	or	
mitotic	phase(233).	It	is	often	used	as	a	marker	of	cellular	proliferation	as	it	is	
not	detected	in	G0	cells,	but	increases	from	G1	through	mitosis(233).	As	a	
result,	the	Ki-67	antibodies	were	deemed	to	be	useful	in	identifying	and	
imaging	the	location	of	the	maximally	proliferating	cells	in	our	constructs.	DAPI	
was	also	used	to	visualize	cellular	generally	to	obtain	a	composite	picture	of	
cellular	location.	The	figures	indicate	that	proliferating	cells	were	seen	in	our	
samples	and	tended	to	be	found	in	the	troughs	of	the	template.	Other	cells	
were	seen	scattered	throughout	the	scaffold	(Figure	7.9).		
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Figure	7.9	Ki67	immunohistochemistry	staining	showing	proliferating	cells	
clustering	along	the	trough	of	the	niche,	illustrating	the	potential	benefit	of	
templating	the	electrospun	scaffolds.	Scale	bar	0.2mm	(x100).	
	
7.7	Discussion		
	
This	chapter	aimed	to	combine	the	steps	outlined	in	previous	chapters	to	
optimise	the	migration	of	cells	from	skin	explants	onto	the	electrospun	
scaffolds	in	the	context	of	a	wound	bed	model.	To	create	this	wound	bed	in	
the	in	vivo	setting,	we	seeded	fibroblasts,	the	main	cell	of	the	dermis,	with	the	
aim	of	releasing	signals	to	chemo	attract	cells	out	the	skin	explants	and	onto	
the	electrospun	scaffolds	for	48	hours	prior	to	application	of	skin	explants	and	
fibrin	glue.	These	were	then	cultured	for	a	further	14	days	at	ALI.	These	
experiments	were	essentially	the	final	checkpoint,	to	test	the	validity	of	the	
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technique	before	it	can	be	progress	to	being	tested	in	animal	models.	
Quantitative	analysis	using	Alamar	blue	and	Sirius	red,	revealed	that	these	
wound	bed	models	had	a	significantly	greater	amount	of	metabolic	activity	and	
collagen	deposition	versus	culturing	the	skin	explants	onto	plain	electrospun	
scaffolds.	This	effect	is	to	be	expected	as	per	unit	of	scaffold,	there	are	more	
cells	and	moreover	the	ones	that	result	in	collagen	formation	and	can	be	
argued	that	it	is	not	coming	from	the	skin	cells	that	have	migrated	out	the	skin	
explants.	However,	this	model	is	the	closest	in	vitro	prototype	that	will	be	
translated	into	in	vivo	studies	and	represents	the	situation	that	will	occur	once	
these	electrospun	scaffolds	are	placed	onto	an	active	wound	bed.		
Imaging	the	constructs	using	confocal	imaging	and	immunohistochemistry	
using	DAPI,	pancytokeratin	allowed	us	to	observe	the	anatomy	of	the	scaffolds	
seeded	with	fibroblasts	and	skin	explants	to	a	much	greater	detail	than	H&E	
staining	confirmed	two	important	technical	points	that	H&E	were	not	able	to	
provide	as	the	process	of	H&E	can	be	quite	destructive	to	scaffolds	and	do	not	
always	illustrate	clearly	the	relationship	between	the	fibres	and	cellular	
migration.	Firstly,	it	shows	that	the	cells	populate	the	scaffold	throughout	its	
depth	and	not	just	along	the	surface	onto	which	it	is	placed.	Additionally,	it	
proves	that	there	are	cells	that	migrate	from	the	skin	explants	and	some	of	
these	were	keratinocytes.	This	is	an	important	fact	as	the	skin	explants	in	these	
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models	were	the	only	source	of	keratinocytes	considering	the	scaffolds	were	
pre	seeded	with	fibroblasts.	This	provides	further	evidence	that	skin	explants	
can	be	used	as	a	cell	source	to	populate	the	scaffolds.		
The	SEM	images,	provide	similar	information	however	it	allowed	us	to	observe	
the	strands	of	collagen	and	extracellular	matrix	produced	by	proliferating	
fibroblasts.	It	is	unknown	whether	this	is	from	fibroblasts	that	were	used	to	
pre-seed	the	scaffolds	or	from	those	that	migrated	from	the	skin	explants	
either	way,	the	edges	of	a	full	thickness	wound	bed	will	have	a	population	of	
fibroblasts	that	will	migrate	into	the	wound	to	have	a	similar	effect	as	our	
model.		
Collagen	immunohistochemistry	using	the	Epifluroscent	microscope	revealed	
that	collagen	was	not	only	deposited	on	the	top	layer	but	also	on	top	of	the	
middle	layer	of	the	electrospun	scaffold.	This	is	an	important	finding	as	
although	it	is	expected	that	fibroblasts	will	populate	the	scaffold	to	form	the	
neodermis,	the	middle	layer	is	intended	to	mimic	the	basement	membrane.		
Skin	conforms	to	a	3d	macrostructure,	with	defined	layers	that	work	
synergistically	to	allow	the	skin	to	function	as	an	organ.	Yet	most	tissue	
engineered	substitutes	are	2D,	flat	sheets	of	scaffold.	The	basement	
membrane	is	an	important	part	of	the	skin;	it	aids	secure	attachment	of	the	
overlying	epidermis	containing	keratinocytes.	Another	important	feature	of	a	
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basement	membrane	is	that	it	resists	cellular	movement	across	it,	to	allow	for	
organisation	into	an	epidermis	and	a	dermis.	The	basement	membrane	is	
made	from	specialized	extracellular	matrix	which	facilitates	these	roles(4).	
Furthermore	morphological	studies	have	revealed	that	the	basement	
membrane	is	predominantly	collagen	IV	in	humans(234).		In	our	constructs	the	
central	layer	that	aims	to	mimic	the	basement	membrane	was	made	from	
nano-porous	/nano	fibrous	PHBV	interwoven	with	micro-porous	poly	L-lactic	
acid	microfibers	on	either	side	to	avoid	separation	of	the	polymers	once	
cultured	in	media.	Previous	H&E	images	(chapter	4,	Figure	5.4B)	revealed	that	
this	layer	is	impermeable	to	cells,	which	is	an	essential	feature	of	the	basement	
membrane.	Therefore,	to	summarize	thus	far,	we	have	created	an	
impermeable	basement	membrane,	which	will	allow	for	a	distinct	epidermis	
and	dermis.		
In	addition	to	having	this	definable	structure,	we	wanted	to	incorporate	its	3D	
topography	in	the	form	of	rete	ridges	which	are	the	peaks	and	troughs	that	are	
present	within	it	(Figure	1.2	Introduction).		
This	topography	not	only	aids	epidermal	and	dermal	attachment	on	either	side	
but	also	creates	to	a	unique	microenvironment	to	house	proliferative	cells.	
These	cells	predominately	tend	to	occupy	the	troughs	of	the	rete	ridges(13).	
The	ability	to	maintain	the	proliferative	capacity	of	skin	must	be	considered	
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when	designing	any	material	that	aims	to	be	its	replacement,	which	is	the	
intended	aim	of	this	model.	Ki67	immunohistochemistry	revealed	that	there	
were	indeed	proliferative	cells	that	occupied	the	troughs	of	our	template	
scaffolds.	The	limiting	feature	here	is	that	it	is	not	clear	which	cell	source	this	is	
i.e.	epidermal	or	dermal.	However,	we	have	established	a	technique	by	
electrospinning	which	not	only	allows	a	trilayer	scaffold	to	maintain	its	
structure	throughout	our	experiments,	but	also	offers	a	niche	for	proliferative	
cells	that	migrate	from	the	skin	explants	onto	the	scaffolds.	This	is	in	the	long	
term	we	believe	is	advantageous	for	the	long	term	aim	of	this	technique,	as	a	
facilitator	for	skin	regeneration,	whereby	the	electrospun	scaffold	integrates	
with	the	underlying	wound	bed	and	it	is	populated	by	cells	migrating	from	the	
skin	explants.	These	proliferating	cells	will	produce	the	ultrastructure	of	a	new	
dermis	by	laying	collagen	and	extracellular	matrix	and	an	epidermis	by	way	of	
keratinocyte	proliferation.	Over	time,	the	polymer	will	hydrolyse	leaving	
behind	the	patient’s	new	skin.	This	is	the	fundamental	principle	of	tissue	
engineered	dermal	substitutes	which	contrasts	current	clinical	products	that	
are	in	use.	The	dermal	scaffolds	are	all	made	of	polymers	eg	bovine	collagen	in	
Integra,	with	no	intention	to	degrade	and	facilitate	regeneration	of	the	
patient’s	own	skin.	Although	this	is	acceptable	and	has	been	in	use	for	many	
years,	the	technology	has	been	refined	from	advances	in	biomaterial	sciences	
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to	manipulate	synthetic	polymers	to	facilitate	process,	which	in	the	future	will	
be	generation	next	of	skin	replacement.		
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Chapter	8	
	
Conclusions	and	Future	Directions	
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8.1	Current	clinical	problem	
	
The	management	of	large	areas	of	full	thickness	skin	loss	is	still	a	
reconstructive	challenge.	Skin	replacement	has	evolved	with	research,	
improved	technology	and	most	importantly	a	better	understanding	of	wound	
healing.	There	are	many	variations	on	the	use	of	autograft	harvest	and	
application	and	the	use	of	cadaveric	allograft	has	been	commonly	used	over	
the	years.	However,	as	assessment	of	clinical	outcomes	evolve	and	the	
definition	of	a	good	outcome	following	skin	reconstruction	changes	from	
simple	survival	to	functional,	a	questioning	approach	to	traditional	techniques	
has	led	to	the	development	of	biomaterials	and	tissue	engineered	biomaterials	
for	skin	replacement.	Globally,	burn	injuries	are	the	4th	most	common	cause	of	
trauma	accounting	for	over	300,000	deaths	each	year(235).	Unfortunately,	low	
and	middle	income	counties	bear	95%	of	this	burden	and	access	to	burn	
treatment	and	follow	up	care	is	limited	by	the	high	cost	of	care	and	adequate	
health	care	infrastructure(236).		
Discussing	the	use	of	allograft	cadaveric	skin	is	interesting	in	that	it	provides	an	
immediate	barrier	to	microorganisms	and	prevents	evaporative	losses.	It	can	
be	used	as	an	immediate	temporary	dressing	or	it	can	be	used	such	that	the	
cadaveric	donor	dermis	remains	in	place	providing	a	decent	wound	bed	over	
which	to	graft	split	thickness	autograft	or	laboratory	expanded	keratinocytes	
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can	be	applied(78).	In	practice	what	has	limited	its	use	in	the	UK	at	the	time	of	
writing	is	its	availability.	Any	human	tissue	gives	the	risk	of	viral	disease	
transmission,	tissue	banking	practices	are	established	to	mitigate	this	risk	by	
doing	extensive	screening	of	blood	samples	from	donors,	including	lifestyle	
questionnaires	and	storage	of	tissue	prior	to	its	release.	
In	Holland,	the	Dutch	Burn	Centres	have	collaborated	to	establish	a	skin	bank	
which	provides	screened	donor	allograft	known	as	Euroskin	to	burn	centres	
throughout	Holland	and	even	to	the	UK	when	requested.	The	NHS	blood	and	
tissues	organisation	which	is	tasked	with	providing	cadaveric	skin	to	burn	
centres	in	the	UK	has	not	achieved	a	similarly	reliable	supply	of	cadaveric	skin	
for	UK	burns	centres.		
The	use	of	donor	skin	in	theory	provides	a	simple	to	use,	cost-effective	
dressing	to	manage	major	burn	patients.	Unfortunately,	in	many	countries	
where	it	could	benefit	burns	patients	there	are	cultural	and	religious	
objections	to	the	use	of	human	skin.		Furthermore,	the	infrastructure	of	tissue	
banks	to	provide	low	risk	donor	skin	has	simply	not	been	organised.	This	is	an	
example	of	a	product	which	works	clinically	(and	has	been	the	basis	of	many	
published	studies	demonstrating	its	clinical	usefulness)	but	availability	dictates	
whether	it	is	actually	used	by	surgeons.	Alternative	approaches	to	using	
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cadaveric	skin	have	led	to	the	development	of	sophisticated	biological	
biomaterials	such	as	Integra	and	Matriderm.			
A	long	term	solution	could	potentially	lie	in	the	field	of	synthetic	biomaterials;	
free	of	animal	and	human	products,	that	are	long	lasting,	off	the	shelf	and	
readily	available	for	use	in	these	settings.	Most	importantly,	they	need	to	be	
affordable.	Currently	used	skin	substitutes	in	the	United	Kingdom	eg	Integra	
and	Matriderm	do	not	fulfil	these	criteria.	Integra	has	been	used	in	the	
treatment	of	acute	and	chronic	burn	wounds	since	the	1980s.	It	is	composed	of	
bovine	collagen	to	which	a	silicon	sheet	is	bonded	to	provide	a	temporary	
barrier	layer	(3).	Many	studies	have	shown	excellent	clinical	results	using	
Integra.	Its	routine	use	is	challenged	by	the	cost	per	sheet,	and	the	risk	of	
infection.	Many	surgeons	have	noted	that	unless	there	is	meticulous	wound	
bed	preparation,	the	anaerobic	environment	provided	by	the	silicon	barrier	
seems	to	facilitate	rapid	development	of	pseudomonas	bacteria.	In	practice	
considerable	care	must	be	taken	to	prepare	and	clean	the	wound	bed	prior	to	
its	application.	Despite	being	commercially	available	as	an	off-the-shelf	
product	it	is	not	economically	viable	in	the	current	NHS	and	in	many	
developing	countries,	where	large	burns	are	still	prevalent.	This	highlights	the	
need	to	further	evolve	our	concept	of	biomaterials,	as	the	answer	to	a	lot	of	
these	issues	may	lie	with	designing	materials	which	are	inherently	not	
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expensive	and	can	be	made	readily	available	and	which	are	relatively	
straightforward	to	use	in	theatre.	
Of	necessity	this	means	that	any	project	that	requires	cultured	live	cells	is	
inherently	more	difficult	to	plan,	organise	and	fund	irrespective	of	whether	
cell-based	products	are	clinically	effective.		The	production	of	tissue	
engineered	skin	is	arguably	the	oldest	and	best	established	of	all	tissue	
engineered	products.	Early	examples	of	laboratory	expanded	keratinocytes	
being	used	to	provide	barrier	cover	for	badly	burned	patients	dates	back	to	the	
early	1980s.	
A	search	of	the	published	literature	will	reveal	a	wealth	of	studies	in	which	
laboratory	expanded	cells	have	been	used	to	give	benefit	to	patients.	For	
example,	CEA	provided	the	first	tissue	engineered	approach	to	skin	
replacement.	A	great	deal	has	been	learnt	in	developing	and	evaluating	these	
techniques.	However,	at	the	time	of	writing	it	is	clear	that	issues	of	availability	
and	ease	of	use	and	cost	ultimately	determine	which	published	clinically	
effective	methodologies	survive	the	test	of	time.	
In	this	study	we	sought	to	combine	thin	split	thickness	skin	grafts,	cut	into	
many	small	pieces	with	a	synthetic	dermal	substitute	which	could	be	used	in	a	
one-step	approach	in	theatre	to	regenerate	split	thickness	skin	in	an	approach	
that	did	not	require	cell	isolation	or	expansion	using	the	patient’s	own	cells.	
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Skin	explants	have	been	used	clinically	in	the	form	of	Meek	Grafting	and	as	
part	of	traditional	fibroblast	culture	using	the	principle	that	epithelial	cells	will	
migrate	from	the	cut	edges	of	the	tissue.		
A	similar	approach	was	developed	from	the	MacNeil	laboratory	in	the	
treatment	of	scarred	corneas	which	have	occurred	as	the	result	of	limbal	stem	
cell	deficiency.	The	approach	which	has	been	used	for	the	past	17	years	has	
been	to	take	a	small	biopsy	of	tissue	from	the	unaffected	limbus	in	the	
contralateral	eye,	expand	cells	under	cleanroom	conditions	and	graft	it	onto	
the	scarred	eye.		A	major	simplification	of	this	technique	now	only	requires	a	
biopsy	of	limbal	tissue	harvested	from	the	contralateral	healthy	eye,	minced	
into	several	tiny	pieces	and	then	spread	onto	amniotic	membrane	(scaffold).	
Using	fibrin	glue	to	hold	the	pieces	in	place,	this	was	grafted	onto	surgically	
prepared	corneas	in	a	single	theatre	session	(7).	Within	a	few	weeks	epithelial	
cells	are	noted	to	have	grown	out	from	the	explants	to	form	a	stable	cornea	in	
situ.	This	simplification	has	meant	that	many	more	ophthalmic	surgeons	can	
offer	it	to	patients.		This	study	highlights	that	for	small	areas	of	tissue	
reconstruction	it	is	possible	to	combine	tissue	biopsies	to	regenerate	new	
epithelium	in	situ.	This	is	what	we	are	aiming	to	achieve	for	skin	epithelium	
regeneration.		
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Against	this	background	this	research	seeks	to	combine	very	thin	split	
thickness	skin	harvested	in	theatre	with	an	off-the-shelf	electrospun	
biodegradable	membrane	which	can	help	promote	rapid	regeneration	of	split	
thickness	skin.	The	design	for	this	membrane	is	that	it	would	have	inherent	3D	
features	within	them	to	mimic	aspects	of	the	basement	membrane	and	rete	
ridges.	Scaffolds	were	also	designed	to	degrade	within	2-3	months	leaving	
new,	viable	tissue	in	place.		
	 As	part	of	this	also	we	want	to	assess	the	role	of	fibrin	as	a	biological	
stimulator	of	the	migration	of	skin	cells	from	the	explants	onto	the	scaffolds	as	
was	found	to	occur	with	the	migration	of	corneal	epithelial	cells	from	limbal	
tissue	explants	for	corneal	regeneration	(8).	Fibrin	is	an	important	blood	
component	responsible	for	haemostasis	and	is	often	used	surgically	as	tissue	
glue.	It	can	be	prepared	from	autologous	plasma	and	is	also	available	as	an	
approved	product	for	surgical	use.		
												Thus	we	aimed	to	have	a	similar	model	for	skin.	Clinically	this	would	translate	
as	follows:	a	small	biopsy	of	the	patient’s	skin	would	be	taken	and	minced	into	
very	fine	explants.	This	would	then	be	combined	with	the	electrospun	scaffold	
and	placed	onto	the	surgically	prepared	wound	bed	in	combination	with	fibrin.		
It	is	expected	that	fibroblasts	and	keratinocytes	will	migrate	along	the	fibres	of	
the	scaffold	without	the	need	for	culturing	cells	in	the	laboratory	and	further	
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procedures	in	theatre.	The	commercial	success	of	tissue-engineered	products	
depends	on	their	ease	of	use	and	their	availability	as	well	as	their	costs	for	
widespread	uptake.	The	approach	we	have	described	could	become	a	key	
addition	to	the	plastic	surgeon’s	armamentarium	in	treating	full-thickness	skin	
defects	to	improve	manage	patients	with	extensive	burns	to	achieve	rapid	skin	
cover.	
	
The	work	to	achieve	this	was	described	using	4	experimental	hypotheses	which	
translated	into	four	experimental	objectives	as	listed	beneath		
The	hypotheses	to	be	tested	were:	
1. Culturing	skin	pieces	on	a	trilayer	scaffold	consisting	of	micro/nano	fibres	
will	lead	to	better	epithelial-stromal	organization	than	would	be	achieved	
on	a	scaffold	consisting	of	microfibers	alone		
2. Inclusion	of	features	that	approximate	the	dimensions	of	the	rete	ridges	
will	help	in	the	outgrowth	of	epithelial	cells	into	the	electrospun	scaffolds.	
3. The	inclusion	of	fibrin	as	tissue	glue	will	act	as	a	stimulant	for	epithelial	
outgrowth	into	these	synthetic	scaffolds.		
4. The	 presence	 of	 fibroblasts	 precultured	 in	 synthetic	 scaffolds	 help	
stimulate	the	outgrowth	of	epithelial	cells	from	skin	explants		
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Following	on	from	these	the	experimental	objectives	were:		
	
1. Evaluation	of	how	a	novel	method	for	spinning	a	basement	membrane	
substitute	can	encourage	epithelial-stromal	organisation.		
2. Investigation	of	whether	the	inclusion	of	features	that	approximate	the	
dimensions	of	rete	ridges	will	help	in	the	outgrowth	of	epithelial	cells	into	
epithelial	cells	into	the	electrospun	scaffolds.	
3. Assessment	of	whether	the	inclusion	of	fibrin	as	tissue	glue	will	act	as	a	
stimulant	for	epithelial	outgrowth	into	these	synthetic	scaffolds.	
4. Evaluation	of	whether	 inclusion	of	 fibroblasts	 in	 the	 templated	 trilayer	
PGLA	 75:25	 /	 PHBV	 electrospun	 scaffolds	 will	 promote	 epithelial	 cell	
outgrowth	in	the	presence	and	absence	of	fibrin.	
This	chapter	now	summarises	to	what	extent	the	objectives	and	were	achieved	
and	the	hypothesis	supported	or	not.	
8.2	Objective	1:	The	use	of	trilayer	micro/nano	electrospun	scaffolds	to	
better	encourage	epithelial-stromal	organisation	vs	microfibers	alone.		
	
We	aimed	to	create	a	novel	method	of	spinning	a	basement	membrane	
substitute	to	see	if	this	would	promote	epithelial	stromal	organization	into	
definable	layers	of	the	skin	compared	to	when	using	microfibers	alone.	To	do	
this	we	spun	trilayer	electrospun	scaffolds,	made	using	a	combination	of	PGLA	
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75:25	(microfibrous	and	microporous)	and	PHBV	(nanofibrous	and	
nanoporous).	The	trilayer	were	shown	to	be	easy	to	handle	with	similar	
mechanical	properties	to	human	skin.	We	chose	these	polymers	based	on	
previous	work	from	the	MacNeil	laboratory	whereby	PGLA	75:25	was	shown	to	
degrade	in	a	time	period	that	matched	the	properties	of	a	healing	wound(124).	
PHBV	was	chosen	for	its	nanoporous/	nanofibrous	properties	and	ease	of	
integration	with	PGLA	75:25,	such	that	it	made	a	good	basement	membrane	
substitute	without	delaminating	from	the	PGLA	75:25	during	experiments.	
Monolayer	scaffolds	of	PGLA	75:25	supported	cellular	migration,	however	the	
fragility	of	the	scaffolds	made	for	difficult	handling	and	the	mechanical	
properties	were	not	as	close	to	skin	as	much	as	the	trilayer	scaffolds.	We	were	
able	to	achieve	definable	layers	in	the	trilayer	scaffold	which	resulted	in	a	top	
layer	of	keratinocytes,	a	middle	layer	devoid	of	cells	and	an	underside	layer	
consisting	of	fibroblasts.	In	conclusion	this	experimental	objective	was	partially	
met	as	although	the	handling	properties	of	trilayer	scaffolds	were	superior	to	
the	monolayers	there	was	more	cellular	activity	and	proliferation	in	the	
monolayer	constructs.		
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8.3	Objective	2:	The	inclusion	of	features	approximating	to	rete	ridges	to	
create	stem	cell	niches	will	aid	in	the	outgrowth	of	epithelial	cells	onto	
scaffolds	
	
The	aim	of	this	was	to	template	the	PHBV	layer	with	a	honeycomb	like	pattern	
to	even	further	mimic	the	natural	topography	of	the	epidermal-dermal	
interface	which	is	undulating	in	nature	known	as	the	rete	ridges.	These	areas	
form	microenvironments	or	stem	cell	niches	which	act	to	house	the	cells	that	
are	key	in	skin	regeneration.	We	were	able	to	use	metal	templates	to	
successfully	create	these	undulating	patterns	that	were	maintained	
throughout	the	experiments	however	in	comparison	with	non-templated	
trilayer	scaffolds	were	no	significant	differences	in	cellular	activity	and	collagen	
production	when	skin	cells	and	explants	were	cultured	onto	the	scaffolds	for	
comparison.	Although	there	was	some	evidence	that	these	ridges	housed	cells	
of	a	higher	proliferative	capacity	on	Ki67	staining	the	exact	origin	of	these	cells	
was	not	clear.		
Thus	in	summary	we	are	uncertain	regarding	the	value	of	the	templates	in	our	
model	in	terms	of	benefit	but	they	certainly	did	not	hinder	the	migration	of	
isolated	cells	or	those	from	skin	explants	throughout	the	scaffold.		
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8.4	Objective	3:	The	use	of	fibrin	glue	as	an	adjunct	to	stimulate	the	
outgrowth	of	skin	cells	from	skin	explants	onto	scaffolds.		
	
Our	initial	experiments	revealed	that	the	trilayer	electrospun	scaffolds	were	
able	to	support	the	migration	and	proliferation	of	isolated	keratinocytes	and	
fibroblasts.	However,	when	skin	explants	were	used	as	a	cell	source,	they	did	
not	proliferate	to	the	same	extent	in	the	given	time	period	as	those	of	isolated	
cells.	Given	that	one	of	the	aims	of	this	research	was	to	use	skin	explants	as	a	
cell	source	we	wanted	to	achieve	a	similar	rate	migration	to	that	of	seeding	
isolated	cells	onto	scaffolds.	To	do	this	we	postulated	that	continuous	contact	
of	the	skin	explants	with	the	fibres	of	the	scaffold	is	essential,	which	was	
difficult	to	achieve	using	in	vitro	conditions	with	cell	culture	media	
continuously	displacing	the	explants.		
As	a	result,	we	hypothesised	the	use	of	fibrin	glue,	a	biological	adhesive	would	
work	not	only	to	allow	adherence	of	the	skin	explants	onto	the	scaffolds	but	be	
porous	enough	to	allow	cellular	migration	through	the	fibres.		
Using	concentrations	of	fibrinogen	and	thrombin	(the	two	parent	components	
of	fibrin)	from	clinically	used	products	in	the	literature	we	were	able	to	derive	
a	suitable	form	of	fibrin	that	not	only	allowed	the	skin	explants	to	adhere	onto	
the	scaffolds	but	did	not	hinder	cellular	migration	and	allowed	for	good	tissue	
handling.	This	concentration	of	fibrinogen	(18.75mg)	and	thrombin	(2.5	I.U)		
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for	use	to	adhere	biological	tissue	to	scaffolds	was	established	in	the	MacNeil	
laboratory	for	adherence	of	limbal	biopsies	on	scaffolds	for	corneal	
regeneration(164).	This	concentration	when	cultured	with	skin	explants	
showed	the	most	cellular	outgrowth	and	allowed	for	handling	of	the	skin	
explant	pieces	before	the	fibrin	set	into	its	gel	like	form.		
We	concluded	that	fibrin	did	make	a	significant	contribution	to	skin	explant	
retention	onto	the	electrospun	scaffolds	which	aided	cellular	migration	and	
proliferation.	Furthermore,	this	is	clinically	translatable	as	fibrin	is	FDA	
approved,	however	the	concentration	of	the	components	of	this	fibrin	doesn’t	
exist	commercially	to	the	best	of	our	knowledge.		
	
8.5	Objective	4:		The	use	of	precultured	scaffolds	with	fibroblasts	as	an	in	
vivo	wound	bed	model	would	help	achieve	better	epithelial	cell	outgrowth	
from	skin	explants	when	used	in	combination	with	fibrin.		
	
The	use	of	skin	explants	to	populate	biodegradable	electrospun	scaffolds	is	a	
fairly	new	concept	and	as	a	result,	the	positive	control	to	which	it	is	compared	
is	the	traditional	model	of	tissue	engineered	skin	using	acellular	dermal	matrix	
seeded	with	isolated	keratinocytes	and	fibroblasts.	Ultimately	this	scaffold	
material	would	be	placed	on	a	debrided	wound	bed	from	a	full	thickness	
wound,	which	will	consist	of	an	underlying	vascular	network	surrounded	by	
stroma,	and	other	tissues	eg	subcutaneous	fat	or	even	fascia	with	a	wound	
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edge.	It	was	thought	that	pre	culturing	the	scaffolds	with	fibroblasts,	would	
allow	them	to	proliferate	and	release	growth	factors	and	cytokines	that	would	
aid	the	migration	of	skin	cells	out	of	the	skin	explants,	which	would	be	much	
closer	to	what	would	happen	in	the	in	vivo	setting	on	the	wound	bed.	
Quantitatively	there	was	more	cellular	activity	on	these	scaffolds	more	so	
when	combined	with	fibrin,	as	expected.	Furthermore,	on	confocal	imaging	
pancytokeratin	immunohistochemistry	we	were	able	to	appreciate	the	
migration	of	keratinocytes	from	the	cut	edge	of	the	skin	explants	into	the	
depths	of	our	trilayer	templated	scaffolds.	This	further	confirmed	that	skin	
explants	are	a	viable	source	of	cells	that	can	provide	a	new	epidermal	cover	on	
our	synthetic	scaffold,	as	indeed	happens	in	Meek	Grafting	when	keratinocytes	
and	fibroblasts	grow	out	of	small	pieces	of	split	thickness	graft	onto	the	wound	
bed		
One	of	the	aims	of	this	research	was	to	avoid	the	need	to	provide	laboratory	
expanded	cultured	cells	in	our	constructs.	In	summary	the	presence	of	the	
fibroblasts	did	improve	the	outgrowth	of	cells	from	the	explants	suggesting	
that	our	main	objective	of	using	electrospun	scaffolds	combined	with	skin	
explants	as	an	approach	to	treating	full	thickness	skin	defects	remains	a	
biological	and	clinical	possibility.	
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Experimental	Objectives		 Main	findings		
1.The	use	of	a	trilayer	PHBV/PGLA	
75:25	electrospun	scaffold	versus	
monolayer	PGLA	75:25	scaffolds	
Mechanical	properties	of	trilayer	
scaffolds	were	closer	to	that	of	skin	
Trilayer	scaffolds	handled	better	than	
monolayers	
Histologically	there	were	definable	
layers	in	our	constructs	which	
mimicked	the	topography	of	skin		
2.The	use	of	metal	templates	to	
mimic	the	rete	ridges	of	the	
epidermal-dermal	interface	
The	results	were	unconvincing	as	
there	were	no	differences	in	cellular	
migration	and	proliferation	when	
templated	and	non-templated	
scaffolds	were	used.		
3.The	use	of	fibrin	as	part	of	the	skin	
explant/	electrospun	scaffold	model	
to	secure	the	attachment	of	the	skin	
explants	to	the	electrospun	scaffold	
Fibrin	that	was	made	by	using	
18.75mg	of	fibrinogen	and	2.5	I.	U	of	
thrombin	was	deemed	to	be	the	
most	appropriate	form	to	allow	skin	
explants	to	adhere	onto	the	
electrospun	scaffold	and	at	the	same	
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time	not	hinder	cellular	migration	
and	proliferation.		
5. 4.	The	use	of	precultured	electrospun	
scaffolds	with	fibroblasts	provided	a	
better	wound	bed	model	to	mimic	
the	in	vivo	microenvironment.	
The	use	of	this	wound	bed	model	
confirmed	the	ability	for	skin	
explants	to	be	cultured	with	fibrin	on	
synthetic	electrospun	scaffolds	to	
create	tissue	engineered	skin	without	
the	need	to	use	isolated	cultured	
cells	
Table	11:	Summary	of	experimental	objectives	and	main	findings		
	
8.6	Future	Directions		
	
The	work	in	this	thesis	concentrated	on	assessing	the	suitability	of	using	a	
trilayer	electrospun	scaffold	for	a	neodermis,	skin	explants	as	a	cell	source	and	
techniques	to	optimise	the	migration	of	skin	cells	from	the	skin	explants	onto	
the	electrospun	scaffolds.	We	learnt	that	it	is	possible,	however	we	needed	to	
define	a	few	characteristics	and	use	adjuncts	to	optimise	this	process.	
Although	the	use	of	trilayer	scaffolds	as	a	potential	for	dermal	replacement	has	
been	previously	been	established	in	the	MacNeil	laboratory	but	with	
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laboratory	cultured	keratinocytes	and	fibroblasts(205),	the	use	of	skin	explants	
as	a	cell	source	in	tissue	engineered	skin	is	novel.		
We	found	the	skin	explants	needed	to	be	further	cut	into	small	pieces	to	
optimise	spread	with	less	dermis	in	skin	explants	facilitate	more	outward	
migration	of	epithelial	cells	and	they	can	be	orientated	randomly.	They	need	to	
stay	in	constant	contact	with	the	electrospun	scaffolds	to	facilitate	cellular	
migration	and	proliferation.	To	do	this	we	used	fibrin,	a	biological	adhesive	
already	in	clinical	use,	with	good	results.	Our	in	vitro	studies	have	
demonstrated	that	it	is	a	possible	to	use	biodegradable	electrospun	scaffolds	
combined	with	fibrin	and	skin	explants	to	achieve	cellular	migration	from	the	
skin	explants	throughout	the	scaffold.	The	next	step	for	this	work	would	be	do	
translate	this	onto	animal	models.	Small	full	thickness	wounds	(to	the	
subcutaneous	layer)	in	the	first	instance	would	be	created	and	reconstructed	
using	our	model.	Scaffolds	would	be	secured	to	the	wound	edges	using	a	quick	
acting	dissolving	suture	like	vicryl	rapide,	commonly	used	to	secure	split	skin	
grafts	onto	wounds.	The	skin	explants	would	be	laid	onto	the	scaffolds	with	
fibrin	and	dressed.	The	dressing	in	this	instance	is	very	important	as	it	needs	to	
facilitate	the	egress	of	fluid,	the	inflow	of	oxygen	and	not	disturb	the	construct.	
One	possibility	is	the	use	of	a	product	akin	to	biobrane,	which	can	be	laid	onto	
the	top	of	the	skin	explants	and	scaffolds.	This	would	be	secured	with	tissue	
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glue	and	lifted	off	as	epithelial	cells	populate	the	wound.	This	would	also	allow	
wound	inspection	for	infection	without	disrupting	the	skin	explants.		
Once	this	work	is	completed	then	there	are	many	more	questions	to	be	
answered.	Clinically	important	questions	like,	the	depth	of	wound	onto	which	
is	most	appropriate	eg	muscle,	tendon	or	bone.	The	maximal	size	of	a	wound	
that	this	would	work	in,	the	appearance	clinically	of	what	a	regenerating	
wound	using	our	model	would	look	like	and	histological	confirmation	of	the	
wound	healing	that	has	occurred.	Other	questions	like	the	susceptibility	to	
infection	and	which	organisms	in	particular	pose	a	potential	threat	to	these	
scaffolds	will	need	to	be	addressed.	These	points	will	all	have	to	be	defined	as	
well	as	every	step	of	the	technique	to	allow	for	safe	translation	in	using	our	
trilayer	electrospun/	skin	explants	into	a	1st	in	man	clinical	safety	study.		
In	conclusion	this	thesis	has	revealed	that	skin	explants	combined	with	fibrin	
and	laid	onto	biodegradable	synthetic	trilayer	electrospun	scaffold	result	in	
cellular	migration	and	proliferation	that	could	facilitate	healing	in	full	thickness	
skin	defects.	These	are	early	but	important	aspects	of	the	groundwork	that	
needs	to	occur	so	that	in	the	future	tissue	engineered	skin	will	be	part	of	the	
routine	armamentarium	of	the	reconstructive	surgeon.		
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Consent form for using samples of human skin for research 
• Thank you for reading the information about our research.
• If you would like to take part, please read and sign this form,
     a copy of which will be retained in your medical records. 
Centre: 
Department of Plastic Surgery, Sheffield Teaching Hospitals Trust
Title of project: Development of tissue engineered wound models for wound healing research for 
patients with burns and chronic wounds. 
Name of Researcher:  Professor Sheila MacNeil 
Contact details for research team:  Professor Sheila MacNeil, Biomaterials &Tissue Engineering 
Group, University of Sheffield, Kroto Research Institute, North Campus, Broad Lane,  
Sheffield, S3 7HQ. 
Tel: +00 44 (114) 222 5995 
Please Initial in the box 
1. I have read the attached information sheet for this project, (version 3 dated 13/04/2016) and 
have been given a copy to keep. I have been able to ask questions about the project and I 
understand why the research is being done and any risks involved.
2. I do understand that some cells from the samples may be used in animal work.
3. I agree to give a sample of skin for research in this project. I understand how the sample will be
collected, and that giving a sample for this research is voluntary.
4. I understand that I will not benefit financially, or otherwise, if this research leads to the
development of a new treatment or medical test.
Patient Identification Sticker 
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Appendix	2:	Ethical	approval	for	the	
collection	of	human	skin		
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A Research Ethics Committee established by the Health Research Authority  
 
 
NRES Committee Yorkshire & The Humber - Sheffield 
Jarrow Business Centre 
Viking Business Park 
Rolling Mill Road 
Jarrow 
Tyne and Wear 
NE32 3DT 
 
Telephone: 0191 4283564 
03 June 2015 
 
Prof Sheila MacNeil 
Kroto Research Institute 
University of Sheffield 
Broad Lane, Sheffield 
S3 7HQ 
 
 
Dear Prof MacNeil 
 
Title of the Research Tissue Bank: Research Tissue Bank 
REC reference: 15/YH/0177 
Designated Individual: Prof Sheila MacNeil 
IRAS project ID: 128409 
 
Thank you for your letter of 21 May 2015, responding to the Committee’s request for further 
information on the above research tissue bank and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this favourable opinion letter.  The expectation is that this information will be published for all 
studies that receive an ethical opinion but should you wish to provide a substitute contact point, 
wish to make a request to defer, or require further information,, please contact the REC 
Manager Miss Kathryn Murray, nrescommittee.yorkandhumber-sheffield@nhs.net. Under very 
limited circumstances (e.g. for student research which has received an unfavourable opinion), it 
may be possible to grant an exemption to the publication of the study. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion of the above 
research tissue bank on the basis described in the application form and supporting 
documentation as revised. 
 
Duration of ethical opinion 
 
The favourable opinion is given for a period of five years from the date of this letter and provided 
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